AU2012202993B2 - Pim kinase inhibitors and methods of their use - Google Patents

Abstract

[--NR~nblDCCKNG431752_I D)OC-2 /5 2l New compounds, compositions and methods of inhibition of kinase activity associated with tLumorigcnesis in a human or animal subject are provided. In certain embodiments. the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The nCw compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

Description

A ustralian Patents Act 1990 - Regulation 3.2A ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title "Pim kinase inhibitors and methods of their use" The following statement is a full description of this invention, including the best method ol performing it known to us:- PIM KINASE INHIBITORS AND MET-IODS OF THEIR USE This is a divisional of Australian Patent Application No. 2008221263, the cntirc contents of which arc incorporated heicin by rcfeience. FIELD OF THE INVENTION 5 [0001] The present invention relates to new compounds and their tautomers and stereoisomers, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cancer. 10 BACKGROUND [0002] Infection with the Maloney retrovirus and/genome integration in the host cell genome results in development of lymphomas in mice. Provirus Integration of Maloney Kinase (PIM-Kinase) was identified as one of the frequent proto-oncogenes capable of being transcriptionally activated by this retrovirus integration event (Cuypers 15 HT et al., "Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region," Cell 37(1):141-50 (1984); Selten G, et al., "Proviral activation of the putative oncogene Pim- I in MuLV induced T-cell lymphomas" EMBO J 4(7):1793-8 (1985)), thus establishing a correlation between over-expression of this kinase and its oncogenic potential. Sequence homology analysis demonstrated that 20 there are 3 highly homologous Pim-Kinases (Piml, 2 & 3), Piml being the proto oncogene originally identified by retrovirus integration. Furthermore, transgenic mice over-expressing Pim1 or Pim2 show increased incidence of T-cell lymphomas (Breuer M et al., "Very high frequency of lymphoma induction by a chemical carcinogen in pim- 1 transgenic mice" Nature 340(6228):61-3 (1989)), while over-expression in conjunction 25 with c-myc is associated with incidence of B-cell lymphomas (Verbeek S et al., "Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally" Mol Cell Biol 11(2):1176-9 (1991)). Thus, these animal models establish a strong correlation between Pim over-expression and oncogenesis in hematopoietic malignancies. In addition to these animal models, Pim over-expression has been reported 30 in many other human malignancies. Piml, 2 & 3 over-expression is frequently observed in many hematopoietic malignancies (Amson R et al., "The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias," PNAS USA 86(22):8857-61 (1989); Cohen AM et al., "Increased expression of the hPim-2 gene -I in human chronic lymphocytic leukemia and non-Hodgkin lymphoma," Leuk Lymph 45(5):951-5 (2004), Huttmann A et al., "Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status," Leukenia 20:1774-1782 (2006)) and in prostate cancer 5 (Dhanasekaran SM, et al., "Delineation of prognostic biomarkers in prostate cancer," Nature 412(6849):822-6 (2001); Cibull TL, et al., "Overexpression of Pim-1 during progression of prostatic adenocarcinoma," J Clin Pathol 59(3):285-8 (2006)), while over expression of Pim3 is frequently observed in hepatocellular carcinoma (Fujii C, et al., "Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma 10 development and its role in the proliferation of human hepatoma cell lines," Int J Cancer 114:209-218 (2005)) and pancreatic cancer (Li YY et al., "Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines," Cancer Res 66(13):6741-7 (2006)). 15 [00031 Piml, 2 & 3 arc Serine/Threonine kinases normally function in survival and proliferation of hematopoietic cells in response to growth factors and cytokines. Cytokines signaling through the Jak/Stat pathway leads to activation of transcription of the Pim genes and synthesis of the proteins. No further post-translational modifications are required for the Kinase Pim activity. Thus, signaling down stream is primarily 20 controlled at the transcriptional/translational and protein turnover level. Substrates for Pim kinases include regulators of apoptosis such as the Bcl-2 family member BAD (Aho T et al., "Pim-l kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Serl 12 gatekeeper site,: FEBS Letters 571: 43-49 (2004)), cell cycle regulators such as p 2 1 WFAl/CIPI (Wang Z, et al., "Phosphorylation of the cell cycle 25 inhibitor p2lCipl/WAFl by Pim-1 kinase," Biochim Biophys Acta 1593:45- 55 (2002)), CDC25A (1999), C-TAK (Bachmann M et al., "The Oncogenic Serine/Threonine Kinase Pim-1 Phosphorylates and Inhibits the Activity of Cdc25C-associated Kinase I (C TAKI). A novel role for Pim-l at the G2/M cell cycle checkpoint," J Biol Chem 179:48319-48328 (2004)) and NuMA (Bhattacharya N, et al., "Pim-1 associates with 30 protein complexes necessary for mitosis," Chromosoma 111(2):80-95 (2002)) and the protein synthesis regulator 4EBPI (Hammerman PS et al., "Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival," Blood 105(11):4477 83 (2005)). The effects of Pim(s) in these regulators are consistent with a role in -2protection from apoptosis and promotion of cell proliferation and growth. Thus, over expression of Pim(s) in cancer is thought to play a role in promoting survival and proliferation of cancer cells and, therefore, their inhibitions should be an effective way of treating cancers on which they are over-expressed. In fact several reports indicate that 5 knocking down expression of Pim(s) with siRNA results in inhibition of proliferation and cell death (Dai JM, et al., "Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim-2 inhibited proliferation of DU-145 cells," Acta Pharmacol Sin 26(3):364-8 (2005); Fujii et al. 2005; Li et al. 2006). Furthermore, mutational activation of several well know oncogenes in hematopoietic malignancies are thought exert its effects at least 10 in part through Pim(s). For example, targeted down regulation of pim expression impairs survival of hematopoietic cells transformed by Flt3 and BCR/ABL (Adam et al. 2006). Thus, inhibitors to Piml, 2 &3 would be useful in the treatment of these malignancies. In addition to a potential role in cancer treatment and mycloproliferative diseases, such inhibitor could be useful to control expansion of immune cells in other pathologic 15 condition such as autoimmune diseases, allergic reactions and in organ transplantation rejection syndromes. This notion is supported by the findings that differentiation of Thi Helper T-cells by IL-12 and IFN-x results in induction of expression of both Piml&2 (Aho T et al., "Expression of human Pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation," 20 Immunology 116: 82-88 (2005)). Moreover, Pim(s) expression is inhibited in both cell types by the immunosuppressive TGF-3 (Aho et al. 2005). These results suggest that Pim kinases are involved in the early differentiation process of Helper T-cells, which coordinate the immunological responses in autoimmune diseases, allergic reaction and tissue transplant rejection. 25 100041 In addition to PIM-Kinase, several other kinases have been shown to be directly involved in cancer, such as Flt3, KDR and PKCc. For example, several types of activating mutations in Flt3 are found in 20-30 % of patients with Acute Myeloid Leukemia (AML). These activating mutations are thought to be the most relevant transformation event on these patients and currently several Flt3 inhibitors are being 30 tested for the treatment on these patients in clinical trials (for a recent review see Tichenbrock L et al., "Emerging Flt3 kinase inhibitors in the treatment of leukaemia," Expert Opin Emerg Drugs 11:153-165 (2006)). KDR is one of the receptors for VEGF that plays a critical role in tumor angiogenesis and it's the target for the clinically -3validated bevacizumab drug (for a recent review see Ranieri G et al., "Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic," Curr Med Chem 13: 1845-1857 (2006)). Finally, over-expression in NIH3T3 cells of PKCE has been shown to transform cell in vitro and promote tumor 5 formation in vivo (Perletti et al. Oncogene 12: 847 (1996); Mischak et al., J Biol Chem 268: 6090 (1993)). In addition, over-expression of PKCc in the LNCaP cell line results in its transformation to an androgen-independent tumor growth in nude nice (Wu et al., Cancer Research 62: 2423 (2002)). Furthermore, over-expression of PKCC in transgenic mouse epithelium accelerates the development of highly malignant and rapidly 10 metastasizing squamous cell carcinomas (Jansen et al., Cancer Research 61: 808 (2001)). Finally, clinically if has been observed that high PKCs expression in human tumors is associated with poor disease-free and poor overall survival (Pan et al., Cancer Research 65: 8366 (2005)). Thus, the compounds described here could be useful in treating cancer by inhibiting these well validated targets of cancer drugs. 15 [0005] A continuing need exists for compounds that inhibit the proliferation of capillaries, inhibit the growth of tumors, treat cancer, modulate cell cycle arrest, and/or inhibit molecules such as Piml, Pim2, Pim3, Flt3, KDR and PKCC, and pharmaceutical formulations and medicaments that contain such compounds. A need also exists for methods of administering such compounds, pharmaceutical formulations, and 20 medicaments to patients or subjects in need thereof. SUMMARY [00061 This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it 25 intended to be used as an aid in determining the scope of the claimed subject matter. 100071 New compounds, their tautomers and stereoisomers, and pharmaceutically acceptable salts thereof or esters having a solubility enhancing moieties or prodrugs thereof are provided of the formula (1): -4- M ec\jlI omapfKrolbIVLLU tt\K JJ/b2Ei dacx-6MJ/20I5 Y H N Z1'Z2 I II X4KN Z X3 'x1 R1

X

2 () wherein,

X

1 , X 2 , X 3 and X 4 are independently selected from CR 2 and N; provided that not more than two of XI, X 2 , X 3 and X 4 can be N; 5 Y is substituted or unsubstituted amino, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

Z

1 , Z 2 and Z 3 are independently selected from CR 2 and N; provided that not more than one of Z 1 , Z2 and Z 3 can be N; R, is selected from the group consisting of hydrogen, halo, alkyl cycloalkyl, -CN, 10 -NO 2 , and -NHR 3 ; each R2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitor, cyano, SO3H and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, 15 aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or 20 unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino, [0007a] In another aspect there is provided a compound of Formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, -5 - H-:Vcc\lnienoien\NRPoibl\DCC\REC\7337628_L dox-6AU2015 Y H N 4Z1Z2 I il N Z3 1 I1

X

3 4 ,X1 R1 X2(I) wherein,

X

2 is N and XI, X 3 and X 4 are CR 2 ; Y is substituted or unsubstituted heterocycloalkyl; 5 Z 1 and Z 2 are CR 2 and Z 3 is N; R, is selected from the group consisting of hydrogen, halo, alkyl, amino and

-NHR

3 ; each R2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, 10 aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, acyl, acylamino and 15 acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 20 [0008] In other embodiments, new compounds are provided of the formula (II): - 5A - R2 Y H N' R N Z3 2 wherein, Y is substituted or unsubstituted amino, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; 5 Z 3 is selected from CR 2 and N; R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN,

-NO

2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, 10 alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, 15 cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 20 10009] In other embodiments, new compounds are provided of the formula (I-): -6- R2 R2 R2 N H N N NZ 3 R1 R2 N () wherein,

Z

3 is selected from CR 2 and N; R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN, 5 -NO 2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, 10 aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or 15 unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. [0010] Also disclosed are compounds of the following formula (IV): N H N R2 N R1 N (IV) 20 wherein, -7- R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN,

-NO

2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, 5 alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, 10 cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, aLkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 15 [00111 In other embodiments, new compounds are provided of formulas (I)-(IV), wherein Y is substituted or unsubstituted piperidinyl or piperazinyl. In other embodiments, new compounds are provided of formulas (I)-(IV), wherein R, is hydrogen. In other embodiments, new compounds are provided of formulas (I)-(IV), wherein R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, amino, 20 nitro, cyano, SO 3 H and substituted or unsubstituted aLkyl, aminoalkyl and phenyl. 100121 In other aspects, the present invention provides methods for treating PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (1), (II), (III) or (IV) effective to PIM activity in the subject. 25 100131 In other aspects, the present invention provides methods for treating PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III) or (IV) effective to reduce or prevent tumor growth in the subject. [00141 In yet other aspects, the present invention provides methods for treating 30 PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III) or (IV) effective to reduce or prevent tumor growth in the subject in combination with at least one additional agent for the treatment of cancer. -8- [00151 In yet other aspects, the present invention provides therapeutic compositions comprising at least one compound of formula (I), (11), (III) or (IV) in combination with one or more additional agents for the treatment of cancer, as are commonly employed in cancer therapy. 5 [00161 The compounds of the invention are useful in the treatment of cancers, including hematopoietic malignancies, carcinomas (e.g., of the lungs, liver, pancreas, ovaries, thyroid, bladder or colon), melanoma, myeloid disorders (e.g., myeloid leukemia, multiple myeloma and erythroleukemia), adenomas (e.g., villous colon adenoma), sarcomas (e.g., osteosarcoma), autoimmune diseases, allergic reactions and in organ 10 transplantation rejection syndromes. [0017] In another aspect, the present invention relates to methods of inhibiting at least one serine/threonine kinase in the Jak/Stat signaling pathway in a subject, or treating a biological condition mediated by a scrinc/threonine kinase in the Jak/Stat signaling pathway in a subject, comprising administering a therapeutic composition 15 comprising at least one compound of formula (I), (II), (Il1) or (IV) effective to inhibit the Jak/Stat signaling pathway in the subject. The therapeutic compositions are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal Jak/Stat signaling). [00181 In another aspect, the present invention relates to methods of inhibiting 20 at least one serine/threonine kinase receptor selected from the group consisting of Piml , Pim2 Pim3, Flt3, KDR and PKCc in a subject, or treating a biological condition mediated by at least one of Piml, Pim2 Pim3, Flt3, KDR and PKCz comprising administering a therapeutic composition comprising at least one compound of formula (I), (11), (111) or (IV) effective to inhibit the kinase receptor in the subject. The therapeutic compounds 25 are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal serine/threonine kinase receptor signaling). [00191 The invention further provides compositions, methods of use, and methods of manufacture as described in the detailed description of the invention. 30 DETAILED DESCRIPTION 100201 In accordance with one aspect of the present invention, compounds, their tautomers and stereoisomers, and pharmaceutically acceptable salts thereof or esters -9having a solubility enhancing moieties or prodrugs thereof are provided of the formula (I): Y H N Z Z 2 I || N Z 3 I I

X

3 x1 * R1

X

2 (I) wherein, 5 XI, X 2 , X 3 and X 4 are independently selected from CR 2 and N; provided that not more than two of XI, X 2 , X 3 and X 4 can be N; Y is substituted or unsubstituted amino, alkoxy, cycloalkyl, heterocycloalkyl, aryl or hetcroaryl; ZI, Z 2 and Z 3 arc independently selected from CR 2 and N; provided that not more 10 than one of ZI, Z 2 and Z 3 can be N; R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN,

-NO

2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, 15 alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, hetcroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, 20 cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, hctcrocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 25 [00211 In other embodiments, new compounds are provided of the formula (II): -10- R2 Y H N R2 N or-, Z 3 z &N (II1, 2 wherein, Y is substituted or unsubstituted amino, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; 5 Z 3 is selected from CR 2 and N; R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN,

-NO

2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, 10 aLkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, 15 cycloatkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 20 10022] In other embodiments, new compounds are provided of the formula (III): -11- R2 R2 R R2 N H N R N ' Z 3 R1 R2 N () wherein,

Z

3 is selected from CR 2 and N; Ri is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN, 5 -NO 2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, 10 aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, cycloaLkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or 15 unsubstituted alkyl, cycloal-kyl, heterocyclyl, aryl and heteroaryl; and

R

4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. [0023] Also disclosed are compounds of the following formula (IV): N H NR

R

2 N N (IV) 20 wherein, -12- R, is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, -CN,

-NO

2 , and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, alkenyl, alkynyl, 5 alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloaLkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, 10 cycloalkyloxy, acyl, acylamino and acyloxy;

R

3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and R4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino. 15 [00241 In other embodiments, new compounds are provided of formulas (1)-(IV), wherein Y is substituted or unsubstituted piperidinyl or piperazinyl. In some embodiments, new compounds are provided of formulas (I)-(IV), wherein X 1 , X 3 , and X 4 are -CH 2 - and X 2 is -NH-. In some embodiments, new compounds are provided of formulas (])-(IV), wherein X 5 is -CH 2 -. In some embodiments, new compounds are 20 provided of formulas (I)-(IV), wherein X 6 is -CH(NH 2 )-. In other embodiments, new compounds are provided of formulas (1)-(IV), wherein R, is hydrogen. In other embodiments, new compounds are provided of formulas (I)-(IV), wherein R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, amino, nitro, cyano, SO 3 H and substituted or unsubstituted alkyl, aminoaLkyl and phenyl. 25 [0025] In other aspects, the present invention provides methods for treating PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III) or (IV) effective to PIM activity in the subject. [0026] In other aspects, the present invention provides methods for treating 30 PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (I), (II), (III) or (IV) effective to reduce or prevent tumor growth in the subject. -13- 10027] In yet other aspects, the present invention provides methods for treating PIM related disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound of formula (1), (II), (III) or (IV) effective to reduce or prevent tumor growth in the subject in combination with at least 5 one additional agent for the treatment of cancer. A number of suitable anticancer agents to be used as combination therapeutics are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., ribozymes); polypeptides (e.g., enzymes); drugs; biological 10 mimetics; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal antibodies conjugated with anticancer drugs, toxins, and/or radionuclides; biological response modifiers (e.g. interferons [e.g. IFN-a, etc.] and interleukins [e.g. IL-2, etc.], etc.); adoptive immunotherapy agents; hematopoictic growth factors; agents that induce tumor cell differentiation (e.g. all-trans-retinoic acid, etc.); 15 gene therapy reagents; antisense therapy reagents and nucleotides; tumor vaccines; inhibitors of angiogenesis, and the like. Numerous other examples of chemotherapeutic compounds and anticancer therapies suitable for coadministration with the disclosed compounds of formula (I), (II), (111) or (IV) are known to those skilled in the art. 10028] In preferred embodiments, anticancer agents to be used in combination 20 with compounds of the present invention comprise agents that induce or stimulate apoptosis. Agents that induce apoptosis include, but are not limited to, radiation (e.g., W); kinase inhibitors (e.g., Epidermal Growth Factor Receptor [EGFR] kinase inhibitor, Vascular Growth Factor Receptor [VGFR] kinase inhibitor, Fibroblast Growth Factor Receptor [FGFR] kinase inhibitor, Platelet-derived Growth Factor Receptor [PGFR] I 25 kinase inhibitor, and Bcr-Abl kinase inhibitors such as STI-571, Gleevec, and Glivec]); antisense molecules; antibodies [e.g., Herceptin and Rituxan]; anti-estrogens [e.g., raloxifene and tamoxifen]; anti-androgens [e.g., flutamide, bicalutamide, finasteride, aminoglutethamide, ketoconazole, and corticosteroids]; cyclooxygenase 2 (COX-2) inhibitors [e.g., Celecoxib, meloxicam, NS-398, and non-steroidal antiinflammatory 30 drugs (NSAIDs)]; and cancer chemotherapeutic drugs [e.g., irinotecan (Camptosar), CPT 11, fludarabine (Fludara), dacarbazine (DTIC), dexamethasone, mitoxantrone, Mylotarg, VP-16, cisplatinum, 5-FU, Doxrubicin, Taxotere or taxol]; cellular signaling molecules; ceramides and cytokines; and staurosprine, and the like. -14- [0029] In yet other aspects, the present invention provides therapeutic compositions comprising at least one compound of formula (I), (II), (III) or (IV) in combination with a pharmaceutically acceptable carrier, and optionally with one or more additional agents for the treatment of cancer, as are commonly employed in cancer 5 therapy. 100301 The compounds of the invention are useful in the treatment of cancers, including hematopoietic malignancies, carcinomas (e.g., of the lungs, liver, pancreas, ovaries, thyroid, bladder or colon), melanoma, mycloid disorders (e.g., myeloid leukemia, multiple myeloma and erythroleukemia), adenomas (e.g., villous colon adenoma), 10 sarcomas (e.g., osteosarcoma), autoimmune diseases, allergic reactions and in organ transplantation rejection syndromes. 100311 In another aspect, the present invention relates to methods of inhibiting at least one scrine/threonine kinase in the Jak/Stat signaling pathway in a subject, or treating a biological condition mediated by a serine/threonine kinase in the Jak/Stat 15 signaling pathway in a subject, comprising administering a therapeutic composition comprising at least one compound of formula (1), (11), (Ill) or (IV) effective to inhibit the Jak/Stat signaling pathway in the subject. The therapeutic compositions are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal Jak/Stat signaling). 20 100321 In another aspect, the present invention relates to methods of inhibiting at least one serine/threonine kinase receptor selected from the group consisting of Piml, Pim2 Pim3, Flt3, KDR and PKCc in a subject, or treating a biological condition mediated by at least one of Piml, Pim2 Pim3, Flt3, KDR and PKCs comprising administering a therapeutic composition comprising at least one compound of formula (I), (II), (III) or 25 (IV) effective to inhibit the kinase receptor in the subject. The therapeutic compounds are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal serine/threonine kinase receptor signaling). 10033] In another aspect, the present invention relates to methods of inhibiting the activity of at least one kinase selected from the group consisting of Piml, Pim2 Pim3, 30 Flt3, KDR and PKCc in a subject, or treating a biological condition mediated by at least one of Piml, Pim2 Pim3, Flt3, KDR and PKCc, in a human or animal subject in need of such treatment, comprising administering to the subject at least one compound of formula (I), (II), (III) or (IV) in an amount effective to inhibit the kinase in the subject. The -15therapeutic compounds are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal serine/threonine kinase receptor signaling). [00341 In other aspects, the present invention provides methods of manufacture 5 of compounds of formula (I), (II), (II1) or (IV) as described herein. [00351 The invention further provides compositions, methods of use, and methods of manufacture as described in the detailed description of the invention. [0036] "PIM inhibitor" is used herein to refer to a compound that exhibits an

IC

50 with respect to PIM Kinase activity of no more than about 100 jM and more 10 typically not more than about 50 iM, as measured in the PIM depletion assays described hereinbelow. 100371 The phrase "aLkyl" refers to alkyl groups that do not contain heteroatoms. Thus the phrase includes straight chain atkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. 15 The phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH 3

)

2 ,

-CH(CH

3

)(CH

2

CH

3 ), -CH(CH 2

CH

3

)

2 , -C(CH 3

)

3 , -C(CH 2

CH

3

)

3 , -CH 2

CH(CH

3

)

2 ,

-CH

2

CH(CH

3

)(CH

2

CH

3 ), -CH 2

CH(CH

2

CH

3

)

2 , -CH 2

C(CH

3

)

3 , -CH 2

C(CH

2

CH

3

)

3 ,

-CH(CH

3

)CH(CH

3

)(CH

2

CH

3 ), -CH 2

CH

2

CH(CH

3

)

2 , -CH 2

CH

2

CH(CH

3

)(CH

2

CH

3 ), 20 -CH 2

CH

2

CH(CH

2

CH

3

)

2 , -CH 2

CH

2

C(CH

3

)

3 , -CH 2

CH

2

C(CH

2

CH

3

)

3 , -CH(CH 3

)CH

2 CH(CH 3

)

2 , -CH(CH 3

)CH(CH

3

)CH(CH

3

)

2 , -CH(CH 2

CH

3

)CH(CH

3

)CH(CH

3

)(CH

2

CH

3 ), and others. The phrase also includes cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl and such rings substituted with straight and branched chain alkyl groups as defined above. Thus the phrase alkyl groups 25 includes primary alkyl groups, secondary aLkyl groups, and tertiary alkyl groups. Preferred alkyl groups include straight and branched chain alkyl groups and cyclic alkyl groups having I to 12 carbon atoms. [00381 As used herein "loweralkyl" includes both substituted or unsubstituted straight or branched chain alkyl groups having from 1 to 6 carbon atoms. Representative 30 loweralkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, tert butyl, neopentyl, trifluoromethyl, pentafluoroethyl and the like. Loweralkyl groups may be substituted, such as with halo, hydroxy, amino, nitro and/or cyano groups, and the like. Representative of halo-substituted and hydroxy-substituted loweralkyl include -16chloromethyl, trichloromethyl, chloroethyl, hydroxyethyl, and the like. Other suitable substituted loweralkyl moieties include, for example, aralkyl, aminoalkyl, aminoaralkyl, carbonylaminoalkyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, aralkylcarbonyl aminoalkyl, aminoalkoxyalkyl and arylaminoalkyl. 5 100391 "Loweralkoxy" as used herein refers to RO- wherein R is loweralkyl. Representative examples of loweralkoxy groups include methoxy, ethoxy, t-butoxy, trifluoromethoxy and the like. 10040] As used herein, the term "halogen" or "halo" refers to chloro, bromo, fluoro and iodo groups. "Haloalkyl" refers to an alkyl radical substituted with one or 10 more halogen atoms. The term "haloloweralkyl" refers to a loweralkyl radical substituted with one or more halogen atoms. The term "haloalkoxy" refers to an alkoxy radical substituted with one or more halogen atoms. The term "haloloweralkoxy" refers to a loweralkoxy radical substituted with one or more halogen atoms. [0041] "Amino" refers herein to the group -NH 2 . The term "alkylamino" 15 refers herein to the group -NRR' where R and R' are each independently selected from hydrogen or a lower alkyl. The term "arylamino" refers herein to the group -NRR' where R is aryl and R' is hydrogen, a lower alkyl, or an aryl. The term "aralkylarmino" refers herein to the group -NRR' where R is a lower aralkyl and R' is hydrogen, a loweralkyl, an aryl, or a loweraralkyl. 20 10042] The term "alkoxyalkyl" refers to the group -alki-O-alk 2 where alk, is alkyl or alkenyl, and alk 2 is alkyl or alkenyl. The term "loweralkoxyaLkyl" refers to an alkoxyalkyl where alki is loweralkyl or loweralkenyl, and alk 2 is loweralkyl or loweralkenyl. The term "aryloxyalkyl" refers to the group -alkyl-0-aryl. The term "aralkoxyalkyl" refers to the group -alkylenyl-O-aralkyl, where araLkyl is a loweraralkyl. 25 [00431 The term "aminocarbonyl" refers herein to the group -C(O)-NH 2 "Substituted aminocarbonyl" refers herein to the group -C(O)-NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl. In some embodiments, R and R', together with the N atom attached to them may be taken together to form a "heterocycloalkylcarbonyl" group. The term "arylaminocarbonyl" refers herein to the 30 group -C(O)-NRR' where R is an aryl and R' is hydrogen, loweralkyl or aryl. "aralkylaminocarbonyl" refers herein to the group -C(O)-NRR' where R is loweraralkyl and R' is hydrogen, loweralkyl, aryl, or loweraralkyl. -17- [0044] "Aminosulfonyl" refers herein to the group -S(0) 2

-NH

2 . "Substituted aminosulfonyl" refers herein to the group -S(O) 2 -NRR' where R is loweralkyl and R' is hydrogen or a loweralkyl. The term "aralkylaminosulfonlyaryl" refers herein to the group -aryl-S(O) 2 -NH-aralkyl, where the aralkyl is loweraralkyl. 5 10045] "Carbonyl" refers to the divalent group -C(O)-. "Carboxy" refers to C(=0)-OH. "Alkoxycarbonyl" refers to ester -C(=O)-OR wherein R is alkyl. "Loweralkoxycarbonyl" refers to ester -C(=O)-OR wherein R is loweralkyl. "Cycloalkyloxycarbonyl" refers to -C(=O)-OR wherein R is cycloalkyl. "Aryloxycarbonyl" refers to -C(=O)-OR wherein R is aryl. "Heterocyclyloxycarbonyl" 10 refers to -C(=O)-OR wherein R is heterocyclyl. 100461 The term "aralkoxycarbonyl" refers herein to the group -C(O)-O aralkyl, where the aralkyl is loweraralkyl. [0047] The term "sulfonyl" refers herein to the group -SO 2 -. The term "sulfanyl" refers herein to the group -S-. "Loweralkylsulfonyl" refers to a substituted 15 sulfonyl of the structure -S0 2 R- in which R is loweralkyl. "Loweralkylsulfanyl" refers to a substituted sulfanyl of the structure -SR- in which R is loweralkyl. Alkylsulfonyl and akylsulfanyl groups employed in compounds of the present invention are typically loweralkylsulfonyl or loweralkylsulfanyl groups having from I to 6 carbon atoms in its backbone structure. Thus, typical alkylsulfonyl and loweralkylsulfanyl groups employed 20 in compounds of the present invention include, for example, methylsulfonyl and methylsulfanyl (i.e., where R is methyl), ethylsulfonyl and ethylsulfanyl (i.e., where R is ethyl), propylsulfonyl and propylsulfanyl (i.e., where R is propyl), and the like. The term "arylsulfonyl" refers herein to the group -S0 2 -aryl. The term "aralkylsulfonyl" refers herein to the group -S0 2 -aralkyl, in which the aralkyl is loweraralkyl. The term 25 "sulfonamido" refers herein to -S0 2

NH

2 . [0048] As used herein, the term "carbonylamino" refers to the divalent group -NH-C(O)- in which the hydrogen atom of the amide nitrogen of the carbonylamino group can be replaced a loweralkyl, aryl, or loweraralkyl group. Such groups include moieties such as carbamate esters (-NH-C(O)-O-R) and amides -NH-C(O)-R, where R is 30 a straight or branched chain loweralkyl, cycloalkyl, or aryl or loweraralkyl. [00491 "Cycloalkyl" refers to a mono- or polycyclic, heterocyclic or carbocyclic alkyl substituent. Typical cycloalkyl substituents have from 3 to 8 backbone (i.e., ring) atoms in which each backbone atom is either carbon or a heteroatom. The -18term "heterocycloalkyl" refers herein to cycloalkyl substituents that have from I to 5, and more typically from I to 4 heteroatoms in the ring structure. Suitable heteroatoms employed in compounds of the present invention are nitrogen, oxygen, and sulfur. Representative heterocycloalkyl moieties include, for example, morpholino, piperazinyl, 5 piperidinyl and the like. Carbocycloalkyl groups are cycloalkyl groups in which all ring atoms are carbon. When used in connection with cycloalkyl substituents, the term "polycyclic" refers herein to fused and non-fused alkyl cyclic structures. [0050] The term "substituted heterocycle" or "heterocyclic group" or heterocycle as used herein refers to any 3- or 4-membered ring containing a heteroatom 10 selected from nitrogen, oxygen, and sulfur or a 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, or sulfur; wherein the 5-membered ring has 0-2 double bonds and the 6-membered ring has 0-3 double bonds; wherein the nitrogen and sulfur atom maybe optionally oxidized; wherein the nitrogen and sulfur heteroatoms may be optionally quarternized; and 15 including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another 5- or 6-membered heterocyclic ring independently defined above. The term "heterocycle" thus includes rings in which nitrogen is the heteroatom as well as partially and fully-saturated rings. Preferred heterocycles include, for example: diazapinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, 20 imidazoyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, N-methyl piperazinyl, azetidinyl, N-methylazetidinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, triazolyl and benzothienyl. 25 [0051] Heterocyclic moieties can be unsubstituted or monosubstituted or disubstituted with various substituents independently selected from hydroxy, halo, oxo (C=O), alkylimino (RN=, wherein R is a loweralkyl or loweralkoxy group), amino, alkylamino, dialkylamino, acylaminoalkyl, alkoxy, thioalkoxy, polyalkoxy, loweralkyl, cycloalkyl or haloalkyl. 30 100521 The heterocyclic groups may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein. -19- O O N "N "N'" N' NN "N NH N NH "I N Y0 0"~~ "N"' 00 H N ONH O N O OH NH2 N O N N__R 0N R , W N S O R where R is H or 5 a heterocyclic substituent, as described herein. 10053] Representative heterocyclics include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, furanyl, triazolyl benzimidazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, indolyl, naphthpyridinyl, indazolyl, and quinolizinyl. 10 [0054] "Aryl" refers to optionally substituted monocyclic and polycyclic aromatic groups having from 3 to 14 backbone carbon or hetero atoms, and includes both carbocyclic aryl groups and heterocyclic aryl groups. Carbocyclic aryl groups are aryl groups in which all ring atoms in the aromatic ring are carbon. The term "heteroaryl" refers herein to aryl groups having from I to 4 heteroatoms as ring atoms in an aromatic 15 ring with the remainder of the ring atoms being carbon atoms. When used in connection with aryl substituents, the term "polycyclic aryl" refers herein to fused and non-fused cyclic structures in which at least one cyclic structure is aromatic, such as, for example, benzodioxozolo (which has a heterocyclic structure fused to a phenyl group, i.e., naphthyl, and the like. Exemplary aryl moieties employed as substituents in 20 compounds of the present invention include phenyl, pyridyl, pyrimidinyl, thiazolyl, indolyl, imidazolyl, oxadiazolyl, tetrazolyl, pyrazinyl, triazolyl, thiophcnyl, furanyl, quinolinyl, purinyl, naphthyl, benzothiazolyl, benzopyridyl, and benzimidazolyl, and the like. -20- [0055] "Aralkyl" refers to an alkyl group substituted with an aryl group. Typically, aralkyl groups employed in compounds of the present invention have from 1 to 6 carbon atoms incorporated within the alkyl portion of the aralkyl group. Suitable aralkyl groups employed in compounds of the present invention include, for example, 5 benzyl, picolyl, and the like. 100561 Representative heteroaryl groups include, for example, those shown below. These heteroaryl groups can be further substituted and may be attached at various positions as will be apparent to those having skill in the organic and medicinal chemistry arts in conjunction with the disclosure herein. \ F 10 N 0 N NN-N NN -N ...... N NN HN/

NH

2 NN H N N NNN N N NN N N N-N N NH N 15 [0057] Representative heteroaryls include, for example, imidazolyl, pyridyl, piperazinyl, azetidinyl, thiazolyl, triazolyl benzimidazolyl, benzothiazolyl, and benzoxazolyl. [0058] "Optionally substituted" or "substituted" refers to the replacement of one or more hydrogen atoms with a monovalent or divalent radical. Suitable substitution 20 groups include, for example, hydroxy, nitro, amino, imino, cyano, halo, thio, sulfonyl, thioamido, amidino, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, loweralkyl, haloloweralkyl, loweralkylamino, haloloweralkylamino, loweralkoxy, haloloweralkoxy, loweralkoxyalkyl, alkylcarbonyl, -21aminocarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl and the like. [00591 The substitution group can itself be substituted. The group substituted onto the substitution group can be carboxyl, halo; nitro, amino, cyano, hydroxy, 5 loweralkyl, loweralkoxy, aminocarbonyl, -SR, thioamido, -S03H, -SO 2 R or cycloalkyl, where R is typically hydrogen, hydroxyl or loweralkyl. [00601 When the substituted substituent includes a straight chain group, the substitution can occur either within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, and the like) or at the chain terminus (e.g., 2-hydroxyethyl, 3-cyanopropyl, and the like). 10 Substituted substituents can be straight chain, branched or cyclic arrangements of covalently bonded carbon or heteroatoms. 100611 It is understood that the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with five fluoro groups or a halogen atom substituted with another halogen atom). Such impermissible substitution 15 patterns are well known to the skilled artisan. [00621 It will also be apparent to those skilled in the art that the compounds of the invention, including the compounds of compounds of formulas (I), (II), (III) or (IV) or their stereoisomers, as well as the pharmaceutically acceptable salts, esters, metabolites and prodrugs of any of them, may be subject to tautomerization and may therefore exist 20 in various tautomeric forms wherein a proton of one atom of a molecule shifts to another atom and the chemical bonds between the atoms of the molecules are consequently rearranged. See, e.g., March, Advanced Organic Chemistrv: Reactions, Mechanisms and Structures, Fourth Edition, John Wiley & Sons, pages 69-74 (1992). As used herein, the term "tautomer" refers to the compounds produced by the proton shift, and it should be 25 understood that the all tautomeric forms, insofar as they may exist, are included within the invention. [00631 The compounds of the invention, including the compounds of formulas (I), (II), (III) or (IV) or their tautomers, as well as the pharmaceutically acceptable salts, esters, metabolites and prodrugs of any of them, may comprise asymmetrically 30 substituted carbon atoms. Such asymmetrically substituted carbon atoms can result in the compounds of the invention existing in enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, such as in (R)- or (S)- forms. As a result, all such possible isomers, individual stereoisomers in their -22optically pure forms, mixtures thereof, racemic mixtures (or "racemates"), mixtures of diastereomers, as well as single diastereomers of the compounds of the invention are included in the present invention. The terms "S" and "R" configuration, as used herein, are as defined by the IUPAC 1974 RECOMMENDATIONS FOR SECTION E, FUNDAMENTAL 5 STEREOCHEMISTRY, Pure Appl. Chem. 45:13-30 (1976). The terms a and 5 are employed for ring positions of cyclic compounds. The a-side of the reference plane is that side on which the preferred substituent lies at the lower numbered position. Those substituents lying on the opposite side of the reference plane are assigned P descriptor. It should be noted that this usage differs from that for cyclic stereoparents, in which "a" means 10 "below the plane" and denotes absolute configuration. The terms a and p configuration, as used herein, are as defined by the CHEMICAL ABSTRACTS INDEX GUIDE-APPENDIX IV (1987) paragraph 203. 100641 As used herein, the term "pharmaceutically acceptable salts" refers to the nontoxic acid or alkaline earth metal salts of the compounds of Formulas (1), (11), (III) 15 or (IV). These salts can be prepared in situ during the final isolation and purification of the compounds of Formulas (1), (11), (111) or (IV), or by separately reacting the base or acid functions with a suitable organic or inorganic acid or base, respectively. Representative salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, 20 camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinatc, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, 25 thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and 30 others. Water or oil-soluble or dispersible products are thereby obtained. 100651 Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulfuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, -23methanesulfonic acid, succinic acid and citric acid. Basic addition salts can be prepared in situ during the final isolation and purification of the compounds of formula (I), or separately by reacting carboxylic acid moieties with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or 5 with ammonia, or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, 10 methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines useful for the formation of base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. [00661 As used herein, the term "pharmaceutically acceptable ester" refers to 15 esters, which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of 20 particular esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. [00671 The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and 25 lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough 30 discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. -24- [0068] It will be apparent to those skilled in the art that the compounds of the invention, including the compounds of formulas (1), (II), (III) or (IV) or their tautomers, prodrugs and stereoisomers, as well as the pharmaceutically acceptable salts, esters and prodrugs of any of them, may be processed in vivo through metabolism in a human or 5 animal body or cell to produce metabolites. The term "metabolite" as used herein refers to the formula of any derivative produced in a subject after administration of a parent compound. The derivatives may be produced from the parent compound by various biochemical transformations in the subject such as, for example, oxidation, reduction, hydrolysis, or conjugation and include, for example, oxides and demethylated derivatives. 10 The metabolites of a compound of the invention may be identified using routine techniques known in the art. See, e.g., Bertolini, G. et al., J. Med. Chem. 40:2011-2016 (1997); Shan, D. et al., J. Pharm. Sci. 86(7):765-767; Bagshawe K., Drug Dev. Res. 34:220-230 (1995); Bodor, N., Advances in Drug Res. 13:224-331 (1984); Bundgaard, H., Design of Prodrugs (Elsevier Press 1985); and Larsen, 1. K., Design and Application 15 of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991). It should be understood that individual chemical compounds that are metabolites of the compounds of formulas (1), (II), (III) or (IV) or their tautomers, prodrugs and stereoisomers, as well as the pharmaceutically acceptable salts, esters and prodrugs of any of them, are included within the invention. 20 [0069] The term "cancer" refers to cancer diseases that can be beneficially treated by the inhibition of Pim kinase, including, for example, solid cancers, such as carcinomas (e.g., of the lungs, pancreas, thyroid, ovarian, bladder, breast, prostate, or colon), melanomas, mycloid disorders (e.g., mycloid leukemia, multiple myeloma and erythroleukemia), adenomas (e.g., villous colon adenoma) and sarcomas (e.g., 25 osteosarcoma). [0070] In other aspects, the present invention relates to the processes for preparing the compounds of Formulas (I), (II) f(III) or IV, and to the synthetic intermediates useful in such processes, as described in detail below. Synthetic Methods 30 [0071] The compounds of the invention can be obtained through procedures known to the skilled in the art. For example, as shown in Scheme 1, 4-chloro, 3-nitro pyridine can be reacted with a nucleophile yielding after nitro reduction a 4-substituted 3 amino pyridine I. Alternatively, 3-bromo 4-nitro pyridine N-oxide can be reacted with a -25nucleophile, yielding after nitro and N-oxide reduction a 3-substituted 4- amino pyridine 11. The substituted amino pyridines I and 11 can be acylated with carboxylic acids with the aid of coupling agents, or with acid halides or acid anhydrides yielding 3, 4 disubstituted pyridines III and IV. Compounds of the invention containing 3, 4 5 disubstituted phenyls can be obtained using chemistry analogous to that in Scheme 1 when 3 halo 4 nitro benzenes are the starting materials. Scheme 1. CI Nu Nu H 1. NuH, heat 3. RCO 2 H, N R

NO

2 2. H 2 , Pd/C

NH

2 coupling agents i Ill Br Nu Nu H rj ,N2 1. NuH, heat N-2 3. RCO 2 H, N R 'N NO 2 NH2. H 2 , Pd/C N NH 2 coupling agents N N,-N N,- 0 11 IV [0072] Alternatively 3,4 disubstituted pyridines, as depicted in Scheme 2, can 10 be obtained by reacting halo nitro pyridines with boronic acids under Suzuki conditions, followed by nitro or nitro and N-oxide reduction yielding amino substituted pyridines V and VII. Subsequent amine acylation yields 3,4-disubstituted pyridines VI and VIII. Compounds of the invention containing 3,4-disubstituted phenyls can be obtained using chemistry analogous to that in Scheme 2 when 3-halo, 4-nitro benzenes are the starting 15 materials. Scheme 2. CI 1.RB0 2 H R R H

NO

2 or RB(OR') 2

NH

2 3 RCO 2 H, N R suzuki conditions Ncouping agents N 2. H2, Pd/C N V N V1 Br 1.RBO 2 H R R H NO2 or RB(OR')2 NH-2 co3. RCO2H, N YR suzuki conditions coupling agents 2. H 2 , Pd/C N,- Vill -26- 10073] In an alternative manner, 3,4-disubstituted pyridines can be obtained as depicted in Scheme 3. Formation of the bis-anion of N-Boc-3-aminopyridine or N pivaloyl-3-aminopyridine and reaction with an electrophile yields 4-substituted, 3-N protected amino pyridine IX. Acidic removal of the Boc or Piv protecting group and 5 subsequent acylation yields the 3,4-substituted pyridine X. Compounds of the invention containing 3,4-disubstituted phenyls can be obtained using chemistry analogous to that in Scheme 3 when suitably protected anilines are the starting materials. Scheme 3. E E H NH-R 1. LDA, NH-R 2. H. N R N R=Boc N 3. RCO 2 H, N or Piv Ix coupling agents X 10 10074] Compounds of the invention containing 5-substituted, 4-aminoacyl pyrimidones such as XII and XIII can be obtained as depicted in Scheme 4. Nucleophilic substitution or Suzuki type coupling of 5-bromocytosine followed by N-acylation yields the 5-substituted, 4-aminoacyl pyrimidones. Scheme 4. Br Nu Nu H

NH

2 1. NuH, heat

NH

2 coupr agentsN R N NH N NH ' N NH O 0 ~00 xl Br Ar/Het Ar/Het H NH NH 2. RCO 2 H, N R NH2 Suzuki or Stille NH2 coupling agents N R N NH N NH N YNH 0 0 0 0 15 XIII [0075] When the amide portion of substituted pyridines, benzenes or pyrimidones contains a haloheteroaryl group, the substituted pyridines, benzenes or pyrimidones can be modified as depicted in Scheme 5. Direct carbon linked groups (R') -27can be attached to the heteroaryl group using Suzuki, Neghishi, Grignard or other organometallic methodologies. Alternatively nitrogen, oxygen, sulfur and carbon nucleophiles can be attached to the heteroaryl group utilizing standard methodologies including SnAr or Buchwald/Hartwig conditions. 5 Scheme 5. R H R R H N .. Het-R' N N Het-X N Het-Nu Y Y , Y N ON 0 N O I R H R H RH N Het-R' N Het-X N Het-Nu Y Y , Y N,- 0 -N 0q N,- 0 IX R H R HR H N NYHet-R' N NyHet-X N Het-Nu 0 '..- 0 R,,,. 0 R R R H R Het-R' N Het-X N Het-Nu Y- _r - yl N NH O N NH O N NH 0 O O XI/XII O [0076] The compounds of the invention are useful in vitro or in vivo in inhibiting the growth of cancer cells. The compounds may be used alone or in compositions together with a pharmaceutically acceptable carrier or excipient. Suitable 10 pharmaceutically acceptable carriers or excipients include, for example, processing agents and drug delivery modifiers and enhancers, such as, for example, calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, dextrose, hydroxypropyl-p cyclodextrin, polyvinylpyrrolidinone, low melting waxes, ion exchange resins, and the 15 like, as well as combinations of any two or more thereof. Other suitable pharmaceutically acceptable excipients are described in "Remington's Pharmaceutical Sciences," Mack Pub. Co., New Jersey (1991), incorporated herein by reference. -28- [00771 Effective amounts of the compounds of the invention generally include any amount sufficient to detectably inhibit Pim activity by any of the assays described herein, by other Pim kinase activity assays known to those having ordinary skill in the art or by detecting an inhibition or alleviation of symptoms of cancer. 5 [0078] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, 10 diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The therapeutically effective amount for a given situation can be readily determined by routine experimentation and is within the skill and judgment of the ordinary clinician. [0079] For purposes of the present invention, a therapeutically effective dose 15 will generally be a total daily dose administered to a host in single or divided doses may be in amounts, for example, of from 0.001 to 1000 mg/kg body weight daily and more preferred from 1.0 to 30 mg/kg body weight daily. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose. [00801 The compounds of the present invention may be administered orally, 20 parenterally, sublingually, by aerosolization or inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or ionophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, 25 intramuscular, intrasternal injection, or infusion techniques. [0081] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally 30 acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may -29be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. [00821 Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and 5 polyethylene glycols, which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug. 100831 Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such 10 dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. 100841 Liquid dosage forms for oral administration may include 15 pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, cyclodextrins, and sweetening, flavoring, and perfuming agents. 100851 The compounds of the present invention can also be administered in the 20 form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a 25 compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.W., p. 33 et seq. (1976). 30 100861 While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents used in the treatment of cancer. The compounds of the present invention are also useful in combination with known therapeutic agents and anti-cancer agents, and -30combinations of the presently disclosed compounds with other anti-cancer or chemotherapeutic agents are within the scope of the invention. Examples of such agents can be found in Cancer Principles and Practice of Oncology, V. T. Devita and S. Hellman (editors), 6 th edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers. 5 A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Such anti-cancer agents include, but are not limited to, the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic/cytostatic agents, antiproli ferative agents, prenyl-protein transferase inhibitors, 10 HMG-CoA reductase inhibitors and other angiogenesis inhibitors, inhibitors of cell proliferation and survival signaling, apoptosis inducing agents and agents that interfere with cell cycle checkpoints. The compounds of the invention are also useful when co administered with radiation therapy. [0087] Therefore, in one embodiment of the invention, the compounds of the 15 invention are also used in combination with known anticancer agents including, for example, estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibitors, reverse transcriptase inhibitors, and other angiogenesis inhibitors. 20 100881 Estrogen receptor modulators are compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifenc, fulvestrant, 4-[7-(2,2-dimcthyl-1 oxopropoxy-4-methyl-2-[4-[2-(I-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl] 25 phenyl-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydra zone, and SH646. 10089] Androgen receptor modulators are compounds which interfere with or inhibit the binding of androgens to an androgen receptor. Representative examples of androgen receptor modulators include finasteride and other 5a-reductase inhibitors, 30 nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate. Retinoid receptor modulators are compounds which interfere or inhibit the binding of retinoids to a retinoid receptor. Examples of retinoid receptor modulators include bexarotene, tretinoin, 13-cis -31retinoic acid, 9-cis-retinoic acid, o.-difluoromethylornithine, LX23-7553, trans-N-(4' hydroxyphenyl) retinamide, and N4-carboxyphenyl retinamide. 100901 Cytotoxic and/or cytostatic agents are compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's 5 functioning or inhibit or interfere with cell mytosis, including alkylating agents, tumor necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-stabilizing agents, inhibitors of mitotic kinesins, inhibitors of kinases involved in mitotic progression, antimetabolites; biological response modifiers; hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal 10 antibody targeted therapeutic agents, topoisomerase inhibitors, proteasome inhibitors and ubiquitin ligase inhibitors. Examples of cytotoxic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prcdnimustine, dibromodulcitol, ranimustinc, fotcmustinc, ncdaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, 15 dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine platinum(]I)]bis [diamine(chloro)platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1 -(11 -dodecylamino- I 0-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, 20 idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino- I 3-deoxo- I 0-hydroxycarmino mycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3 aziridinyl-4-methylsulphonyl-daunorubicin (sec WO 00/50032). A representative example of a hypoxia activatable compound is tirapazamine. Proteasome inhibitors 25 include, but are not limited to, lactacystin and bortezomib. Examples of microtubule inhibitors/microtubule-stabilizing agents include paclitaxel, vindesine sulfate, 3',4' didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydro 30 vinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butyl amide, TDX258, the epothilones (see for example U.S. Pat. Nos. 6,284,781 and 6,288,237) and BMS188797. Representative examples of topoisomerase inhibitors include topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo -32benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2 (6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H benzo[de]pyrano[3',4':b,7]-indolizino[1,2b]quinoline-10,13(9H,15H)dione, lurtotecan, 7 [2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPIl100, BN80915, 5 BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxy etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3 b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa, 9b)-9-[2-[N-[2-(dimethylamino) ethyl]-N-methylamino]ethyl]-5-[4-hydroOxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexa hydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7 10 hydroxy-8-methoxybenzo[c]-phenanthridinium, 6,9-bis [(2-aminoethyl)amino]benzo [g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethyl aminomethyl)-6H-pyrazolo[4,5,I'-de]acridin-6-one, N-[I -[2(diethylamino)ethylamino]-7 methoxy-9-oxo-9H-thioxanthcn-4-ylmcthyl]formamide, N-(2-(dimcthylamino)cthyl) acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1 15 c]quinolin-7-one, and dimesna. Examples of inhibitors of mitotic kinesins, such as the human mitotic kinesin KSP, are described in PCT Publications WO 01/30768 and WO 01/98278, WO 03/050,064 (Jun. 19, 2003), WO 03/050,122 (Jun. 19, 2003), WO 03/049,527 (Jun. 19, 2003), WO 03/049,679 (Jun. 19, 2003), WO 03/049,678 (Jun. 19, 2003) and WO 03/39460 (May 15, 2003) and pending PCT Appl. Nos. US03/06403 (filed 20 Mar. 4, 2003), US03/15861 (filed May 19, 2003), US03/15810 (filed May 19, 2003), US03/18482 (filed Jun. 12, 2003) and US03/18694 (filed Jun. 12, 2003). In an embodiment inhibitors of mitotic kinesins include, but are not limited to inhibitors of KSP, inhibitors of MKLPI, inhibitors of CENP-E, inhibitors of MCAK, inhibitors of Kifl4, inhibitors of Mphosph I and inhibitors of Rab6-KIFL. 25 [0091] Inhibitors of kinases involved in mitotic progression include, but are not limited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases (PLK) (e.g., inhibitors of PLK-1), inhibitors of bub-1 and inhibitors of bub-R1. Antiproliferative agents include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, 30 carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2' methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydro-benzo -33furyl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradeca dienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ectein ascidin, troxacitabine, 4-[2-amino-4-oxo4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b] [1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, 5 alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,1-diaza tetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. Examples of monoclonal antibody targeted therapeutic agents include those therapeutic agents which 10 have cytotoxic agents or radioisotopes attached to a cancer cell specific or target cell specific monoclonal antibody. Examples include, for example, Bexxar. HMG-CoA reductase inhibitors are inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art such as those described or cited in U.S. 15 Pat. No. 4,231,938 and WO 84/02131. Examples of HMG-CoA reductase inhibitors that may be used include, but are not limited to, lovastatin (MEVACOR@; see U.S. Pat. Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR@; see U.S. Pat. Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL@.; see U.S. Pat. Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL@; see 20 U.S. Pat. Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896) and atorvastatin (LIPITOR@; see U.S. Pat. Nos. 5,273,995, 4,681,893, 5,489,691 and 5,342,952). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", Chemistry & Industry, pp. 85-89 (5 Feb. 25 1996) and U.S. Pat. Nos. 4,782,084 and 4,885,314. In an embodiment, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin. [00921 Prenyl-protein transferase inhibitors are compounds which inhibit any one or any combination of the prenyl-protein transferase enzymes, including famesyl protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and 30 geranylgeranyl-protein transferase type-II (GGPTase-Jl, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (+)-6-[amino(4 chlorophenyl)(1-methyl-IH-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H) quinolinone, (-)-6-[amino(4-chlorophenyl)(1-methyl-IH-imidazol-5-yl)methyl]-4-(3 -34chlorophenyl)-1-methyl-2(1H)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-IH imidazol-5-yl) methyl]-4-(3-chlorophenyl)- 1 -methyl-2(l H)-quinolinone, 5(S)-n-butyl-1 (2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl-2-piperazinone, (S)-1-(3 chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl) methyl) 5 2-piperazinone, 5(S)-n-butyl-1 -(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5 imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5 imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3 -[N-(1 -(4-cyanobenzyl)- 1 H imidazol-5-ylethyl)carbamoyl]piperidine, 4- {-[4-hydroxymethyl-4-(4-chloropyridin-2 ylmethyl)-piperidine- 1 -ylmethyl]-2-methylimidazol- I -ylmethyl} benzonitrile, 4-{-5-[4 10 hydroxymethyl-4-(3-chlorobenzyl)-piperidine- I -ylmethyl]-2-methylimidazol- I-yl methyl}benzonitrile, 4-{3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2']bipyridin-5'-ylmethyl]-3H-imidazol-4-yl methyl}bcnzonitrilc, 4-{3-[4-(2-oxo-2H-[1,2']bipyridin-5'-ylmcthyl]-3H-imidazol4-yl methyl}benzonitrile, 4-[3-(2-oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3H-imidazol 15 4-ylmethyl}benzonitrile, 18,19-dihydro- I 9-oxo-5H, 17H-6,10:12,16-dimetheno- 1 H imidazo[4,3-c][1,11 ,4]dioxaazacyclo-nonadecine-9-carbonitrile, (+)-19,20-dihydro-19 oxo-5H-18,21-ethano-12,14-etheno-6,10-metheno-22H-benzo[d]imidazo[4,3-k] [1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5H,17H-18,21 ethano-6,10:12,16-dimetheno-22H-imidazo[3,4-h][1,8,11,14]oxatriazacycloeicosine-9 20 carbonitrile, and (.+-.)-19,20-dihydro-3-methyl-19-oxo-5H-18,21-ethano-12,14-etheno 6,1 0-metheno-22H-benzo[d]imidazo[4,3-k][1,6,9,12]oxa-triazacyclooctadecine-9 carbonitrile. Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Pat. No. 25 5,420,245, U.S. Pat. No. 5,523,430, U.S. Pat. No. 5,532,359, U.S. Pat. No. 5,510,510, U.S. Pat. No. 5,589,485, U.S. Pat. No. 5,602,098, European Patent Publ. 0 618 221, European Patent PubL. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Pat. No. 5,661,152, WO 95/10515, WO 95/10516, WO 30 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO 96/05169, WO 96/00736, U.S. Pat. No. 5,571,792, WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, -35- WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359. For an example of the role of a prenyl-protein 5 transferase inhibitor on angiogenesis see European J. of Cancer 35(9):1394-1401 (1999). [00931 Angiogenesis inhibitors refers to compounds that inhibit the formation of new blood vessels, regardless of mechanism. Examples of angiogenesis inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors of the tyrosine kinase receptors Fit-I (VEGFRI) and Flk-1/KDR (VEGFR2), inhibitors of epidermal 10 derived, fibroblast-derived, or platelet derived growth factors, MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon-. alpha., interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxygenase-2 inhibitors like celecoxib and rofecoxib (PNAS 89:7384 (1992); JNCI 69:475 (1982); Arch. Ophthalmol. 15 108:573 (1990); Anat. Rec., (238):68 (1994); FEBS Letters 372:83 (1995); Clin, Orthop. 313:76 (1995); J. Mol. Endocrinol. 16:107 (1996); Jpn. J. Pharmacol. 75:105 (1997); Cancer Res. 57:1625 (1997); Cell 93:705 (1998); Intl. J. Mol. Med. 2:715 (1998); J. Biol. Chem. 274:9116 (1999)), steroidal anti-inflammatories (such as corticosteroids, mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred, beta 20 methasone), carboxyamidotriazole, combretastatin A4, squalamine, 6-0-chloroacetyl carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, angiotensin 11 antagonists (see Fernandez et al., J. Lab. Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, Nature Biotechnology, 17:963-968 (October 1999); Kim et al., Nature, 362:841-844 (1993); WO 00/44777; and WO 00/61186). Other therapeutic agents that modulate or 25 inhibit angiogenesis and may also be used in combination with the compounds of the instant invention include agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in Clin. Chem. La. Med. 38:679-692 (2000)). Examples of such agents that modulate or inhibit the coagulation and fibrinolysis pathways include, but are not limited to, heparin (see Thromb. Haemost. 80:10-23 (1998)), low molecular weight 30 heparins and carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see Thrombosis Res. 101:329-354 (2001)). TAFla inhibitors have been described in PCT Publication WO 03/013,526 and U.S. Ser. No. 60/349,925 (filed Jan. 18, 2002). The invention also encompasses combinations of -36the compounds of the invention with NSAIDs which are selective COX-2 inhibitors (generally defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of IC 50 for COX-2 over IC 50 for COX-1 evaluated by cell or microsomal assays). Such compounds include, but are not limited to 5 those disclosed in U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, U.S. Pat. No. 6,020,343, issued Feb. 1, 2000, U.S. Pat. No. 5,409,944, issued Apr. 25, 1995, U.S. Pat. No. 5,436,265, issued Jul. 25, 1995, U.S. Pat. No. 5,536,752, issued Jul. 16, 1996, U.S. Pat. No. 5,550,142, issued Aug. 27, 1996, U.S. Pat. No. 5,604,260, issued Feb. 18, 1997, 10 U.S. Pat. No. 5,698,584, issued Dec. 16, 1997, U.S. Pat. No. 5,710,140, issued Jan. 20, 1998, WO 94/15932, published Jul. 21, 1994, U.S. Pat. No. 5,344,991, issued Jun. 6, 1994, U.S. Pat. No. 5,134,142, issued Jul. 28, 1992, U.S. Pat. No. 5,380,738, issued Jan. 10, 1995, U.S. Pat. No. 5,393,790, issued Feb. 20, 1995, U.S. Pat. No. 5,466,823, issued Nov. 14, 1995, U.S. Pat. No. 5,633,272, issued May 27, 1997, and U.S. Pat. No. 15 5,932,598, issued Aug. 3, 1999, all of which are hereby incorporated by reference. Representative inhibitors of COX-2 that are useful in the methods of the present invention include 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and 5-chloro 3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine. Compounds which are described as specific inhibitors of COX-2 and are therefore useful in the present 20 invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published Jul. 21, 1994, U.S. Pat. No. 5,344,991, issued Jun. 6, 1994, U.S. Pat. No. 5,134,142, issued Jul. 28, 1992, U.S. Pat. No. 5,380,738, issued Jan. 10, 1995, U.S. Pat. No. 5,393,790, issued Feb. 20, 1995, U.S. Pat. No. 5,466,823, issued Nov. 14, 1995, 25 U.S. Pat. No. 5,633,272, issued May 27, 1997, U.S. Pat. No. 5,932,598, issued Aug. 3, 1999, U.S. Pat. No. 5,474,995, issued Dec. 12, 1995, U.S. Pat. No. 5,861,419, issued Jan. 19, 1999, U.S. Pat. No. 6,001,843, issued Dec. 14, 1999, U.S. Pat. No. 6,020,343, issued Feb. 1, 2000, U.S. Pat. No. 5,409,944, issued Apr. 25, 1995, U.S. Pat. No. 5,436,265, issued Jul. 25, 1995, U.S. Pat. No. 5,536,752, issued Jul. 16, 1996, U.S. Pat. No. 30 5,550,142, issued Aug. 27, 1996, U.S. Pat. No. 5,604,260, issued Feb. 18, 1997, U.S. Pat. No. 5,698,584, issued Dec. 16, 1997, and U.S. Pat. No. 5,710,140, issued Jan. 20,1998. Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1 -37oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-I-[[3,5-di chloro-4-(4-chlorobenzoyl)phenyl]methyl]- 1 H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RP14610, NX31838, sulfated mannopentanose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-pyrrole] 5 carbonylimino]-bis-(I ,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5 yl)methylene]-2-indolinone (SU5416). 100941 Agents that interfere with cell cycle checkpoints are compounds that inhibit protein kinases that transduce cell cycle checkpoint signals, thereby sensitizing the cancer cell to DNA damaging agents. Such agents include inhibitors of ATR, ATM, the 10 ChkI and Chk2 kinases and cdk and cdc kinase inhibitors and are specifically exemplified by 7-hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS 387032. [0095] Inhibitors of cell proliferation and survival signaling pathway are pharmaceutical agents that inhibit cell surface receptors and signal transduction cascades 15 downstream of those surface receptors. Such agents include inhibitors of inhibitors of EGFR (for example gefitinib and erlotinib), inhibitors of ERB-2 (for example trastuzumab), inhibitors of IGFR, inhibitors of cytokine receptors, inhibitors of MET, inhibitors of P13K (for example LY294002), serine/threonine kinases (including but not limited to inhibitors of Akt such as described in WO 02/083064, WO 02/083139, WO 20 02/083140 and WO 02/083138), inhibitors of Raf kinase (for example BAY-43-9006 ), inhibitors of MEK (for example CI-1040 and PD-098059) and inhibitors of mTOR (for example Wyeth CCI-779). Such agents include small molecule inhibitor compounds and antibody antagonists. [0096] Apoptosis inducing agents include activators of TNF receptor family 25 members (including the TRAIL receptors). [0097] In certain presently preferred embodiments of the invention, representative agents useful in combination with the compounds of the invention for the treatment of cancer include, for example, irinotecan, topotecan, gemcitabine, 5 fluorouracil, leucovorin carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, 30 vinca alkaloids, imatinib (Gleevec), anthracyclines, rituximab, trastuzumab, as well as other cancer chemotherapeutic agents. [0098] The above compounds to be employed in combination with the compounds of the invention will be used in therapeutic amounts as indicated in the -38- Physicians' Desk Reference (PDR) 47th Edition (1993), which is incorporated herein by reference, or such therapeutically useful amounts as would be known to one of ordinary skill in the art. [00991 The compounds of the invention and the other anticancer agents can be 5 administered at the recommended maximum clinical dosage or at lower doses. Dosage levels of the active compounds in the compositions of the invention may be varied so as to obtain a desired therapeutic response depending on the route of administration, severity of the disease and the response of the patient. The combination can be administered as separate compositions or as a single dosage form containing both agents. When 10 administered as a combination, the therapeutic agents can be formulated as separate compositions, which are given at the same time or different times, or the therapeutic agents, can be given as a single composition. [01001 Antiestrogens, such as tamoxifen, inhibit breast cancer growth through induction of cell cycle arrest, that requires the action of the cell cycle inhibitor p27Kip. 15 Recently, it has been shown that activation of the Ras-Raf-MAP Kinase pathway alters the phosphorylation status of p27Kip such that its inhibitory activity in arresting the cell cycle is attenuated, thereby contributing to antiestrogen resistance (Donovan et al., J. Biol. Chem. 276:40888, 2001). As reported by Donovan et al., inhibition of MAPK signaling through treatment with MEK inhibitor changed the phosphorylation status of 20 p 2 7 in hormone refactory breast cancer cell lines and in so doing restored hormone sensitivity. Accordingly, in one aspect, the compounds of formulas (I), (11), (III) and (IV) may be used in the treatment of hormone dependent cancers, such as breast and prostate cancers, to reverse hormone resistance commonly seen in these cancers with conventional anticancer agents. 25 [0101] In hematological cancers, such as chronic myelogenous leukemia (CML), chromosomal translocation is responsible for the constitutively activated BCR ABI tyrosine kinase. The afflicted patients are responsive to Gleevec, a small molecule tyrosine kinase inhibitor, as a result of inhibition of Ab 1 kinase activity. However, many patients with advanced stage disease respond to Gleevec initially, but then relapse later 30 due to resistance-conferring mutations in the AbI kinase domain. In vitro studies have demonstrated that BCR-Avl employs the Raf kinase pathway to elicit its effects. In addition, inhibiting more than one kinase in the same pathway provides additional protection against resistance-conferring mutations. Accordingly, in another aspect of the -39invention, the compounds of formulas (1), (II), (Ill) and (IV) are used in combination with at least one additional agent, such as Gleevec, in the treatment of hematological cancers, such as chronic myelogenous leukemia (CML), to reverse or prevent resistance to the at least one additional agent. 5 [0102] In another aspect, the present invention relates to methods of inhibiting at least one serine/threonine kinase in the Jak/Stat signaling pathway in a subject, or treating a biological condition mediated by a serine/threonine kinase in the Jak/Stat signaling pathway in a subject, comprising administering a therapeutic composition comprising at least one compound of formula (1), (11), (III) or (IV) effective to inhibit the 10 activity of the at least one serine/threonine kinase in the Jak/Stat signaling pathway in the subject. [01031 The therapeutic compositions in accordance with this aspect of the invention are useful for treating patients with a need for such inhibitors (e.g., those suffering from cancer mediated by abnormal Jak/Stat signaling). Cancer types mediated 15 by abnormal Jak/Stat signaling include, for example, melanoma, papillary cancer, thyroid cancer, ovarian cancer, colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia. 101041 In one embodiment, the invention provides a method of inhibiting Piml, Pim2 Pim3, Flt3, KDR or PKCE in a human or animal subject. The method 20 includes administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof, of any of the embodiments of compounds of formula (1), (II), (111) or (IV) to a subject in need thereof. [0105] The present invention will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to 25 be limiting of the present invention. 10106] Representative side chains for use in the compounds of the following examples may generally be prepared in accordance with the following procedures: EXAMPLES [0107] Referring to the examples that follow, compounds of the preferred 30 embodiments were synthesized using the methods described herein, or other methods, which are known in the art. -40- [01081 The compounds and/or intermediates were characterized by high performance liquid chromatography (HPLC) using a Waters Millenium chromatography system with a 2695 Separation Module (Milford, MA). The analytical columns were reversed phase Phenomenex Luna C18 -5 p, 4.6 x 50 mm, from Alltech (Deerfield, IL). 5 A gradient elution was used (flow 2.5 mL/min), typically starting with 5% acetonitrile/95% water and progressing to 100% acetonitrile over a period of 10 minutes. All solvents contained 0.1% trifluoroacetic acid (TFA). Compounds were detected by ultraviolet light (UV) absorption at either 220 or 254 nm. HPLC solvents were from Burdick and Jackson (Muskegan, MI), or Fisher Scientific (Pittsburgh, PA). 10 [0109] In some instances, purity was assessed by thin layer chromatography (TLC) using glass or plastic backed silica gel plates, such as, for example, Baker-Flex Silica Gel IB2-F flexible sheets. TLC results were readily detected visually under ultraviolet light, or by employing well-known iodine vapor and other various staining techniques. 15 [01101 Mass spectrometric analysis was performed on one of three LCMS instruments: a Waters System (Alliance HT HPLC and a Micromass ZQ mass spectrometer; Column: Eclipse XDB-C18, 2.1 x 50 mm; gradient: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitrile in water with 0.05% TFA over a 4 min period; flow rate 0.8 mL/min; molecular weight range 200-1500; cone Voltage 20 V; column temperature 20 40'C), another Waters System (ACQUITY UPLC system and a ZQ 2000 system; Column: ACQUITY UPLC HSS-CI8, 1.8um, 2.1 x 50mm; gradient: 5-95% (or 35-95%, or 65-95% or 95-95%) acetonitrile in water with 0.05% TFA over a 1.3 min period; flow rate 1.2 mL/min; molecular weight range 150-850; cone Voltage 20 V; column temperature 50*C) or a Hewlett Packard System (Series 1100 HPLC; Column: Eclipse 25 XDB-C18, 2.1 x 50 mm; gradient: 5-95% acetonitrile in water with 0.05% TFA over a 4 min period; flow rate 0.8 mL/min; molecular weight range 150-850; cone Voltage 50 V; column temperature 30*C). All masses were reported as those of the protonated parent ions. [0111] GCMS analysis was performed on a Hewlett Packard instrument 30 (HP6890 Series gas chromatograph with a Mass Selective Detector 5973; injector volume: 1 PL; initial column temperature: 50*C; final column temperature: 250'C; ramp time: 20 minutes; gas flow rate: 1 mL/min; column: 5% phenyl methyl siloxane, Model No. HP 190915-443, dimensions: 30.0 m x 25 m x 0.25 in). -41- [01121 Nuclear magnetic resonance (NMR) analysis was performed on some of the compounds with a Varian 300 MHz NMR (Palo Alto, CA). The spectral reference was either TMS or the known chemical shift of the solvent. Some compound samples were run at elevated temperatures (e.g., 75*C) to promote increased sample solubility. 5 [01131 The purity of some of the compounds is assessed by elemental analysis (Desert Analytics, Tucson, AZ). 101141 Melting points are determined on a Laboratory Devices Mel-Temp apparatus (Holliston, MA). 10115] Preparative separations are carried out using a Flash 40 10 chromatography system and KP-Sil, 60A (Biotage, Charlottesville, VA), or by flash column chromatography using silica gel (230-400 mesh) packing material, or by HPLC using a Waters 2767 Sample Manager, C-18 reversed phase column, 30X50 mm, flow 75 mL/min. Typical solvents employed for the Flash 40 Biotage system and flash column chromatography are dichloromethane, methanol, ethyl acetate, hexane, acetone, aqueous 15 ammonia (or ammonium hydroxide), and triethyl amine. Typical solvents employed for the reverse phase HPLC are varying concentrations of acetonitrile and water with 0.1% trifluoroacetic acid. 10116] It should be understood that the organic compounds according to the preferred embodiments may exhibit the phenomenon of tautomerism. As the chemical 20 structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embodiments encompasses any tautomeric form of the drawn structure. [0117] It is understood that the invention is not limited to the embodiments set forth herein for illustration, but embraces all such forms thereof as come within the scope 25 of the above disclosure. [0118] The examples below as well as throughout the application, the following abbreviations have the following meanings. If not defined, the terms have their generally accepted meanings. -42- ABBREVIATIONS DAST (diethylamino)sulfurtrifluoride DCM dichloromethane DIEA diisopropylethylamine DMA dimethylacetamide DMAP 4-dimethylaminopyridine DME 1,2-dimethoxyethane DMF NN-dimethylformamide DPPF 1,1l'-bis(diphenylphosphino)ferrocene EDC Ethyl dimethylaminopropylazodicarboxylate hydrochloride EtOAc ethyl acetate EtOH Ethanol HOAT Hydroxyazabenzotriazole MeCN acetonitrile MeOH methanol Na 2

CO

3 sodium carbonate NaHCO 3 sodium bicarbonate NBS N-bromosuccinimide NMP N-methyl-2-pyrrolidone RT or rt room temperature TDMSCI tert-butyldimethylsilylchlonde TEA triethylamine THF tetrahydrofuran Example I Synthesis of 3-nitro-4-(piperidin- 1 -yl)pyridine N

NO

2 5 N -43- 101191 A solution of 4-chloro-3-nitropyridine (1.0 equiv.) and piperidine (2.0 equiv.) in ethanol, at a concentration of 0.5 M, was stirred at rt for 48 hours at which time the ethanol was removed in vacuo. The residue was partitioned between EtOAc (300 mL) and Na 2

CO

3 (.t.) (75 mL), was washed further with H 2 0 (50 mL), NaCl(sat.) (50 mL), 5 was dried over MgSO 4 , was filtered and the volatiles were removed in vacuo yielding 3 nitro-4-(piperidin-1-yI)pyridine (95%). LCMS (m/z): 207.7 (MH 4 ); LC R, = 1.60 min. 'H NMR (CDCl 3 ): 8 8.80 (s, IH), 8.31 (d, J=5.7, IH), 6.84 (d, J=6.3, IH), 3.18-3.21 (m, 4H), 1.64-1.78 (m, 6H). Example 2 10 Synthesis of tert-butyl 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate a NHBoc N

NO

2 (N 101201 The method of Example I was followed using I eq each of 4-chloro-3 nitropyridine, 3-N-Boc-amino piperidine and diisopropylethylamine yielding tert-butyl 1 (3-nitropyridin-4-yl)piperidin-3-ylcarbamate, ( 89%). LCMS (mn/z): 323.1 (MH 4 ); LC Rt 15 =2.13 min. Example 3 Synthesis of (R)-tert-butyl 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate Cf NHBoc N

~NO

2 CN7 [0121] The method of Example 1 was followed using I eq each of 4-chloro-3 20 nitropyridine, (R)-3-N-Boc-amino piperidine and diisopropylethylamine yielding (R) tert-butyl 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate, (99 %). LCMS (n/z): 323.1 (MH*); LC R, = 2.13 min. -44- Example 4 Synthesis of (S)-tert-butyl 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate 0 , NHBoc N NO2 [0122] The method of Example I was followed using I eq each of 4-chloro-3 5 nitropyridine, (S)-3-N-Boc-amino piperidine and diisopropylethylamine yielding (S)-tert butyl 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate, (99 %). LCMS (m/z): 323.1 (MH*); LC Rt = 2.13 min. Example 5 Synthesis of tert-butyl (1-(3-nitropyridin-4-yl)piperidin-3-yl)mcthylcarbamatc NHBoc N

NO

2 10 10123] The method of Example I was followed using I eq each of 4-chloro-3 nitropyridine, tert-butyl piperidin-3-ylmethylcarbamate and diisopropylethylamine yielding tert-butyl (1-(3-nitropyridin-4-yl)piperidin-3-yl)methylcarbamate (99%). LCMS (m/z): 336.9 (MH*); LC R, = 2.27 min. 'H NMR (CDCl 3 ): 6 8.80 (s, 1H), 8.33 (d, 15 J=6.0Hz, IH), 6.85 (d, J=6.3Hz, IH), 4.63 (bs, 1H), 3.28-3.46 (m, 2H), 2.89-3.15 (in, 3H), 2.69-2.86 (in, 1 H), 1.55-1.99 (m, 5H), 1.45 (s, 9H). Example 6 Synthesis of I-(3-nitropydridin-4-yl)piperazine (N O N NO2 -45- [0124] The method of Example 1 was followed using I eq of 4-chloro-3 nitropyridine and 10 eq of piperazine yielding tert-butyl 1-(3-nitropyridin-4-yl)piperazine (99%). LCMS (n/z): 208.6 (MH'); LC R, = 0.42 min. 'H NMR (CDCl 3 ): 6 8.83(s, 1 H), 8.37 (d, J=6.0, 1H), 6.85 (d, J=6.0, IH), 3.20-3.23 (m, 4H), 3.00-3.03 (m, 4H). 5 Example 7 Synthesis of tert-butyl 1-(2-nitrophenyl)piperidin-3-vlcarbamate (CY NHBoc N

NO

2 [0125] The method of Example 1 was followed using 1-fluoro-2-nitrobenzene 10 (1.0 eq), 3-N-Boc-aminopiperidine (1.0 eq), and DIEA (2.0 eq) in EtOH at 50'C for 48 hours yielding tert-butyl 1-(2-nitrophenyl) piperidin-3-ylcarbamate (85%). LCMS (m/z): 322.2 (MH*); LC Rt = 3.23 min. Example 8 Synthesis of tert-butyl 1 -(2-nitrophenyl)piperidin-4-vlcarbamate NHBoc N5NO 2 15 [01261 The method of Example 1 was followed using 1-fluoro-2-nitrobenzene (1.0 eq), 4-N-Boc-aminopiperidine (1.2 eq), and TEA (2.0 eq) in EtOH at 55 0 C for 48 hours yielding tert-butyl 1-(2-nitro phenyl) piperidin-4-ylcarbamate (100%). LCMS (m/z): 322.2 (MH); LC R,= 3.15 min. -46- Example 9 Synthesis of tert-butyl 4-(2-nitrophenyl)piperazine- I -carboxylate Boc N - NO 2 [0127] The method of Example I was followed using 1-fluoro-2-nitrobenzene 5 (1.0 eq), 1-Boc-piperazine (1.2 eq), and TEA (2.0 eq) in EtOH at 55'C for 72 hours yielding tert-butyl 4-(2-nitro phenyl) piperazine-1-carboxylate (100%). LCMS (n/z): 308.1 (MH'); LC Rt = 3.25 min. Example 10 Synthesis of tert-butyl 1-(3-nitropyridin-2-yl)piperidin-3-ylcarbamate CT NHBoc N N NO 2 10 " 10128] The method of Example 1 was followed using 2-chloro-3-nitropyridinc (1.0 eq), 3-N-Boc-aminopiperidine (1.2 eq), and DIEA (2.0 eq) yielding tert-butyl 1-(3 nitropyridin-2-yl)piperidin-3-yl carbamate (95%). LCMS (m/z): 323.2 (MH+); LC Rt = 3.00 min. 15 Example 11 Synthesis of NN-dimethyl- 1 -(3-nitropyridin-4-yl)piperidin-4-amine N NO2 101291 The method of Example 1 was followed using 4-dimethylamino piperidine yielding N,N-dimethyl-1-(3-nitropyridin-4-yl)piperidin-4-amine . LCMS 20 (m/z): 251.2 (MH). -47- Example 12 Synthesis of 8-(3-nitropyridin-4-yl)-1,4-dioxa-8-azaspiro[4.5]decane N NO2 10130] The method of Example 1 was followed using 1,4 dioxa-8 5 azaspiro[4.5]decane yielding 8-(3-nitropyridin-4-yl)-1,4-dioxa-8-azaspiro[4.5]decane. LCMS (n/z): 266.2 (MH). Example 13 Synthesis of tert-butyl 4-(3-nitropyridin-4-yl)-1,4-diazepane-1-carboxylate NBoc N NO2 10 101311 The method of Example 1 was followed using 1-Boc-homopiperazine yielding tert-butyl 4-(3-nitropyridin-4-yl)- 1,4-diazepane- I -carboxylate. LCMS (m/z): 293.3 (MH*); Example 14 Synthesis of N N,N2-trimethyl-N2-(3-nitropyridin-4-yl)ethane-1,2-diamine N NO2 15 N 101321 The method of Example 1 was followed using 4-chloro-3-nitropyridine (1.0 eq), N ,N',N2-trimethyl ethane-l ,2-diamine (2.0 eq), and DIEA (2.0 eq) in EtOH yielding N',N',N2-trimethyl-N 2 -(3-nitropyridin-4-yl)ethane-1,2-diamine which was concentrated and taken on as is. LCMS (m/z): 225.1 (MH ); LC R 1 = 0.574 min. -48- Example 15 Synthesis of tert-butyl 1-(3-nitropyridin-4-yl)pyrrolidin-3-ylcarbamate NHBoc

.NO

2 N 10133] The method of Example 1 was followed using 4-chloro-3-nitropyridine 5 (1.0 eq), tert-butyl pyrrolidin-3-ylcarbamate (2.0 eq), and DIEA (2.0 eq) in EtOH yielding tert-butyl 1-(3-nitropyridin-4-yl)pyrrolidin-3-ylcarbamate (95%) LCMS (m/z): 309.1 (MH*); LC Rt = 1.922 min. Example 16 Synthesis of (R)-tert-butyl [ -(3-nitropyridin-4-yl)pyrrolidin-2-yllmethylcarbamate NHBoc N

NO

2 10 N [01341 The method of Example 1 was followed using 4-chloro-3-nitropyridine (1.0 cq), (R)-pyrrolidin-2-ylmethanamine (2.0 eq), and DIEA (2.0 eq) in EtOH yielding (R)-tert-butyl [1 -(3-nitropyridin-4-yl)pyrrolidin-2-yl]methylcarbamate (95%) LCMS (m/z): 323.1 (MH 4 ); LC R, = 1.855 min. 15 Example 17 Synthesis of 2-chloro-5-nitro-4-(piperidin-1-yl)pyrimidine Q N C N [0135] Method 1 was followed using 2,4-dichloro-5-nitropyrimidine (1.0 eq), and piperidine (2.0 eq) in EtOH at 0 0 C to rt, yielding after washing with IM citric acid 20 and 1M HCl (to remove the bis addition product), 2-chloro-5-nitro-4-(piperidinyl)pyrimidine (67%) LCMS (m/z): 242.9 (MH*); LC Rt = 4.09 min. -49- Example 18 Synthesis of tert-butyl 1-(3-fluoro-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc N F 101361 Method I was followed using I eq each of 2,6-difluoronitrobenzene, 4 5 (N-Boc-amino) piperidine, and TEA in EtOH yielding tert-butyl 1-(3-fluoro-2 nitrophenyl)piperidin-4-ylcarbamate (93%). LCMS (n/z): 340.1 (MH*); LC Rt = 3.30 min. Example 19 Synthesis of tert-butyl 1-(5-fluoro-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc N 10 F NO2 101371 Method 1 was followed using I eq each of 1,3-difluoro-4-nitrobenzene, 4-(N-Boc-amino) piperidine, and TEA yielding tert-butyl 1-(5-fluoro-2-nitrophenyl) piperidin-4ylcarbamate (93%). LCMS (m/z): 340.1 (MH 4 ); LC Rt = 3.24 min. Example 20 15 Synthesis of tert-butyl 1-(4-fluoro-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc

NO

2 F 101381 Method I was followed using 2,5-difluoronitrobenzene (1.0 eq), 4-(N Boc-amino) piperidine (1.4 eq), and TEA (2.0 eq) at 55'C overnight yielding tert-butyl 1 (4-fluoro-2-nitrophenyl)piperidin-4-ylcarbamate (97%). LCMS (m/z): 340.1 (MH*); LC 20 R, = 3.28 min. -50- Example 21 Synthesis of tert-butyl 1-(4-benzoyl-2-nitrophenyl)piperidin-3-ylcarbamate C- NHBoc N

NO

2 .- ; 0 101391 Method 1 was followed using 4-chloro-3-nitrobenzophenone (1.0 eq), 5 3-(N-Boc-amino) piperidine (1.1 eq), and TEA (2.0 eq) in NMP yielding tert-butyl 1-(4 benzoyl-2-nitro phenyl)piperidin-3-ylcarbamate (90%). LCMS (m/z): 426.2 (MH t ); LC R, = 3.49 min. Example 22 Synthesis of tert-butyl 1-(4-benzoyl-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc N

NO

2 100 10 c [0140] Method I was followed using 4-chloro-3-nitrobenzophenone (1.0 eq), 4-(N-Boc-amino) piperidine (1.1 eq), and TEA (2.0 eq) in NMP yielding tert-butyl 1-(4 benzoyl-2-nitro phenyl) piperidin-4-ylcarbamate (95%). LCMS (m/z): 426.2 (MH*); LC R= 3.46 min. 15 Example 23 Synthesis of tert-butyl 4-(4-benzoyl-2-nitrophenyl)piperazine-1-carboxylate Boc NNO NO2 -51- [0141] Method I was followed using 4-chloro-3-nitrobenzophenone (1.0 eq), 1-Boc-piperazine (1.1 eq), and TEA (2.0 eq) in NMP yielding tert-butyl 4-(4-benzoyl-2 nitrophenyl) piperazine-l-carboxylate (93%). LCMS (m/z): 412.2 (MH*); LC R, = 3.59 min. 5 Example 24 Synthesis of tert-butyl 4-(4-acetyl-2-nitrophenyl)piperazine- I -carboxylate Boc CN N

<NO

2 0 [0142] Method I was followed using 4-chloro-3-nitroacetophenone (1.0 eq), 1 Boc-piperazine (1.2 eq), and TEA (2.0 eq) at 55 0 C overnight yielding tert-butyl 4-(4 10 acetyl-2-nitro phenyl)piperazine-1-carboxylate (99%). LCMS (n/z): 350.1 (MH'); LC R 1 = 3.06 min. Example 25 Synthesis of tert-butyl 1-(4-acetyl-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc N0 2 15 [0143] Method 1 was followed using 4-chloro-3-nitroacetophenone (1.0 eq), 4 (N-Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 55'C overnight yielding tert butyl I-(4-acetyl-2-nitrophenyl)piperidin-4-ylcarbamate (95%). LCMS (m/z): 364.1 (MH*); LC R, = 2.99 min. -52- Example 26 Synthesis of tert-butyl 1-(4-acetyl-2-nitrophenyl)piperidin-3-ylcarbamate NHBoc N

NO

2 0 [0144] Method 1 was followed using 4-chloro-3-nitroacetophenone (1.0 eq), 3 5 (N-Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 55'C overnight tert-butyl 1-(4 acetyl-2-nitro phenyl)piperidin-3-ylcarbamate (99%). LCMS (m/z): 364.1 (MH*); LC R, = 3.03 min. Example 27 Synthesis of tert-butyl 1-(4-acetyl-2-nitrophenyl)piperidin-3-ylcarbamate C' NHBoc N

NO

2 10 N [01451 Method I was followed using 4-chloro-3-nitroanisole (1.0 eq), 3-(N Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 60*C for 72 hours yielding tert-butyl 1-(4-methoxy-2-nitrophenyl)piperidin-3-ylcarbamate (50%). LCMS (m/z): 352.1 (MH*); LC Rt = 3.27min. 15 Example 28 Synthesis of tert-butyl 1-(4-methoxy-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc

NO

2 [01461 Method 1 was followed using 4-chloro-3-nitroanisole (1.0 eq), 4-(N Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 60'C for 72 hours yielding tert-butyl -53- 1-(4-methoxy-2-nitrophenyl)piperidin-4-ylcarbamate (75%). LCMS (m/z): 352.1 (MH*); LC Rt = 3.22 min. Example 29 Synthesis of tert-butyl 4-(4-methoxy-2-nitrophenyl)piperazine-1-carboxylate Boc N N

NO

2 5 101471 Method 1 was followed using 4-chloro-3-nitroanisole (1.0 eq), I-Boc piperazine (1.2 eq), and TEA (2.0 eq) in NMP at 100*C for 16 hours yielding tert-butyl 4 (4-methoxy-2-nitro phenyl) piperazine-]-carboxylate (50%). LCMS (m/z): 338.2 (MH*); LC Rt = 3.37 min. 10 Example 30 Synthesis of tcrt-butyl 4-(4-chloro-2-nitrophcnyl)piperazine- I -carboxylate Boc (N)

NO

2 Cl [01481 Method I was followed using 1 eq each of 4-chloro-1-fluoro-2 nitrobenzene, I -Boc-piperazine, and TEA yielding tert-butyl 4-(4-chloro-2 15 nitrophenyl)piperazinc-1-carboxylate (95%). LCMS (m/z): 342.0 (MH*); LC R, = 3.50 min. -54- Example 31 Synthesis of tert-butyl 1-(4-chloro-2-nitrophenyl)piperidin-4-ylcarbarnate NHBoc N

NO

2 C1 [0149] Method 1 was followed using 1 eq each of 4-chloro-1-fluoro-2 5 nitrobenzene, 4-N-Boc-aminopiperidine, and TEA yielding tert-butyl 1-(4-chloro-2 nitrophenyl) piperidin-4-ylcarbamate (95%). LCMS (m/z): 356.1 (MH 4 ); LC R, = 3.43 min. Example 32 Synthesis of tert-butyl 1-(4-chloro-2-nitrophenyl)piperidin-3-ylcarbamate NHBoc N

NO

2 10 Cl [01501 Method 1 was followed using I eq each of 4-chloro-1-fluoro-2 nitrobenzene, 3-(N-Boc-amino) piperidine, and TEA yielding tert-butyl 1-(4-chloro-2 nitrophenyl) piperidin-4-ylcarbamate (97%). LCMS (m/z): 356.1 (MH*); LC Rt = 3.47 min. 15 Example 33 Synthesis of tert-butyl 4-(4-methyl-2-nitrophenyl)piperazine- I -carboxylate Boc N N NO2 -55- 10151] Method 1 was followed using 4-fluoro-3-nitrotoluene (1.0 eq), 1-Boc piperazine (1.2 eq), and TEA (1.5 eq) at 55'C for 48 hours yielding tert-butyl 4-(4-methyl -2-nitrophenyl) piperazine-1-carboxylate (90%). LCMS (m/z): 322.1 (MH*); LC Rt = 3.46 min. 5 Example 34 Synthesis of tert-butyl 1-(4-methyl-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc

NO

2 101521 Method I was followed using 4-fluoro-3-nitrotoluene (1.0 eq), 4-(N Boc-amino) piperidine (1.2 eq), and TEA (1.5 eq) at 55 0 C for 48 hours yielding tert-butyl 10 [-(4-methyl -2-nitro phenyl)piperidin-4-ylcarbamate (87%). LCMS (m1/z): 336.1 (MH*); LC R, = 3.32 min. Example 35 Synthesis of tert-butyl 1-(4-methyl-2-nitrophenyl)piperidin-3-ylcarbamate NHBoc N

NO

2 15 10153] Method I was followed using 4-fluoro-3-nitrotoluene (1.0 cq), 3-(N Boc-amino) piperidine (1.2 eq), and TEA (1.5 eq) at 55 0 C for 48 hours yielding tert-butyl I-(4-methyl -2-nitrophenyl)piperidin-3-ylcarbamate (87%). LCMS (mn/z): 336.1 (MH); LC R,= 3.41 min. -56- Example 36 Synthesis of tert-butyl 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidin-3-ylcarbamate NHBoc N

NO

2

CF

3 101541 Method I was followed using 1-fluoro-2-nitro-4 5 (trifluoromcthyl)bcnzene (1.0 cq), 3-(N-Boc-amino) pipcridinc (1.2 eq), and TEA (1.5 eq) at 55 C for 1 hour yielding tert-butyl 1-(2-nitro-4-(tri fluoromethyl)phenyl)piperidin 3-ylcarbamate (99%). LCMS (n/z): 390.1 (MH*); LC Rt = 3.58 min. Example 37 Synthesis of tert-butyl 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidin-4-ylcarbamate NHBoc

NO

2 10 CF 3 101551 Method 1 was followed using 1-fluoro-2-nitro-4 (trifluoromethyl)benzene (1.0 eq), 4-(N-Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 55 0 C for 1 hour yielding tert-butyl 1-(2-nitro-4-(trifluoromethyl)phenyl)piperidin 4-ylcarbamate (99%). LCMS (m/z): 390.1 (MH*); LC R, = 3.51 min. 15 Example 38 Synthesis of tert-butyl 4-(2-nitro-4-(trifluoromethyl)phenyl)piperazine- I -carboxylate Boc N N r NO 2

CF

3 -57- [01561 Method I was followed using 1-fluoro-2-nitro-4 (trifluoromethyl)benzene (1.0 eq), 1-Boc-piperazine (1.2 eq), and TEA (2.0 eq) at 55*C for 1 hour yielding tert-butyl 4-(2-nitro-4-(trifluoro- methyl)phenyl)piperazine-1 carboxylate (99%). LCMS (m/z): 376.1 (MH'); LC Rt = 3.58 min. 5 Example 39 Synthesis of tert-butyl 4-(5-methyl-2-nitrophenyl)piperazine-l-carboxylate Boc N N

NO

2 [01571 Method 1 was followed using 3-fluoro-4-nitrotoluene (1.0 eq), 1-Boc piperazine (1.2 eq), and TEA (2.0 eq) at 55'C for 48 hours yielding tert-butyl 4-(5 10 methyl-2-nitrophenyl) piperazine-l-carboxylate (97%). LCMS (m/z): 322.1 (MH*); LC Rt = 3.43 min. Example 40 Synthesis of tert-butyl 1-(5-methyl-2-nitrophenyl)piperidin-4-ylcarbamate NHBoC N & NO 2 15 [01581 Method 1 was followed using 3-fluoro-4-nitrotoluene (1.0 eq), 4-(N Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 55 0 C for 48 hours yielding tert-butyl 1-(5-methyl-2-nitrophenyl)piperidin-4-ylcarbamate (97%). LCMS (m/z): 336.1 (MH*); LC Rt = 3.32 min -58- Example 41 Synthesis of tert-butyl 1-(4-methyl-2-nitrophenyl)piperidin-3-ylcarbamate NHBoc

NO

2 10159] Method 1 was followed using 3-fluoro-4-nitrotoluenc (1.0 eq), 3-(N 5 Boc-amino) piperidine (1.2 eq), and TEA (2.0 eq) at 55*C for 48 hours yielding tert-butyl l-(4-methyl -2-nitrophenyl)piperidin-3-ylcarbamate (98%). LCMS (m/z): 336.1 (MH*); LC Rt = 3.40 min. Example 42 Synthesis of tert-butyl I-(4-cyano-2-nitrophenyl)piperidin-3-ylcarbamate NHBoc N

NO

2 10 CN 101601 Method I was followed using 4-chloro-3-nitrobenzonitrile (1.0 eq), 3 (N-Boc-amino) piperidine (1.0 eq), and DIEA (2.4 eq) at 55'C for 24 hours yielding tert butyl 1-(4-cyano -2-nitrophenyl)piperidin-3-ylcarbamate (95%). LCMS (m/z): 347.2 (MH*); LC Rt = 3.06 min. 15 Example 43 Synthesis of tert-butyl 1-(2-nitro-4-(1 H-pyrazol-5-yl)phenyl)piperidin-4-ylcarbamate NHBoc N

NO

2 NH [0161] Method I was followed using 5-(4-chloro-3-nitrophenyl)-1H-pyrazole (1.0 eq), 4-(N-Boc-amino) piperidine (1.1 eq), and TEA (2.0 eq) at 55 0 C for 24 hours -59yielding tert-butyl 1-(2-nitro-4-(1 H-pyrazol-5-yl)phenyl)piperidin-4-ylcarbamate. LCMS (m/z): 388.1 (MH 4 ); LC R 1 = 2.84 min. Exampic 44 Synthesis of tert-butyl 1-(4-(methylsulfonyl)-2-nitrophenyl)piperidin-4-ylcarbamate NHBoc N

NO

2 S=O 5 b% 101621 Method 1 was followed using 1-fluoro-4-(methylsulfonyl)-2 nitrobenzene (1.0 eq), 4-(N-Boc-amino) piperidine (1 .1 eq), and TEA (2.0 eq) at 55*C for 24 hours yielding tert-butyl I -(4-(methylsulfonyl)-2-nitrophenyl)piperidin-4-ylcarbamate. LCMS (m/z): 400.1 (MH*); LC R, = 2.83 min. 10 Example 45 Synthesis of tert-butyl 4-(4-(cyclopropanecarbonyl)-2-nitrophenyl)piperazine- 1 carboxylate Boc N N

NO

2 0 [0163] Method I was followed using 4-chloro-3-nitrophenyt cyclopropyl 15 ketone (1.0 eq), 1-Boc-piperazine (1.2 eq), and TEA (1.5 eq) at 55'C for 48 hours yielding tert-butyl 4-(4-(cyclo propanecarbonyl)-2-nitrophenyl)piperazine- 1 -carboxylate (98%). LCMS (in/z): 376.1 (MH); LC R,= 3.33 min. -60- Example 46 Synthesis of tert-butyl 1-(4-(cyclopropanecarbonyl)-2-nitrophenyl)piperidin-4 ylcarbamate NHBoc

NO

2 0 5 [0164 Method 1 was followed using 4-chloro-3-nitrophenyl cyclopropyl ketone (1.0 eq), 4-(N-Boc-amino)piperidine (1.2 eq), and TEA (1.5 eq) at 55*C for 48 hours yielding tert-butyl 1-(4-(cyclopropanecarbonyl)-2-nitrophenyl)piperidin-4 ylcarbamate (95%). LCMS (n/z): 390.1 (MH 4 ); LC Rt= 3.25 min. Example 47 10 Synthesis of tert-butyl I-(4-(cyclopropanecarbonyl)-2-nitrophenyl)piperidin-3 vlcarbamate CT NHBoc N

NO

2 0 [01651 Method I was followed using 4-chloro-3-nitrophenyl cyclopropyl ketone (1.0 eq), 3-(N-Boc-amino)piperidine (1.2 eq), and TEA (1.5 eq) at 55*C for 48 15 hours yielding tert-butyl 1-( 4 -(cyclopropanecarbonyl)-2-nitrophenyl)piperidin-3 ylcarbamate (96%). LCMS (m/z): 390.1 (MH); LC Rt = 3.28 min. Example 48 Synthesis of tert-butyl 2-(3-nitropyridin-4-yloxy)ethylcarbamate NHBoc N02

N-

-61- [01661 To a cooled solution (0 0 C) of tert-butyl 2-hydroxyethylcarbamate (1.1 eq) in THF, NaH (1.3 eq) was added, stirred for I hr, and then 4-chloro-3-nitropyridine (1.0 eq) was added. The reaction mixture was stirred at RT overnight, poured into cold water, and extracted with EtOAc. Organic layer was dried over Na 2

CO

3 , filtered, and 5 concentrated to yield tert-butyl 2-(3-nitropyridin-4-yloxy)ethylcarbamate. LCMS (m/z): 284.1 (MH*); LC R, = 2.09 min. METHOD 2 Example 49 Synthesis of 4-(piperidin-l -yllpyridin-3-amine Q N

NH

2 10 N [01671 To a solution of 3-nitro-4-(piperidin-1-yl)pyridine (1.0 equiv.) in ethanol, at a concentration of 0.1 M, was added 10% palladium on carbon (0.1 eq.). The resultant heterogeneous solution was put under an atmosphere of hydrogen and was stirred for 15 hours. At this time the mixture was filtered through a pad of elite eluting 15 with methanol. The volatiles were removed in vacuo yielding 4-(piperidin-1-yl)pyridin 3-amine (93%) as an oil. LCMS (n/z): 178.0 (MH-); LC R, = 1.68 min. 'H NMR (CDCl 3 ): 6 8.01 (s, 1 H), 7.96 (d, J=5.4, 1 H), 6.78 (d, J=5.1, 1 H), 3.64-3.74 (m, 2H), 2.86 2.94 (m, 4H), 1.66-1.78 (m, 4H), 1.58-1.64 (m, 2H). Example 50 20 Synthesis of tert-butyl 1-(3-aminopyridin-4-yl)piperidin-3-ylcarbamate Cr NHBoc N

NH

2 N [01681 Following the method of Example 49 (Method 2), tert-butyl 1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate was reduced yielding tert-butyl 1-(3 -62aminopyridin-4-yl)piperidin-3-ylcarbamate, (65%). LCMS (m/z): 293.1 (MH*); LC Rt = 2.10 min. Example 51 Synthesis of (R)-tert-butyl 1-(3-aminopyridin-4-yl)piperidin-3-ylcarbamate c7T NHBoc N 5 NH 2 5 CN 10169] Following the method of Example 49 (Method 2), (R)-tert-butyl 1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate was reduced yielding (R)-tert-butyl 1-(3 aminopyridin-4-yl)piperidin-3-ylcarbamate, (89%). LCMS (m/z): 293.1 (MH); LC R, = 2.08 min. 10 Example 52 Synthesis of (S)-tert-butyl 1-(3-aminopyridin-4-yl)piperidin-3-vlcarbamate Q " ~NHBoc N NH2 101701 Following the method of Example 49 (Method 2), (S)-tert-butyl 1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate was reduced yielding (S)-tert-butyl 1-(3 15 aminopyridin-4-yl)piperidin-3-ylcarbamate, (78%). LCMS (n/z): 293.1 (MH); LC R, = 2.08 min. Example 53 Synthesis of tert-butyl (1-(3-aminopyridin-4-yl)piperidin-3-yl)methylcarbamate NHBoc N

NH

2

I

-63- [0171] Following the method of Example 49 (Method 2), tert-butyl (1-(3 nitropyridin-4-yl)piperidin-3-yl)methylcarbamate was reduced yielding tert-butyl (1-(3 aminopyridin-4-yl)piperidin-3-yl)methylcarbamate (72%). LCMS (n/z): 307.2 (MH*); LC R, = 2.28 min. 'H NMR (CDCl 3 ): 5 8.01 (s, 1H), 7.96 (d, J=5.4Hz, 1H), 6.78 (d, 5 J=5.4Hz, 1H), 4.60 (bs, 1H), 3.68 (bs, 2H), 3.04-3.28 (m, 4H), 2.53-2.65 (m, 1H), 2.35 2.47 (m, 1H), 1.77-1.93 (m, 3H), 1.55-1.75 (m, 2H), 1.44 (s, 9H). Example 54 Synthesis of tert-butyl 1-(2-aminophenyl)piperidin-3-ylcarbamate Cy NHBoc N

NH

2 10 [01721 Following the method of Example 49 (Method 2), tert-butyl 1-(2 nitrophenyl) piperidin-3-ylcarbamate was reduced yielding tert-butyl 1-(2-aminophenyl) piperidin-3-ylcarbamate, (90%). LCMS (m/z): 292.2 (MH*). LC Rt = 2.17 min. Example 55 Synthesis of tert-butyl 1-(2-aminophenyl)piperidin-4-ylcarbamate NHBoc 15

NH

2 [0173] Following the method of Example 49 (Method 2), tert-butyl 1-(2 nitrophenyl) piperidin-4-ylcarbamate was reduced yielding tert-butyl 1-(2-aminophenyl) piperidin-4-ylcarbamate, (90%). LCMS (m/z): 292.1 (MH*); LC R, = 2.13 min. -64- Example 56 Synthesis of tert-butyl 4-(2-aminophenyl)piperazine-1-carboxylate Boc N - NH 2 [01741 Following the method of Example 49 (Method 2), tert-butyl 4-(2 5 nitrophenyl) piperazine-l-carboxylate was reduced for 2 hours yielding tert-butyl 4-(2 aminophenyl) piperazine-1-carboxylate, (99%). LCMS (n/z): 278.2 (MH*); LC R, = 2.22 min. Example 57 Synthesis of tert-butyl 1-(3-aminopyridin-2-vl)piperidin-3-ylcarbamate a NHBoc N 10 N NH 2 [0175] Following the method of Example 49 (Method 2), tert-butyl 1-(3 nitropyridin-2-yl) piperidin-3-ylcarbamate was reduced yielding tert-butyl 1-(3 aminopyridin-2-yl) piperidin-3-ylcarbamate, (95%). LCMS (n/z): 293.2 (MH*); LC R, = 1.87 min. 15 Example 58 Synthesis of 4-(4-(dimethylamino)piperidin-I -yl)pvridin-3-amine 1- N H N NH2 101761 Following the method of Example 49 (Method 2), N,N-dimethyl-1-(3 nitropyridin-4-yl)piperidin-4-amine was reduced yielding 4-(4-(dimethylamino)piperidin 20 I-yl)pyridin-3-amine. LCMS (m/z): 221.2 (MH); -65- Example 59 Synthesis of 4-(1,4-dioxa-8-azaspiror4.51decan-8-vl)pvridin-3-amine N

NH

2 N 101771 Following the method of Example 49 (Method 2), 8-(3-nitropyridin-4 5 yl)-1,4-dioxa-8-azaspiro[4.5]decane was reduced yielding 4-(1,4-dioxa-8 azaspiro[4.5]decan-8-yl)pyridin-3-amine. LCMS (m/z): 236.2 (MH*). Example 60 Synthesis of tert-butyl 4-(3-aminopyridin-4-yl)-1,4-diazepane-1 -carboxylate NBoc N NH2 10 101781 Following the method of Example 49 (Method 2), tert-butyl 4-(3 nitropyridin-4-yl)- 1,4-diazepane- 1 -carboxylate was reduced yielding tert-butyl 4-(3 aminopyridin-4-yl)-1,4-diazepane-l-carboxylate. LCMS (m/z): 293.3 (MH). Example 61 Synthesis of N 4 -r2-(dimethylamino)ethyll-N 4 -methylpyridine-3,4-diamine N N NH2 15 N 101791 Following the method of Example 49 (Method 2), N',N,N 2 -trimethyl

N

2 -(3-nitropyridin-4-yl)ethane-1,2-diamine was reduced yielding N'-[2 (dimethylamino)ethyl]-N-methylpyridine-3,4-diamine. Concentrated and took on as is. LCMS (m/z): 195.2 (MH*); LC R,= 0.31 min. -66- Example 62 Synthesis of tert-butyl 1-(3-aminopyridin-4-yl)pyrrolidin-3-ylcarbamate NHBoc N QNH2 [0180] Following the method of Example 49 (Method 2), tert-butyl ]-(3 5 nitropyridin-4-yl)pyrrolidin-3-ylcarbamate was reduced yielding tert-butyl 1-(3 aminopyridin-4-yl)pyrrolidin-3-ylcarbamate. Concentrated and took on as is. LCMS (m/z): 279.1 (MH); LC Rt= 1.75 min. Example 63 Synthesis of (R)-tert-butyl [1 -(3-aminopyridin-4-yl)pyrrolidin-2-yllmethylcarbamate NHBoc N

NH

2 10 N [0181] Following the method of Example 49 (Method 2), (R)-tert-butyl [1-(3 nitropyridin-4-yl)pyrrolidin-2-yl]methyl carbamate was reduced yielding (R)-tert-butyl [1-(3-aminopyridin-4-yl)pyrrolidin-2-yl]methylcarbamate. Concentrated and took on as is. LCMS (n/z): 293.1 (MH); LC R, = 1.79 min. 15 Example 64 Synthesis of 4-(piperidin-1 -yl)pyrimidin-5-amine Q N N -- NH 2 N 10182] Following the method of Example 49 (Method 2), 2-chloro-5-nitro-4 (piperidin-1-yl)pyrimidine was reduced yielding 4-(piperidin-1-yl)pyrimidin-5-amine as 20 the HCl salt (100%). LCMS (m/z): 179.0 (MH*); LC R,= 1.51 min -67- Example 65 Synthesis of tert-butyl 1-(2-amino-3-fluorophenyl)piperidin-4-ylcarbamate NHBoc C NH2 F [0183] Following the method of Example 49 (Method 2), tert-butyl ]-(3 5 fluoro-2-nitrophenyl)piperidin-4-ylcarbamate was reduced in 75 min yielding tert-butyl 1-(2-amino-3-fluorophenyl)piperidin-4-y-carbamate (95%). LCMS (mn/z): 310.2 (MH*); LC Rt= 2.64 min. Example 66 Synthesis of tert-butyl 1-(2-amino-5-fluorophenyl)piperidin-4-ylcarbamate NHBoc N SNI 12 10 F NH2 101841 Following the method of Example 49 (Method 2), tert-butyl 1-(5 fluoro-2-nitrophenyl)piperidin-4ylcarbamate was reduced in 75 min yielding tert-butyl 1 (2-amino-5-fluorophenyl)piperidin-4-ylcarbamate (97%). LCMS (m/z): 310.1 (MH*); LC Rt = 2.25 min. 15 Example 67 Synthesis of tert-butyl 1-(2-amino-4-fluorophenyl)pincridin-4-ylcarbamate NHBoc N r NH 2 F [0185] Following the method of Example 49 (Method 2), tert-butyl 1-(4 fluoro-2-nitrophenyl)piperidin-4-ylcarbamate was reduced yielding tert-butyl 1-(2-amino -68- 4-fluorophenyl)piperidin-4-ylcarbamate (90%). LCMS (n/z): 310.1 (MH*); LC R, = 2.36 min. Example 68 Synthesis of tert-butyl 1-(2-amino-4-methoxyphenyl)piperidin-3-ylcarbamate NHBoc N

NH

2 5 N [01861 Following the method of Example 49 (Method 2), tert-butyl 1-(4 methoxy-2-nitrophenyl)piperidin-3-ylcarbamate was reduced for 24 hours yielding tert butyl 1-(2-amino-4-methoxyphenyl)piperidin-3-yI-carbamate (25%). LCMS (n/z): 322.2

(MH

4 ); LC R, = 2.27 min. 10 Example 69 Synthesis of tert-butyl 1-(2-amino-4-methoxyphenyl)piperidin-4-ylcarbamate NHBoc

NH

2 101871 Following the method of Example 49 (Method 2), tert-butyl 1-(4 methoxy-2-nitrophenyl)piperidin-4-ylcarbamate was reduced for 24 hours yielding tert 15 butyl 1-(2-amino-4-methoxyphenyl)piperidin-4-ylcarbamate (50%). LCMS (n/z): 322.2 (MH*); LC R, = 2.16 min. -69- Example 70 Synthesis of tert-butyl 4-(2-amino-4-methoxyphenyl)piperazine- I -carboxylate BOc N H N NH2 [01881 Following the method of Example 49 (Method 2), tert-butyl 4-(4 5 methoxy-2-nitrophenyl)piperazine-1-carboxylate was reduced for 24 hours yielding tert butyl 4-(2-amino-4-methoxyphenyl)piperazine- 1 -carboxylate (20%). LCMS (n/z): 308.2 (MH*); LC Rt = 2.35 min. Example 71 Synthesis of tert-butyl 4-(2-amino-4-methylphenvl)piperazine- I -carboxylate Boc N N

NH

2 10 [01891 Following the method of Example 49 (Method 2), tert-butyl 4-(4 methyl -2-nitrophenyl) piperazine-1-carboxylate was reduced for 2 hours yielding tert butyl 4-(2-amino-4-methylphenyl)piperazine- I -carboxylate (93%). LCMS (m/z): 292.1 (MH*); LC Rt = 2.33 min. 15 Example 72 Synthesis of tert-butyl I-(2-amino-4-methylphenyl)piperidin-4-ylcarbamate N H Boc N N H 2 -70- [0190] Following the method of Example 49 (Method 2), tert-butyl 1-(4 methyl -2-nitrophenyl)piperidin-4-ylcarbamate was reduced for 2 hours yielding tert butyl 1-(2-amino-4-methylphenyl)piperidin-4-ylcarbamate (95%). LCMS (n/z): 306.2 (MH); LC R, = 2.22 min. 5 Example 73 Synthesis of tert-butyl 1-(2-amino-4-methylphenyl)piperidin-3-ylcarbamate NHBoc N

NH

2 10191] Following the method of Example 49 (Method 2), tert-butyl l-(4 methyl -2-nitrophenyl)piperidin-3-ylcarbamate was reduced for 2 hours yielding tert 10 butyl 1-(2-amino-4-methylphenyl)piperidin-3-ylcarbamate (95%). LCMS (m/z): 306.2 (MH*); LC R, = 2.30 min. Example 74 Synthesis of tert-butyl 4-(2-amino-5-methylphenyl)piperazine-l -carboxylate Boc C) N & NH 2 15 [0192] Following the method of Example 49 (Method 2), tert-butyl 4-(5 methyl-2-nitrophenyl) piperazine-1-carboxylate was reduced yielding tert-butyl 4-(2 amino-5-methylphenyl)piperazine-l-carboxylate (90%). LCMS (n/z): 292.1 (MH'); LC Rt = 2.29 min. -71- Example 75 Synthesis of tert-butyl 1-(2-amino-5-methylphenyl)piperidin-4-ylcarbamate NHBoc N

NH

2 10193] Following the method of Example 49 (Method 2), tert-butyl 1-(5 5 methyl-2-nitrophenyl)piperidin-4-ylcarbamate was reduced for 1 hour yielding tert-butyl 1-(2-amino-5-methylphenyl)piperidin-4-yI-carbamate (93%). LCMS (m/z): 306.2 (MH*); LC Rt = 2.25 min. Example 76 Synthesis of tert-butyl I-(2-amino-5-methylphenyl)piperidin-3-ylcarbamate NHBoc K:; 10

NH

2 10 [01941 Following the method of Example 49 (Method 2), tert-butyl 1-(5 methyl-2-nitrophenyl)piperidin-3-ylcarbamate was reduced for 1 hour yielding tert-butyl 1-(2-amino-5-methylphenyl)piperidin-3-yl-carbamate (95%). LCMS (m/z): 306.2 (MH 4 ); LC Rt= 2.29 min. 15 Example 77 Synthesis of tert-butyl 1-(2-amino-4-(trifluoromethyl)phenyl)piperidin-3-ylcarbamate NHBoc N

NH

2

CF

3 [0195] Following the method of Example 49 (Method 2), tert-butyl 1-(2-nitro 4-(trifluoromethyl)phenyl)piperidin-3-yl carbamate in MeOH was reduced yielding tert 20 butyl 1-(2-amino-4-(trifluoromethyl) phenyl) piperidin-3-ylcarbamate (95%). LCMS (n/z): 360.1 (MH); LC Rt = 3.30 min -72- Example 78 Synthesis of tert-butyl 1-(2-amino-4-(trifluoromethyl)phenyl)piperidin-4-ylcarbamate NHBoc

NH

2

CF

3 10196] Following the method of Example 49 (Method 2), tert-butyl 1-(2-nitro 5 4-(trifluoromethyl)phenyl)piperidin-4-yl-carbamate in MeOH was reduced yielding tert butyl 1-(2-amino-4-(trifluoromethyl) phenyl)piperidin-4-ylcarbamate (97%). LCMS (m/z): 360.1 (MH); LC R, = 3.20 min. Example 79 Synthesis of tert-butyl 4-(2-amino-4-(trifluoromethyl)phenvl)piperazine-I -carboxylate Boc CN N

NH

2 10 CF 3 10197] Following the method of Example 49 (Method 2), tert-butyl 4-(2-nitro 4-(trifluoro- methyl)phenyl)piperazine-1-carboxylate in MeOH was reduced yielding tert butyl 4-(2-amino-4-(trifluoromethyl) phenyl)piperazine-l-carboxylate (99%). LCMS (n/z): 346.1 (MH*); LC R, = 3.38 min. 15 Example 80 Synthesis of tert-butyl 1-(2-amino-4-cyanophenyl)piperidin-3-ylcarbamate NHBoc N

SNH

2 CN [01981 Following the method of Example 49 (Method 2), tert-butyl 1-(4 cyano-2-nitrophenyl)piperidin-3-ylcarbamate was reduced yielding tert-butyl ]-(2-amino -73- 4-cyanophenyl)piperidin-3-ylcarbamate (95%). LCMS (m/z): 317.2 (MH*); LC R, = 2.92 min. Example 81 Synthesis of tert-butyl 1-(2-amino-4-( H-pVyrazol-5-yllphenyllpiperidin-4-ylcarbamate NHBoc

NH

2 NH 5-N [0199] Following the method of Example 49 (Method 2), tert-butyl 1-(2-nitro 4-(1H-pyrazol-5-yl)phenyl)piperidin-4-ylcarbamate was reduced yielding tert-butyl 1-(2 amino-4-(IH-pyrazol-5-yl)phenyl) piperidin-4-ylcarbamate (87%). LCMS (mn/z): 258.1

(MH

4 ); LC Rt = 2.15 min. 10 Example 82 Synthesis of tert-butyl 1-(2-amino-4-(methylsulfonyl)phenyl)piperidin-4-ylcarbamate NHBoc

NH

2 s o 102001 Following the method of Example 49 (Method 2), tert-butyl 1-(4 (methylsulfonyl)-2-nitrophenyl)piperidin-4-yl-carbamate was reduced yielding tert-butyl 15 1-(2-amino-4-(methylsulfonyl) phenyl) piperidin-4-ylcarbamate (76%). LCMS (mn/z): 370.1 (MH'); LC R, = 2.52 min. -74- Example 83 Synthesis of tert-butyl 2-(3-aminopyridin-4-yloxy)ethylcarbamate o NHBoc rk NH 2 N 10201] Following the method of Example 49 (Method 2), tert-butyl 2-(3 5 nitropyridin-4-yloxy)ethylcarbamate was reduced to yield tert-butyl 2-(3-aminopyridin-4 yloxy)ethylcarbamate. LCMS (n/z): 254.1 (MlH*); LC Rt = 1.76 min. METHOD 3 Example 84 Synthesis of tert-butyl 3-(4-(3-nitropyridin-4-yl)piperazin-I -yl)-3-oxopropylcarbamate O NHBoc CN N

NO

2 10 N [0202] A solution containing 1.0 eq each of 1-(3-nitropyridin-4-yl)piperazine, N-Boc-beta-alanine, HOAT and EDC in DCM, at a concentration of 0.1 M, was stirred for 16 hours. The solution was diluted with EtOAc and was washed with H20, Na 2

CO

3 (sat), NaCl(sat.), was dried over MgSO 4 , was filtered and the volatiles were removed in 15 vacuo yielding tert-butyl 3-(4-(3-nitropyridin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate (93%). LCMS (m/z): 379.9 (MH*); LC R,= 1.92 min. Example 85 Synthesis of tert-butyl 3-(4-(3-aminopyridin-4-yl)piperazin-I -yl)-3-oxopropylcarbamate O, NHBoc N H N NH2 -75- 102031 Following the method of Example 49 (Method 2), tert-butyl 3-(4-(3 nitropyridin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate was reduced yielding tert-butyl (tert-butyl 3-(4-(3-aminopyridin-4-yl)piperazin-1-yl)-3-oxopropylcarbamate (99 % yield). LCMS (n/z): 349.9 (MH*); LC Rt = 1.84 min. 5 Example 86 Synthesis of tert-butyl 2-(4-(3-nitropyridin-4-yl)piperazin- 1 -yl)-2-oxoethylcarbamate NHBoc CN O N NO2 102041 Following the method of Example 84 (Method 3), 1-(3-nitropyridin-4 yl)piperazine was coupled to N-Boc-glycine yielding tert-butyl 2-(4-(3-nitropyridin-4 10 yl)piperazin-1-yl)-2-oxoethylcarbamate (99 % yield). LCMS (m/z): 365.8 (MH*); LC Rt = 1.81 min Example 87 Synthesis of tert-butyl 2-(4-(3-aminop~yridin-4-yl)piperazin-1-yl)-2-oxoethylcarbamate O NHBoc N N C TNH2

N

15 [02051 Following the method of Example 49 (Method 2), tert-butyl 2-(4-(3 nitropyridin-4-yl)piperazin-1-yl)-2-oxoethylcarbamate was reduced yielding tert-butyl (tert-butyl 2-(4-(3-aminopyridin-4-yl)piperazin-1-yl)-2-oxoethylcarbamate (88% yield). LCMS (m/z): 335.8 (MH*); LC Rt = 1.79 min. -76- METHOD 4 Example 88 Synthesis of 4-nitro-3-(piperidin-1-yl)pyridine I-oxide N Oi N

NO

2 5 [0206] 3-bromo-4-nitropyridine-N-oxide (1.0 equiv.) and piperidine (2.0 equiv.) in ethanol, at a concentration of 0.2 M, was heated at reflux for 16 hours. Upon cooling the ethanol was removed in vacuo. The residue was partitioned between EtOAc and Na 2

CO

3 (sat.>, and washed further with H 2 0, NaCI(at.), was dried over MgSO 4 , was filtered and the volatiles were removed in vacuo yielding 4-nitro-3-(piperidin-1 10 yl)pyridine 1-oxide (92%). LCMS (m/z): 224.0 (MH*); LC Rt = 2.48 min. Example 89 Synthesis of tert-butyl 1 -(4-nitropyridin-3-yl)piperidin-3 -ylcarbamate NHBoc N 9-,

NO

2 N02 [02071 The method of Example 88 (Method 4) was followed using I eq each of 15 3-bromo-4-nitropyridine-N-oxide, 3-N-Boc-amino piperidine and diisopropylethylamine yielding tert-butyl 1-(4-nitropyridin-3-yl)piperidin-3-ylcarbamate (65 %). LCMS (m/z): 339.1 (MH*); LC R, = 2.88 min. -77- METHOD 5 Example 90 Synthesis of 3-(pipcridin- 1 -ylpyridin-4-aminc Q N N

NH

2 N ,r 5 10208] To a solution of 4-nitro-3-(piperidin-1-yl)pyridine 1-oxide (1.0 equiv.) in ethanol, at a concentration of 0.1 M, was added 10% palladium on carbon (0.1 eq.). The resultant heterogeneous solution was put under an atmosphere of hydrogen and was stirred for 15 hours. At this time LC/MS analysis indicated that the nitro was reduced to the amine, but the N-oxide was remaining. More 10% palladium on carbon (0.2 eq.) was 10 added and the mixture was resubmitted to a balloon atmosphere of hydrogen. After stirring for 24 hours, more 10% palladium on carbon (0.2 eq.) was added and the mixture was resubmitted to a balloon atmosphere of hydrogen. After stirring for an additional 3 days the mixture was filtered through a pad of celite eluting with methanol. The volatiles were removed in vacuo yielding 3-(piperidin-1-yl)pyridin-4-aminc (73%). LCMS (m/z): 15 178.0 (MH*); LC Rt = 1.66 min Example 91 Synthesis of tert-butyl 1-(4-aminopyridin-3-yl)piperidin-3-ylcarbamate NHBoc N N NH 2 [02091 The method of Example 90 (Method 5) was followed using 1 eq of tert 20 butyl 1-(4-nitropyridin-3-yl)piperidin-3-ylcarbamate in 1:1 ethanol/ethyl acetate at 30 psi for 72 hours, yielding tert-butyl 1-(4-aminopyridin-3-yl)piperidin-3-ylcarbamate (79 %). LCMS (m/z): 293.1 (MH*); LC R,= 2.14 min. -78- METHOD 6 Example 92 Synthesis of 4-cyclohcxcnyl-3-nitropyridine

NO

2 N 5 [0210] A solution of 4-chloro-3-nitro pyridine (1 eq.), cyclohexenyl boronic acid (1.7 eq.), and Pd(dppf)C 2

-CH

2 Cl 2 (0.05 eq) in 3:1 DME/2M Na 2

CO

3 , at a concentration of 0.1 M was heated at 95'C for 16 hours. Upon cooling the reaction was partitioned between EtOAc and H 2 0, was washed with NaCl(sat.), dried over MgSO 4 , was filtered and the volatiles were removed in vacuo. The material was purified by SiO 2 10 chromatography (20% EtOAc/hexanes eluant) to yield 4-cyclohexenyl-3-nitropyridine (82%). LCMS (m/z): 205.0 (MH); LC R, = 3.84 min. Example 93 Synthesis of 3-nitro-4-o-tolylpyridine

NO

2 N 15 10211] The method of Example 92 (Method 6) was followed using ortho-tolyl boronic acid for 3 hours, yielding 3-nitro-4-o-tolylpyridine (88%). LCMS (m/z): 215.1 (MH*); LC R, = 3.58 min. -79- METHOD 7 Example 94 Synthesis of 4-cyclohexenylpyridin-3-aminc

NH

2 N 5 [0212] A heterogeneous solution of 4-cyclohexenyl-3-nitropyridine (1.0 eq.) and iron (6.0 eq) in acetic acid, at a concentration of 0.4 M, was stirred vigorously for 2 hours. The mixture was then passed through a celite pad, eluting with MeOH. Upon removal of the volatiles in vacuo, the residue was dissolved in EtOAc, washed with Na 2

CO

3 (st.>, NaCl(sat.), was dried over MgSO 4 , was filtered and the volatiles were 10 removed in vacuo yielding 4-cyclohexenylpyridin-3-amine (99%) as an oil. LCMS (m/z): 175.0 (MH); LC Rt = 1.86 min. Example 95 Synthesis of 4-o-tolylpyridin-3-amine

NH

2 N 15 [0213] The method of Example 94 (Method 7) was followed using 3-nitro-4-o tolylpyridine yielding 4-o-tolylpyridin-3-amine (97%). LCMS (m/z): 185.1 (MH*); LC Rt = 1.78 min. -80- Example 96 Synthesis of tert-butyl 1-(2-amino-4-benzoylphenyl)piperidin-3-ylcarbamate ~ NHBoc N

NH

2 [0214] Following method 7, tert-butyl 1-(4-benzoyl-2-nitrophenyl)piperidin-3 5 ylcarbamate was reduced for 16 hours, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert butyl 1-(2-amino-4-benzoylphenyl)piperidin-3-ylcarbamate (90%). LCMS (n/z): 396.2 (MH*); LC Rt = 3.07 min. Example 97 10 Synthesis of tert-butyl I-(2-amino-4-benzoylphenyl)piperidin4-ylcarbamate NHBoc

NH

2 N .

0 [0215] Following method 7, tert-butyl 1-(4-benzoyl-2-nitrophenyl)piperidin-4 ylcarbamate was reduced for 16 hours, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert 15 butyl 1-(2-amino-4-benzoylphenyl)piperidin-4-ylcarbamate (83%). LCMS (mn/z): 396.2 (MH*); LC R, = 2.81 min. -81- Example 98 Synthesis of tert-butyl 4-(2-amino-4-benzoylphenyl)piperazine- I -carboxylate Boc N) N

NH

2 [02161 Following method 7, tert-butyl 1-(4-benzoyl-2-nitrophenyl)piperidin-4 5 ylcarbamate was reduced for 16 hours, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert butyl 4-(2-amino-4-benzoylphenyl)piperazine-1-carboxylate (61%). LCMS (m/z): 382.2 (MH*); LC R, = 3.01 min. Example 99 10 Synthesis of tert-butyl 4-(4-acetyl-2-amino phenyl)piperazine-1-carboxylate Boc N N NH2 [0217] Following method 7, tert-butyl 4-(4-acetyl-2-nitrophenyl)piperazine-1 carboxylate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 4-(4 15 acetyl-2-amino phenyl)piperazine-l-carboxylate (87%). LCMS (m/z): 320.2 (MH*); LC Rt = 2.58 min. -82- Example 100 Synthesis of tert-butyl 1-(4-acetyl-2-aminophenyl)piperidin-4-ylcarbamate NHBoc N I NH 2 0 102181 Following method 7, tert-butyl 1-(4-acetyl-2-nitrophenyl)piperidin-4 5 ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 1-(4 acetyl-2-amino phenyl)piperidin-4-ylcarbamate (90%). LCMS (rn/z): 334.2 (MH-); LC R, 2.42 min. Example 101 10 Synthesis of tert-butyl I -(4-acetyl-2-aminophenyl~piperidin-3-ylcarbamate NHBoc N

NH

2 0 [0219] Following method 7, tert-butyl 1-(4-acetyl-2-nitro phenyl)piperidin-3 ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 1-(4 15 acetyl-2-amino phenyl)piperidin-3-ylcarbamate (88%). LCMS (n/z): 334.2 (MH4); LC R, = 2.49 min. -83- Example 102 Synthesis of tert-butyl 4-(2-amino-4-chlorophenyl)piperazine- 1 -carboxylate Boc (N) N

NH

2 CI 102201 Following method 7, tert-butyl 4-(4-chloro-2-nitrophenyl)piperazine-1 5 carboxylate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 4-(2 amino-4-chloro phenyl)piperazine-1-carboxylate (80%). LCMS (n/z): 312.1 (MH*); LC Rt= 2.85 min. Example 103 10 Synthesis of tert-butyl 1-(2-amino-4-chlorophenyl)phiperidin-4-ylcarbamate NHBoc N r NH2 Cl [02211 Following method 7, tert-butyl 1-(4-chloro-2-nitrophenyl)piperidin-4 ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 1-(2 15 amino-4-chloro phenyl)piperidin-4-ylcarbamate (68%). LCMS (m/z): 326.1 (MH*); LC R, = 2.67 min. Example 104 Synthesis of tert-butyl 1-(2-amino-4-chlorophenyl)piperidin-3-vlcarbamate NHBoc N NH2 CI -84- 10222] Following method 7, tert-butyl 1-(4-chloro-2-nitrophenyl)piperidin-3 ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 1-(2 amino-4-chloro phenyl)piperidin-3-ylcarbamate (85%). LCMS (mn/z): 326.1 (MH 4 ); LC Rt 5 2.76 min. Example 105 Synthesis of tert-butyl 4-(4-(cyclopropanecarbonyl)-2-nitrophenyl)Tiperazine- 1 carboxylate Boc N N

NH

2 0 10 10223] Following method 7, tert-butyl 4-(4-(cyclopropanecarbonyl)-2 nitrophenyl)piperazine-l -carboxylate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo yielding tert-butyl 1-(2-amino-4-chloro phenyl)pipcridin-4-ylcarbamate (90%). LCMS (m/z): 346.2 (MH); LC R, = 2.83 min. 15 Example 106 Synthesis of tert-butyl 1-(2-amino-4-(cyclopropanecarbonyl)phenyl)piperidin-4 ylcarbamate NHBoc

NH

2 0 10224] Following method 7, tert-butyl 1-(4-(cyclopropanecarbonyl)-2 20 nitrophenyl)piperidin-4-ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo -85yielding tert-butyl 1-(2-amino-4-(cyclopropanecarbonyl)phenyl)piperidin-4-ylcarbamate (93%). LCMS (n/z): 360.1 (MH*); LC Rt = 2.65 min. Example 107 Synthesis of tert-butyl 1-(2-amino-4-(cyclopropanecarbonvl)phenyl)piperidin-3 5 ylcarbamate 0Y NHBoc N

NH

2 0 [02251 Following method 7, tert-butyl 1-(4-(cyclopropanecarbonyl)-2 nitrophenyl)piperidin-3-ylcarbamate was reduced, filtered, and concentrated. Water was added to the residue. The resulting solids were collected by filtration and dried in vacuo 10 yielding tert-butyl I-(2-amino-4-(cyclopropanecarbonyl)phenyl)piperidin-3-ylcarbamate (90%). LCMS (m/z): 360.1 (MH 4 ); LC Rt = 2.74 min. METHOD8 Example 108 Synthesis of 6-amino-5-(4-(trifluorornethyl)piperidin-I-yl)pyrimidin-2(IH)-one F F F N ( NH 2 N NH 15 6 [02261 A solution of 5-bromocytosine (1.0 equiv.), 4 (trifluoromethyl)piperidine (1.25 equiv.) and diisopropylethylamine (1.25 equiv.) in N methylpyrrolidinone (NMP), at a concentration of 0.525 M was degassed by bubbling argon through for 10 minutes in a 125mL high-pressure glass vessel. The glass bomb 20 was then sealed and heated at 120*C for 3 days. The reaction mixture was purified -86directly by reverse-phase HPLC and lyophilized yielding a TFA salt of the product as a crunchy orange solid (50%). LCMS (m/z): 263.0 (MH~); LC R, = 1.81 min. Example 109 Synthesis of 6-amino-5-(4,4-difluoropiperidin-1-yl)pyrimidin-2(1 H)-one

NH

2 N NH 5 [02271 Method 8 was followed using I eq. of 5-bromocytosine, 1.25 eq. of 3 fluoropiperidine and 2.5 eq. of diisopropylethylamine at 120 0 C for 2 days yielding 6 amino-5-(4,4-difluoropiperidin-1-yl)pyrimidin-2(1H)-one as an orange crunchy solid (34%). LCMS (m/z): 231.0 (MH); LC Rt = 1.28 min. 10 Example 110 Synthesis of 6-amino-5-(3-fluoropiperidin-1 -yl)pyrimidin-2(1 H)-one a F N

HNH

2 TNH [0228] Method 8 was followed using I eq. of 5-bromocytosine, 1.25 eq. of 3 fluoropiperidine and 2.5 eq. of diisopropylethylamine at 120 0 C for 2 days yielding 6 15 amino-5-(3-fluoropiperidin-1-yl)pyrimidin-2(IH)-one as an orange crunchy solid (24%). LCMS (m/z): 213.0 (MH'); LC R,= 1.07 min. -87- Example 111 Synthesis of tert-butyl(1 -(6-amino-2-oxo- 1,2-dihydropyrimidin-5-yl)piperidin-3 yl)methylcarbamate NHBoc N

NH

2 N NH 5 10229] Method 8 was followed using I eq. of 5-bromocytosine, 1.05 eq. of tert-butyl piperidin-3-ylmethylcarbamate and 1.05 eq. of diisopropylethylamine yielding tert-butyl(1 -(6-amino-2-oxo- 1,2-dihydropyrimidin-5-yI)pipcridin-3 -yl)methylcarbamate as an orange crunchy solid (18%). LCMS (m/z): 324.1 (MH+); LC Rt = 1.90 min. Example 112 10 Synthesis of tert-butyl(1 -(6-amino-2-oxo- I,2-dihydro pyrimidin-5-yl)pitperidin-3-yl)carbamate NHBoc N -- NH 2 N NH [02301 Method 8 was followed using I eq. of 5-bromocytosine, 1.05 eq. of tert-butyl piperidin-3-ylmethylcarbamate and 1.05 eq. of diisopropylethylamine yielding 15 tert-butyl(1-(6-amino-2-oxo-1,2-dihydropyrimidin-5-yl)piperidin-3-yl)carbamate as an orange crunchy solid (26%). LCMS (m/z): 310.1 (MH); LC Rt = 1.78 min. -88- Example 113 Synthesis of tert-butyl 3-(4-(6-amino-2-oxo- 1,2-dihydropyrimidin-5-yl)piperazin- I -yl)-3 oxopropylcarbamate NHBoc N N

NH

2 N NH 5 10231] Method 8 was followed using I eq. of 5-bromocytosine, 1.5 eq. of tert butyl 3-oxo-3-(piperazin-1-yl)propylcarbamate and 1.2 eq. of diisopropylethylamine yielding tert-butyl 3-(4-(6-amino-2-oxo-1,2-dihydropyrimidin-5-yl)piperazin-l-yl)-3 oxopropyl carbamate as an orange crunchy solid (65%). LCMS (m/z): 367.2 (MH*); LC Rt = 1.68 10 min. Example 114 Synthesis of 6-amino-5-(piperidin-1-yl)pyrimidin-2(1H)-one N N NH 2 N NH [0232] Method 8 was followed using 1 eq. of 5-bromocytosine and 15 eq. of 15 piperidine (as solvent). The reaction was cooled and added to CH 2 Cl 2 and H 2 0. The solid was filtered, rinsed with H 2 0, and dried yielding 6-amino-5-(piperidin-1 yl)pyrimidin-2(I H)-one as a solid (89%). LCMS (m/z): 195.0 (MH); LC Rt = 1.28 min. -89- METHOD 9 Example 115 Synthesis of 3-amino-N-(4-(piperidin-1-yl)pyridin-3-yl)pyrazine-2-carboxamide N N'

NH

2 5 [02331 A solution of 1 eq of 4-(piperidin-I-yl)pyridin-3-amine and 2 eq each of 3-aminopyrazine-2-carboxylic acid, HOAT and EDC in NMP, at a concentration of 0.2 M, was stirred for 48 hours at which time the mixture was directly purified by HPLC. Upon lyophilization, the TFA salt of 3-amino-N-(4-(piperidin-1-yl)pyridin-3-yl)pyrazine 2-carboxamide was obtained (61%). Alternatively, the HPLC fractions could be added to 10 EtOAc and solid Na 2

CO

3 , separated and washed with NaCl(sat.). Upon drying over MgSO 4 , filtering and removing the volatiles in vacuo the free base was obtained. Upon dissolving in MeCN/H 2 0, adding 1 eq. of 1 N HCl and lyophilizing, the HCI salt of 3 amino-N-(4-(piperidin-1 -yl)pyridin-3-yl)pyrazine-2-carboxamide was obtained (40 %). LCMS (m/z): 298.8 (MH*); LC Rt = 1.88 min. 'H NMR of HCI salt (DMSOd.: 6 15 10.45(s, IH), 8.55(d, J=0.9, IH), 8.32(d, J=2.1, 1H), 8.27(dd, J=5.7, IH), 7.93(d, J=1.8, 1H), 7.57(s, 1H), 7.32(d, J=6.9, 1H), 3.76(s, 4H), 1.59(s, 6H). Example 116 Synthesis of 3-amino-6-bromo-N-(4-(piperidin- I -yllpyridin-3-yl)picolinamide Br N H N N NH2 I - NH 2 CN 20 102341 The method of Example 115 (Method 9) was followed using 4 (piperidin-1-yl)pyridin-3-amine yielding 3-amino-6-bromo-N-(4-(piperidin-1-yl)pyridin 3-yl)picolinamide (32%). LCMS (m/z): 376.1 (MH*); LC Rt = 2.77 min. -90- Example 117 Synthesis of 3-amino-6-bromo-N-(4-o-tolylpyridin-3-yl)picolinamide Br N' H N N I N H2 102351 The method of Example 115 (Method 9) was followed using 4-o 5 tolylpyridin-3-amine yielding 3-amino-6-bromo-N-(4-o-tolylpyridin-3-yl)picolinamide (74%). LCMS (m/z): 383.0 (MH); LC R,= 2.99 min. The following compounds were prepared using Method 9. Example Structure Name MH+ LC N 3-amino-N-(4-cyclohex- 1-en 118 N N N 1-ylpyridin-3-yl)pyrazine-2- 296.1 2.32 carboxamide N 2 Br CN) N 3-amino-6-bromo-N-(4 119 N piperidin-1-ylpyridin-3- 377 2.46 yl)pyrazine-2-carboxamide N NH N 2 C1 NQ N N H 3,5-diamino-6-chloro-N-(3 120 H I piperidin- I -ylpyridin-4-yl)- 348.1 2.43 pyrazine-2-carboxamide N 0

NH

2 CI Q NH 2 3,5-diamino-6-chloro-N-(4 121 I piperidin- 1 -ylpyridin-3-yl)- 347.8 2.17 y 2 pyrazine-2-carboxamide N' 0 NH 2 N N 3-amino-N-(3-piperidin-1-yl 122 pyridin-4-yl)pyrazine-2-carbox-6 qt N amide N 0

NH

2 -91- Example Structure Name MH+ LC QN N') -amino-N-(4-piperi din- Il-yl 123 H pyri~:din3-y)pyrazinc-2carbox-2881 mride N

NH

2

CH

3 N N 'CH 3 Br 3-amino-6-bromo-N-(4- {[2 124 H3CS N jHN (rehyai) A 3fl 396.0 YI)- 1)pyrazine-2-carboxamide 0 NH N2 N N 3-amino-N-(4-chloropyridin-3- 250 1.34 125.1 - N 2 )pyrazine-2-carboxamide N

H

3 C..N' CH, 3-amino-N- {4-[4-(dimnethyl 126 N H N I amino)piperidin-I-yl]pyridin-3- 342.2 0.92 r N J N 1}) pyrazine-2-carboxamide N 2 n 3-amino-N-[4-(1 ,4-dioxa-8 127 N HNW-j 1 aspiro[4.5]dec-8-yl)pyridin-3- 357.1 1.66 N N Ifpyrazine-2-carboxami de QN 3-amino-N-(4-piperidin- I1-yI 128 H yrimidin-5-yI)pyrazine-2- 299.7 1.72 N 'N N carboxamide IL 0 NH 2 N H N-;"j~ 3-amino-N-(5 -carbamoyl-2 129 N -y iperidin-1I-ylphenyl)pyrazine-2- 340.8 3.11 NAN _abxmd 0 NH 2 cabx id Q H NW~ 3-amino-N-(2-oxo-5-piperidin-1 130 rl k~r)ryN Il-2,3 -dihydropyrimidin-4-yl)- 315.7 2.21 N y NH0 NH2 yrazine-2-carboxamide 0 -92- Example Structure Name MH+ LC CI N , N H, 3,5-diamino-6-chloro-N-(2-oxo 13 NH NI5-pipenidin- I -yl-2,3-dihydro- 36. 22 13 NH N pyrimidin-4-yl)pyrazine-2- 36. 22 Ny NH0 N2carboxamide 3r-amino-6-bromo-N-(2-oxo-5 ON H N iperidin- 1 -yl-2,3-dihydro 132 r yypyrimidin-4-yl)pyrazine-2- 394 2.81 N yNH 0 NH 2 carboxamide 0 133 carbamoyl-2-piperi din- I-yl- 419 3.98 0 NH2 henyl)pyrazine-2-carboxamide 0 N.H 2 (.TJH ,,L N H 2 3,5 -diami no-N- [5 -(3 -amino 13 H iperidin- I-yI)-2-oxo-2,3- 30112 134 (At 1,Ntr),yNdihydropyrimidin-4-yI]-6- 30112 N NH 0 NH 2 chloropyrazine-2-carboxamide 0 NH, 3-amino-N- {5-[3-(amino 135N H *) ethyl)piperidin- I-yl]-2-oxo- 35113 2,3-dihydropyrimidin-4-yI} N yNH 0 NH 2 pyrazinc-2-carboxamide 0 H AN 3-amino-N-[5-(2-furyl)-2-oxo 136 Ny yN ,3-dihydropyrimidin-4-yI]- 299 1.93 N yNH 0 NH 2 pyrazine-2-carboxamide 0 HS-mn 3-mn--[2-oxo-5-(2-thienyl) 137 N N 2,3-dihydropyrimidin-4-yI]- 315 2.02 N yNH 0 NH 2 pyrazine-2-carboxamide 0 S N 3-amino-N-[2-oxo-5-(1 ,3 138 ~ AN J N thiazol-2-yl)-2,3-dihydro- 316 1.92 ,--y Y y- yrimidin-4-yI]pyrazine-2 N yNH 0 NH, carboxamide 0 -93- Example Structure Name MH+ LC

H

3 C-N N 3-amino-N-[5-(1-methyl-I H 139 N N pyrrol-2-yl)-2-oxo-2,3-dihydro- 312.1 2.02 N1NH3O9NH pyrimidin-4-yl]pyrazine-2 N yNH 0 NH 2 carboxamide 0 N H N 3-amino-N-(2-oxo-5-pyridin-2 140 _, Ny N yl-2,3-dihydropyrimidin-4-yl)- 310 1.82 N NH O NH 2 pyrazine-2-carboxamide 0 Br 0 N 3-amino-6-bromo-N-[5-(2 141 N . N furyl)-2-oxo-2,3-dihydro- 376.9 3.98 N NH O NH pyrimidin-4-yI]pyrazinc-2 N H carboxamide 0 Br S N 3-amino-6-bromo-N-[2-oxo-5 142 N N (2-thienyl)-2,3-dihydro- 392.9 2.66 N NH 0 NH 2 pyimidin-4-yI]pyrazine-2 2 carboxamide 0 Br N 3-amino-6-bromo-N-[2-oxo-5 143 N N (I,3-thiazol-2-yl)-2,3-dihydro- 393.9 2.53 N NH NH pyrimidin-4-yI]pyrazine-2 2 carboxamide 0 Br H C- H N 3-amino-6-bromo-N-[5-(1 144 1 ", Nyly, N methyl- IH-pyrrol-2-y)-2-oxo- 390 2.57 N NH 0 NH 2,3-dihydropyrimidin-4-yl] Y 2 pyrazine-2-carboxamide 0 3-amino-6-bromo-N-(2-oxo-5 145 N - N pyridin-2-yl-2,3-dihydro- 387.9 2.36 N NH ~ NH, pyrimidin-4-yl)pyrazine-2 Ny NH O NH2 carboxamide 0 F F 3-amino-N- {2-oxo-5-[3 N H N' (trifluoromethyl)piperidin-1-yI] 146 r N N 2,3dihydropyrimidin-4-yl} - 384.1 2.59 N yNH O NH2 pyrazinC-2-carboxamidc 0 -94- Example Structure Name MH+ LC F F C FBr 3-amino-6-bromo-N- {2-oxo-5 147 N N ~ [3-(trifluoromethyl)piperidin- 1 -42 31 r - N Y),y N 1I-2,3-dihydropyrimidin-4-yl - 42 31 N yNH 0 NH 2 pyrazine-2-carboxamide 0 F-3(rfurmty~pprdn 3125 NHy 3,5-diamino-6-chloro-N- {2-oxo N) yN I~~ -yl]-2,3-dihydropyrimidin-4- 13125 N. NH 0 NH 2 1}lpyrazine-2-carboxamide 0 3-amino-N-[5-(4-flUOTo 149 N )H N Ij1 iperidin-1I-yl)-2-oxo-2,3- 341 2 rll -( NrQN ihydropyrimidin-4-yllpyrazine-34. 2 N y H 0 H 2 -carboxamide 0 F Br 3 -amino-6-bromo-N- [5-(4 150 C'N H N -") fluoropiperidin- I -yl)-2-oxo-2,3 rJ,, NrJ~yN dihydropyrimidin-4-yflpyrazine- 412 2.58 N y H 0 H2 -carboxamide 0 F 151 NH Nrl flUoropiperidin- I-yl)-2-oxo-2,3- 33120 r,,rylNdihydropyrimidin-4-yl]pyrazine-38. N y <NH 0 NH 2 2-carboxamide 0 Fj5F 3-amino-N-{(2-oxo-5-14 152 N H W") (tri fluoromethyl)piperi din-1I-yl]- 34126 N)y ,3-dihydropyrimidin-4-yl ~- 34126 N yNH 0 NF H 2 yazine-2-carboxamide 0 F 153- N YN ~ I1]-2,3-dihydropyrimidin-4-yi ) - 42 30 N yNH 0 NH2 pyrazine-2-carboxamide 0 F~ 3-amino-N-[5-(3-fluoro 15 pieidn d -yl)-2-oxo-2,3 154 ly Y), N ihydropyrimidin-4-yl]pyrazinc- 334.1 1.99 N y H 0 H 2 -carboxamide 0 -95- Example Structure Name MH+ LC C)Br -amnino-6-bromno-N-[5-(3 N N , I fluoropiperidin-1I -yl)-2-oxo-2,3 155 ,Ly I N dihydropyrimidin-4-yl]pyrazine- 412 2.58 N yNH 0 NH 2 2-carboxamide 0 F F b 3-amino-N-[5-(4,4-difluoro 156 N H N') pipenidini I yl)-2oxo-2,3- 352.1 2.21 rJ,,rNIrtiN dihydropyrmidin.-4-yI]pyrazine N yNH 0 NH 2 2-carboxamide 0 F F 3-amino-6-bromno-N-[5 -(4,4 157 yN), N 2,3-dihydropyrimidin-4-yl]- 430 2.78 N yNH 0 NH 2 pyrazine-2-carboxamide 0 ON H N 3-amnino-N-(2-oxo-5-piperidin-1I 158 1l-2,3 -dihydropyrimi din -4-yl)- 315.1 1.97 N N 0NH 2 pyndine-2-carboxamide 0 F Fj 1 3,5-diamlno-6-chloro-N- f 2-oxo 1 ~ H N,, NH 2 5-[4-(trifluoromnethyI)piperidin- 3. . 6-1Nrl N I1-yI]-2,3-dihydropyrimidin-4 N y NH 0 NH 2 y1}pyrazine-2-carboxamide 0 C F C NT yNH 2 3,S-diamino-6-chloro-N-[5-(3 160 fluoropiperidin-1I-yl)-2-oxo-2,3- 33119 160 6)zzr YyN dihydropyrimidin-4-yl]pyrazine- 33119 N yNH 0 NH 2 2-carboxamide 0 F F <) I3,5-diamnino-6-chloro-N-[5-(4,4 161 6'H N~ NH difluoropiperidin-1401.122.23 r, ,INA?-N 2,3-dihydropyrimidin-4-yI]- 01123 NyNH 0 NH 2 pyrazine-2-carboxamide 0 CH I 3-Amino-6-(2-fluoro-phenyl) C dH AF pyridine-2-carboxylic acid (3 162 N N- hydroxy-3-methyl-3,4,5,6-tetra- 422.2 2.77 N hydro-2H-[ 1,4']bipyridinyl-3' N 0 NH 2 V)-amide -96- Example Structure Name MH+ LC 0 F- FH 3-Amino-6-(2-fluoro-5 (j HF NH < sopropylcarbamoyl-phenyl) 163 CH 3

CH

3 pyridine-2-carboxylic acid (3- 561.2 3.06 N N h ydroxy-3-trifluoromethyl N 3,4,5,6-tetrahydro-2H-[ 1 ,4']bi

______NH

2 yridinyl-3'-yl)-amide F NN OH 3-Amino-6-(2-fluoro-phenyi) OHF pyridine-2-carboxylic acid (3 164 N H N- hydroxy-3-trifluoromethyl- 476.1 3.14 N '-.,4,5,6-tetrahydro-2H-[ 1,4']bi NH2, yridinyl -3-yI)-amnide OH F F henyl)-pyrimidine-4-carboxylic 165 N H Noll I N trfluoromethyl-3,4,5,6-tetra- 45126 N hydro-2H-[1 ,4']bipyridinyI-3' ______ I '___ & N___ H___2____ )-amide OH 5-Amino-2-(2-fluoro-phcnyl) -1 F yrimidine-4-carboxylic acid (3 166 N H Nall N hydroxy-3-trifluoromcthyl- 477.1 2.72 N Z ,3,4,5,6-tetrahydro-2H-[ 1,4']bi NN (~) F F 3-Aniino-6-(2,6-difluoro 167 O'N N- henyl)-pyridine-2-carboxylic 48132 H acid (4-azocan-1I-yi-pynidin-3- 48132 N y1)-amide ___~~ NH 2 __ _ _ _ _ _ (0 ) F F 3-Amino-6-(2,6-difluoro 168 K N~~' N N henyl)-pyridine-2-carboxylic 42. .6 168 N H ~acid (4-[1,4]oxazepan-4-yI- 45926 N pyridin-3-yl)-amide NH () F F 3-Amino-6-(2,6-difluoro 169 KN 2 N phenyl)-pyri din e-2-carboxyli H acid (4-azepan-1I-yI-pyridin-3- 44131 ~ir'~

NH

2 -97- Example 170 3-amino-N-(5-carbamoyl-2-(pipcridin-1-yl)phenyl)pyrazine-2-carboxamide N N N IN 0

NH

2 0

NH

2 5 102361 A solution of 3-amino-4-(piperidin-1-yl)benzamide (1.0 equiv.), HOAT (1.3 equiv.) and EDC (1.3 equiv.) in NMP at a concentration of 0.182 M, was stirred for 15 hours, then purified directly by reverse-phase HPLC and lyophilized yielding a TFA salt of 3-amino-N-(5-carbamoyl-2-(piperidin-1-yl)phcnyl)pyrazine-2-carboxamide as a tan powder (82%). LCMS (m/z): 341.1 (MH*); LC R,= 3.10 min. 10 Example 171 Synthesis of 3-amino-N-(5-cyano-2-(piperidin- I -yl)p2henyl)pyrazine-2-carboxamide N N N N O

NH

2 || N 102371 A milky yellow suspension of 3-amino-N-(5-carbamoyl-2-(piperidin-1 yl)phenyl)pyrazine-2-carboxamide (1 equiv.) in dichloromcthane (0.0247_M) was cooled 15 in ice bath. A solution of triflic anhydride (4.4 equiv.) in dichloromethane (0.0405_M) was added dropwise, keeping the internal temperature of the solution <2.5'C. After 5 minutes the reaction was quenched with 6 mL water and the solution allowed to warm up to room temperature, then extracted with dichloromethane. The organics were washed with Na 2

CO

3 (sat.), then brine, dried over Na 2

SO

4 , filtered and concentrated in vacuo. 20 The crude residue was purified by reverse-phase HPLC and lyophilized yielding a TFA salt of 3-amino-N-(5-cyano-2-(piperidin-1-yl)phenyl)pyrazine-2-carboxamide as a yellow fluffy solid (24%). LCMS (nz/z): 323.1 (MH*); LC R, = 4.62 min. -98- METHOD 10 Example 172 Synthesis of 3-amino-N-(4-(3-aminopipcridin- I -yl)pyridin-3-yl)pyrazine-2-carboxamide

NH

2 NH N IT NH 2 N 5 10238] Following method 9, 3-aminopyrazine-2-carboxylic acid was coupled to tert-butyl 1-(3-aminopyridin-4-yl)piperidin-3-ylcarbamate yielding tert-butyl 1-(3-(3 aminopyrazine-2-carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate as the TFA salt after lyophilization of the HPLC product fraction. Alternatively, the free base could be obtained as described in method 8, (83% yield). LCMS (m/z): 414.2 (MH*); LC R, = 10 2.18 min. [02391 A homogeneous solution of tert-butyl 1-(3-(3-aminopyrazine-2 carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate, either TFA salt or free base, in 25% TFA/DCM was allowed to sit for 2 hours. Upon removal of volatiles in vacuo, the residue was purified by HPLC. Direct lyophilization led to the isolation of 3-amino-N 15 (4-(3-aminopiperidin- I -yl)pyridin-3-yl)pyrazine-2-carboxamide as the TFA salt. Alternatively, the free base and HCI salt could be obtained as described in Method 8. LCMS (m/z): 314.1 (MH*); LC R,= 1.02 min. 10240] An alternative manner of removing the Boc protecting group and isolating the HCl salt was as follows: a heterogeneous solution of tert-butyl 1-(3-(3 20 aminopyrazine-2-carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate in 4 M HC/dioxane, at a concentration of 0.01 M, was stirred for 24 hours at which time the volatiles were removed in vacuo. After triturating and rinsing with diethyl ether the resultant solid was dissolved in McCN/H 2 0 and lyophilized yielding 3-amino-N-(4-(3-aminopipcridin-1 yl)pyridin-3-yl)pyrazine-2-carboxamide as the HCI salt. 25 The following compounds were prepared using Method 10. -99- Example Structure Name MH+ LC H 23-amino-N-[3-(3-aminopiperidin 173 N H I1-yl)pyridin-4-yI]pyrazine-2- 314.1 1.03 I~ , carboxamide N~, 0 NH 2 (N) N' 3-amino-N-[3-(3-aminopipcridin 174 HjI I-yI)pyridin-4-yI]pyridIne-2- 313.2 1.23 6 N Ip arboxamide N Ir 0 NH 2 N H 2Nhia 3-amino-N- {4- [(3 S)-3 -amino 17 H iperidin- I-yI]pyridin-3-yl} - 313.1 1.25 ~~pyridine-2-carboxamide 0NH 2 Cia 16N H Chra N-{4-[(3S)-3-aminopiperidin-1 17I H Ny]pyridin-3-yI) pyrazine-2- 314.1 1.05 carboxamide o N H CDI* N H2 Chral 3 -amino-N - f{4-[(3 R)-3 -amino 177 N H N 1 piperidin-1I-yf]pyridin-3- 314.1 1.06 N 1- N ypyrazine-2-carboxamide N> 0 NH 2 N) Br3-amino-N- {4-[4-(3-amino 178 N N p~ropanoyl)piperazin-1I-yI]- 491 13 NHr ~ pyridin-3-yl} -6-bromopyrazine- 491 13 < Yr' Y N.*y-carboxamidc N)0 NH 2 NH, N r 3-amino-N - f{4-[4-(aminoacetyl) 179 N N;, iperazin-1I-yl]pyridin-3-yI} -6- 435.1 1.23 H lN romopyrazine-2-carboxamide CJr NH 2 Br 3-amino-N- f{4-[3-(amino 180 N ethyl)plperidin- 1 -ylpyridin-3- 406 1.48 N Yl:: N y1I -6-bromopyrazinc-2 _____0 ( 0 NH carboxamide -100- Example Structure Name MH+ LC C N2 Br 3-amino-N-[4-(3-aminopiperidin 18 1, 1-yl)pyridin-3-yI]-6- 392 1.39 1 bromopyrazine-2-carboxamide N 0 N 2 NHH ci 3,5-diamino-N- {4-[3-(amino 182~ C JNH NAyNH2 methyl)piperidin- 1 -yl]pyrdin-3- 371 12 182 N H N I yl I}6-chloropyrazine-2-371 .2 rIN carboxamide 0 N H 2

SNH

2 C1 183N N --'Y NH 2 3,5-diamino-N-[4-(3-amino 18 IPeri din -I-yl)pyridin-3-yl]-6- 363.1 1.13 _ yN hloropyrazine-2-carboxamide 0N NH 2

NH

2 N~'N 3-amnino-N- (4-[3-(amninomnethyl) 184 H pipcridin-1I-yI]pyridin-3- 328.1 1.13 N Y y N y1)pyrazine-2-carboxamide 0 N2 ON) NH 3,5-Diamino-6-chloro-pyrazine , NH2 2-carboxylic acid (4-[4-(3- 2. . 185 N H N amino-propionyl)-piperazin-- 42. 1. 0 NH 2 ,), 1l]-pyridin-3 -yl}I-amide QN c 3,5-diamino-N-{(4-[4-(amnino H ~ }l -6-chloropyrazine-2 Y-I)- arboxamide 0NH CT N 3 -amino-N- [4-(3 -aminopiperi din 187 N H 0') 1 -yl)pyridin-3-yI]pyrazine-2- 313.8 1.04 NT carboxamide 0 N2 (N) 3-amino-N- {4-[4-(3 188 N H N: -), aminopropanoyl)piperaz in- I- 311 08 188 N H N' y ]pyidin3-yI pyazine-2-311 08 carboxamide N -101- Example Structure Name MH+ LC oY

NH

2 N 3-amino-N- {4-[4-(amino 189 N H N acetyl)piperazin-1-yl]pyridin-3- 356.8 0.83 N yJ- N yljpyrazine-2-carboxamide N0 NH2 NH 3-amino-N-[4-(3-amino 190 N H N pyrrolidin- 1 -yl)pyridin-3-yl]- 300.1 pyrazine-2-carboxamide O NH 2 H 3-amino-N-(4-piperazin- I-yl 191 N H N pyridin-3-yl)pyrazine-2- 300.1 N ) N carboxamide (N/ O NH 2 NH 2 Chiral N ,, N 3-amino-N-{ 4-[2R)-2-(amino H 192 N N methyl)pyrrolidin-1-yl]pyridin-3- 314.1 yl}pyrazine-2-carboxamide 0 NH2 N H 2

NH

2 3-amino-N-[4-(4-aminopiperidin 193 N H N I-yl)pyridin-3-yI]pyrazine-2- 314.1 ~N N carboxamide KNO

NH

2

NH

2 0O N11 3 -amino -N -[4-(2-amino 194 N ethoxy)pyridin-3-ylpyrazine-2- 275.1 (J N" Y,,, carboxamide o

NH

2 NH2 NT N 3-amino-N-[2-(3-aminopiperi din 195 N N N 1-yl)phenyl]pyrazine-2- 313.2 2.03 carboxamide O NH 2 NH2 N N 3-amino-N-[2-(3-aminopiperidin 196 1-yl)pyridin-3-yI]pyrazine-2- 314.2 1.66 N N carboxamide O

NH

2 -102- Example Structure Name MH+ LC

NH

2 N N N-[4-(3-aminopiperidin-1 -yl) 197 N pyridin-3-yI]pyrazine-2- 299.2 0.86 carboxamide N O

NH

2 N NCH N-[4-(3-aminopipcridin- 1 198 N H N yl)pyridin-3-yl]-5-methyl- 313.2 1.05 pyrazine-2-carboxamide N N H N N7) N"-N 3-amino-N-[4-(1,4-diazepan-1 199 N H NI yI)pyridin-3-yl]pyrazine-2- 314.1 0.55 N N carboxamide N-0 NH2 NH2 200 N H I 2-amino-N-[4-(3-aminopiperidin- 313.2 N N l-y1)pyridin-3-yl]nicotinamide N 0 NH 2 O NH 2 N HN 3-amino-N-{2-[(3S)-3-amino 201 N H N piperidin-] -yI]phenyl} pyrazine- 313.12 2.39 2-carboxamide 0 NH2 N (N) J3-amino-N-(2-piperazin- 1 202 N H N yiphenyl)pyrazine-2-carbox- 299.1 N.),rSN amide O0 NH2

NH

2 3 -amino-N-[2-(4-aminopiperidin 203 N H N I -yI)phenyl]pyrazine-2- 313.2 N N carboxamide N Br N 3-amino-N-[2-(3 -aminopiperidin 204 N N N 1-yI)phenyl]-6-bromopyrazine-2- 391 2.25 carboxamide O NH2 -103- Example Structure Name MH+ LC NH 2 Br -amino-N-[2-(4-aminopiperidin 205 N H N~T 1 -yl)phcnyl]-6-bromopyrazinc-2- 391 2.2 N _fJ-y N arboxamide (N) Br 3-amino-6-bromo-N-(2 206 N H N-, iperazin-1I-ylphenyl)pyrazine-2- 377 2.12 N NfO carboxamide 0 H 2 N N 3-amino-N-[2-(4-aminopipcridin 207 Ny!, I y)5( Hprzl5 379.1 2.01 0 NH2 1I)phenyl]pyrazine-2-carbox ~JNH amide NH, C ~ 3-amino-N-[2-(4-aminopiperidin 208 H~)~ I-yI)-5-fluoropflenyl~pyrazine-L- 311 24 rf carboxamide 0 NH, F

NH

2 3-amino-N-[2-(4-aminopiperidin 209 N H Ij 1-yI)-6-fluorophenylpyrazine-2- 331.2 1.99 ~Ny~yN carboxamide 3 -amino-N-[2-(4-aminopiperidin 210 N H N~j I-yl)-4-fluorophenyl]pyrazine-2- 331.1 2.38 F lr0 NH 2 NH2 Nd- 3-amino-N-[2-(4-aminopipcridin 211 H 1 y)5mtoyhnl--421.1 2.74 0 NH2 romopyrazine-2-carboxamide N H N 3 -amino-N-[2-(3 -aminopiperi din 212 N )1,,N I-yl)-5-methoxypheny]-6- 421.1 2.6 - 0 NH, bromopyrazine-2-carboxamide

HC

0 -104- Example Structure Name MH+ LC N N) 3-amino-N-(5-chloro-2 213 N pipcrazin-1-ylphcnyl)pyrazinc-2- 333.1 2.48 O NH 2 carboxamide CI

NH

2 3-amino-N-[2-(4-aminopiperidin 214 N N 1-yl)-5-chlorophenyl]pyrazine-2- 347.1 2.69 o Ncarboxamide o0 NH 2 CI

NH

2 N H N' 3-amino-N-[2-(3-aminopiperidin 215 N N 1-yl)-5-chlorophenyl]pyrazine-2- 347.1 2.66 o NH 2 carboxamide CI H N N> 3-amino-N-(5-methyl-2 216 N N piperazin- I -ylphenyl)pyrazine-2- 313.2 2.36 o NH 2 Carboxamide

CH

3

NH

2 NW 3-amino-N-[2-(4-aminopiperidin 217 k.H IN 1-yl)-5-methylphenyl]pyrazine-2- 327.1 2.48 0 NH 2 carboxamide

CH

3

NH

2 N H N3-amino-N-[2-(3-aminopiperidin 218 N1N 1-yl)-5-methylphenyl]pyrazine-2- 327.1 2.55 o NH 2 carboxamide CH, N NQ N-(5-acetyl-2-piperazin- I-yl 219 y N phenyl)-3-aminopyrazine-2- 341.1 1.99 O NH2 CarboXamide

H

3 C 0

NH

2 NHN N-[5-acetyl-2-(4-aminopiperidin 220 N N 1-yI)phenyl]-3-aminopyrazine-2- 355.2 2.11 O NH 2 arboxamide HIC 0 -105- Example Structure Name MH+ LC

KNH

2 ~N H N'j N-[5-acetyl-2-(3-aminopiperidin 221 1I-yl)phcnyl]-3-aminopyrazinc-2- 355.2 2.2 0 NH 2 carboxamide 0 CH 3

NH

2 H N-) 3-amino-N-[2-(4-aminopiperidin 222 r,, I1-yI)-5-mcthoxyphcnyl]pyrazine- 343.1 2.33 0 NH 2 2-carboxamide

SNH

2 (NJ H N> 3-amino-N-[2-(3-aminopiperidin 223 r Nyr),N I1-yI)-5-methoxyphenyI]pyrazine- 343.1 2.39 0 NH 2 2-carboxamide H3C' 0 (N)~ 3-amino-N-[2-piperazin- I -yI-5 224 N IlYN(trifluoromethyl)phenyl]pyrazine 367.1 2.72 0 NH, -2-carboxamide F

NH

2 ON N ~ -amino-N-[2-(4-aminopiperidin 225 YI I-yI)-5-(trifluoromethyl)phenyfl- 381.1 2.87 0 NH 2 pyrazine-2-carboxamide NH, ~N H N>3-amino-N-[2-(3-aminopiperidin 226 N1 N I-yi)-5-(trifluoromethyl)phenyl]- 381.1 2.88 - 0 NH, pyrazine-2-carboxamide F H N )j 3aioN(-ehl2 227 NI HN N perazin- 1 -ylphenyl)pyrazine-2- 3.2 2.32 1 -1 N--r N carboxamide31.

H

3 C (2

NH

2 3- amino-N-[2-(4-aminopiperidin 228 N HN"j I1-yl)-4-methylphenylpyrazine-2- 327.2 2.46

NH

2 T carboxamide -106- Example Structure Name MH+ LC 1 y NH 2 - m n - -2( - m n p p rd 229 N 1y1).4-rnethylphenyl]pyrazine-2- 327.2 2.53 I carboxamide _____ H 3 C,: 0 NH 2 CrNH, ~N H N ~ 3 -amino-N-[2-(3 -ami nopiperi din 230 Ny , ]-yl)-5-cyanophcnyl]pyrazinc-2- 338.2 2.33 ,- 0 NH 2 carboxamide N, N > -amino-pyrazine-2-carboxylic N N 231 - INH? acid [2-(3-amino-piperidin-1-yl)- 417.1 2.79 0 5-benzoyl-phenyl]-amide N N"-), 3-amino-pyrazine-2-carboxylic 232 N acid (5-benzoyl-2-piperazin-1-yi- 403.2 2.7 0 NH, henyl)-amide 'N a NH, O No'), 3-amino-pyrazine-2-carboxylic 233 NY1 N acid [2-(4-amino-piperidin-1-yI)- 417.2 2.83 0NH, 5-benzoyl-phenyl]-amide N 0 N HN'N 3-amino-N-[2-(4-anIinopiperidin 234 <&.NylI ,N 1-yl)-5-(methylsulfonyl)phenyl]- 391.1 1.89 0t.r NH 2 pyrazine-2-carboxamide S. 0 NH 2 N N'N 3-amino-N-[5-(3-aminopiperidin H~'~ I1-yl)-2-oxo-2,3-dihydro 235 1 Nn t,,Y pyrimidin-4-ylpyrazine-2- 331.1 1.18 NyNH 0 NH 2 carboxamide 0

NH

2 K~r 1 ~ 3,5-diamino-N- {5-r3-(amino 236 "N' N (2 ethyl)piperidin- I -yl]-2-oxo- 394.1 1.47 rArNYzN 2,3-dhydropyrimidin-4-yl}1-6 N y<NH 0 NH 2 chloropyrazine-2-carboxamide 0 -107- Example Structure Name MH+ LC OyfNH 3 -amino-N-(5 -[4-(3-amnino 237 N N"'), p~ropanoyl)pipcrazin-1I -yl]-2-oxo- 381 11 237ll N N 23-dihydropyrimidin4-yl - 381 11 NfNH 0 H 2 yrazinc-2-carboxamide 0,fNH, ,5-diamino-6-chloro-pyrazine-2 238N> ) " Harboxylic acid t5-[4-(3-amino 23 H~ N yH prop ionyl)-pi1perazin-1I-yl]j-2-oxo- 437.1 1.27 rl-,r N~zzN ,3-dihydro-pyrimidin-4-yl} N yNH 0 NH 2 amide 0 CTNH2 Br NH 3-amino-N-[5-(3-aminopiperidin 'N H N I1-yl)-2-oxo-2,3-dihydro 239 ry Vy yrimidin-4-yl]-6-bromo- 409 1.58 NyNH 0 NH 2 pyrazine-2-carboxamide 0 ~f~N~j~ 3-amino-N-{(5-[3-(aminomethyl) 240 N Nf iperidin-1I-yl]-2-oxo-2,3- 43 17 I Y- - dihydropynrnidin-4-yl) 6 0 (N Br 3-amino-N- 5 -[4-(3-amino 241 )HNJN propanoyl)pipcrazin-1I -yl]-2-oxo- 461 14 241y N,,N ,3-dihydropyrimidin-4-yi) -6- 461 14 N yNH 0 NH 2 bromopyrazine-2-carboxamide 0 NH2 N) 3-amino-N-[5-(3-aminopiperidin H I1-yI)-2-oxo-2,3-dihydro 242 ~ 1 pyrmidin-4-yl]pyridine-2- 301 12 N H N2 carboxamide 0 N NH N") 3-amino-pyrazine-2-carboxylic 243 Ny- ,N acid [2-(3-amino-piperidin-l-yl) 311 24 243 LI~J 0 NH, 5-cyclopropanecarbonyl-phenyl]- 311 24 amide -108- Example Structure Name MH+ LC N*'),3-amino-pyrazine-2-carboxylic 24 N acid [2-(4-amino-piperi din-1I-yOI8) 1 24 ) NHy 5-cyclopropanecarbonyl-phenyl]-I311 24 oz amide H (N) N H N!' ' 3-amino-N-[5-(cyclopropyl 245 )-,- carbonyl)-2-piperazin-1-yI- 367.1 2.32 0 NH 2 henyl]pyrazine-2-carboxamide Chiral H FH 5-Amino-2-(2,6-difluoro 2N F IF hcnyl)-pyrimidine-4-carboxylic 246 N9 acid (3,5-diamino-3,4,5,6-tetra- 441.2 1.30 N H oll N ydro-2H-[ I ,4']bipyridinyl-3'-yI) &NH2 amide Chiral

I

2 ~ ~ . > H ", 5-A rino-2-(2-fluoro-phenyl) 247 ). ? yrmidine-4-carboxylic acid 423.2 1.39 N H N;1 I N (3,5-diamino-3,4,5,6-tetrahydro Chiral H2 NF -Amino-6-(2-fluoro-phenyl) 248.<>#H F yrdine-2-carboxylic acid (3,5- 422 16 N H N diamino-3,4,5,6-tetrahydro-2H N [1,4']bipyridinyl-3'-yI)-amide NN

H

2 Cra N- f 4 -[(3 S)-3 -am inop ip eri din O ,NN~~p I N -yI]pyridin-3-yl }-2-(2,6 Cfdifluorophcnyl)pyrimidinc-4 249 N N r N carboxarm'deN-{(4-[(3SJ-3- 411.1 1.67 N ~ aminopiperidin- I-yI]pyridin-3 pyrimidine-4-carboxamide ____ ..... NH2 K>.F Chm - f 4-(3S)-3-aminopiperidin-1 K) .LY1]Pyridin-3-yI}-2-(2-fluoro 250 N H f henyl)pyrimidine-4-carbox- 393.2 1.71 amide -109- Example Structure Name MH+ LC

NH

2 N N- 3-Amino-6-(2-fluoro-phenyl) 251 F pyridine-2-carboxylic acid {4-[4 251 N 3-amino-propionyl)-piperazin-1I - 464.2 1.98 H ylI]-pyridin-3-yl}I-amide N N N 3-Amino-6-(2-fluoro-phenyl) 252 (N F pyridine-2-carboxylic acid {4-[~4- 450.2 1.94 N - 2-amino-acetyl)-piperazin-1I-yl] _______~N H pyridin-3-yll}-amide NH2

CH

3 NH 3-Amino-6-(2-fluoro-5 F 0 isopropylcarbamoyl-phenyl) 253 ~ !>\NH yridine-2-carboxylic acid (3- 510.3 2.09 K) amino-4-fluoro-3 ,4,5 ,6-tetra C H N ydro-2H-[ I ,4']bipyridinyl-3'-yI) N a mide

NH

2 NN NHI 3-Amino-6-(2-fluoro-phenyl) NF12 F yr idine-2-carboxylic acid (3 254 N N amino-4,4-difluoro-3,4,5,6-tctra- 443.2 2.14 NZ N ydro-2H-[ 1 ,4']bipyridinyl-3'-yl) amide

CH

3 NH 3-Amino-6-(2-fluoro-5 N 0 isopropylcarbamoyl-phenyl) 255 NH -yridine-2-carboxylic acid (3- 583 21 amino-4,4-difluoro-3,4,5,6-tetra- 583 21 N H N N ydro-2H-[ I ,4']bipyridinyl-3'-yl) N amide NH1 2 F 5-Amino-2-(2,6-difluoro 11 N$7 F henyl)-pyrimidine-4-carboxylic 256 NHNNacid (3-amino-4-fluoro-3,4,5,6- 444.1 1.71 HN N tetrahydro-2H-[ 1 ,4'Ijbipyridinyl 0 NH 2 3-yl)-amide -110- Example Structure Name MH+ LC F f_

(INH

2 S _N 3-amino-N-{f4- [(3R,4R)-3 -amino 257N 4-fluoropiperidin- I-yI]pyr-idin-3 27N H -1 l -6-(1I,3-thiazol-2-yI)pyridine- 441 15 III -carboxamide 0 NH

FCH

3 1NH 3-Amino-6-(2-fluoro-5 F NH 2 0 . isopropylcarbamoyl-phenyl) 258 F pyridine-2-carboxylic acid (3- 510.3 1.62 K) 'amino-4-fluoro-3 ,4,5 ,6-tetra N H: ydro-2H-[ 1,4']bipyridinyl-3'-yl) JN amide

NH

2 (UsNH2 Br Chiral 3amino-N-{(4- [(3S-3 -amino N5 N H r iperidin-I-yI]pyrid in-3-yll-6- 491 17 259 r 4 N y bromo-5-fluoropyridine-2-491 .7 N 0 NH 2 arboxamide 0 1' NH2Chiral N NylF 3-amino-N-{f4- [(3S)-3 -amino 260 N iperidin- I-yIlpyridin-3-yi} -5- 331.1 1.42 (1 r~yfluoropyridine-2-carboxamide N 0 NH2

CH

3 NH 2 '' 5-Amino-2-phenyl-pyrimidine-4 261C N N carboxylic acid (3-amino-3- 442 19 261 N H N all I N ethyI-3,4,5,6-tetrahydro-2H- 442 19 ' I N N H2 1 ,4']bipyridiny-3'-yI)-amide I 5-Amino-2-phenyl-pyrimidine-4 (OH ~ carboxylic acid (3-hydroxy-3 262 N H N. I N trifluoromethyl-3,4,5,6-tetra- 459.1 2.89 hdro-2H-[ 1 ,4']bipyridinyl-3'-yl) amnide

NH

2 H2N F5-Amino-2-(2-fluoro-phenyl) 263 N ~~yrmidine-4-carboxylic acid (3- 482 17 263 nN H We I N amino-3,4,5,6-tetrahydro-2H- 482 17 C 1 Iz N ,4'Ibipyridiny-3'-y)-amide IN &NH 2 Example Structure Name MH+ LC H2I 3-Amino-5-phenyl-pyridine-2 264 N H N- carboxylic acid (3 -amino -3,4,5,6- 393 2.12 1<11 N etrahydro-2H-[ 1 ,4']lipyr-idinyl N NH 2 3-yl)-amide H2N 5-Amino-2-phenyl-pyrimidine-4 265 H 2 N N.(N crboxylic acid (3 -amino -3,4,5,6- 390.1 1.86 H 11 etrahydro-2H-f I ,4'lbipyridinyl _______N

NH

2 FFg NH 2 I3-Amino-6-(2,6-difluoro F1 F hnyl)-pyridine-2-carboxylic 266 N 1 N acid [4-(6-amino-2- 488.1 2.97 H IN t~ri fluoromethyl -pyri mi din -4-yi) -~~ NH 2 pyr ii--I-m N

CH

3 HN O_ H 3 03 -Amino-6-(2-fluoro-5 CH 3

N

2 i~0 .sopropylcarbamoyl-phenyl) 267 N11 F yridine-2-carboxylic acid [4-(2- 517.2 2.69 N VN amino-6-methoxy-pyrimidin-4 H 1l)-pyridin-3-yl]-amide N NH2 CH3< N NH 2 5-Amino-2-phcnyi-pyrimidinc-4 268 NZ N -N carboxylic acid [4-(6-amino-2- 399.2 2.13 H A Ij methyl-pyrimidin-4-yi)-pyridin N N NH2 3-yi]-anide

CH

3 N NH 2 I 5Amiuno-2-phenyl-pyrimidine-4 269 N N carboxylic acd('aio2- 398.2 2.02 H I methyl-[4,4'jbipyridinyl-3-yl) I Z NN mide ______&

H

2 -112- Example Structure Name MH. LC Chiral ~NHF I 'I I 5-Am-ino-2-(2,6-difluoro 27 F9 phenyl)-pyimidine-4-carboxylic 462 17 20N H Nol IN acid (3-amino-3,4,5,6-tctrahydro- 462 17 N! I &,- " H-[ 1 ,4']bipyridinyl-3'-yl)-amide CH N 6 N NH 2 3Amiino-6-(2,6-difluoro F-r - F henyl)-pyridine-2-carboxylic 271 N 1~ N a cid [4-(6-amino-2-methoxy- 450.2 2.70 H rN N yrmidin-4-yl)-pyridin-3-yI] N

H

2 N N CH 3 5 5-Amino-2-(2-fluoro-phenyl) 272 N ;1I pyrmidine-4-carboxylic acid [4- 2.0 417.00 H (6-amino-2-methy1-pyrimidin-4 _______N

NH

2 0 CH 3 N N CH33-Amino-6-(2-fluoro-5

H

2 N N_ F 3 H isopropylcarbamoyl-phenyl) 273 1 yridine-2-carboxylic acd[4-(6- 50.2 2.29 H Iamino-2-methyl-pyrimidin-4-yI) N ______ I NH 2 yridin-3-yl]-amide _________ N N________H,2_________

H

2 N N CH/ 3-Amino-6-(2,6-difluoro F IF phenyl)-pyridine-2-carboxylic 27 cid [4-(6-amino-2-methyl- 434.1 2.30 N pyrimidin-4-yi)-pyridin-3-yI] -NH 2 amide N2

CH

3 N H2N N 1 - I F 3-Amino-6-(2,6-difluoro F hey)pndie2croyi 275 H N- acid [4-(6-amino-2- 466.1 2.89 H methylsulfanyl-pyrimidin-4-yl)

INH

2 pyridin-3-yI]-amide FF N7 N N' acid (3-amino-4-fluoro-3,4,5,6- 443.2 2.05 H tetrahydro-2H-[ 1 ,4']bipyridinyl

N

Example Structure Name MH+ LC Chiral I\ 3-Amino-6-(2,6-difluoro IF F phenyl)-pyridine-2-carboxylic 277N NNZai 3aio4fur-,,,- 432 20 2 H N "c d (

-

m n

-

-

l or

-

, , ,

-

4 3 2 2 0 N tetrahydro-2H-[ 1 ,4'Ilbipyridinyl N e5 '-yl)-amide (NH

H

2 N i3-Amino-6-(2,6-difluoro F F phenyl)-pyridine-2-carboxylic 278 N H N, '-.. acid (5-amino-3-fluoromethyl- 457.1 2.17 I) 3,4,5,6-tetrahydro-2H-[ 1,4']bi KN) NH 2 yridinyl-3'-yI)-amide FI1 F F NH, 3 -Amino-6-cyclohexyl-pyri dine F 2-carboxylic acid (3-amino-5 279 ' NTH N *-. rifluoromethyl-3,4,5,6-tctra- 463.1 2.30 N hydro-2H-[ 1 ,4']bipyridinyl-3'-yI) 'mide F N NI1 F IF NH, F 3-Fluoro-6-(2-fluoro-phenyl) F F yr-idine-2-carboxylic acid (3 280 N H N . mino-5-trifluoromethyl-3,4,5,6- 478.0 2.32 N - etrahydro-2H-[ 1 ,4']bipyridinyl L F 3'-yl)-amide FNH, .- 5-Fluoro-6-(2-fluoro-phenyl) F F pyridine-2-carboxylic acid (3 281 N IN, F amino-5-trifluoromethyl-3,4,5,6- 478.1 2.42 N - 10 etrahydro-2H-[ 1,4']bipyridinyl ~jj I 3-yI)-amide F N FNH ~- 3-Amino-6-(2,6-difluoro F> 2 F F phenyl)-pyridine-2-carboxylic 282 N IN - acid (3-amino-5-trifluoroniethyl- 493.1 2.36 N 3,4,5,6-tetrahydro-2H-[ 1,4']bi

L~JJNH

2 pyridinyl-3'-yI)-amide CH, NH, 3-Amino-6-cyclohexyl-pyri dine 283 %NH 2 N-carboxylic acid (3-amino-5- 492 24 rjH N 1 methyl-3,4,5,6-tetrahydro-2H- 492 24 N 1I,4']bipyridinyl-3'-yI)-amidc _______N NH 2 -114- Example Structure Name MH+ LC Chiral F//i .\\H2 -Amino-6-cyclohexyl-pyridine 284 [2)-carboxylic acid (3-amino-5- 413.1 2.27 NNH N fluoro-3,4 ,5 ,6-tetrahydro-2H N[1 ,4']bipyridinyl-3'-yl)-amide Chiral

CH

3 \NH2 3-Amino-6-cyclohexyl-pyridine 285 2~-carboxylic acid (3-amino-5- 452 23 285 N H N ' ethoxy-3,4,5,6-tetrahydro-2H- 452 23 N [1,4']bipyridinyI-3'-yl)-amide NH2 N'

CH

3 S NH 2 F -Fluoro-6-(2-fluoro-phenyl) N N yrdine-2-carboxylic acid (5 286 N Namino-3-mcthyl-3,4,5,6-tctra- 424.1 2.20 N hydro-2H-[ 1,4']bipyridinyl-3'-yI) K) F amide (UTI

CH

3 " NH 2 F 5-Fluoro-6-(2-fluoro-phenyl) F pyridine-2-carboxylic acid (3 287 N N F mino-5-methyl-3,4,5,6-tetra- 424.1 2.31 NA I ydro-2H--[ 1,4']bipyridinyl-3'-yl) KIJ amide CH NH- 2 I -Ami~no-6-(2,6-difIuoro ,C>- F F phenyl)-pyridine-2-carboxylic 288 N N N 1acid (3-amino-5-methyl-3,4,5,6- 439.1 2.27 NiSj I -trahydro-2H-[ 1 ,4']bipyn~dinyl

H

2 N OH 5-Fluoro-6-(2-fluoro-phenyl) F 289 N N N amino-3-hydroxymethyl-3,4,5,6- 440.1 1.94 N tetrahydro-2H-[ 1,4']bipyridinyl KN) '-yl)-amide H, N F F 3-Amino-6-(2,6-difluoro 290 N phenyl)-pyridine-2-carboxylic 465.1 2.12 NH acid [4-(2,7-diaza-spirol4.5]dec _______N NH 2 Example Structure Name MH+ LC H N N 3-Amino-6-(2-fluoro-5 F .sopropylcarbamoyl-phenyl) 291 pyridine-2-carboxylic acid [4- 532.1 2.02 N H N (2,7-diaza-spiro[4.5]dec-7-yl) N pyridin-3-yl]-amide CN

NH

2 0 CH 3 N C 3-Amino-6-(2-fluoro-5 F/, ,NH 2 H isopropylcarbamoyl-phenyl) 292 F pyridine-2-carboxylic acid (3- 510.0 2.12 N N1 amino-5-fluoro-3,4,5,6-tetra hydro-2H-[ 1,4']bipyridinyl-3'-yl) amide N NH 2 Chiral F NH2 3-Amino-6-(2,6-difluoro F F phenyl)-pyridine-2-carboxylic 293 N N acid (3-amino-5-fluoro-3,4,5,6- 443.0 2.07 H_ Ctetrahydro-2H-[ 1,4']bipyridinyl 3'-yl)-amnide __ N N1H 2 No 0 Benzoic acid 5-amino-3'-{[3 DH H amino-6-(2-fluoro-5 294 ,\NH2IF isopropylcarbamoyl-phenyl)- 612.1 2.49 N pyridine-2-carbonyl]-amino) | 3,4,5,6-tetrahydro-2H-[1,4']bi pyridinyl-3-yl ester

NH

2 Chire

\NH

2 F Benzoic acid 5-amino-3'-{[3 ' F F amino-6-(2,6-difluoro-phenyl) 295 H N pyridine-2-carbonyl]-amino}- 545.0 2.51 H N 3,4,5,6-tetrahydro-2H-[1,4']bi

NH

2 pyridinyl-3-yl ester 0 CH NA 3-Amino-6-(2-fluoro-5 HO \NH H isopropylcarbamoyl-phenyl) 296 IF pyr ridine-2-carboxylic acid (3- 508.2 2.00 N N amino-5-hydroxy-3,4,5,6-tetra H hydro-2H-[ 1,4']bipyridinyl-3'-yl) amnide N

NH

2 -116- Example Structure Name MH+ LC Chiral HO IH 3-Amino-6-(2,6-difluoro F\H F phenyl)-pyridine-2-carboxylic 297 n . N acid (3-amino-5-hydroxy-3,4,5,6- 441.1 1.80 N tetrahydro-2H-[ 1 ,4'Ijbipyridinyl

NH

2 3'-yI)-amide o CH 3

CH

3 N N) '.C Amino6(2-fluoro-5 11 NH 2 H isopropylcarbamoyl-phenyl) 298 I\F pyridine-2-carboxylic acid (3 29 0 1~ amino-5-methoxy-3,4,5,6-tetra- 522.2 2.01 )..,N ' hydro-2H-[ I ,4']bipyridinyl-3'-yl) amide _____ __ NNH 2

CH

3 0 N -Amino-6-(2-fluoro-5 N-2' ...- J sopropylcarbamoyl-phenyl) 299 F CH 3

CH

3 pyridine-2-carboxylic acid (3- 520 20 N N -amino-4-methoxy-3,4,5,6-tetra- 520 20 )JI N'ydro-2H-[ 1 ,4']bipyridinyl-3'-yl)

NH

2 amide N_ NH,2 Chiral

CH

3 N I%\H 3-Amino-6-(2,6-difluoro *QjjS F F phenyl)-pyridine-2-carboxylic 300 N acid (3-amino-5-methoxy- 455.2 1.98 HI 3 ,4,5,6-tetrahydro-2H-[ 1 ,4']bi

NH

2 yridinyl-3'-yI)-amide

CH

3

NI

0 1 N 3-Amino-6-(2,6-difluoro (L~ F 'F phenyl)-pyridine-2-carboxylic 301 H N acid (3-amino-4-methoxy- 455.0 1.96 H 3,4,5,6-tetrahydro-2H-[ 1 ,4']bi pyridinyl-3'-yI)-amide ($N N _ _ _ _ N2 Ch iral 04 3-Amino-6-(2,6-difluoro K NH F F phenyl)-pyridine-2-carboxylic 302 -acid [4-(2-oxo-hexahydro- 467.0 2.40 N H N 1 xazolo[4,5-c]pyrIdin-5-yl) N pyridin-3-yl]-amide ________ NNH 2 -117- Example Structure Name MH+ LC 0 Chiral %\NH 3-Amino-6-(2,6-difluoro F F phenyl)-pyridine-2-carboxylic 303N N acid [4-(2-oxo-hexahydro- 467.0 2.40 H oxazolo[4,5-c]pyridin-5-yl) ____ _ NH 2 Npyridin-3-yl]-amide NH Example 304 Synthesis of N-(4-(3-acetamidopiperidin- I -yl) pyridin-3-yl)-3-amino-6-bromopyrazine-2-carboxamide Br N N 5 H N5 NH 2 10241] To solution of 3-amino-N-(4-(3-aminopiperidin-I -yl)pyridin-3-yl)-6 bromopyrazine-2-carboxamide in CH 2 Cl 2 at a concentration of 0.5 M at room temperature was added triethylamine (3 eq) followed by acetic anhydride (1.2 eq). The reaction was stirred at room temperature for 30 minutes, concentrated, purified by reverse 10 phase HPLC and lyophilized to provide N-(4-(3-acetamidopiperidin-I-yl)pyridin-3-yl)-3 amino-6-bromopyrazine-2-carboxamide, as the TFA salt. LCMS (mn/z): 434.1 (MH-. METHOD II Example 305 Synthesis of tert-butyl 1-(3-(3-amino-6-bromopyrazine 15 2-carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate NHBoc Br N N S -18- N -118-1 [0242] A solution containing I eq each of tert-butyl 1-(3-aminopyridin-4 yl)piperidin-3-ylcarbamate, 3-amino-6-bromopyrazine-2-carboxylic acid, HOAT and EDC in DMF, at a concentration of 0.5 M, was stirred for 60 hours. The solution was diluted with EtOAc and was washed with H20 (4x), NaCl(sat.), was dried over MgSO 4 , 5 was filtered and the volatiles were removed in vacuo. After purification by silica gel chromatography (EtOAc eluant), tert-butyl 1-(3-(3-amino-6-bromopyrazine-2 carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate was obtained (78%). LCMS (m/z): 492.2 (MH*); LC R, = 2.68 min. Example 306 10 Synthesis of tert-butyl 1-(2-(3-amino-6-bromopyrazine 2-carboxamido)-4-benzoylphenyl) piperidin-4-ylcarbamate NHBoc Br H N N NN

NH

2 [0243] Following method 11, tert-butyl 1-(2-amino-4 benzoylphenyl)piperidin-4-ylcarbamate was coupled to 3-amino-6-bromopyrazine-2 15 carboxylic acid with TEA (1.5 eq) in ACN at 55'C for 48 hours. Concentrated, triturated in cold ACN, filtered, and dried in vacuo yielding tert-butyl 1-(2-(3-amino-6 bromopyrazine-2-carboxamido)-4-benzoylphenyl) piperidin-4-ylcarbamate (46 %). LCMS (mL/z): 595.2 (MH+); LC Rt = 3.94 min. Example 307 20 Synthesis of tert-butyl 1-(2-(3-amino-6-bromopyrazine 2-carboxamido)-4-benzoylphenyl) piperidin-3-ylcarbamate NHBoc Br NN N H N- I

NH

2 0 -119- [02441 Following method 11, tert-butyl 1-(2-amino-4 benzoylphenyl)piperidin-3-ylcarbamate was coupled to 3-amino-6-bromopyrazine-2 carboxylic acid with TEA (1.5 eq) in ACN at 55'C for 48 hours. Concentrated, triturated in cold ACN, filtered, and dried in vacuo yielding tert-butyl 1-(2-(3-amino-6 5 bromopyrazine-2-carboxamido)-4-benzoylphenyl) piperidin-3-ylcarbamate (30 %). LCMS (m/z): 595.1 (MH+); LC Rt = 3.87 min. Example 308 Synthcsis of tcrt-butyl 4-(2-(3-amino-6-bromopyrazinc 2-carboxami do)-4-benzoylphenyl) piperazine- 1 -carboxylate Boc (N) Br N H N N Tz4 N

NH

2 100 10I 102451 Following method 11, tert-butyl 4-(2-amino-4 benzoylphenyl)piperazine- 1 -carboxylate was coupled to 3-amino-6-bromopyrazine-2 carboxylic acid with TEA (1.5 eq) in ACN at 55'C for 48 hours. Concentrated, triturated in cold ACN, filtered, and dried in vacuo yielding tert-butyl 4-(2-(3-amino-6 15 bromopyrazinc-2-carboxamido)-4-benzoylphcnyl) piperazine- 1 -carboxylate (50%). LCMS (m/z): 581.1 (MH+); LC Rt = 4.00 min. Example 309 Synthesis of tert-butyl I-(2-(3-amino-6-bromopyrazine 2-carboxamido)-4-mcthoxyphcnyl) piperidin-4-ylcarbamate NHBoc H Br 20 N H H N N 20 [02461 Following method 11, tert-butyl 1-(2-amino-4 methoxyphenyl)piperidin-4-ylcarbamate was coupled to 3-amino-6-bromopyrazine-2 carboxylic acid with TEA (3 eq) in ACN at 55'C for 48 hours. Concentrated, triturated in -120cold ACN, filtered, and dried in vacuo yielding tert-butyl 1-(2-(3-amino-6 bromopyrazine-2-carboxamido)-4-methoxyphenyl) piperidin-4-ylcarbamate (7%). LCMS (m/z): 521.1 (MH*); LC R 1 = 3.63 min. Example 310 5 Synthesis of 3,5-diamino-6-chloropyrazine-2-carboxylic acid C1

NH

2 HO N

NH

2 102471 To a solution of methyl 3,5-diamino-6-chloropyrazine-2-carbamate (5 g, 0.025 mols ) in 2:1 THF/MeOH (90 mL) was added IM LiOH (62 mL, 0.062 mols ). After the reaction was stirred at r.t. 72 hrs, IN HCI (62 mL, 0.062 mols ) was added. The 10 reaction was filtered and washed with water (3 x 10 mL) to give 3,5-diamino-6 chloropyrazine-2-carboxylic acid as white solid 4.3 g (93 % yield). LCMS (m/z): 189.1 (MH+); LC Rt = 1.05 min. Example 311 Synthesis of 3,5-diamino-6-chloro 15 N-(4-(piperidin- I -yl)pyridin-3-yl)pyrazine-2-carboxamide N C NH 2 HH NI NH NH [0248] Following method 11, 4-(piperidin-1-yl)pyridin-3-amine was coupled to 3,5-diamino-6-chloropyrazine-2-carboxylic acid yielding 3,5-diamino-6-chloro-N-(4 (piperidin-1-yl)pyridin-3-yl)pyrazine-2-carboxamide (76 %). LCMS (m/z): 347.8 20 (MH+); LC Rt = 2.17 min. -121- Example 312 Synthesis of 3,5-diamino-N-(4-(piperidin- I -yl)pyridin-3-yl)pyrazine-2-carboxamide C) NH 2 N H N H 2 N N 102491 Following method 2 where diethylamine (4.0 eq) was also included and 5 the reaction was recharged with Pd/C and H 2 after 2 and 4 days, 3,5-diamino-6-chloro-N (4-(piperidin-1-yl)pyridin-3-yl)pyrazine-2-carboxamide was reduced in 7 days yielding 3,5-diamino-N-(4-(piperidin-1-yl)pyridin-3-yl)pyrazine-2-carboxamide as the TFA salt LCMS (m/z): 314.1 (MH+); LC Rt = 1.67 min. Example 313 10 Synthesis of tert-butyl 1-(3-(3,5-diamino-6-chloropyrazine-2-carboxamidolpvridin-4 yl)piperidin-3-ylcarbamate NHBoc CI N N NH 2 NN 10250] Following method 11, tert-butyl 1-(3-aminopyridin-4-yl)piperidin-3 ylcarbamate was coupled to 3,5-diamino-6-chloropyrazine-2-carboxylic acid yielding (S) 15 tert-butyl 1-(3-(3,5-diamino-6-chloropyrazine-2-carboxamido)pyridin-4-yl)piperidin-3 ylcarbamate (57 %). LCMS (m/z): 463.1 (MH+); LC Rt = 2.36 min. Example 314 Synthesis of 3-amino-6-bromopicolinic acid Br HO N

NH

2 20 102511 To a solution of methyl 3-amino-6-bromopicolinate ( 2 .31g, 10 mmoles) in 2:1 THF/MeOH (51 mL) was added 1.0 M LiOH (17 mL, 17 mmoles). After stirring -122for 16 hours, 1 N HCl (17 mL, 17 mmoles) was added and the THF/MeOH was removed in vacuo. The resulting solid was filtered, rinsed with cold H 2 0 (4 x 20 mL) and pumped on yielding 3-amino-6-bromopicolinic acid (97%). LCMS (m/z): 216.9 (MH+); LC Rt = 1.93 min. 5 Example 315 Synthesis of (S)-tert-butyl 1-(3-(3-amino 6-bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbamate 0NyNHBoc Br N H

N

N N H2 [02521 Following method 11, (S)-tert-butyl 1-(3-aminopyridin-4-yl)piperidin 10 3-ylcarbamate was coupled to 3-amino-6-bromopicolinic acid and purified by SiO2 chromatography (EtOAc eluant) yielding (S)-tert-butyl 1-(3-(3-amino-6 bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (45 %). LCMS (m/z): 491.1 (MH+); LC Rt = 2.89 min. METHOD 12 15 Example 316 Synthesis of 3-amino-N-(4-(3-aminopiperidin-1-yl) pyridin-3-vl)-6-(2-chlorophenyl)pyrazine-2-carboxamide NH2 "CI H 14 I N N NN [0253] A solution of tert-butyl 1-(3-(3-amino-6-bromopyrazine-2 20 carboxamido)pyridin-4-yl)piperidin-3-ylcarbamate (1.0 eq), ortho-chlorophenyl boronic acid (3.0 eq.), Pd(dppf)C1 2

-CH

2

CI

2 and triethylamine (9.0 eq.) in dimethylacetamide ( concentration = 0.1 M) was heated at 130"C with microwave irradiation for 900 seconds. Upon cooling the N-Boc Suzuki product was directly purified by reverse phase HPLC. -123- The product fraction was lyophilized and the resulting solid was treated with 25% TFA/DCM (at a resulting concentration of 0.05 M). After sitting for 2 hours, the volatiles were removed in vacuo and the residue was purified by reverse phase HPLC. After lyophilization, 3-amino-N-(4-(3-aminopiperidin-I -yl)pyridin-3-yl)-6-(2 5 chlorophenyl)pyrazine-2-carboxamide was obtained (56 %) as the TFA salt. LCMS (m/z): 424.1 (MH+); LC Rt = 1.94 min. 102541 Alternatively, the free base and HCI salt could be obtained as described in Method 9. [02551 The following compounds were prepared using Method 12. In some 10 instances NMP or DMF was used in place of dimethylacetamide. Example Structure Name MH+ LC 3-amino-6-(2-fluoro-5-iso HN CH propylcarbamoyl-phenyl) 317 yridine-2-carboxylic acid 4922 24 31 HN'' (S)-3-amino-3,4,5,6-tetra N Ihydro-2H-[1,4']bipyridinyl-3' N 0 NH2 1)-amide_ 3-amino-6-[2-methyl-5 (piperidine- 1 -sulfonyl) 318 phenyl]-pyridine-2-carboxylic 550.3 2.44 N acid ((S)-3-amino-3,4,5,6 tetrahydro-2H-[ 1,4']bi N NH2 ydinyl-3'-y)-amide 0 ,CH cn1 O' 3-amino-6-(4-methane ,NH | Sulfonyl-phenyl)-pyridine-2 319 [^' carboxylic acid ((S)-3-amino- 467.2 1.77 N HN 3,4,5,6-tetrahydro-2H-[1,4']bi 0 NH, yrdinyl-3'-yl)-amide o oa (N. CH, 3-amino-6-(3-methane 2 Sulfonyl-phenyl)-pyridine-2 320 N carboxylic acid ((S)-3-amino- 467.2 1.77 N 3,4,5,6-tetrahydro-2H-[ 1,4']bi 0NH pyridinyl-3'-yl)-amide

NH

2 0 o ""o3-amino-6-[2-methyl-5 N -pyrrolidinc-1-sulfonyl) 321 H C phenyl]-pyridine-2-carboxylic 536.2 2.27 NH N acid ((S)-3-amno-3,4,5,6 tetrahydro-2H-[ l,4']bi NONH2 pyridinyl-3'-yl)-amide -124- Example Structure Name MH+ LC 0H~ 3-amino-6-(2-chloro-5 e'"'"NH, ethoxy-phenyl)-pyridine-2 322 N() N carboxylic acid ((S)-3-amino- 467.2 2.43 , I 3,4,5,6-tetrahydro-2H-[ I ,4']bi 0NI NH2 pyridinyl-3'-yI)-amide o Cl 3-amino-6-(2-fluoro-5 II NH phenylcarbamoyl-phenyl) 33F pyridine-2-carboxylic acid 562 23 323 H N((S)-3-amino-3,4,5,6-tetra- 562 23 N hydro-2H-[I ,4']bipyridinyl 0N NH 2 3 -yI)-amide NH 3 -amino-6-(5 -cyclohexyl ~NH carbamoyl-2-fluoro-phenyl) 324 byridine-2-carboxylic acid N2 HCOS)3-aio3 4"5,-tta 532.3 2.44 N N N hydro-2H-[ 1 ,4']bipyridinyl-3'

KN

2 0 NH ~ yl)-amide___ HC"~ 0 0 4 - [5 -amino-6-((S)-3 -amino NH 3,4,5 ,6-tetrahydro-2H-[ I ,4'j]bi 325 pyridinyl-3'-ylcarbamoyl)- 465.2 2.24 No H N yridin-2-yl]-3-fluoro-benzoic acid methyl ester 0 Chiral NH NH 3 -amino-6-(2-fluoro-5 -propyl carbamoyl-phenyl)-pyridine 326 CH H N-carboxylic acid ((S)-3- 492.2 2.11 ,,N amino-3,4,5,6-tetrahydro-2H 0 NH, [I,4']bipyridinyl-3'-yl)-amide NH NH 3-amino-6-(5 -ethyl carbamoyl 327 -N ~ CH3 2-fluoro-phenyl)-pyridine-2 32 carboxylic acid ((S)-3-amino- 478.2 1.97 H 3,4,5,6-tetrahydro-2H-[ 1,4']bi 0N NH, pyridinyl-3'-yI)-amide o -H C2hia 3-amino-6-(5-dimethyl N IC~ carbamoyl-2-fluoro-phenyl) %NH CH, ci 7)F vnrdine-2-carboxyic ai 328 N 478.2 1.98 H N ((S)-3-amino-3,4,5,6-tetra N ydro-2--[ I ,4']bipyridinyi-3' ________ 0 NH -amide ___ __ -125- Example Structure Name MH+ LC SN\ sulfamoyl-2-methyl-phenyl) 329 CH,H yridinc-2-carboxylic acid NIN ((S)-3-amino-3,45 ,6-tetra- 583 24 IN h ydro-2H-[ 1 ,4']bipyridinyl-3' o NH 2 1~y)-amide_______ .0Chiral 3-amino-6-(5-dimethyl N !N-CH 3 sulfamoyl-2-methyl-phenyl) 330 yndine-2-carboxylic acid .30N HN- (S)-3-amino-3,4,5,6-tetra- 510.2 2.12 IN' 0NH h~ydro-2H-[ I ,4']bipyridinyl-3' o NH 2 yl)-amide_______

NH

2 1 hia 5-amino-2'-chloro-[2,3']bi 2 Ci pyidinyl-6-carboxylic acid 331 HI N'H ((S)-3-amino-3,4,5,6-tetra- 424.1 1.78 _N y ydro-2H-[ 1,4 t ]bipyridinyl-3' Chiral ,NH2 3-amino-6-(2-cyano-phenyl) pyridine-2-carboxylic acid .332 NHN-((S)-3-amino-3,4,5,6-tetra- 414.2 1.87 N hydro-2H-[ I ,4 t ]bipyridinyl-3' 0 NH 2 y)-amide Chiral NH CH , 3-amino-6-(2-fluoro-5 ~ ~ - ethyl-phenyl)-pyridine-2 333 IF carboxylic acid ((S)-3-amino- 421.2 2.29 NIN 3,4,5,6-tetrahydro-2H-[ 1 ,4']bi N o NH2 pyridinyl-3-I-rd 0 C~nraI 3-amino-6-(2-fluoro-5 NH NH ethylcarbamoyl-phenyl) - CH 3 334 p~yridine-2-carboxylic acid 442 18 No HN ((S)-3-amino-3,4,5,6-tctra- 442 18 IN 0NH ydro-2H-[ 1 ,4 t ]bipyridinyl-3' o ,. NHira 0 C, a 3-amino-6-(5-tert-butyl NH ulfamoyl-2-methyl-phenyl) 3) N 3 C+H, yridine-2-carboxylic acid INH ((S)-3 -amino-3 ,4,5 ,6-tetra- 583 23 N N ydro-2H-[ 1 ,4']bipyridinyl-3' o NH 2 -126- Example Structure Name MH+ LC ."NH2 FChiral 3 -ami no-6-(5 -tert-butylI

NH

2 I F sulfamoyl-2-methyl-phenyl) 336 F F yridinc-2-carboxylic acid HK~N ((S)-3-amino-34,56-tetra- 472 22 0 NH, ydro-2H-[ 1 ,4]bipyridinyl-3' (N 21y)-amide Chiral ,NH2 CH, 3 -amino-6-(2-methoxy (U~NH2 0 CH phenyl)-pyridine-2-carboxylic :337 N0 " N acid ((S)-3-amino-3,4,5,6- 419.2 2.11 I I NkN etrahydro-2H-[ 1,4']bi 0N NH 2 yridinyl-3 -yI)-amide Chiral IN2 H 3-arnino-6-o-tolyl-pyridine-2 K> CH 2 carboxylic acid ((S)-3-amino 33No H N3,4,5,6-tetrahydro-2H-[ 1 ,4']bi- 403.2 2.17 0 NH 2 yridinyI-3-y1)-amide N Chiral INH,1 I 5-amino-3'-fluoro-[2,4']bI (1F pyridinyt-6-carboxylic acid 339 N N- 1 ((S)-3-amino-3,4,5,6-tetra- 408.2 1.48 N hydro-2H-[ I ,4']bipyridinyl-3' 0N NH 1l)-amide

NH-

2 1LH, 3,5-diamino-6-o-tolyl 340~N-1 p yrazine-2-carboxylic acid (3- 492 16 NH ai.mino-3,4,5,6-tetrahydro-2H [1,4']bipyridinyl-3'-yl)-amide I F 3,5-diamino-6-(2-trifluoro F NF methyl-phenyl)-pyrazine-2 341 FH 31N H N~ N 2 carboxylic acid (3-amnino- 473.2 1.76 Nz ri-,,,N ,4,5,6-tetrahydro-2H-[ I ,4']bi 0N NI-H 2 pyridinyl-3'-yl)-amide I 3,5-diamino-6-(2-chloro yNH2 'ci phenyl)-py-razine-2-carboxylic 342 N HN~ NH 2 acid (3-amino-3,4,5,6-tetra- 439.1 1.68 Ny),)-,,N ydro-2H-[ 1 ,4 t ]bIpyridinyl-3' N N-2 1l)-amide I 3 ,5-diamino-6-(2-fluoro rN-2 F phenyl)-pyrazine-2-carboxylic 343 NH NI-12 acid (3-arnino-3,4,5,6-tetra- 423.1 1.59

~

4 N<IN hydro-2H-[I ,4']bipyridinyl-3' ______ (N 2H 1)-amide -127- Example Structure Name MH+ LC NHI CH, 3 ,5-diamino-6-(2-mcthoxy NH 2 0 henyl)-pyrazine-2-carboxyli'c 344 N NH 2 acid (3-amino-3,4,5,6-tctra- 435.2 1.58 rN N N hydro-2H-[1 ,4']bipyridinyl-3' 0N) NH2 )-amide NS NH 2 3-amino-6-(2-cyano-phenyl) 345 N N yrazine-2-carboxylic acid (3- 452 16 H amino-3 ,4,5 ,6-tetrahydro-2H [1 ,4']bipyridinyl-3'-yl)-amide NH2 c 3-amino-6-(2-chloro-phenyl) Hmino-3 ,4,5 ,6-tetrahydro-2H [1,4']bipyridinyl-3'-yI)-amide N N2 NH, FF 3-amino-6-(2-trifluoro 0 )~< F methoxy-phenyl)-pyrazine-2 347 N HN carboxylic acid (3-amino- 474.2 2.16 rAN <~N 3,4,5,6-tetrahydro-2H-[ 1 ,4']bi 0 NH 2 pyridinyl-3'-yl)-amide I 3 -amino-6-(2-trifluoromethyl

NH

2 .- F KT F phenyl)-pyrazine-2-carboxylic 348 F acid (3-amino-3,4,5,6-tetra- 458.2 2.03 Nt -_N ydro-2H-[ 1 ,4']bipyridinyl-3' N 0NH 2 1)-amide NH2 oCH 3 -amino-6-(2-methoxy phenyl)-pyrazine-2-carboxylic 349 N N acid (3-amino-3,4,5,6-tetra- 420.2 1.86 Sz N ,, N ydro-2H-[ 1 ,4']bipyridinyl-3' _____ N 0N2y1)-amide NH 2 -amino-6-(2-fluoro-phenyl) C~r pyrazine-2-carboxylic acid (3 350 N NHf, amino-3 ,4,5 ,6-tetrahydro-2H- 481 18 I Nr ,,[1 ,4']bipyrdinyl-3'-yI)-amide -128- Example Structure Name MH+ LC NH, H 3-amino-6-o-tolyl-pyrazine-2 351 N~a carboxylic acid (3-amino- 40. 19 H .4 11 ,4,5,6-tetrahydro-2H-[ 1 ,4']bi oyridinyl-3'-yl)-amide N N 2 352 ~ NH 3-amino-6-(3-chloro-phenyl)-42. pyrazine-2-carboxylic acid (3 H amino-3,4,5,6-tetrahydro-2H [I,4']bipyridinyl-3'-yI)-amide C1 I 3-amino-6-(4-chloro-phcnyl) 353H pyrazine-2-carboxylic acid (3-42. Hamino-3,4,5,6-tetrahydro-2H- 42. N N LN)O[ 2 ,4']bipyridinyl-3'-yl)-amide N,3-amino-6-(1pyraol-4-yi) rf pyrazine-2-carboxylic acid (3 N amino-3,4,5,6-tetrahydro-2H-38. 0NH 2 N- 2 NH, NH, Q 3-amino-6-pyridin-3-yl-4y) 356 ~yrazine-2-carboxylic acid (3-39. 355 NH N"- amino-3,4,5,6-tetrahydro-2H-38. 0NH, IN N2 3-amino-6-pyriidin--y N N pyrazine-2-carboxylic acid (3 N , amino-3,4,5,6-tetrahydro-2H-39. NH ~ 1,4'Ilbipyridinyl-3'-yL)-amide NH 2 ~ 3-amino-6-(4-ymdoy

K~H

2 hy)pyrazine-2-carboxylic i 3 358 N) Hi (3aino-3,4,5,6-tetra 2- 406.2 15 Y -yr2H[1,4']bipyridiny-3'-d _______ N I )am d -129- Example Structure Name MH+ LC H N 3-amin&-6-phenyl-pyrazine-2 359 N N' carboxylic acid (4-piperazin-1-yI- 376.2 1.68 NIJ,),,N pyridin-3-yI)-amide 'L 0 NH2 H N 1 ,CH, i..N~ N 5-amino-6'-methoxy 360 KN N ~ [2,2']bipyrazinyl-6-carboxylic 408.2 1.6 H acid (4-piperazin- l-yl k I pyridin-3-y!)-amide 1 2 H 0 31H NH, 3-amino-6-(3-carbamoyl 361 N henyl)-pyrazine-2-carboxylic 419.2 1.36 aid (4-pipcrazin- Il-yI N pyrdin-3-yl)-amide 0 ' CH 3 H 3 -amino-6-(4-methoxy 362 C henyl)-pyrazine-2-carboxylic 406.2 1.76 NH N cid (4-piperazin- Il-yI N, N yridin-3 -yl)-amide 0N H N -F 3-amino-6-(2-fluoro-phenyl) 363 N~~~ yrazine-2-carboxylic acid (4- 342 17 H Piperazin- I -yI-pyridin-3-yl) amide <I> Q -amino-6-phcnyl-pyrazine-2 364 ~ C c)arboxylic acid (4-aiino- 302 17 H< i N 3,4,5,6-tetrahydro-2H-[ 1,4']bi N NH 2 yrdinyl-3'-yl)-amide NH 23-amino-6-(2-phenoxy K' ~ o 0 phcnyl)-pyrazinc-2-carboxylic 365 C N Nacid (4-amino-3,4,5,6-tetra- 482.2 2.33 N N~'N iydro-2H-[ 1 ,4']bipyridinyl-3' 0 NH, 1l)-amide NH N 1 0 OCH 3 5-amino-6'-methoxy-[2,2']bi 366 - Nyrazinyl-6-carboxylic acid 366 N N(4-amino-3,4,5,6-tetrahydro- 422.2 1.64 N N H-[I ,4']bipyrdinyl-3'-yI) N, 0N 2 amide -130- Example Structure Name MH+ LC

CH

3 NH 3 -amino-6-(4-mcthoxy henyl)-pyrazine-2-carboxylic 367 a)cid (4-amino-3,4,5,6-tctra- 420.2 1.8 'N hydro-2H-[ 1 ,4']bipyridinyl-3' N , N,2y) -amide F -amino-6-(2-fluoro-phenyl) 368 ~ ~ HY~I yrazine-2-carboxylic acid (4- 482 17 H amino-3 ,4,5 ,6-tetrahydro-2H I [1 ,4']bipyridinyl-3'-yI)-amide (N 0 NH2 3 -amino-6-(3 -carbamoyl NHphenyl)-pyrazine-2-carboxylic 369 (N N 1 acid (3-amino-3,4,5,6-tetra- 433.2 1.51 N , N ydro-2H-[ 1,4']bipyridinyl-3' ______0 N H 2 )-amide 3-amino-6-(4-methoxy NH phenyl)-pyrazine-2-carboxylic 370 a)cid (3-amino-3 ,4,5 ,6-tetra- 420.2 1.8 N ll hydro-2H-[1,4']bipyridinyI-3 ______0 N H 2 )-amide

CTNH

2 CH3 3-amino-6-methyl-pyrazine-2 371 N H Ncarboxylic acid (3-ami~no- 328.2 1.23 Ny , ,4,5,6-tctrahydro-2H-[ 1,4'Ilbi pyridinyl-3'-yl)-amide ( NH 2 9 3 -amino-6-phenyl-pyrazine-2 372 a'N N carboxylic acid [2-(3-amino- 389.2 2.99 NkNy -,,N piperidin-1I-yl)-phenyl]-amide 0.J NH 2 0 NH2 3-amino-6-(3-carbamoyl 373 Cf N" 2 phenyl)-pyrazine-2-carboxyl ic 432.1 2.54 N H N "),acid [2-(3-amino-piperidin- I Ny ,I) ,N y)-phenyl]-am ide NH 2 F -amino-6-(2-fluoro-phenyl) 374 a N yrazine-2-carboxylic acid [2- 407.2 3.03 H . (3-amino-piperidin- Il-yl) _ _ & N2 2 _ _ _ _ _ _ _ _ __lami 0 H,-aid -131- Example Structure Name MH+ LC 0 CH, 3-amino-6-(4-methoxy 375 iNH2 phenyl)-pyrazine-2-carboxylic 419.2 3.06 H N acid [2-(3-amino-piperidin- 1 N N)-phenyll-amide /0 NH2 C,

NH

2 CH, N) N 3-amino-6-methyl-pyrazine-2 376 N arboxylic acid [2-(3-amino- 327.2 2.44

NH

2 piperidin-1 -yl)-phenyl]-amide O NH2 NH2 F 3-amino-6-(2-fluoro-phenyl) 377 N N pyrazine-2-carboxylic acid [2- 407 (4-amino-pipeidin- I -yI) phenyl]-amide NH2 cH 3 3-amino-N-[2-(4-amino CH 3 peridin-I -yI)phenyl]-6 378 N HN pp327.2 2.36 3 ~N methylpyrazine-2 O NH2 carboxamide NHN2 0 3-amino-6-furan-3-yi N N pyrazine-2-carboxylic acid [2 N J,2y N (4-amino-piperidin-1-yl) | / O

NH

2 phenyl]-amide 0 NH2 NH 2 3-amino-6-(3-carbamoyl 380 Nphenyl)-pyrazine-2-carboxylic 432.2 2.56 H N acid [2-(4-amino-piperidin-

I

N N yi)-phenyl]-amide O NH2 O.CH, NH, 3-amino-6-(4-methoxy 381 phenyl)-pyrazine-2-carboxylic 419.1 2.96 N N acid [2-(4-amino-piperidin-1 9 N N y)-phenyl]-amide O NH2 N N 3-amino-6-phenyl-pyrazine-2 382 N N carboxylic acid (2-piperazin- 375.1 2.76 N1 N 1-yl-phenyl)-amide /3 NH2 -132- Example Structure Name MH+ LC H N F 3-amino-6-(2-fluoro-phenyl) 383 N N, yrazine-2-carboxylic acid (2- 393.1 2.8 N N piperazin- 1 -yl-phenyl)-amide /0 NH2 H O N 3-amino-6-furan-3-yl 384 N H N pyrazine-2-carboxylic acid (2- 365.1 2.71 N N piperazin- 1 -yl-phenyl)-amide O NH 2 0 H NH2 3-amino-6-(3-carbamoyl 385 ) phenyl)-pyrazine-2-carboxylic 418.2 2.36 H acid (2-piperazin-1-yl N N phenyl)-amide 0 NH2 ,CH, 3-amino-6-(4-methoxy 386 (N )phenyl)-pyrazine-2-carboxylic 405.1 3 N N acid (2-piperazin-1-yl N N phenyl)-amide O NH 2 S0 3-amino-6-(2-phenoxy 387 N N phenyl)-pyrazine-2-carboxylic 467.2 3.28 N acid (2-piperazin- I-yl O NH2 phCnyl)-amidC 0 N CH, H N 3-amino-6-m-tolyl-pyrazine 388 N H N 2-carboxylic acid (2-piper- 389.2 2.95 N N azin- 1-yl-phenyl)-amide / 0 NH2 H N 3 -amino-6-naphthalen-1-yl 389 N N pyTazine-2-carboxylic acid (2- 425.2 3.06 N N piperazin- 1 -yl-phenyl)-amide /, O NH2 H N H N 0 3-amino-6-(2-methoxy 390 N yridin-3-yl)-pyrazine-2- 8 N N carboxylic acid (2-piperazin I -yl-phenyl)-amide -133- Example Structure Name MH+ LC OCH, H Nv 3-amino-6-(2-methoxy 391 N) pyrimidin-5-yl)-pyrazine-2- 407.2 2.55 H N carboxylic acid (2-piperazin IN N 1-yl-phenyl)-amide O NH2 0 NH2 N 3-amino-6-[3-(morpholine-4 392 carbonyl)-phenyl]-pyrazine-2- 502.1 2.71 N HN Carboxylic acid [2-(4-amino N N piperidin-1-yi)-phenyl]-amide O NH2 yH3 NH2 0 3-amino-6-(2-fluoro-5 393 6 F methoxy-phenyl)-pyrazine-2- 437.1 3.05 N N carboxylic acid [2-(4-amino N N piperidin-1 -yl)-phenyl]-amide O NH2 CH NH2 O OCH, 3-amino-6-(3,4,5-trimethoxy 394 phenyl)-pyrazine-2-carboxylic 479.2 2.89 N H N acid [2-(4-amino-pipendin- I 6 N _ _ _ N yl)-phenyl]-amide / NH2 .CH, H O'CH, 3-amino-6-(3,4,5-trimethoxy 395 N phenyl)-pyrazine-2-carboxylic 465.2 2.74 N H N acid (2-piperazln-1-y 6 N ?,N phenyl)-amide /0 NH2 CH3 0 H 3-amino-6-(2-fluoro-5 396 F methoxy-phenyl)-pyrazine-2- 423.2 2.96 N N Carboxylic acid (2-piperazin N _ N I-yl-phenyl)-amide O NH2 NH2 3-amino-6-phenyl-pyrazine-2 397 N HN carboxylic acid [2-(4-amino- 389.2 2.37 N N piperidin-1-yl)-phenyl]-amide O

NH

2 0 NN 3-amino-6-[3-(morpholine-4 398 ] carbonyl)-phenyl]-pyrazine-2- 488.2 2.5 N HN carboxylic acid (2-piperazin N N 1 -yl-phenyl)-amide O NH2 -134- Example Structure Name MH+ LC NH 2 rSt %~ 3 -amino-6-phenyl-pyrazine-2 399 'N ~ Nj carboxylic acid [2-(4-amino- 389.2 2.37 c~N NKriperidin-1-yI)-phenyl-amide

SNH

2 I C, 3-amino-6-o-totyl-pyrazine-2 carboxylic acid [5-(3-amino 400 Niperidin-1I-yI)-2-oxo-2,3- 411 1.96 N .. NH 0 NH2 dihydro-pyrimidin-4-yi] y amide 0 SNH, I F 3-amino-6-(2-fluoro-phenyl) pyrazine-2-carboxylic acid [5 401 . 1(3-amino-piperidin- I-yi)-2- 425.1 1.92 N NH N oxo-2 ,3-dihydro-pyrimidin-4 N T H 0 H2 y]-arnide 0 NH, 3-amino-6-(2-chloro-phenyt) CTJ pCIyrazine-2-carboxylic acid [5 N AN rl~rN YIY N xo-2,3-dihydro-pynimidin-4 N yNH 0 N11 2 ]amd 0 SNH, 3-amino-6-(2-cyano-phenyl) N yrazine-2-carboxylic acid [5 403 rr(~k3-amino-piperidin- I-yI)-2- 432.1 1.7 rN'y1 H0N2x-2 ,3-dihydro-pyrimidin-4 0

SNH

2 .. F 3-amino-6-(2-trifluoromethyl F F phenyl)-pyrazine-2-carboxylic 404 H cid [5-(3-amino-piperidin- 1- 475.1 2.09 Ny H 0 N 1l)-2-oxo-2,3-dihydro N 0 NHyrimidin-4-yl]-amide 1 F F 3 -amino-6-(2-trifluoro KY NH2 0)F ethoxy-phenyl)-pyrazine-2 405 N N carboxylic acid [5-(3-amino- 411 21 ( rHyNzy N piperidin- 1-yl)-2-oxo-2,3- 411 21 N yNH 0 NH2 dihydro-pyrimidin-4-yl] 0 amnide ___ -135- METHOD 13 Example 406 Synthesis of(S)-3-amino-N-(4-(3-aminopiperidin-1-yl) pyridin-3-yl)-6-(2-fluoro-4-methylphenyl)picolinamide NH2 / F N N H N N

NH

2 [0256] A solution of (S)-tert-butyl 1-(3-(3-amino-6 bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (1.0 eq), 2-fluoro-4-methyl phenyl boronic acid (3.0 eq.), Pd(dppf)C1 2

-CH

2

CI

2 (0.15 eq.) in 3:1 DME/2M Na 2

CO

3 (concentration = 0.1 M) was heated at 120*C with microwave irradiation for 1200 10 seconds. Upon cooling the organic layer was separated, concentrated and the N-Boc Suzuki product was directly purified by reverse phase HPLC. The product fraction was lyophilized and the resulting solid was treated with 25% TFAIDCM (at a resulting concentration of 0.05 M). After sitting for 2 hours, the volatiles were removed in vacuo and the residue was purified by reverse phase HPLC. After lyophilization, (S)-3-amino 15 N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-6-(2-fluoro-4-methylphenyl)picolinamide was obtained (44%) as the TFA salt. LCMS (m/z): 2.23 (MH+); LC Rt = 421.2 min. [0257] Alternatively, the free base and HCl salt of (S)-3-amino-N-(4-(3 aminopiperidin-1-yl)pyridin-3-yl)-6-(2-fluoro-4-methylphenyl)picolinamide could be obtained as described in Method 9. 20 [0258] The following compounds were prepared using Method 13. Example Structure Name MH+ LC N N Chiral .eNH 2 - 3-amino-6-pyrimidin-5-yl 407 N' pyridine-2-carboxylic acid ((S)-3- 91 Samino-3,4,5,6-tetrahydro-2H I 0 NH 2 1,4']bipyridinyl-3'-yl)-amide -136- Example Structure Name MH+ LC F Chiral - N NHZ I ,2'-diamino-6'-fluoro-[2,3'jbi 408 _2Y NH, pyridinyl-6-carboxylic acid ((S)- 423.2 1.79 IN HN -amino-3,4,5,6-tetrahydro-2H ~ N ~ 1 ,4']bipyridinyl-3'-yl)-amide

NH

2 Chir N)I 3-amino-6-(2-amino-4-methyl 409 rXNH, O-H3 pyrimidin-5-yl)-pyridine-2 40 N H N I carboxylic acid ((S)-3-amino- 420.2 1.21 N~r N,4,5,6-tetrahydro-2H-[ 1,4']bi 0 NH, pyridinyl-3'-yI)-amide

NH

2 Chiral NH, N 115,6'-diamino-4'-chloro-[2,3']bi 410 (U' pyrdinyl-6-carboxylic acid ((S)- 439.2 1.41 IN H N 3-amino-3,4,5,6-tctrahydro-2H N [1,4']bipyridinyl-3'-yI)-amide

NH

2 Chiral IN ,N 3-amino-6-(2-amino-pyrimidin-5 411 I.~NH N' I)-pyridine-2-carboxylic acid 462 12 IN N ((S)-3-amino-3,4,5,6-tctrahydro- 462 12 &xN 2H-[ 1,4']bipyridinyl-3'-yI)-amide 0 NH 2 N,, NH 2 Chiral

S~NH

2 -5 ,2'-diamino-[2,4']bipyridinyl-6 412 N~~~ carboxylic acid ((S)-3-amino- 452 12 412N NI 3,4,5,6-tetrahydro-2H-[I ,4']bi- 452 12 KN) 0 NHyridinyl-3'-yl)-amide 0 H2 ra K>N2 0N CH, hia 5-amino-6'-rnethoxy-[2,2']bi 413 N~~~ yridinyl-6-carboxylic acid ((S)- 402 18 41 NHN 3-amino-3,4,5,6-tetrahydro-2H- 402 18 ~~~ NH[,4']bipyridinyl-3'-yl)-amIde (N 0N2 Chiral NH 5-amino-[2,3']bipyridinyl-6 carboxylic acid ((S)-3-amino 414H 3 ,4,5,6-tetrahydro-2H-[ 1 ,4']bi- 302 11 1 0 NH, pyrdinyl-3'-yl)-amide N Chiral NH 5 -amino- [2,4']bipyridinyl-6 415 N ~ carboxylic acid ((S)-3-amino-11 H I ,4,5,6-tetrahydro-2H-[1,4']bi ~.N N 9. ______ K~ NH 2 yridinyl-3'-yl)-amidc -137- Example Structure Name MH+ LC NH-, 01,117 0 IN I CH, 5,6'-diamino-5'-mcthoxy-[2,3']bi 416NH pyridinyl-6-carboxyli'c acid ((S)- 45213 416 NHN 3-amirio-3,4,5,6-tctrahydro-2H- 452 13 IN2 NH ~ Chiral INAl N 3-amino-6-(2,4-diamino (USH N, 2 yrmidn-5-yl)-pyridine-2 N4H17 carboxylic acid ((S)-3-amino- 421.2 1.07 I 3,4,5,6-tetrahydro-2H-[ 1,4']bi I 0 NH2 pyridinyl-3'-yl)-amide

NH

2 Ch NH IN 115,6'-diarnino-[2,3']Jbipyridiny1-6 418N 2 carboxylic acid ((S)-3-amino- 45212 HN "N 3,4,5,6-tctrahydro-2H-[ 1,4] IN 0 yridinyl-3'-yI)-amide Chirl

J,,NH

2 I F 5-amino-2'-fluoro-[2,3']bi (U ~~yridinyl-6-carboxylic acid ((S)-40. 17 19H N 1 -amino-3 ,4,5,6-tctrahydro-2H [1,4'Ebipyridinyl-3'-yI)-amide CI Chirl NH, I3-amino-6-(4-chloro-2-fluoro K~rN, IF henyl)-pyridine-2-carboxylic 420 KN~ N- acid ((S)-3 -amino- 3,4,5,6-tetra- 441.2 2.29 N H ydro-2H-[ I ,4']bipyridinyl.3'-yl) 0 NH 2 amide _) Chiral O"IN

-

0 'CH, 5-am-ino-4'-methoxy-[2,3']bi 421 NH p~yr-idinyl-6-carboxylic acid ((S)- 420.2 1.7 H 3-amino-3 ,4,5 ,6-tetrahydro-2H 0 NH[1 ,4']bipyridinyl-3 t -yI)-amide CNT 2 N Chiral J,%NH, ... 5-amino-3'-choro-[2,4']bi 422 N p~yridinyl-6-carboxylic acid ((S)- 441 16 IN H N 3-amino-3,4,5,6-tetrahydro-2H- 44116 (A~N NH 2 1,4']bipyridinyl-3'-yI)-amide Chiral 'NH, 0 CH 5-amino-2'-methoxy-[2,3']bi 423 0U" pyridinyl-6-carboxylic acid ((S)- 402 18 Ir 3-amino-3 ,4,5 ,6-tetrahydro-2H 1 0 NH1 ,4']bipyridinyl-3'-yI)-amide -138- Example Structure Name MH+ LC J,,NH 2 NF~ha 3-amino-6-(2,3-difluoro-phcnyl) (U4 C pyridine-2-carboxylic acid ((S)-3- 452 21 424N H N amino-3,4,5,6-tctrahydro-2H- 452 21 ~jyNN [1 ,4']bipyridinyl-3'-yI)-amide 0CHr9 N FH -amino-6-(2,6-difl uoro-phenyl) [)5 F F yridine-2-carboxylic acid ((S)-3 425 NHN amino-3,4,5,6-tetrahydro-2H- 452 20 0NH NH, 3-amino-6-(2,6-dimethyl 4.6 C CH 3 henyl)-pyridine-2-carboxylic 46N H N ~ acid ((S)-3-amino-3,4,5,6-tetra- 417.2 2.2 N hydro-2H-[ I ,4']bipyridinyl-3'-yI) 0o H amideQ F NChiral ,N 2 CH. 3 -amino-6-(5-fluoro-2-methoxy 427 0 henyl)-pyridine-2-carboxylic 47 NH N- acid ((S)-3-amino-3,4,5,6-tetra- 437.2 2.11 N ' hydro-2H-[ I ,4']bipyridinyl-3'-yI) N 0 NH 2 amide F CNrw N ~ 3-amino-6-(4-fluoro-2-methoxy -%H OIH henyl)-pyridine-2-carboxylic 428 acid ((S)-3-amino-3,4,5,6-tetra- 437.2 2.15 N N 0 NH, amide N 3-amino-6-(4-chloro-2-methyl NH, CH3 henyl)-pyridine-2-carboxylic 429 acid ((S)-3-amino-3,4,5,6-tetra- 437.2 2.39 N H Nydro-2H-[1,4']bipyridinyl-3'-yI) o NH 2 amide F Qn N 3-amino-6-(4-fluoro-2-methyl ,N2 CH3 henyl)-pyridine-2-carboxylic 430 LJacid ((S)-3-amino-3,4,S,6-tetra- 421.2 2.23 N H Nydro-2H-[ 1,4']bipyridinyl-3'-yI) KN 0 NH2 amide 431 ()NH2 F pyridine-2-carboxylic acid ((S)-3- 452 21 N H N ~ amino-3,4,5,6-tetrahydro-2H- 452 21 )yN ~ 1,4'Ijbipyidinyl-3'-yI)-amide o NH 2 -139- Example Structure Name MH. LC Cl- 3 Chr" 3 -amino-6-(2-fluoro-4-methyl 432 (,>NH2 p..henyl)-pyridine-2-carboxylic N3 a ~cid ((S)-3-amino-3 ,4,5,6-tetra- 421.2 2.27 yN hydro-2H-[ 1,4']bipyridinyl-3'-yI) KN 0 NH 2 amide Chiral 0 ,,,NH2 -amino-6-(2-chloro-phenyl) K) ~ c pyridine-2-carboxylic acid ((S)-3- 432 21 N H IN amino-3,4,5,6-tetrahydro-2H 0 H1 ,4']bipyrdiny-3'-y)-amide Chi~ral 0 ,,NH2 I 3 F -amino-6-(2-fluoro-phenyl) pyridine-2-carboxylic acid ((S)-3- 472 20 NH N amino-3,4,5,6-tetrahydro-2H [1,4']bipyridinyl-3'-yi)-amide N Q 3-amino-6-phenyl-pyrazine-2 Ni carboxylic acid [2-(3-amino 435 N - zII432 33 0 NH2 piperidin-1I-yl)-5-bcnzoyl- 432 33 ~~phenyl]-amide 3-amino-6-phenyl-pyrazine-2 436 carboxylic acid [2-(4-amino- 49. 33 -0 NH, piperidin- I-yl)-5-benzoyl 0 phcnyl]-amide ~ 3-amino-6-phenyl-pyrazine-2 N N' carboxylic acid [2-(4-amino- 491 30 437 Ny~~yIN p~peridin-1I-yl)-5-methoxy- 49130 ( 0 NH, phenyl]-amide

C)

0 ( I? -amino-6-(2-fluoro-phenyl) 438 Nl-y pyrazine-2-carboxylic acid (5- 497.2 3.25 0 NIH2 enzoyl-2-piperazin- Il-yI C 0 phenyl)-amide F 3-amino-6-(2-fluoro-phenyl) 439N H yrazine-2-carboxylic acid [2-(4- 511 32 C phenyll-amide -140- Example Structure Name MH+ LC H N N ~ 3-amino-6-methyl-pyrazine-2 44 NYL N carboxylic acid (5-benzoyl-2- 417.2 2.75 0 NH, piperazin- I -yi-phenyl)-amide H I 3-amino-6-(4-methoxy-phenyl) 44 H yrazine-2-carboxylic acid (5- 593 32 YIYI benzoyl-2-pipcrazin- I -yI C .0 N C-hr-a- henyl)-amide IIH 5-Fiuoro-6-phenyl-pyridine-2 442 F ~carboxylic acid (3-amino-3,4,5,6- 322 21 N H N- ctrahydro-2H-[ 1,4']bipyridinyl N 3'-yl)-amide N__________________ Chiral 0 N NH 5Fluoro-6-(2-fluoro-5 .,\NH2 sopropylcarbamoyl-phcnyl) 443 IF {HCH 3 pyridine-2-carboxylic acid (3- 495.2 2.13 N H N amino-3,4,5,6-tetrahydro-2- N [ 1,4']bipyridinyl-3'-yI)-amide Chiral In%\H 5-Fluoro-6-(2-fluoro-phenyl) I> F 444 K~~)IF pyridine-2-carboxylic acid (3- 401 21 H Namino-3,4,5,6-tetrahydro-2H N[1 ,4']bipyridInyl-3'-y!)-amide -Chiral F\ 2 I 6-(2,6-Difluoro-phenyl)-5-fluoro 4F4 IF pyridine-2-carboxylic acid (3- 428.1 2.14 ON H N- F mino-3,4,5,6-tetrahydro-2H NZ N [1,4']bipyridinyl-3'-yI)-amide Example Structure Name MH+ LC Chiral -S -N2 3-Amino-6-[2,2']bithiophcnyl-5 4,46 I~N 2 -pyridine-2-carboxylic acid (3- 47125 t~~~) ~amino-3,4,5,6-tetrahydro-2H- 471 25 N

NH

2 0 3 -Amino-6-(2,3-dihydro 4,47 0 'N2s hieno[3,4-b][1,4]dioxin-5-yl)- 43120 pyiNne2-arNIli acid (3- 431 20 N [ 1,4 t jbipyridinyl-3 '-yl)-amide NI1 -Chiral \N2S CH 3 3-Amino-6-(3-methyl-thiophen 4,48 K)-yi)-pyridine-2-carboxylic acid 409.2 2.10 N N (3-amino-3,4,5,6-tetrahydro-2H IN [1,4']bipyridinyl-3'-yI)-amide ____ N) NH 2 Ch iralI

\NH

2 3-Amino-6-thiophen-3-yl 4,49 N Npyridine-2-carboxylic acid (3- 395.1 1.95 Ni H N arnino-3,4,5,6-tetrahydro-2H N *[1,4']bipyridinyl-3'-yI)-amide &N-

NH

2 CI \NH2 S 3-Amino-6-(5-chloro-thiophen-2 450 (yl2 )-pyridine-2-carboxylic acid (3- 429.1 2.23 N H N - mino-3 ,4,5 ,6-tetrahydro-2H N [1,4']bipyridinyl-3'-yI)-amide _ NH2___

CH

3 Chiral sNH S 3-Amino-6-(4-methyl-thiophen 451 0 -yi)-pyridine-2-carboxylic acid 492 21 NH N -(3 -amino- 3,4,5,6-tetrahydro-2H- 492 21 N [1,4']bipyridinyl-3'-yl)-amide ____N N H 2 -142- Example Structure Name MH+ LC Chiral NH2 3-Amino-6-(3-ethyl-phenyl) 452 pyridine-2-carboxylic acid (3- 417.2 2.43 N H N amino-3,4,5,6-tetrahydro-2H N [1,4']bipyridinyl-3'-yl)-amide N

NH

2 O Chiral %H NH 6-(2-Fluoro-5 C CH isopropylcarbamoyl-phenyl) 453 pH 3

OH

3 yridine-2-carboxylic acid (3- 477.2 2.06 N N amino-3,4,5,6-tetrahydro-2H N [1,4']bipyridinyl-3'-yl)-amide N __Tra_________________ Chiral NH2 6-(2,6-Difluoro-phenyl)-pyridine 454 F F 2-carboxylic acid (3-amino- 410.1 2.02 N H N 3,4,5,6-tetrahydro-2H-[1,4']bi N pyridinyl-3'-yl)-amide Chiral NH2 I 6-(2-Fluoro-phenyl)-pyridine-2 455F carboxylic acid (3-amino-3,4,5,6- 392.2 2.10 N N tetrahydro-2H-[1,4']bipyridinyl N 3'-yl)-amide Chiral

OH

3

CH

3 3-Amino-6-(3-isopropyl-phenyl) 456 pyridine-2-carboxylic acid (3- 431.2 2.61 ' N amino-3,4,5,6-tetrahydro-2H [1,4']bipyridinyl-3'-yl)-amide N NH2 N I I Chiral 3-Amino-6-(3-cyanomethyl 457 'NH2 phenyl)-pyridine-2-carboxylic 428.2 2.06 0) Nacid (3-amino-3,4,5,6-tetrahydro N 2H-[ l,4']bipyridinyl-3'-yl)-amide

NH

2 -143- Example Structure Name MH+ LC Ch-iral 3-Amino-6-biphenyl-3-yl 458 (~JNH2 yridine-2-carboxylic acid (3- 452 27 N45N amino-3,4,5,6-tetrahydro-2H- 45227 IN H [r1,4']bipyridinyl-3'-yI)-amide ____N

NH

2 Chiral NBr

\NH

2 I3-Amino-6-(3-bromo-phenyl) 459 pyridinc-2-carboxylic acid (3- 467.1 2.30 N H Namino-3 ,4,5 ,6-tetrahydro-2H N [1,4'Ebipyridinyl-3'-yl)-amidc ___ 1K) NH, F IF Chiral

~NH

2 F -Amino-6-(3-trifluoromethyl 460 hcnyl)-pyridine-2-carboxylic N60H;N acid (3-amino-3,4,5,6-tetrahydro- 457.2 2.41 N 2H-[ 1,4']bipyridinyl-3'-yI)-amidc N NH 2

\H

2 Chra 3-Amino-6-(3-cyano-phenyl) 461 p Nyridine-2-carboxylic acid (3- 414.2 2.02 IN H mino-3 ,4,5 ,6-tctrahydro-2H N [1,4']bipyridinyl-3 '-yI)-amIde _____ NNH 2 Chiral

~NH

2 I3-Amino-6-(2,6-difluoro-phenyl) 462* FN IF yridirie-2-carboxylic acid (3- 452 22 N H Narnino-3 ,4,5 ,6-tetrahydro-2H N N 1,4']bipyridinyl-3'-yl)-amidc

NH

2 Chiral

NH

2 IF 3 -Amino-6-(2-fluoro-phenyl) 463 N F yridine-2-carboxylic acid (3- 407.2 2.29 N H amino-3,4,5,6-tetrahydro-2H N- N [I,4']bipyridinyl-3'-yI)-amide INNH 2 -144- Example Structure Name MH+ LC PChiral C, 3-Amino-6-[3-(2-chloro benzyloxy)-2,6-difluoro-phenyl] 464 NH 2 Z, 46 F IF yridine-2-carboxylic acid (3- 565.2 2.98 N N- amino-3,4,5,6-tetrahydro-2H H I 1,4']bipyridinyl-3'-yI)-amidc Chiral rpF 3-Amino-6-[2,6-difluoro-3-(2 \NH 2 1*1fuoro-benzyloxy)-phenyfl 465 IF F yridine-2-carboxylic acid (3- 549.2 2.70 N N ~ amino-3 ,4,5 ,6-tetrahydro-2H I [1,4']bipyridinyl-3'-yI)-amide NN NH 2

GH

3 91 Chral -Amino-6-(3-butoxy-2 ,6 466 %\NH 2 Idifluoro-phenyl)-pyridine-2 46F IF carboxylic acid (3-amino-3,4,5,6- 497.3 2.83 N tetrahydro-2H-[I ,4']bipyridinyl I 3'-yI)-amide N

NH

2 8 H Chra -Amino-6-(2-fluoro-5 .,N H 2 IF sopropoxy-phenyl)-pyridine-2 4167 c arboxylic acid (3-amino-3,4,5,6- 465.3 2.59 ON H N' etrahydro-2H-[I1,4']bipyridinyl N N '-yl)-amide NH

CH

3 K~ Chiral 3-Amino-6-(2-fluoro-5-propoxy 468 "'\H F phenyl)-pyridine-2-carboxylic 452 26 ON Nacid (3-amino-3,4,5,6-tetrahydro- 452 26 IJH N H-[1,4']bipyridinyl-3'-yI)-amide N ______N KNH 2 -145- Example Structure Name MH+ LC CHI C hiral

,\NH

2 I3-Amino-6-(5-ethoxy-2-fluoro 469 F phenyl)-pyridine-2-carboxylic 451.2 2.47 N H N -acid (3-amino-3,4,5,6-tetrahydro H NH2H-[I ,4']bipy-ridinyl-3'-yI)-amide

CH

3 Chiral INH 3-Amino-6-(2-fluoro-5 -methoxy 470 F phenyl)-pyridine-2-carboxylic 437.2 2.33 N H N -acid (3-amino-3,4,5,6-tetrahydro N 2 H-[l ,4']bipyridinyl-3'-yl)-amide KN) NH 2 Chiral

,\NH

2 0,CH 3-Amino-6-(2-fluoro-3-methoxy 471 F phcnyl)-pyridine-2-carboxylic 472 22 N H N- acid (3-amino-3,4,5,6-tetrahydro- 472 22 (LrN N ' 2H-[ ,4']bipy-ridinyl-3'-y)-amidc N -NH 2 Chiral

\NH

2 C3 5 -Amino-4'-m ethyl -[2,3']bi 472 0 ') pr 3 ydinyl-6-carboxylic acid (3- 442 11 N H N mino-3,4,5,6-tetrahydro-2H- 442 11 L $N N 1,4']bipyridinyl-3'-yI)-amide N- ~ NH 2 Chiral N 3-Amino-6-biphenyl-4-yI 473 \NH 2 I yridine-2-carboxylic acid (3- 465.2 2.71 0' amino-3 ,4,5 ,6-tetrahydro-2H N H N 1 ,4']bipyridinyl-3'-yl)-amide N H2

NH

2 CNH - 3-Amino-6-(3-chloro-thiophen-2 A'7A 0 I 1)-pyridine-2-carboxylic acid (3- 429.1 2.21 N H N 'aniino-3 ,4,5 ,6-tetrahydro-2H S[1 ,4]jbipyridinyl-3'-yl)-amide N'2 -146- Example Structure Name MH+ LC Chiral .NH S 3-Amino-6-thiophen-2-yl 475 N pyridine-2-carboxylic acid (3- 395.2 1.97 N H N mino-3,4,5,6-tetrahydro-2H NZ [I1,4'Ebipyridinyl-3'-yl)-amide

CH

3 ChIrFal

NH

2 I5-Amino-2'-fluoro-6-methyl 476 F [2,3']bipyridinyl-6-carboxylic 42219 476 ~ '- H N ~ acid (3-amino-3,4,5,6-tetrahydro- 422 19 N 2H-[ 1 ,4']bipyridinyl-3 '-yI)-amide ______ NNH 2 0 r CH 3 Chiral F N -Amino-6-(2,5-difluoro-4 INH ethoxy-phenyl)-pyridine-2 477 F carboxylic acid (3-amino-3,4,5,6- 455.2 2.29 NH N - ctrahydro-2H-[1 ,4']bipyridinyl N 3'-yI)-amide N

NH

2

CH

3 Ch-iral Nl 3 -Amino-6-(5-chloro-2-fluoro-4 \NH F methyl-phenyl)-pyridine-2 478 0) carboxylic acid (3-arnino-3,4,5,6- 455.2 2.48 N H N I etrahydro-2H-[ 1,4']bipyridinyl N 3'-yl)-amide ___ _ IN NH 2 CI ()" NH 2 F Chrl3-Amino-6-(3-chloro-2-fluoro 479 N - ~henyl)-pyridine-2-carboxylic 412 23 47 N H I acid (3-amino-3 ,4,5 ,6-tetrahydro- 41223 1$ IN 2H-[1 ,4']bipyridinyl-3'-yI)-amide __NNH,2

NH

2 Chiral o=s=o I 3-Amino-6-(4-sulfamoyl 48 .\H henyl)-pyridine-2-carboxy! ic 48217 480 N) acid (3-amino-3 ,4,5 ,6-tetrahydro- 482 17 N

NH

2 -147- Example Structure Name MH+ LC " ,S hira \N H 2 Chrl3-Amino-6-(3-sulfamoyl 481 0 ' ~henyl)-pyridine-2-carboxylic 48217 481H acid (3-amino-3,4,5,6-tetrahydro- 482 17 NYAZ N . 2H-[ I ,4'jjbipyridinyl-3'-yl)-amide _____ N H,

NH

2 Chiral F , F NI I 5,6'-Diamino-5'-trifluoromethyl 482 2[2,3']bipyridinyl-6-carboxylic 473.1 1.688 0) acid (3 -amino-3 ,4,5 ,6-tetrahydro- (7.838) N H N H-[ I ,4']bipynidinyI-3'-yI)-amide _____ N NH 2

NH

2 Chiral \H IF 5,6'-Diamino-4'-trifluoromethyl 483 I)F IF [2,3'Ijbipyridinyl-6-carboxylic 43215 IN H N -acid (3-amino-3,4,5,6-tctrahydro- 432 15 Ck 2H-[ 1,4']bipyridinyl-3'-yI)-amide N NH 2

NH

2 Chiral .N2 N 5,6'-Diamino-2'-fluoro-[2,3']bi 4:84 .\ANH IF pyridinyl-6-carboxylic acid (3- 423.2 1.69 N H -mino-3,4,5,6-tetrahydro-2 NZ N [I,4']bipyridinyl-3'-yl)-amide

NH

2

NH

2 Chiral N 'N 3-Amino-6-(2-amino-4-methoxy K>NH2 0 pyrimidin-5-yl)-pyridine-2 4:85 K) CH carboxylic acid (3-amino-3,4,5,6- 436.2 1.26 N Ietrahydro-2H -[1I,4']bipyridinyl N 3'-yI)-amide N NH 2

NH

2 Chiral N I N IF 3-Amino-6-(2-amino-4 ~~N\NH2 I F rifluoromethyl-pyrimidin-5-yl) 4:86 0) IF IF yridine-2-carboxylic acid (3- 474.2 1.87 N H N amino-3,4,5,6-tetrahydro-2H N. [1,4'Ijbipyridinyl-3'-yI)-amide N NH 2 -148- Example Structure Name MH+ LC H2N I 44-n 6-Phenyl-pyn'dine-2-carboxylic 487 N N ~- acid (3-amino-3,4,5,6-tetrahydro- 374.2 2.01 H 2H-[ 1 ,4']bipyridinyl-3'..yl)-amide CH. CH 3 t Chral -Amino-6-(2,6-difluoro-3 \IF isopropoxy-phenyl)-pyridine-2 488 arboxylic acid (3-amino-3,4,5,6- 483.2 2.51 ______ ~ IN tetrahydro-2H-I1 ,4']bipyridinyl

N______NNHN

2 Chiral S \NH2 CH 3 3-Amino-6-(4-methyl-thiophen 489 n , 3-yl)-pyridine-2-carboxylic acid 409.2 2.11 N H N 1 (3-amino-3,4,5,6-tetrahydro-2H N [1,4']bipyridinyl-3'-yI)-amide C-hiralI SNH s 3-Amino-6-(3-cyano-thiophen-2 4190~*- N, 1)-pyridine-2-carboxylic acid (3- 402 19 490 N H N iamino-3,4,5,6-tetrahydro-2H- 402 19 NZ N [1,4']bipyridinyl-3'-yI)-amide KN

NH

2 CH3 Chiral 3-Amino-6-(2,6-difluoro-3 propoxy-phenyl)-pyridine-2 491 \NF carboxylic acid (3-amino-3,4,5,6- 483.2 2.70 N) tetrahydro-2H- 1 ,4']bipyridinyl N 3'-yl)-amide N NH N *H2CH 3 \NN2 Chral -Amino-6-(3-ethoxy-2,6 Fdifluoro-phcnyl)-pyridinc-2 492 F FF carboxylic acid (3-amino-3,4,5,6- 469.2 2.29 NH N ~ etrahydro-2H-[ 1,4']bipyridinyl NII N '-yl)-amide ______ NNH 2 -149- Example Structure Name MH+ LC

CH

3 (! Chiral NH, -Amino-6-(2,6-difluoro-3 F F methoxy-phenyl)-pyridine-2 493 ) carboxylic acid (3-amino-3,4,5,6- 455.2 2.17 NH N ttrahydro-2H-[1 ,4']bipyridinyl N NH 2 NChira 3-Amino-6-(2,6-difluoro-3 F IF ropoxy-phenyl)-5-fluoro 49 N-yridine-2-carboxylic acid (3- 501.2 2.63 N .. amino-3,4,5,6-tetrahydro-2H [1 ,4']bipyridinyl-3 '-yL)-amide N

NH

2

N

0 -- ,-CH 3 I - Chiral 3-Amino-6-(3-ethoxy-2,6 F F difluoro-phenyl)-5-fluoro 49 N0- F pyridine-2-carboxylic acid (3- 487.2 2.38 <1 N i amino-3 ,4,5 ,6-tetrahydro-2H _____ N)

NH

2 [I,4']bipyridinyI-3'-yl)-amide

FH

3 C H 3 NH Chiral 3-Amino-6-(2,6-difluoro-3

~NH

2 sopropoxy-phenyl)-5-fluoro 496 L F F yridine-2-carboxylic acid (3- 501.2 2.48 NH N -amino-3,4,5,6-tetrahydro-2H N [1,4']bipyridiriyl-3'-yI)-amide NN Chra 3-Amino-5-fluoro-6-(3 %\N H 2 Cia ulfamoyl-phenyl)-pyridine-2 49 F carboxylic acid (3-amino-3,4,5,6- 486.1 1.77 H tetrahydro-2H-[ 1,4']bipyridinyl N 3'-yl)-amide N

N

2 0

IICH

3 NH Chiral 3-Amino-5-fluoro-6-(3 \NH2 ethanesulfonylamino-phenyl) 498 0 1' Fyridine-2-carboxylic acid (3- 500.2 1.96 HIF amino-3,4,5,6-tetrahydro-2H Njj

NH

2 -150- Example Structure Name MH+ LC '. Chiral \NH2 3-Amino-5-fluoro-6-phcnyl 499 I~N F pyridine-2-carboxylic acid (3- 471 21 499 N H N amino-3,4,5,6-tctrahydro-2H- 47121 N[1 ,4']bipyridinyl-3'-yI)-amide N N H 2 HN Chira \NH N-f 6-(3-Acctylamino-phenyl)-3 500 NH 0 'I amino-5-fluoro-pyridine-2 50 K carboxylic acid (3-amino-3,4,5,6- 464.2 1.90 N Y-yt)-amidc NH1 2 FChiral INH 3 -Amino- 5-fluoro-6-(5 41luoro-2 5010H , CH 3 methoxy-phenyl)-pyridine-2 5101 H Ncarboxylic acid (3-amino-3,4,5,6- 455.2 2.24 N tetrahydro-2H-[ I ,4']bipyridinyl

NH

2 '-yl)-amide NHH, I1 hia 3-Amino-5-fluoro-6-(2-fluoro-5 <>ANH 2 IF methoxy-phenyl)-pyridine-2 50132 ON N F carboxylic acid (3-amino-3,4,5,6- 455.2 2.26 SH tetrahydro-2H-[ 1,4']bipyridinyl N ' 3-yI)-amide N

NH

2

H

3 Chiral

CH

3 NH ~ 0 3-Amino-6-(2,6-difluoro-3 IH isopropylcarbamoyl-phenyl) 503 I~JF IF yridine-2-carboxylic acid (3- 510.3 2.10 N N a mino-3 ,4,5 ,6-tetrahydro-2H H [1 ,4']bipyridinyl-3 '-yI)-amidc ___ (_NY NH1 2

NH

2 0 Chiral ,2 -: 10, H 5,5'- Diamino-6'-(3 -amino 0 .i F -N ~C 3 34,5,6-tetrahydro-2H-[I1,4']bi 504 yridinyI-3'-ylcarbamoyl)-3- 481.2 1.90 N N I- fluoro-[2,2']bipyridinyI-6 (~JN NH 2 carboxylic acid methyl ester -151- Example Structure Name MH+ LC - Chiral 3-Amino-6-(3-benzyloxy-2,6 -_NH2difluoro-phenyl)-5-fluoro 505 F IF pyridine-2-carboxylic acid (3- 549.2 2.80 ~ N IF amino-3 ,4,5 ,6-tetrahydro-2H N H N [ 1,4']bipyridinyl-3'-yI)-amidc __ _ _ N

INH

2 CH Chiral

NH

2 3-Amino-6-(3-butoxy-2,6 ~ I difluoro-phenyl)-5-fluoro 506 F F yridinc-2-carboxylic acid (3- 515.3 2.83 0' F N N -amino-3 ,4,5 ,6-tetrahydro-2H NI [1,4']bipyridinyl-3'-yI)-amide N

NH

2 ... CH 3 N Chiral 3-Amino-S-fl uoro-6-(6-methoxy KN \NH2 .- N pyrazin-2-yi)-pyridine-2 507 I)N' F carboxylic acid (3-amino-3,4,5,6- 439.2 1.95 H tetrahydro-2H-[1,4']bipyridinyl 3'-yl)-amide N NH 2 CH, Chiral H N CH 3

\NH

2 N-Amino-5-fluoro-6-(2-fluoro-5 508 \N2 I yridine-2-carboxylic acid (3- 510.3 2.14 KN>N IF amino-3 ,4,5,6-tetrahydro-2H N ~ 1,4']bipyridinyI-3'-y1)-amide NH Ch iralI

NH

2 IN3-Amino-6-(2,6-dimethyl

OH

3

CH

3 phenyl)-5-fluoro-pyridine-2 09 N H N F carboxylic acid (3-amnino-3,4,5,6- 435.2 2.41 N t~etrahydro-2H-[1,4']bipyridinyl <11 '-y )-am id e

-NH

2 Chiral 3-Amidno-6-(2,6-difluoro-3 IIJ F IF ethoxy-phenyl)-5 -fluoro 510 N N yridine-2-carboxylic acid (3- 473.2 2.32 HLA N'mino-3 ,4,5 ,6-tetrahydro-2H [1,4'Ilbipyridinyl-3'-yl)-amidc ____IN N H 2 -152- Example Structure Name MH+ LC Chiral 'N \NH2 01 5-Amino-3-fluoro-2'-methoxy 511 I)F CH 3 [2,3']bipyridinyl-6-carboxylic 48219 N H N acid (3-amino-3,4,5,6-tetrahydro- 482 19 N NH, H-[ 1 ,4']bipyridinyI-3'-yI)-amide ______ N H 2 01 Chira 0-NH N Chrl5-Amino-3-fluoro-6'-methoxy 512 K) N IF [2,2']bipyridinyl-6-carboxylic 482 18 N H Nacid (3-amino-3,4,5,6-tetrahydro N 2H-[ 1,4'Ilbipyridinyl-3'-yl)-amide ___ __ N NH 2

<>NH

2 Chra 5-Amino-3-fluoro-[2,4']bi 513 N1 IF pyridinyl-6-carboxylic acid (3 N H N mino-3,4,5,6-tctrahydro-2H- 408.2 1.24 NZ N 1 ,4'Ijbipyridinyl-3'-yl)-amide __ ti_ N NH 2

NH

2 Chiral

N'

\NH

2 5,6'-Diamino-3-fl uoro-[2,3']bi 514 I'iF pyridinyl-6-carboxylic acid (3- 423.2 1.34 N H N amino-3,4,5,6-tctrahydro-2H NN [1 ,4']bipyridinyl-3'-yl)-amide ____ N) NH 2 C 3 / I C H 3 C h i a l -A m i n o -6 -( 5 0 N imethylcarbamoyl-2-fluoro 515 \NH2 IF phenyl)-5-fluoro-pyridine-2- 46221 515 I)F carboxylic acid (3-amino-3,4,5,6- 462 21 N H N etrahydro-2H-[ 1,4']bipyridinyl N N -yI)-amide

NH

2 Chiral N\NH IFH IF -Amino-6-(2,6-difluoro-phcnyl) 516 0 F 5-fluoro-pyridine-2-carboxylic 443.2 2.25 N H Nacid(3-amino-3,4,5,6-tetrahydro N N2H-[ 1,4']bipyridinyl-3'-yl)-arnide KN

NH

2 -153- Example Structure Name MH+ LC Chiral \NH2 F 3 -Amino- 5-fluoro-6-(2 -fluoro K)F phenyl)-pyridine-2-carboxylic 517 N cid (3-amino-3,4,5,6-tetrahydro- 425.2 2.25 ( N H-[ 1 ,4']bipyridinyl-3'-yl)-amide _____ N" NH 2 F I 2. 5-Amino-2-(2,4-difluoro-phenyl) F11 pyrimidinc-4-carboxylic acid (3- 462 18 58N H N N amino-3,4,5,6-tetrahydro-2H N 11, [ 1,4']bipyridinyl -3 -yI)-ami de N~ NH N2 - N ri fluoro-ethoxy)-pyrazin-2-yI] 51 N) yridine-2-carboxylic acid (3- 504.2 2.10 N9 H N-amino-3,4,5,6-tetrahydro-2H

NH

2 [1,4']bipyridinyl-3'-yI)-amide

NH

2 N r0,_,-CCH3-Amino-6-[5-amino-6-(2 H2N ~ ~ N methoxy-ethoxy)-pyrazin-2 -yl] 520 "4N N ~ yridine-2-carboxylic acid (3- 480.2 1.64 NH amino-3 ,4,5 ,6-tetrallyuro-2n

NH

2 [ [1,4']bipyridinyl-3'-yl)-amidc H N 11 ^' -- o'- -Amino-6-(6 2AnN cyclopropylmethoxy-pyrazin-2 521 N) N Il)-pyridine-2-carboxylic acid (3- 461.1 2.38 N amino-3,4,5,6-tctrahydro-2H _______ NH [1,4']bipyridinyl-3'-yl)-amide H2N~~>.'N 3-Amino-6-(6-hydroxy-pyrazin 522 K) N-yl)-pyridine-2-carboxylic acid 407.1 1.35 Hj (3-arrnno-3,4,5,6-tetrahydro-2H ____N N H 2

C;H

3 N( (oNACH 3 3-Amino-6-(6-isobutoxy-pyrazin 5:23 2tiiN-yI)-pyridine-2-carboxylic acid 463.2 2.59 N H N ~ (3-amino-3,4,5,6-tetrahydro-2H (~N N 1,4']jbipyridinyI-3'-y1)-amide

NH

2 -154- Example Structure Name MH+ LC H2N *'nI 3-Amino-6-phenyl-pyridine-2 524 N N carboxylic acid (3-amino-3,4,5,6- 389.1 2.07 H tetrahydro-2H-[1,4']bipyridinyl N 3'-yl)-amide

NH

2 H N N 6-(4-Piperazin- 1 -yl-phenyl) F pyridine-2-carboxylic acid [4-(6 525 F',_TN NH 2 amino-2-trifluoromethyl- 521.1 2.20 N pyrimidin-4-yl)-pyridin-3-yl] H N amide N N N F F 5-Amino-i ',2',3',6'-tetrahydro F N NH 2 [2,4']bipyridinyl-6-carboxylic 526 N N acid [4-(6-amino-2- 457.2 1.83 H trifluoromethyl-pyrimidin-4-yl) N N H pyridin-3-yl]-amide N NH 2 F

FNH

2 6-(2,4-Difluoro-phenyl)-pyridine 527 F N F 2-carboxylic acid [4-(6-amino-2- 473.0 3.33 N - tifluoromethyl-pyrimidin-4-yl) N pyridin-3-yl]-amide N F 2 F NH F F 6-(2,6-Difluoro-phenyl)-pyridine 528 N/~ N 2-carboxylic acid [4-(6-amino-2 H trifluoromethyl-pyrimidin-4-yl) N N pyridin-3-yl]-amide N IF N NH 2 F 6-(2-Fluoro-phenyl)-pyridine-2 529 N / N carboxylic acid [4-(6-amino-2- 455.1 3.21 H trifluoromethyl-pyrimidin-4-yl) N Nyridin-3-yl]-amide N -15 5- Example Structure Name MH+ LC IFN N,.,Ly NH 2 6-Phcnyl-pyridinc-2-carboxylic 530 N I N acid [4-(6-amino-2- 437.1 31 H N rfluoromcthyl-pyrimidin-4-yl)-31 N ' yii--I-md N y _______NT________________ ___ F F N NH 2 3-Amino-6-phenyl-pyridinc-2 531 N - N ~ carboxylic acid [4-(6-amino-2- 42130 H trfluoromethyl-pyrimidin-4-yi)- 421 30 N N yridin-3-yi]-amide N

NH

2 .3 NH 2 N '3H-Amino-6-(2,6-difluoro-3 NjjgN F F propoxy-phenyl)-pyr-idinc-2 532 N - N carboxylic acid [4-(6-amino-2- 524.1 3.33 HN ethylsulfanyl-pyrimidin-4-yI) - NH 2 yridin-3-yl]-amide NN

CH

3 gN NH 2 I 'CH3-Amino-6-(2,6-difluoro-3 ) 1 F F propoxy-phenyl)-pyridine-2 533 N H N- carboxylic acid [4-(6-amino-2- 492.1 2.85 H methyl-pyrimi din-4-yI)-pyridin N NH 2 3-yI]-amidc 0 CH 3 )l 3-Amino-6-(2-fluoro-5 I I H sopropylcarbamoyl-phenyl) HN NN-SF pyridine-2-carboxylic acid [4-(6 H3 amino-2-methylsulfanyl- 533.2 2.70) NN N yrimidin-4-yi)-pyrdin-3-yI] - NH, amide

H

2 C H 3 N NCH33-Amino-6-(5 I I IH dimcthylcarbamoyl-2-fluoro 535 N N H henyl)-pyn'dine-2-carboxylic 592 25 H N cid [4-(6-amino-2 N N ethylsulIfanyl-pyrimidin-4-yI) ____ N NH 2 pyridin-3-yl]-amide CH 0CH 3 SN N y 3-Amino-6-(2,6-difluoro-3 F2 F CH 3 sopropoxy-phenyl)-pyridine-2 536 N N ~ carboxylic acid [4-(6-amino-2- 524.0 3.26 N metbylsulfanyl-pyrimidin-4-yI)

NH

2 pyridin-3-yl]-amide -156- Example Structure Name MH+ LC CH3 0 QyCHT 3-Amino-6-(2,6-difluoro-3

H

2 N N F F FCH3 isopropoxy-phenyl)-pyridine-2 537 N arboxylic acid [4-(6-amino-2- 492.2 2.72 N methylI-pyrimi din-4-yi)-pyri din

-

NH

2 3-yi]-amide

H

2 N 0O H 3 3-Amino-6-(2,6-difluoro-3 H2 N F F CH3 isopropoxy-phenyl)-pyri din e-2 538 H N -carboxylic acid (2'-amino-6'- 491.2 2.57 HN Iethyl-[4,4']bipyridinyl-3-yl)

NH

2 amide NH HN CH 3 N -Amino-6-(2-fluoro-5

H

2 N 0 N Hsopropylcarbamoyl-phenyl) 539 HN N C3 F pyridine-2-carboxylic acid (2'- 500.2 2.15 N amino -6'-methyl- [4,4']bi H pyridinyl-3-yl)-amide NN N N N H 2

-NH

2 N NH 5-Amino-2-(5-ethylcarbamoyl-2 IN JC uoro-phcnyl)-pyrimidinc-4 540 0 "carboxylic acid (3-amino-3,4,5,6- 479.2 1.64 N H N IN tetrahydro-2H-[ 1,4']bipyridinyl I-kz N3'-yI)-amide N ,rCH 3

-NNH

2 C H 3 Chira 5-Amino-2-(2-fluoro-5 0 "F isopropoxy-phenyl)-pyrimi dine 541 N N N 4-carboxylic acid (3-amino- 466.3 2.15 N, 3,4,5,6-tetrahydro-2H-[ 1,4']bi N gNH 2 ynidinyl-3'-yI)-amide 0 Chiral

\NH

2 N NH 5-Amino-2-(2-fluoro-5 IF H CH 3 opropylcarbamoyl-phcnyl) 542 0 yrimidine-4-carboxylic acid (3- 493.2 1.84 11N. -1 N amino-3 ,4,5 ,6-tetrahydro-2H N N[1 ,4']bipyridinyl-3'-yl)-amide -157- Example Structure Name MH+ LC

NH

2

CH

3 F ChiralI 5-Amino-2-(2-fluoro-5-methyl 54 K)henyl)-pyrimidinc-4-carboxylic 421 19 N H N IN acid (3-amino-3 ,4,5 ,6-tetrahydro- 421 19 N;1 N H-[1I,4']bipyridinyl-3'-yI)-amide N~ CH 3 %NH2 Chiral 2-(3-Acetylamino-phenyl)-5 544 N0 ' amino -pyrimidine-4 -carboxylic 472 16 N N;11N acid (3-amino-3,4,5,6-tetrahydro- 472 16 N Z 11 H-[I ,4']bipyridinyl-3'-yI)-amidc N ]YS NKChra 5-Amino-2-(2,6-difluoro-3 FIJ F~jF CH 3 propoxy-phenyl)-pyrimidine-4 545 N H . N-l N carboxylic acid (3-amino-3,4,5,6- 484.2 2.19 N tetrahydro-2H-[ 1,4']bipyridinyl LI gNH 2 '-yi)-amide F Chiral N H F 5-Amino-2-(2,3-difluoro-phenyl) 54 N -Nyrimidinc-4-carboxylic acid (3- 462 18 5216 N H N; , N amino -3,4,5,6-tetrahydro-2H- 462 18 NZ N & Z,[ 1,4']bipyridinyl-3'-yl)-amide INI Chiral IZNH 5-Amino-2-(4-chloro-2 -fluoro 547 F phcnyl)-pyrimidinc-4-carboxylic 42120 N N;1 N acid (3-amino-3,4,5,6-tetrahydro- 421 20 Nz N&--,11 H-[ 1 ,4']bipyridinyl-3'-yI)-amide NH 0 Chiral IF CH 3 5-Amino-2-(5-ethoxy-2-fluoro 548 q phenyl)-pyrimidine-4-carboxylic 422 20 H Nacid( -amino-3 ,4,5 ,6-tetrahydro _____ YYI 2H-[ I ,4'Ijbipyridinyl-3'-yl)-amide

H

2 K>1 IF ' Chi ral 5-Amino-2-(2-fluoro-5-methoxy 549 0 , q henyl)-pyrimidine-4-carboxylic 481 18 N acid (3-amino-3,4,5,6-tetrahydro 2H-[ 1,4']bipyridinyl-3'-yl)-amide -158- Example Structure Name MH+ LC ,,N 0 1Chiral 5Aio2(-loo5pooy 550 I H phenyl)-pyrimidine-4-carboxylic 466.2 2.25 N H N Nacid (3-amino-3,4,5,6-tetrahydro 2H-[ 1 ,4']bipyridinyl-3'-yl)-amide N H I ' Chiral Nj\NH2 K'~ 0 5-Amino-2-(2-methoxy-phenyl) 551 N.~..NCH3 pyrimidine-4-carboxylic acid (3- 401 16 H amino-3,4,5,6-tetrahydro-2F1 N [1 ,4']bipyridinyl-3'-yl)-amide NN

NH

2 F 5-Amino-2'-fluoro-[2,3']bi 5452 a Npyridinyl-6-carboxylic acid (3- 408.1 1.88 H amino-3,4,5,6-tetrahydro-2H N r N . [1,3']bipyridinyl-4'-yl)-amide IF N CH, 6-(2-Fluoro-5 F FN NH 2 H - sopropylcarbamoyl-phenyl) 553 FN- F pyridine-2-carboxylic acid [4-(6- 503 29 H Namino-2-trifluoromethyl- 503 29 I pyrirnidin-4-yl)-pyridin-3-yI] N amide OU OH 3 IF ~ N H -Amino-6-(2-fluoro-5 F FN NH 2 H isopropylcarbamoyl-phenyl) F' pyridine-2-carboxylic acid [4-(6 554 N -H N ~ amino-2-trifluoromethyl- 552 28 NNN pyrimidin-4-yl)-pyridin-3-yl

NNH

2 amide N. CH CH IN NH 2 - H 3-Amino-6-(3-cthyl-phcnyl) 555 N ;N p~yridine-2-carboxylic acid [4-(6- 461 27 H amino-2-methyl-pyrimidin-4-yl)- 461 27 N N N H, yridin-3-yi]-amide

CH

3

H

2 N N z~CIH 3 S 3-Amino-6-(4-metbyl-thiophen 556 N -yl)-pyridine-2-carboxylic acid 418.1 2.33 55 N N [4-(6-arnino-2-methyl-pyrimi din H N. N N. H, -yi)-pyridin-3-yl-amide -159- Example Structure Name MH* LC F F F N 3-Amino-6-(2-fluoro-4

H

2 N N CH 3 F trifluoromethyl-phcnyl)-pyridine 55 H N'T F2-carboxylic acid [4-(6-amino-2- 484.2 2.86 N m~ethylI-pyrimidin-4-yl)-pyri din NNN 3-yi]-amide N

NH

2 N -Amino-6-(2-fluoro-4-methyl 558 HN NrC3 F phcnyl)-pyridinc-2-carboxylic -N N cid [4-(6-amino-2-methyl- 430.2 2.57 H I yrimidin-4-yl)-pyridin-3-yI] N amide N

NH

2

H

2 N N NCH 3 3-Amino-6-phenyl-pyridine-2 559 -N N carboxylic acid [4-(6-amino-2- 382 22 H methyl-pyrimidin-4-yi)-pyridin- 382 22 N N -yl]-amide NN, 0 H 3

NH

2 H CH 3 3-Amino-5 -fluoro-6-(2-fluoro-5 CH Ny' FH isopropylcarbamoyi-phenyl) 560 N N F pyr idine-2-carboxylic acid [4-(2- 519.2 2.70 H amino-6-methyl-pyrimidin-4-yI) N N yridin-3-yl]-amide it N

NH

2 N NCH33-Amino-6-(5

H

2 N N /' CH 6H 3 dmethylcarbamoyl-2-fluoro 561 N F F phcnyl)-5-fluoro-pyridinc-2- 505.1 2.22 N carboxylic acid [4-(6-amino-2 N ethyl-pyrimidin-4-yI)-pyri din - NH 2 3-yl]-amide ____N_ NH C3N NH 2 N '"CH3-Amino-6-(2,6-difluoro-3 i~'F F propoxy-phenyl)-pyr-idine-2 562 N H N -carboxylic: acid [4-(2-amino-6- 492.1 3.11 ______N NH ethyl-pyrimidin-4-yI)-pyridin -160- Example Structure Name MH+ LC o CH 3 NH )N CH33-Amino-6-(2-fluoro-5 56 3 N./ l/ HF sopropylcarbamoyl-phenyl) N N pyridine-2-carboxylic acid [4-(2- 501.2 2.38 H Iamino-6-methyl-pyrimidin-4-yI) N N NH, pyrdin-3-yI]-amide N CHa3-Amino-6-(5 CH IN 2 I 3 dimethylcarbamoyl-2-fluoro 564 N IF phenyl)-pyridine-2-carboxylic 487.2 2.24 N IN acid [4-(2-amino-6-methyl H pyrimidin-4-yI)-pyridin-3-yI] N

NH

2 amide _ _ _ _ N_ N , _ _ _ _ _ _ _ _ _ _ _ _ _ __H_ _ 2 N N./pIH ropylcarbamoyl-phenyl) 565 N N ynidine-2-carboxylic acid [4-(6- 501.2 2.29 H jami no-2-m ethyl -pyri mi din -4-yI) NN N N NH 2 pyridin-3-yl]-arnide r0) Chiiral N 3-Amino-6-(3-morpholin-4 N Imethyl-phenyl)-pyridine-2 566 HN( carboxylic acid (3-amino-3,4,5,6- 488.0 1.43 N N tetrahydro-2H-[1I,4']bipyridinyl SH 3'-yl)-amide N NH

NH,

2 3-Amino-6-(4-morpholin-4 N2 Ilmethyl-phenyl)-pyridine-2 567 2 ~(jcarboxylic acid (3-amino-3,4,5,6- 488.0 1.42 N IN etrahydro-2H-[ I ,4']bipyridinyl H 3'-yl)-amide

NQNH

2 N NH2 CiralI H N H2N4N I 3-Fluoro-6-phenyl-pyridine-2 568 carboxylic acid (3-amino-3,4,5,6- 392.2 1.96 N tetrahydro-2H-[I ,4']bipyridin'yl' N 3'-yI)-amidc IF -161- Example Structure Name MH+ LC CH, Chira HN 1,CH 3 3-Fluoro-6-(2-fluoro-5 I2*# 0 sopropylcarbamoyl-phenyl) 569 *n F pyridine-2-carboxylic acid (3- 495.2 2.02 N ; N NZ amino-3 ,4,5 ,6-tetrahydro-2H N 4[1 ,4']bipyridinyl-3'-yl)-amide Chiral HNF IF -(2,6-Difluoro-phcnyl)-3-fluoro 570 N N ~yridine-2-carboxylic acid (3- 482 20 57iNH N amino-3,4,5,6-tctrahydro-2H- 48220 Ohiral IF 3-Fluoro-6-(2-fluoro-phenyl) 571 N N pyridine-2-carboxylic acid (3- 410.2 2.08 N amino-3 ,4,5 ,6-tetrahydro-2H IN [1,4']bipyridinyl-3'-yI)-amide 3-Amino-6-(4-morpholin-4 F IF -N NH 2 ylmethyl-phenyl)-pyridine-2 572 F7Ni .. carboxylic acid [4-(6-amino-2- 551.1 2.10 N N trifluoromethyl-pyrimidin-4-yI) H pyridin-3-yl]-amide N N N.. 5-Amino-2'-(4-methyl-piperazin

-NNH

2 -1-yl)-[2,4']bipyridinyl-6 573 F 1carboxytic acid [4-(6-amino-2- 551.1 1.73 H tiifluoromethyl-pyrimidin-4-yl) N p'yridin-3-yi]-amide N

NH

2 C H3 Q 3-Amino-6-[4-(4-methyl F F N iperazin- I-yl)-phenyl]-pyridine 574 IF N NH 2 2-carboxylic acid [4-(6-amino-2- 550.1 2.14 IFTNI trifluoromethyl-pyrimidin-4-yl) H N - pyridin-3-yl]-amide N N N H 2 -162- EapeStructure Name MH+ LC OH

H

2 N OHy F 6-(2,6-Difluoro-phenyl)-3-fluoro F F yri dine-2 -carboxy tic acid (5 575 N N N mino-3-hydroxymethyl-3,4,5,6- 458.1 2.10 N trahydro-2H-[ 1,4']bipyridinyl F Y-yI)-amide OHN F F -Amino-6-(2,6-di fluoro-phenyl)

H

2 N F F yridinc-2-carboxylic acid (5 576 N N N mino-3-hydroxymethyl-3,4,5,6- 455.1 1.89 N tetrahydro-2H-[1 ,4']bipyridinyl N NH 2 3'-yI)-amide ", ON', Chira F/ NH 2

I"

0

-'CH

3 3-Amino-6-(2-fluoro-5-propoxy "0 F henyl)-pyridine-2-carboxylic 43125 N7 N H N acid (3-amino-5-fluoro-3,4,5,6 431 25 N tetrahydro-2H-[ I ,4']bipyridinyl NH2 3-l-md N Chral F/,, \NH 2 I3-Amino-6-phenyl-pyridine-2 578 N N N. carboxylic acid (3-amino-5- 471 19 H fuoro-3 ,4,5 ,6-tetrahydro-2H Chra CH3 ,NH -~cH 3-Amino-6-(2-fluoro-5-propoxy 6y . NH F phcnyl)-pyridine-2-carboxylic 579 N cid (3-amino-5-methoxy- 495.2 2.48 H N - 3,4,5,6-tetrahydro-2H-[ 1 ,4']bi NH2 pyridinyl-3'-yl)-amide CH3 \NH 2NH '1, 3-Amino-6-phenyi-pyridine-2 580 Ocarboxylic acid (3-amino-5- 419.1 1.97 N N N. cthoxy-3,4,5,6-tctrahydro-2H N .11 [I ,4']bipyridinyl-3'-yl)-amide

NH

2 Chira 10N 2 1CH3 3-Amino-6-(2-fluoro-5-propoxy \NHF phenyl)-pyridine-2-carboxylic 5:H1 N acid (3-amino-5-hydroxy-3 ,4,5 ,6- 481.2 2.45 N HV I N t-etrahydro-2H-[ 1,4'Ijbipyridinyl NH, r'-yl)-amide -163- Example Structure Name MH+ LC Chiral H ,\NH 2 3-Amino-6-phenyl-pyridine-2 582 carboxylic acid (3-amino-5- 405.1 1.86 N N hydroxy-3,4,5,6-tetrahydro-2H N 1,4']bipyridinyl-3'-yl)-amide METHOD 14 Example 583 Synthesis of 3-amino-6-(2-fluorophenyl)-N-(4-(piperidin-1-yl)pyridin-3-yl)picolinamide F N N H N 5 O Q NH 2 5 N [0259] A solution of 3-amino-6-bromo-N-(4-(piperidin-I-yl)pyridin-3 yl)picolinamide (1.0 eq), 2-fluorophenyl boronic acid (3.0 eq.), Pd(dppf)C1 2

-CH

2

CI

2 (0.15 eq.) in 3:1 DME/2M Na 2

CO

3 (concentration = 0.1 M) was heated at 120 0 C with microwave irradiation for 1200 seconds. The organic layer was separated, concentrated 10 and directly purified by reverse phase HPLC. After lyophilization, (S)-3-amino-N-(4-(3 aminopipendin- I -yl)pyridin-3 -yl)-6-(2-fluoro-4-methylphenyl)picolinamide was obtained (44%) as the TFA salt. LCMS (m/z): 421.2 (MH+); LC Rt = 2.23 min. 102601 Alternatively, the free base and HCl salt of 3-amino-6-(2 fluorophenyl)-N-(4-(piperidin- I -yl)pyridin-3-yl)picolinamide could be obtained as 15 described in Method 8. [02611 The following compounds were prepared using Method 14. In some cases the anhydrous Suzuki conditions of method 12 (DMF as solvent with 10 equivalents of triethylamine) were used. -164- ID Structure Name MH+ LC 'N SCH, 5-amino-2'-methoxy-[2,3']bi 584 HC H pyridinyl-6-carboxylic acid (4-o- 412.2 3.01 N tolyl-pyridin-3-yl)-amide N. 0 NH2 F F 3-amino-6-(2,6-difluoro-phenyl) 585 HC H N pyridine-2-carboxylic acid (4-o- 417.1 3.24 N N N tolyl-pyridin-3-yl)-amide N 0 NH 2 ' F 3-amino-6-(2-fluoro-phenyl) 586 H 3 c H N pyridine-2-carboxylic acid (4-o- 399.1 3.35 N NH Nolyl-pyridin-3-yl)-amide N N2 "N O. CH, 5-amino-2'-methoxy-[2,3']bi 587 LN~ Np yridinyl-6-carboxylic acid (3,4,5,6- 405.2 2.83 tetrahydro-2H-[1,4']bipyridinyl-3' & O NH 2 yl)-amide N 2 F F 3-amino-6-(2,6-difluoro-phenyl) 588 N- pyridine-2-carboxylic acid (3,4,5,6- 410.2 3.14 5 N H tetrahydro-2H-[ 1,4']bipyridinyl-3' SNH2 yl)-amide 0NH F 3-amino-6-(2-fluoro-phenyl) 589 N' pyridine-2-carboxylic acid (3,4,5,6- 3922 3.22 N tetrahydro-2H-[1,4']bipyridinyl-3' 0 NH yl)-amide 3-amino-6-phenyl-pyrazine-2 -N N carboxylic acid (2-oxo-5-piperidin 590r N N I -yl-2,3-dihydro-pyrimidin-4-yl) N yNH 0 NH 2 amide 0 CH 3-amino-6-o-tolyl-pyrazine-2 N N carboxylic acid (2-oxo-5-piperidin 591 N N -yI-2,3-dihydro-pyrimidin-4-yl)- 406.2 3.12 N yNH 0 NH 2 amide 0 -165- ID Structure Name MH+ LC <> 1 F 3-amino-6-(2-fl uoro-phenyl) 592 ~ N N> pyrazine-2-carboxylic acid (2-oxo-5- 401 30 592 H .4iperdin- I -yI -2,3 -dihydro- 401 30 N yNH 0 NH, pyrimidin-4-yi)-amide 0 O ~ F 3-amino-6-(2-trifluoromethyl F N phenyl)-pyrazine-2-carboxylic acid 593 H I460.1 3.21 (11N .~N (2-oxo-5-piperidin-1I -yl-2,3 -dihydro N yNH 0 NH, pynmidin-4-yi)-amide 0 0'C, 3-amino-6-(2-methoxy-phenyl) N Na"yrazine-2-carboxylic acid (2-oxo-5-42. 3 r - NIr-1Y N iperidin-1I-yl-2,3-dihydro N y NH 0 NH, pyrrnidin-4-yl)-amide 0 3-amino-6-(2-chloro-phenyl) N N pyrazine-2-carboxylic acid (2-oxo-5 r'- NY - iperidin- I-yl-2,3-dihydro- 461 31 N yNH 0 NH, pynmidin-4-yl)-amide 0 0 ) 3-aino-6-(2-tifluoromnethoxy KN) N ~ henyl)-pyrazine-2-carboxylic acid 596 r-, (2-oxo-5-piperidin- I -yi- 2 ,3 -dihydro- 461 33 N yNH 0 NH, pyrimidin-4-yl)-amide 0 -166- METHOD 15 Example 597 Synthesis of 3-amino-6-bromo-N-(4-(3-(I-methylpiperidin-4-ylamino) piperidin- I -yl)pyridin-3-yl)pyrazine-2-carboxamide N NH Br N N 5 H N N NH NN 102621 To a solution of 3-amino-N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-6 bromopyrazine-2-carboxamide in CH 2

CI

2 at room temperature was added 1 methylpiperidin-4-one (1.5 eq) followed by sodium triacetoxyborohydride (5.0 eq). The reaction was stirred at room temperature for 12 hours, concentrated, purified by reverse 10 phase HPLC and lyophilized to provide 3-amino-6-bromo-N-(4-(3-(1-methylpiperidin-4 ylamino)piperidin-1-yl)pyridin-3-yl)pyrazine-2-carboxamide, (66%). LCMS (m/z): 489.2 (MH+). 102631 Following Method 15, the following compounds were prepared. Example Structure Name MH+ LC ro 3-amino-6-bromo-pyrazine-2 598 NH Br carboxylic acid (3-benzylamino- 482.1 2.31 N H N- , 3,4,5,6-tetrahydro-2H-[1,4']bi pyridinyl-3'-yl)-amide N Ni N ON2 3-amino-6-bromo-pyrazine-2 599 01"Nn r carboxylic acid (3-dibenzylamino- 572.2 242 N H N-I 3,4,5,6-tetrahydro-2H-[1,4']bi N r yridinyl--yl)-amide N NH2 -167- Example Structure Name MH+ LC N 3-amino-6-bromo-pyrazine-2 Y carboxylic acid [3-(1-methyl 600 HN ] piperidin-4-ylamino)-3,4,5,6-tetra- 489.2 1.29 N Hhydro-2H-[1,4']bipyridinyl-3'-yl] &fYI amide Synthesis of trans (+/-)-Benzyl 3 -(tert-butoxycarbonylamino)-4-hydroxypiperidine-1 carboxylate OH .'!\NHBoc Cbz 5 Synthesis of trans (+/-)-Benzyl 4-(tert-butoxycarbonylamino)-3-hydroxypiperidine-1 carboxylate NHBoc N .O H Cbz 102641 A solution of (+/-) benzyl 7-oxa-3-azabicyclo[4. 1.0]heptane-3 carboxylate (1.0 equiv.) in saturated ammonium hydroxide aqueous solution and ethanol 10 (1:1, 0.05 M solution) in a scaled steel bomb was heated to 70 C for 5 h. After all volatile materials were removed by N 2 gas stream, ethyl acetate and water were added for work-up. The crude regioisomeric mixture, (+/-) benzyl 3-amino-4-hydroxypiperidine-1 carboxylate and (+/-) benzyl 4-amino-3-hydroxypiperidine-1-carboxylate was reacted with Boc 2 0 (1.0 equiv.) and triethylamine (1.0 equiv.) in dichloromethane (0.1 M 15 solution). After stirred for 2 h at room temperature, the reaction mixture was extracted with dichloromethane. The polar (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4 hydroxypiperidine- I -carboxyl ate and nonpolar (+/-)-benzyl 4-(tert butoxycarbonylamino)-3-hydroxypiperidine-1-carboxylate were obtained by flash column chromatography (20% to 40% EtOAc in hexanes, 28% and 51% each). LCMS 20 (n/z): 351.1 (MH), Rt = 0.81 min, LCMS (m/z): 351.1 (MH 4 ), Rt = 0.83 min. -168- [0265] The enantiomerically pure (3S,4S)-benzyl 3-(tert butoxycarbonylamino)-4-hydroxypiperidine-1-carboxylate and (3R,4R)-benzyl 3-(tert butoxycarbonylamino)-4-hydroxypiperidine- 1 -carboxylate were resolved by chiral HPLC (For analysis R, = 6.8 min and 9.1 min respectively; n-heptane:ethanol= 70:30 (v:v), 5 Chiralpak AD-H prep 250X4.6 mm at I mL/min. For preparative separation, n heptane:ethanol = 80:20 (v:v), Chiralpak AS 50 x 500 mm.at 90 mL/min). METHOD 16 Synthesis of (+/-)-Benzyl 3-(tcrt-butoxycarbonylamino)-4-(tert butyldimethylsilyloxylpiperidine- I -carboxylate OTBDMS NHBoc 10 Cbz [0266] To a solution of (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4 hydroxypiperidine-l-carboxylate (1.0 equiv.) in dichloromethane (0.1 M solution) was added imidazole (1.1 equiv.), DMAP (0.1 equiv.), and TBDMSCI (1.1 equiv.) sequentially The reaction mixture was stirred at room temperature for 20 h. After worked 15 up with dichloromethane, the crude (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4-(tert butyldimethylsilyloxy)piperidine- I -carboxylate was purified by silica column chromatography (10% to 20% EtOAc in hexancs, 76%). LCMS (n/z): 365.2. Synthesis of (3RAR)-benzyl 3-(tert-butoxycarbonvlamino)-4-(tert butyldimethylsilyloxy)piperidine- 1 -carboxylate OTBDMS (N.',NNHBoc 20 Cbz [0267] Following Method 16, (3R,4R)-benzyl 3-(tert-butoxycarbonylamino) 4-hydroxypiperidine-1-carboxylate was reacted with TBDMSCl, imidazole and DMAP yielding (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy) piperidine-1-carboxylate. LCMS (m/z): 365.2 (MH*); LC Rt = 6.05 min. -169- Synthesis of (3S, 4S)-benzyl 3-(tert-butoxycarbonylamino)-4-(tert butyldimethylsilyloxy)piperidine-I -carboxylate OTBDMS NHBoc N Cbz 10268] Following Method 16, (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4 5 hydroxypiperidine-I-carboxylate was reacted with TBDMSCI, imidazole and DMAP yielding (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy) piperidine-1-carboxylate. LCMS (m/z): 365.2 (MI-); LC Rt = 6.05 min. Synthesis of (+/-)-Benzyl 4-(tert-butoxycarbonylamino)-3-(tert butyldimethylsilyloxy)piperidine-1-carboxylate NHBoc (Nk.'OTBDMS 10 Cbz 102691 Following Method 16, (+/-)-benzyl 4-(tert-butoxycarbonylamino)-3 hydroxypiperidine-1-carboxylate was reacted with TBDMSCl, imidazole and DMAP yielding (+/-)-benzyl 4-(tert-butoxycarbonylamino)-3 -(tert-butyldimethylsilyloxy) piperidine-1-carboxylate, (8 1%). LCMS (m/z): 365.2 (MH t ); LC R, = 6.05 min. 15 Synthesis of (3R,4R)-Benzyl 3-(tert-butoxycarbonylamino)-4-fluoropiperidine- 1 carboxylate and (3S,4S)-Benzyl 3-(tert-butoxycarbonylamino)-4-fluoropiperidine- 1 carboxylate .{\NHBoc NHBoc NN Cbz Cbz 20 [0270] To a solution of (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4 hydroxypiperidine-1-carboxylate (1.0 equiv.) in dichloromethane (0.3 M solution) was added DAST at -78 C. The reaction mixture was slowly warmed up to room temperature for 15 h. After quenched with saturated sodium bicarbonate aqueous solution, ethyl -170acetate and water were added for work-up. The (+/-)-benzyl 3-(tert butoxycarbonylamino)-4-fluoropiperidine- I -carboxylate was obtained by silica column chromatography (30% EtOAc in hexanes, 40%). LCMS (n/z): 253.1; LC R, = 4.08 min. The enantiomerically pure (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4 5 fluoropiperidine-l-carboxylate and (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4 fluoropiperidine-1-carboxylate were resolved by chiral HPLC (for analysis: R, = 9.4 min and 12.6 min respectively; n-heptane:isopropanol = 90:10 (v:v), Chiralpak AS 250 x 4.6 mm at 1 mL/min. For preparative separation, n-heptane:isopropanol = 90:10 (v:v), Chiralpak AS 50 x 500 mm.at 90 mL/min). 10 Synthesis of trans-(+/-)-Benzyl 4-fluoro-3-hydroxypiperidine- I -carboxylate F OH N Cbz [0271] A solution of (+/-)-benzyl 7-oxa-3-azabicyclo[4. 1.0]heptane-3 carboxylate (1.0 equiv.) and Et 3 N.3HF (1 equiv.) in a sealed glass flask were heated to 100 C for 15 h. The reaction mixture was extracted with ethyl acetate, which was 15 washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and filtered. After volatile materials were removed, (+/-)-benzyl 4-fluoro-3 hydroxypiperidine- I -carboxylate was obtained by silica column chromatography (20% to 40% EtOAc in hexanes, 53%). LCMS (n/z): 254.1 (MH*); LC Rt = 2.86 min. Synthesis of trans (+/-)-Bcnzyl 3-(1,3-dioxoisoindolin-2-yl)-4-fluoropiperidine- 1 20 carboxylate 0\ N Cbz [0272] To a solution of triphenylphosphine (3.0 equiv.) in toluene (0.25 M solution) was added DEAD (3.0 equiv.) at room temperature, which was stirred for 15 min. Then, (+/-)-benzyl 4-fluoro-3-hydroxypiperidine- I -carboxylate (1.0 equiv.) was 25 added to the reaction mixture. After being stirred for 10 min, phthalimide (3.0 equiv.) was -171added and the reaction mixture was stirred for 15 h. The reaction mixture was extracted with ethyl acetate, which was washed with water and brine. The organic phase was dried over anhydrous sodium sulfate and filtered. After volatile materials were removed, (+/-)-benzyl 3-(I,3-dioxoisoindolin-2-yl)-4-fluoropiperidine-1-carboxylate was obtained 5 by silica column chromatography (10% to 20% EtOAc in hexanes, 20%). LCMS (n/z): 383.0 (MH 4 ), R, = 1.0 min. Synthesis of (+/-)-Benzyl 3-(tert-butoxycarbonylamino)-4-oxopiperidine-1-carboxylate 0 NHBoc C~N Cbz 10273] To a solution of (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4 10 hydroxypiperidine-1-carboxylate in dichloromethane (0.1 M solution) was added Dess Martin periodinane (1.5 equiv.). The reaction mixture was stirred at room temperature for 16 h. Then, the saturated NaHCO 3 and 0.1 N Na 2

S

2 0 3 aqueous solutions were added to the reaction mixture, which was stirred for 30 min and worked up with ethyl acetate. The crude benzyl 3-(tert-butoxycarbonylamino)-4-oxopiperidine-1-carboxylate was purified 15 by flash chromatography (30% EtOAc in hexanes, 70%). LCMS (m/z): 249.2 (MH); LC R, = 3.98 min. 'H NMR (CDCl 3 ): 1.41 (1H, s), 2.1-2.59 (IH, m), 2.73 (1H, m), 3.09 (1H, m), 4.30 (1H, m), 4.52 (1 H, m), 4.90 (1H, m), 5.19 (2H, m), 5.45 (1H, m), 7.39 (5H, m). Synthesis of (+/-)-Benzyl 3 -(tert-butoxycarbonylaImino)-4,4-difl uoropiperidine- 20 carboxylate FF ,NHBoc N Cbz 102741 To a solution of (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4 oxopiperidine-1-carboxylate in dichloromethane (0.3 M solution) was added DAST (3.0 equiv.). The reaction mixture was stirred at room temperature for 20 h. After quenched 25 with saturated NaHCO 3 aqueous solution until no bubbling, the reaction mixture was extracted with CH 2

CI

2 . The crude (+/-)-benzyl 3-(tert-butoxycarbonylamino)-4,4 -172difluoropiperidine-1-carboxylate was purified by flash chromatography (10% to 40% EtOAc in hexanes, 35%). LCMS (m/z): 271.0 (MW), LC Rt = 4.2 min. 'H NMR (CDCl 3 ): 1.26 (9H, s), 1.90 (lH, m), 2.11 (1 H, m), 2.98 (1H, t , J = 11.2 Hz), 3.20 (1H, t , J= 11.6), 4.00 (1 H, m), 4.13 (1 H, m), 4.76 (1H, m), 5.11(1 H, m), 7.36 (1H, m). 5 METHOD 17 Synthesis of cis-(+/-)-2-(4-fluoropiperidin-3-yl)isoindoline-1,3-dione \N/ N H [02751 To a solution of (+/-)-benzyl 3-(1,3-dioxoisoindolin-2-yl) 4-fluoropiperidine-1-carboxylate (1.0 equiv.) in ethanol and ethyl acetate (1:1, 0.2 M 10 solution) was added Pd/C (20 wt%) under N 2 atmosphere. The reaction mixture was flushed with H 2 gas, equipped with H 2 gas balloon, and stirred for 16 h at room temperature. The reaction mixture was filtered through Celite@ Pad and the filtrate was dried in vacuo. The crude (+/-)-2-(4-fluoropiperidin-3-yl)isoindoline-1,3-dione was used for the next step without further purification (>99%). LCMS (m1/z): 249.1 (MH*), R, = 15 0.49 min. Synthesis of trans-(+/-)-tert-Butyl 4-fluoropiperidin-3-ylcarbamate F NHBoc H 10276] Method 17 was followed using (+/-)trans -benzyl 3-(tert butoxycarbonylamino)-4-fluoropiperidine-1-carboxylate (1.0 equiv.) yielding crude 20 (+/-)-trans tert-butyl 4-fluoropiperidin-3-ylcarbamate (93%). LCMS (m/z): 219.2 (MH~), LC Rt = 0.45 min. -173- Synthesis of tert-butyl (3R,4R)-4-fluoropiperidin-3-ylcarbamate F NHBoc H [0277] Method 17 was followed using (3R,4R)-benzyl 3-(tert butoxycarbonylamino)-4-fluoropiperidine-l-carboxylate (1.0 equiv.) yielding crude 5 (+/-)-tert-butyl 4-fluoropiperidin-3-ylcarbamate(93%). LCMS (n/z): 219.2 (MH*), LC Rt = 0.45 min. Synthesis of tert-butyl (3S,4S)-4-fluoropiperidin-3-ylcarbamate F CI$ NHBoc N H 10278] Method 17 was followed using (3S,4S)-benzyl 3-(tert 10 butoxycarbonylamino)-4-fluoropiperidine-l-carboxylate (1.0 equiv.) yielding crude (+/-)-tert-butyl 4-fluoropiperidin-3-ylcarbamate (93%). LCMS (m/z): 219.2 (MH*), LC Rt = 0.45 min. Synthesis of trans-(+/-)-Butyl 4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate OTBDMS -IN\NHBoc N H 15 [02791 Method 17 was followed using (+/-)-benzyl 3-(tert butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)piperidine- I -carboxylate (1.0 equiv.) yielding crude (+/-)-butyl 4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate (>99%). LCMS (n/z): 331.3 (MH*). Synthesis of tert-butyl (3R,4R)-4-(tert-butyldimethylsilyloxy)tiperidin-3-ylcarbamate OTBDMS (!~N HBoc 20 H -174- 102801 Method 17 was followed using (3R,4R)-benzyl 3-(tert butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)piperidine- 1 -carboxylate (1.0 equiv.) yielding crude tert-butyl (3R,4R)-4-(tert-butyldimethylsilyloxy)piperidin-3 ylcarbamate (>99%). LCMS (m/z): 331.3 (MH). 5 Synthesis of tert-butyl (3R,4R)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate OTBDMS NHBoc N H [0281] Method 17 was followed using (3S,4S)-benzyl 3-(tert butoxycarbonylamino)-4-(tert-butyldimethylsilyloxy)piperidine- I -carboxylate (1.0 equiv.) yielding crude tert-butyl (3S,4S)-4-(tert-butyldimethylsilyloxy)piperidin-3 10 ylcarbamate (>99%). LCMS (m/z): 331.3 (MH 4 ). Synthesis of trans-(+/-)-tert-Butyl 3-(tert-butyldimethylsilyloxy)piperidin4-ycarbamate NHBoc N)..OTBDMS H 102821 Method 17 was followed using (+/-)--benzyl 4-(tert butoxycarbonylamino)-3 -hydroxypiperidine-l-carboxylate (1.0 equiv.) yielding (+/-)-tert 15 butyl 3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate (>99%). LCMS (m/z): 331.2 (MH*). Synthesis of (+/-)-tert-Butyl 4,4-difluoropiperidin-3-ylcarbamate . ,NHBoc H 102831 Method 17 was followed using (+/-)-benzyl 3-(tert 20 butoxycarbonylamino)-4,4-difluoropiperidine- I -carboxylate (1.0 equiv.) yielding crude (+/-)-tert-butyl 4,4-difluoropiperidin-3-ylcarbamate, (>99%). LCMS (n/z): 237.0 (MH 4 ). -175- Synthesis of trans-(+/-)-tert-Butyl 4-(tert-butyldimethylsilyloxy) 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate OTBDMS CN '\NHBoc

NO

2 IN" 10284] Method I of Example I was followed using 1 eq each of 4-chloro-3 5 nitropyidine, trans-(+/-)-butyl 4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and triethylamine in DMF yielding (+/-)-tcrt-butyl 4-(tert-butyldimethylsilyloxy)-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate, (98%). LCMS (m/z): 453.3 (MH); LC R= 4.01 min. Synthesis of tert-butyl (3R,4R)-4-(tert-butyldimethylsilyloxy) 10 1-(3-nitropyridin-4-vl)piperidin-3-vlcarbamate OTBDMS C~~N HBoc N [0285] Method I of Example I was followed using 1 eq each of 4-chloro-3 nitropyidine, tert-butyl (3R,4R)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and triethylamine in DMF yielding tert-butyl (3R,4R)-4-(tcrt-butyldimethylsilyloxy)-1 15 (3-nitropyridin-4-yl)piperidin-3-ylcarbamate (98%). LCMS (mz/z): 453.3 (MH+); LC R, = 4.01 min. -176- Synthesis of tert-butyl (3S,4S)-4-(tert-butyldimethylsilyloxy) 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate OTBDMS NHBoc N

SNO

2 CN [02861 Method I of Example I was followed using I eq each of 4-chloro-3 5 nitropyidine, tert-butyl (3S,4S)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and triethylamine in DMF yielding tcrt-butyl (3S,4S)-4-(tcrt-butyldimethylsilyloxy)-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate (98%). LCMS (n/z): 453.3 (MH 4 ); LC Rt = 4.01 min. Synthesis of trans-(-/-)-tert-butyl 3-(tert-butyldimethylsilyloxy) 10 1-(3-nitropyridin-4-yl)piperidin-4-ylcarbamate NHBoc C "OTBDMS N NO2 (N [02871 Method 1 of Example 1 was followed using 1 eq each of 4-chloro-3 nitropyidine, (+/-)-tert-butyl 3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate and triethylamine in ethanol yielding (+/-)-tert-butyl 3-(tert-butyldimethylsilyloxy)-1-(3 15 nitropyridin-4-yl)piperidin-4-ylcarbamate, (75%). LCMS (m/z): 453.2 (MH*); LC Rt = 3.46 min. -177- Synthesis of trans-(+/-)-tert-Butyl 4-fluoro 1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate F .I,NHBoc N NO2 N [02881 Method I of Example I was followed using 1 eq each of 4-chloro-3 5 nitropyidine, (+/-)-tert-butyl 4-fluoropiperidin-3-ylcarbamate and triethylamine in ethanol yielding (+/-)-tert-butyl 4-fluoro-1-(3-nitropyridin-4-yl)pipendin-3-ylcarbamate, (91%). LCMS (m/z): 341.0 (MH); LC R, = 2.37 min. Synthesis of tert-butyl (3R,4R)-4-fluoro-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate F C!,\NHBoc N NO2 10 10289] Method 1 of Example 1 was followed using I eq each of 4-chloro-3 nitropyidine, tert-butyl (3R,4R)- 4-fluoropiperidin-3-ylcarbamate and triethylamine in ethanol yielding tert-butyl (3R,4R)-4-fluoro-I -(3-nitropyridin-4-yl)piperidin-3 ylcarbamate, (91%). LCMS (m/z): 341.0 (MH*); LC R, = 2.37 min. Synthesis of tert-butyl (3S,4S)-4-fluoro-I -(3-nitropyridin-4-yl)piperidin-3-ylcarbamatc 15 F NHBoc N

NO

2 CN1 [0290] Method 1 of Example I was followed using 1 eq each of 4-chloro-3 nitropyidine, tert-butyl (3S,4S)- 4-fluoropiperidin-3-ylcarbamate and triethylamine in -178ethanol yielding tert-butyl (3S,4S)-4-fluoro- 1 -(3-nitropyridin-4-yl)piperidin-3 ylcarbamate, (91%). LCMS (n/z): 341.0 (MH*); LC Rt= 2.37 min. Synthesis of (+/-)-tcrt-Butyl 4,4-difluoro-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamatc .\NHBoc

~.NO

2 N 5 102911 Method 1 of Example I was followed using 1 eq each of 4-chloro-3 nitropyidine, (+/-)-tert-butyl 4,4-difluoropiperidin-3-ylcarbamate and triethylamine in ethanol yielding (+/-)-tert-butyl 4,4-difluoro-1-(3-nitropyridin-4-yl)piperidin-3 ylcarbamate, (91%). LCMS (n/z): 359.1 (MH*). Synthesis of cis-(+/-)-2-(4-fluoro-1-(3-nitropyridin-4-yl)piperidin-3-yl)isoindoline-1,3 10 dione 0 .N No

~.NO

2 N [0292] Method I of Example I was followed using I eq each of 4-chloro-3 nitropyidine, (+/-)-2-(4-fluoropiperidin-3-yl)isoindoline-1,3-dione and triethylamine in DMF yielding (+/-)-2-(4-fluoro- 1 -(3-nitropyridin-4-yl)piperidin-3-yl)isoindoline- 1,3 15 dione, (45%). LCMS (m/z): 371.1 (MH'); LC R,= 2.23 min. -179- Synthesis of trans-(+/-)-tert-Butyl 1-(3-aminopyridin-4-yl)-4-(tert butyldimethylsilyloxy)piperidin-3-ylcarbamate OTBDMS N HBoc

NH

2 CN [02931 Following Method 2 of Example 49, (+/-)-tert-butyl 4-(tert 5 butyldimethylsilyloxy)-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding (+/-)-tert-butyl 1-(3 aminopyridin-4-yl)-4-(tert-butyldimethylsi lyloxy)piperidin-3-ylcarbamate, (>99%). LCMS (m/z): 423.2 (MH*); LC R, = 3.78 min. 10 Synthesis of tert-butyl (3R,4R)-I-(3-aminopvridin-4-yl)-4-(tert butyldimcthylsilyloxy)piperidin-3-ylcarbamate OTBDMS N HBoc

NH

2 IN' 102941 Following Method 2 of Example 49, tert-butyl (3R,4R)- 4-(tert butyldimethylsilyloxy)-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and 15 ethyl acetate (1:1, 0.1 M solution) was reduced yielding tert-butyl (3R,4R)-1-(3 aminopyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate, (>99%). LCMS (m/z): 423.2 (MH*); LC Rt = 3.78 min. -180- Synthesis of tert-butyl (3S,4S)-I -(3-aminopyridin-4-yl)-4-(tert butyldimethylsilyloxy)piperidin-3 -ylcarbamate OTBDMS 0 rNHBoc N

NH

2 N" 10295] Following Method 2 of Example 49, tert-butyl (3R,4R)- 4-(tert 5 butyldimethylsilyloxy)-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding tert-butyl (3R,4R)-I-(3 aminopyridin-4-yl)-4-(tert-butyldimethylsi lyloxy)piperidin-3-ylcarbamate, (>99%). LCMS (m/z): 423.2 (MH*); LC R 1 = 3.78 min. Synthesis of trans-(+/-)-tert-Butyl 1-(3-aminopyridin-4-yl)-3-(tert 10 butyldimethylsilyloxy)piperidin-4-ylcarbamate NHBoc K i O T B D M S N NH2 102961 Following Method 2 of Example 49, (+/-)-tert-butyl 3-(tert butyldimethylsilyloxy)-]-(3-nitropyridin-4-yl)piperidin-4-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding (+/-)-tert-butyl 1-(3 15 aminopyridin-4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate, (>99%). LCMS (n/z): 423.3 (MH*); LC Rt = 3.62 mm. -181- Synthesis of trans-(+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-4-fluoropiperidin-3 ylcarbamate F C! \NHBoc N NH2 N 10297] Following Method 2 of Example 49, (+/-)-tert-butyl 4-fluoro-l-(3 5 nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding (+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-4-fluoropiperidin 3-ylcarbamate, (>99%). LCMS (m/z): 311.2 (MH 4 ); LC R, = 2.14 min. Synthesis of tert-butyl (3R,4R)- 1 -(3-aminopyridin-4-yl)-4-fluoropiperidin-3-ylcarbamate F I,\NHBoc N NH2 10 [02981 Following Method 2 of Example 49, tert-butyl (3R,4R)-4-fluoro-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding tert-butyl (3R,4R)- 1 -(3-aminopyridin-4-yl)-4 fluoropiperidin-3-ylcarbamate, (>99%). LCMS (m/z): 311.2 (MH*); LC Rt = 2.14 min. Synthesis of tcrt-butyl (3S,4S)-I -(3-aminopyridin-4-yl)-4-fluoropiperidin-3-ylcarbamate 15 F NH Boc N

NH

2 N 8 -182- [02991 Following Method 2 of Example 49, tert-butyl (3S,4S)-4-fluoro-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding tert-butyl (3R,4R)- 1-(3-aminopyridin-4-yl)-4 fluoropiperidin-3-ylcarbamate, (>99%). LCMS (m/z): 311.2 (MH*); LC R, = 2.14 min. 5 Synthesis of (+/-)-tert-Butyl 1-(3-aminopyridin-4-yl)-4,4-difluoropiperidin-3-ylcarbamate .,NHBoc

NH

2 CN1 [03001 Following Method 2 of Example 49, (+/-)-tert-butyl 4,4-difluoro-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamateand triethylamine in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding (+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-4,4 10 difluoropiperidin-3-ylcarbamate, (>99%). LCMS (n/z): 329.1 (MH). Synthesis of cis-(+/-)-2-(I-(3-aminopyridin-4-yl)-4-fluoropiperidin-3-yl)isoindoline-1,3 dione F / N CNINH2 [0301] Following Method 2 of Example 49, (+/-)-2-(4-fluoro-I-(3 15 nitropyridin-4-yl)piperidin-3-yl)isoindoline-1,3-dione in ethanol and ethyl acetate (1:1, 0.1 M solution) was reduced yielding (+/-)-2-(1-(3-aminopyridin-4-yI)-4-fluoropiperidin 3-yl)isoindoline-1,3-dione, (87%). LCMS (m/z): 341.1 (MH 4 ); LC R, = 2.23 min. -183- METHOD 18 Synthesis of 3-methylpiperidine-3-carboxylic acid OH H [03021 TFA was added to a solution of 1-(tert-butoxycarbonyl)-3 5 methylpiperidine-3-carboxylic acid (1 eq) in CH 2

CI

2 (0.5 M). After stirring for 3 h at rt the reaction mixture was concentrated in vacuo and azeotroped once with toluene to give 3-methylpiperidine-3-carboxylic acid (TFA salt). The crude product was used for the next step without further purification. METHOD 19 10 Synthesis of 3-methyl-1-(3-nitropyridin-4-yl)piperidine-3-carboxylic acid N 1

NO

2 N [0303] 4-chloro-3-nitropyridine (1.1 eq) was added to a solution of 3 methylpiperidinc-3-carboxylic acid (1 eq) and DIEA (3 cq) in iPrOH (0.1 M). The reaction mixture was heated in a 60 'C oil bath for 3 h then concentrated in vacuo. The 15 crude residue was diluted with EtOAc and washed with 1.0 N NaOH. The combined aqueous washes were acidified to pH = 4 with 1.0 N HCI and extracted with CH 2

CI

2 . The combined organic phases were dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo to give 3-methyl-(3-nitropyridin-4-yl)piperidine-3-carboxylic acid. LC/MS (m/z): 266.2 (MH*). 20 Synthesis of tert-butyl 3-methyl-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate NHBoc

NO

2 N -184- 103041 Diphenylphosphoryl azide (1.2 eq) was added to a mixture of 3 methyl-(3-nitropyridin-4-yl)piperidine-3-carboxylic acid (1 eq) and anhydrous tBuOH (0.3 M), followed shortly by Et 3 N (2 eq). The reaction flask was fitted with an air-cooled reflux condenser and bubble vent, then heated in an 85 *C oil bath for 3 days. The crude 5 mixture was diluted with EtOAc, washed with brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was dissolved in CH 2

CI

2 , loaded onto a SiO 2 column, and purified by flash chromatography (10-20-40 % EtOAc in hexanes) to give tert-butyl 3-methyl-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate. LC/MS (n/z): 337.2 (MH). 10 Synthesis of tert-butyl I -(3-aminopyridin-4-yl)-3-methylpiperidin-3-ylcarbamate NHBoc CN INH 2 [03051 10 % Palladium on carbon (0.1 eq) was added to a N 2 -flushed solution of tert-butyl 3-methyl-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate (1 eq) in MeOH (0.2 M). The reaction was purged with H 2 under atmospheric pressure for 16 h at rt. The 15 crude solids were filtered through a pad of Celite on a paper lined Buchner funnel, washed with EtOAc and MeOH, then concentrated in vacuo. The crude residue was dissolved in CH 2 Cl 2 , loaded onto a SiO 2 column, and purified by flash chromatography (1:2 EtOAc in hexanes + 5 % MeOH) to give tert-butyl 1-(3-aminopyridin-4-yl)-3 methylpiperidin-3-ylcarbamate. LC/MS (m/z): 307.2 (MH). 20 Synthesis of tert-butyl 3-(trifluoromethyl)-3-(trimethylsilyloxy)piperidine- I -carboxylate 0~

CF

3 OSiMe 3 Boc 103061 To an ice-bath cooled solution of tert-butyl 3-oxopiperidine-1 carboxylate (1 eq) in THF (0.4 M) was added trimethyl(trifluoromethyl)silane (1.2 eq) followed shortly by a 1.OM solution of TBAF in THF (0.05 eq). The reaction was 25 warmed to rt and stirred for 4 h, then concentrated in vacuo. The resulting residue was -185dissolved in EtOAc, washed with brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo to give tert-butyl 3-(trifluoromethyl)-3 (trimethylsilyloxy)piperidine-1-carboxylate, which was carried on crude and used without further purification. 5 Synthesis of tert-butyl 3-hydroxy-3 -(trifluoromethyl)piperidine- 1 -carboxylate CK CF 3 fOH Boc 10307] A 1.0 M solution of TBAF in THF (1 eq) was added to a solution of tert-butyl 3-(trifluoromethyl)-3-(trimethylsilyloxy)piperidine-1-carboxylate (1 eq) in THF (0.2 M). After stirring for 16 h at rt the reaction mixture was concentrated in vacuo. The 10 resulting residue was dissolved in EtOAc, washed with brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was dissolved in CH 2

CI

2 , loaded onto a SiO 2 column, and purified by flash chromatography to give tert-butyl 3 hydroxy-3-(trifluoromethyl)piperidine-1-carboxylate. 'F NMR (282 MHz, CDCl 3 ): 6 83.74 ppm; 1 H NMR (300 MHz, CDCl 3 ): 6 4.04-4.16 (m, 2H), 2.72-3.01 (in, 2H), 1.50 15 2.04 (in, 4H), 1.47 (s, 9 H). Synthesis of 3-(trifluoromcthyllpiperidin-3-ol 0K CF 3 1OH H [0308] Method 18 was followed using tert-butyl 3-hydroxy-3 (trifluoromethyl)piperidine- 1 -carboxylate, yielding 3-(trifluoromethyl)piperidin-3-ol 20 (TFA salt). The crude product was used for the next step without further purification. Synthesis of 1-(3-nitropyridin-4-yl)-3-(trifluoromethyl)piperidin-3-ol

CF

3 OH N -8NO 2 -186- 10309] Method 19 was followed using 3-(trifluoromethyl)piperidin-3-ol, yielding 1-(3-nitropyridin-4-yl)-3-(trifluoromethyl)piperidin-3-ol. LC/MS (m/z): 292.0 (MH). Synthesis of 1-(3-aminopyridin-4-yl)-3-(trifluoromethyl)piperidin-3-ol

CF

3 CfrOH N (N NH 2 [03101 Method 2 of example 49 was followed using 1-(3-nitropyridin-4-yl)-3 (trifluoromethyl)piperidin-3-ol, yielding 1-(3-aminopyridin-4-yl)-3-(trifluoromethyl) piperidin-3-ol. LC/MS (m/z): 262.0 (MH 4 ). Synthesis of tert-butyl (3S,5R)-5-(tert-butyldimethylsilyloxy)pipcridin-3-ylcarbamate TBDMSO,,. 0 .NHBoc N 10 H 103111 tert-Butyl (3S,5R)-5-(tert-butyldimethylsilyloxy)piperidin-3 ylcarbamate was prepared according to the patent procedure as described by Y, Zhou; W02005028467. Synthesis of tert-butyl (3S.5R)-5-(tert-butyldimethylsilyloxy)-I-(3-nitropyridin-4 15 yl)piperidin-3-ylcarbamate TBDMSO,,,n,,NHBoc N N 02 [0312] Method 19 was followed was followed using tert-Butyl (3S,5R)-5-(tert butyldimethylsilyloxy)piperidin-3-ylcarbamate, yielding tert-butyl (3S,5R)-5-(tert 20 butyldimethylsilyloxy)- I -(3-nitropyridin-4-yl)piperidin-3-ylcarbamate. LC/MS (n/z): 453.2 (MH 4 ). -187- Synthesis of tert-butyl (3S,5R)-1-(3-aminopyridin-4-yl)-5-(tert butyldimethylsilyloxy)piperidin-3-ylcarbamate TBDMSO,,.n .NHBoc N

NH

2 N [0313] Method 2 was followed using tert-butyl (3S,5R)-5-(tert 5 butyldimethylsilyloxy)-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate, yielding tert-butyl (3S,5R)-l-(3-aminopyridin-4-yl)-5-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate. LC/MS (m/z): 423.2 (MH 4 ). Synthesis of cis-(+/-)-1-(benzyloxycarbonyl)-5-(tert-butoxycarbonylamino)piperidine-3 carboxylic acid BocHN CO2H N 10 Cbz [0314] To a solution of cis-(+/-)-5-(tert-butoxycarbonylamino)piperidine-3 carboxylic acid (1.0 eq.) in dichloromethane (0.2 M) was added DIEA(1.1 eq.), followed by N-(benzyloxycarbonyloxy)succinimide (1.0 eq.); the reaction was stirred at r.t. overnight. The solvent was removed under reduced pressure. To the crude was added 15 EtOAc and IN HCl. After extraction, the organic layer was washed with brine, dried and filtered, and concentrated to yield cis-(+/-)-1-(benzyloxycarbonyl)-5-(tert butoxycarbonylamino)piperidine-3-carboxylic acid (99 % yield ) LCMS (n/z): 379.2 (MH*); LC R1 = 3.55 min. Synthesis of cis-(+/-)-benzyl 3,5 -bis(tert-butoxycarbonylamino)piperidine- I -carboxylate BocHN NHBoc N 20 Cbz [0315] To a solution of cis-(+/-)- I -(benzyloxycarbonyl)-5-(tert butoxycarbonylamino) pipcridinc-3-carboxylic acid (1.2 g, 3.17 mmol), DPPA( Diphenylphosphoryl azide, 1.04 g, 3.81mmol) and DIEA(1.1 mL, 6.35mmol) in t BuOH( 10 mL) was heated to 90 0 C over night. The solvent was removed under reduced -188pressure. To the crude was added EtOAc(300 mL), the organic layer was washed with saturated NaHCO 3 (15OmL) and brine, dried and filtered, and concentrated to give the crude. The crude material was further purified by silica gel chromatography to yielding cis-(+/-)-benzyl 3,5-bis(tert-butoxycarbonylamino)piperidine- I -carboxylate, (23% ). 5 LCMS (m/z): 350(minus one Boc(MH*); LC R, = 4.40 min. Synthesis of tert-butyl cis-(+/-)-piperidine-3,5-diyldicarbamate BocHN NHBoc N H [03161 Method 17 was followed using cis-(+/-)-benzyl 3,5-bis(tert butoxycarbonylamino)piperidine-1-carboxylate yielding tert-butyl cis-(+/-)-piperidine 10 3,5-diyldicarbamate, (% yield 99%). LCMS (m/z): 316.2 (MH*). Synthesis of tert-butyl cis-(+/-)- I -(3-nitropyridin-4-yl)piperidine-3,5-diyldicarbamate BocHN NHBoc N

NO

2 CN1 [03171 Method I of Example I was followed using I equivalent each of 4 chloro-3-nitropyridine, tert-butyl cis-(+/-)-piperidine-3,5-diyldicarbamate and 15 triethylamine in DMF yielding tert-butyl cis-(+/-)-1-(3-nitropyridin-4-yl)piperidine-3,5 diyldicarbamate, LCMS (m/z): 438.2 (MH'); LC Rt = 2.95 min. Synthesis of cis-tert-butyl (+/-)-]-(3-aminopyridin-4-yl)piperidine-3,5-diyldicarbamate BocHN NHBoc N

NH

2 CN [0318] Following Method 2 of Example 49, cis -(+/-)l-(3-nitropyridin-4 20 yl)piperidine-3,5-diyldicarbamate in ethanol was reduced yielding cis-tert-butyl (+/-)-1 -189- (3-aminopyridin-4-yl)piperidine-3,5-diyldicarbamate, (78 %). LCMS (m/z): 408.2 (MH*); LC R, = 2.63 min. Synthesis of (S)- I -(3-nitropyridin-4-yl)pipcridin-3-ol OOH N

.NO

2 5 [0319] Method I of Example I was followed using I equivalent each of 4 chloro-3-nitropyridine, (S)-3-hydroxypiperidine and triethylamine in DMF yielding (S) 1-(3-nitropyridin-4-yl)piperidin-3-ol, LCMS (m/z): 224.1 (MH*); LC R, = 1.06 min. Synthesis of (R)- 1 -(3-nitropyridin-4-yl)piperidin-3-ol J OH N

~.NO

2 10 103201 Method 1 of Example I was followed using I equivalent each of 4 chloro-3-nitropyridine, (R)-3-hydroxypiperidine and triethylamine in DMF yielding (R) 1-(3-nitropyridin-4-yl)piperidin-3-ol, LCMS (m/z): 224.1 (MH*); LC Rt = 1.06 min. Synthesis of (+/-)-1-(3-nitropyridin-4-yl)piperidin-3-ol OH N

SNO

2 15 [03211 Method I of Example 1 was followed using I equivalent each of 4 chloro-3-nitropyridine, (+/-)-3-hydroxypipcridine and triethylamine in DMF yielding (+/-)-1-(3-nitropyridin-4-yl)piperidin-3-ol, LCMS (m/z): 224.1 (MH); LC Rt = 1.06 min. -190- Synthesis of (S)-4-(3-(tert-butyldimethylsilyloxy)piperidin- I -yl)-3-nitropyridine 0 \\,\OTBDMS N N2 10322] To a solution of (S)-1-(3-nitropyridin-4-yl)piperidin-3-ol and TBDMSCI (2.1 equiv.) in DMF was added imidazole ( 4 equiv.). The reaction was 5 heated to 50 C overnight. The reaction was dissolved in EtOAC and washed with water followed by saturate brine, dried and filtered, and concentrated to give the crude. The crude material was further purified by silica gel chromatography to yield desired product (S)-4-(3-(tert-butyl dimethylsilyloxy)piperidin-1-yl)-3-nitropyridine. LCMS (m/z): 338.2 (MH); LC R 1 = 3.43 min. 10 Synthesis of (R)-4-(3-(tert-butldimethylsilyloxy)piperidin-1-yl)-3-nitropyridine OTBDMS N C N2 10323] To a solution of (R)-I-(3-nitropyridin-4-yl)piperidin-3-oI and TBDMSCl (2.1 equiv.) in DMF was added imidazole ( 4 equiv.). The reaction was heated to 50 C over night. The reaction was dissolved in EtOAc and washed with water 15 followed by saturate brine, dried and filtered, and concentrated to give the crude. The crude material was further purified by silica gel chromatography to yield desired product (R)-4-(3-(tert-butyl dimethylsilyloxy)piperidin-1-yl)-3-nitropyridine. LCMS (m/z): 338.2 (MH*); LC R, = 3.43 min. Synthesis of (+/-)-4-(3-(tert-butyldimethylsilyloxy)piperidin-1-yl)-3-nitropyridine OTBDMS N

SNO

2 20 CN -191- 10324] To a solution of (+/-)-1-(3-nitropyridin-4-yl)piperidin-3-ol and TBDMSCl (2.1 equiv.) in DMF was added imidazole ( 4 equiv.). The reaction was heated to 50 0 C over night. The reaction was dissolved in EtOAc and washed with water followed by brine, dried and filtered, and concentrated to give the crude. The crude 5 material was further purified by silica gel chromatography to yield desired product (+/-)-4-(3-(tert-butyl dimethylsilyloxy)piperidin-I-yl)-3-nitropyridine. LCMS (m/z): 338.2 (MH*); LC R, = 3.43 min. Synthesis of (+/-)-4-(3-(tert-butyldimethylsilyloxy)piperidin- I -yl)pyridin-3-amine OTBDMS N

~.NH

2 10 CN [0325] Following Method 2 of Example 49, (+/-)-4-(3-(tert-butyl dimethylsilyloxy)piperidin-I-yl)-3-nitropyridine in ethanol was reduced yielding tert butyl (+/-)-4-(3-(tert-butyldimethylsilyloxy)piperidin- 1 -yl)pyridin-3 -amine. LCMS (m/z): 308.2 (MH); LC R, = 3.47 min. 15 Synthesis of (S)-4-(3-(tert-butyldimethylsilyloxy)piperidin- 1 -yl)pyridin-3-amine ,\\OTBDMS N CNINH2 [0326] Following Method 2 of Example 49, (S)-4-(3-(tert-butyl dimethylsilyloxy)piperidin- I -yl)-3-nitropyridine in ethanol was reduced yielding tert 20 butyl (S)-4-(3-(tcrt-butyldimethylsi lyloxy)piperidin- 1 -yl)pyridin-3-amine (67 % yield 3 steps). LCMS (n/z): 308.2 (MH t ); LC Rt = 3.47 min. -192- Synthesis of (R)-4-(3-(tert-butyldimethylsilyloxy)piperidin- I -yl)pyridin-3-amine 0 \\\OTBDMS N CNINH2 [03271 Following Method 2 of Example 49, (R)-4-(3-(tert-butyl dimethylsilyloxy)piperidin- I -yl)-3-nitropyridine in ethanol was reduced yielding tert 5 butyl (S)-4-(3-(tert-butyldimethylsilyloxy)piperidin- I -yl)pyridin-3-amine. LCMS (n/z): 308.2 (MH*); LC R = 3.47 min. Synthesis of 3-amino-6-bromo-N-(4-(3-(tert-butyldimethylsilyloxy)piperidin-1 yl)pyridin-3-yl)picolinamide OTBDMS Br N N H N14 NH, CN INH2 10 [03281 Following Method I1 of Example 305, tert-butyl (+/-)-4-(3-(tert butyldimethylsilyloxy)piperidin-1-yl)pyridin-3-amine was coupled to 3-amino-6 bromopicolinic acid yielding 3-amino-6-bromo-N-(4-(3-(tert butyldimethylsilyloxy)piperidin- I -yl)pyridin-3-yl)picolinamide. LCMS (n/z): 506.2 (MH*); LC R,= 4.03 min. 15 Synthesis of 3-amino-6-bromo-N-(4-(3-(tert-butyldimethylsilyloxy)piperidin-1 yllpyridin-3-yl)picolinamide OTBDMS Br N N H N CN T NH2 [03291 Following Method 11 of Example 305, tert-butyl (+/-)-4-(3-(tert butyldimethylsilyloxy)piperidin-1-yl)pyridin-3-amine was coupled to 3-amino-6 -193bromopicolinic acid yielding 3-amino-6-bromo-N-(4-(3-(tert-butyldimethylsilyloxy) piperidin-1-yl)pyridin-3-yl)picolinamide. LCMS (m/z): 506.2 (MH4); LC Rt = 4.03 min. Synthesis of (S)-3-amino-6-bromo-N-(4-(3-(tcrt-butyldimethylsilyloxy)piperidin-1 yl)pyridin-3-yl)picolinamide 0 ,\,OTBDMS Br N N H NI 5 N NH 2 103301 Following Method 11 of Example 305, tert-butyl (S)-4-(3-(tert butyldimethylsilyloxy)piperidin-1-yl)pyridin-3-amine was coupled to 3-amino-6 bromopicolinic acid yielding (S)-3-amino-6-bromo-N-(4-(3-(tert-butyldimethyl silyloxy)piperidin- I -yl)pyridin-3-yl)pi colinamide. LCMS (n/z): 506.2 (MH*); LC R, = 10 4.03 min. Synthesis of (R)-3-amino-6-bromo-N-(4-(3-(tert-butyldimethylsilyloxy)pipcridin- I yl)pyridin-3-yl)picolinamide OTBDMS Br N H N NI N NH 2 10331] Following Method 11 of Example 305, tert-butyl (R)-4-(3-(tert 15 butyldimethylsilyloxy)piperidin-1-yl)pyridin-3-amine was coupled to 3-amino-6 bromopicolinic acid yielding (R)-3-amino-6-bromo-N-(4-(3-(tert-butyldimethyl silyloxy)piperidin- I -yl)pyridin-3-yl)picolinamide. LCMS (mn/z): 506.2 (MH*); LC R, = 4.03 min. Synthesis of benzyl 3-hydroxy-3-methylpiperidine- I -carboxylate OH 20 uAOBn -194- [0332] To a solution of benzyl 3-oxopiperidine-1-carboxylate (2.33 g, 10 mmol) in dry THF (50 mL) at -78 C was added McMgBr (3.6 mL, 3M solution in THF, 11 mmol) slowly. The reaction was allowed to stir at -78*C for 10 min then slowly warmed to r.t. The reaction was quenched with NH 4 Cl and dissolved in EtOAc (300 mL) 5 and washed with saturated NH 4 Cl and brine, dried and filtered, and concentrated to give the crude. The crude material was further purified by silica gel chromatography to yield benzyl 3-hydroxy-3-methylpiperidine-1-carboxylate. (53 % yield). LCMS (m/z): 250.1 (MH*); LC R, = 2.98 min. Synthesis of 3-methylpiperidin-3-ol OH 10 H 103331 Method 17 was followed using benzyl 3-hydroxy-3-methylpipendine 1-carboxylate yielding 3-methylpiperidin-3-ol (70%). LCMS (n/z): 116.1 (MH*). Synthesis of 3-methyl-i -(3-nitropxyridin-4-yl)piperidin-3-ol OH N

NO

2 N 15 [0334] Method 1 of Example 1 was followed using I equivalent each of 4-chloro-3-nitropyridine, 3-methylpiperidin-3-ol and triethyl amine in DMF yielding 3-methyl-1-(3-nitropyridin-4-yl)piperidin-3-ol. LCMS (n/z): 238.1 (MH); LC Rt = 1.39 min. Synthesis of 1-(3-aminopyridin-4-yl)-3-methylpiperidin-3-ol OH N

NH

2 20 N -195- 10335] Following method 2 of Example 49, 3-methyl-1-(3-nitropyridin 4-yl)piperidin-3-olin ethanol was reduced yielding 1-(3-aminopyridin-4-yl) 3-methylpiperidin-3-ol, (80 %). LCMS (m/z): 208.1 (MH); LC R, = 1.32 min. Synthesis of Methyl 3-amino-5-fluoropicolinate F MeO 5 NH 2 [03361 A solution of 2-bromo-5-fluoropyridin-3-amine (1.0 equiv.), triethylamine (1.6 equiv.), and Pd(BINAP)Cl 2 (0.0015 equiv.) in anhydrous methanol (0.4 M solution) in a sealed steel bomb was heated to 100 *C. After 3 h, more Pd catalyst (0.0015 equiv.) was added, the reaction mixture was re-heated to the same temperature 10 for 3 h. After cooled down to room temperature, a brown precipitate was filtered off and the filtrate was extracted with EtOAc, which was washed with water and brine, dried over anhydrous sodium sulfate, and filtered. After removing volatile materials, the crude yellow product was obtained and used for the next step without further purification (40%). LCMS (m/z): 271.2 (MH); LC Rt = 3.56 min. 15 Synthesis of Methyl 3-amino-6-bromo-5-fluoropicolinate Br F MeO /

NH

2 [0337] To a solution of methyl 3-amino-5-fluoropicolinate (1.0 equiv.) in acetonitrile (0.3 M solution) was added NBS (1.1 equiv.) for 2 minutes at room temperature. After quenched with water, the reaction mixture was extracted with EtOAc. 20 The crude product was purified by silica column chromatography (20% to 50% EtOAc in hexanes) to give methyl 3-amino-6-bromo-5-fluoropicolinate, (41%). LCMS (nz/z): 249.1 (MH*); LC Rt = 2.80 min. -196- Synthesis of 3-Amino-6-bromo-5-fluoropicolinic acid Br F

NH

2 [0338] To a solution of methyl 3-amino-5-fluoropicolinate (1.0 equiv.) in tetra hydrofuran and methanol (2:1, 0.2 M solution) was added LiOH (1.8 equiv., I M aqueous 5 solution) at room temperature. The reaction mixture was stirred for 3 h and neutralized with 1.0 N aqueous HCl solution. Then, the reaction mixture was extracted with EtOAc, which was washed with water and brine, dried over anhydrous sodium sulfate, and filtered. After removing volatile materials, the crude 3-amino-6-bromo-5-fluoropicolinic acid was obtained and used for the next step without further purification (92%). LCMS 10 (m/z): 234.2 (MH); LC R = 2.25 min. Synthesis of 3-amino-6-(2,6-difluorophenyl)-5-fluoropicolinic acid F F F HO

NH

2 103391 To a solution of methyl 3-amino-5-fluoropicolinate (1.0 equiv.) in DME/2M Na 2

CO

3 (3:1, 0.05 M) equipped with microwave vial was added 15 2,6-difluorophenylboronic acid (3.0 equiv.) and Pd(dppf)C1 2 -DCM (0.1 equiv.). The reaction mixture was heated to 140 "C for 10 min in microwave reactor. After 2,6-difluorophenylboronic acid (3.0 equiv.) was added more, the reaction mixture was heated once more to 140 *C for 10 min in microwave reactor. After the reaction mixture was cooled to room temperature, H 2 0 and EtOAc were added and the organic phase was 20 washed with brine, then dried with Na 2

SO

4 , and concentrated. The crude material was purified via preparative HPLC. The pure methyl 3-amino-6-(2,6-difluorophenyl) 5-fluoropicolinate was obtained after the pure fractions were neutralized with NaHCO 3 , extracted with EtOAc, and concentrated (34%). The methyl 3-amino-6 (2,6-difluorophenyl)-5-fluoropicolinate (1.0 equiv.) was dissolved in THF and MeOH -197- (2:1, 0.2 M) followed by addition of LiOH (1.8 equiv., I M aqueous solution). After the reaction mixture was stirred for 1.5 h at room temperature, the reaction mixture was quenched with 1 N HCl solution (1.8 equiv.) and extracted with EtOAc. The organic phase was washed with brine, then dried with Na 2

SO

4 , and concentrated. The crude 3 5 amino-6-(2,6-difluorophenyl)-5-fluoropicolinic acid was used for the next step without further purification (88%). LCMS (m/z): 269.0 (MH*); LC R, = 3.26 min. Synthesis of 3-amino-N-(4-chloropyridin-3-yl)-6-(2,6-difluorophenyl)-5 fluoropicolinamide F F C1 NF H N N NH2 10 103401 To a solution of 4-chloropyridin-3-amine (1.0 equiv.) and 3-amino 6-(2,6-difluorophenyl)-5-fluoropicolinic acid (1.0 equiv.) in NMP (1 M) was added HOAt and EDCI sequentially. The reaction mixture was stirred at room temperature for 2 days. The crude reaction was purified by prep HPLC to give 3-amino-N-(4-chloropyridin 15 3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (14%). LCMS (m/z): 379.0 (MH ); LC Rt = 3.49 min Synthcsis of trans-(+/-)-tcrt-butyl 1-(3-(3-amino-6-bromopicolinamido)pyridin-4-yl)-4 fluoropiperidin-3-ylcarbamate F NHBoc N),H N Br N/ 20 N

NH

2 [03411 Following Method 11 of Example 305, trans-(+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-4-fluoropipcridin-3-ylcarbamate and 3-amino-6-bromopicolinic -198acid were reacted yielding after purification (+/-)-tert-butyl 1-(3-(3-amino 6-bromopicolinamido)pyridin-4-yI)-4-fluoropiperidin-3-ylcarbamate, (20%). LCMS (n/z): 510.9 (MH*). Synthesis of trans-(+/-)-tert-butyl 1-(3-(3-amino-6-bromopicolinamido)pyrdin-4-yl) 5 4-(tert-butyldimethylsilyloxy)piperidin-3-vlcarbamate OTBDMS .NHBoc Br (N NBr N N NH 2 103421 Following Method 11 of Example 305, trans-(+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and 3-amino-6-bromo-picolinic acid was reacted yielding trans-(+/-)-tert-butyl 1-(3-(3-amino 10 6-bromo-picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)pipendin-3 ylcarbamate, (27%). LCMS (m/z): 621.2 (MH 4 ); LC R 1 = 4.41 min. Synthesis of (+/-)-tert-Butyl 1-(3-(3-amino-6-bromopicolinamido)pyridin-4-yl)-3-(tert butyldimethylsilyloxy)piperidin-4-ylcarbamate NHBoc .,OTBDMS (N Br N N S NH 2 15 NH [03431 Following Method 11 of Example 305, trans-(+/-)-tert-butyl 1-(3 aminopyridin-4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate and 3-amino 6-bromo-picolinic acid was reacted yielding trans-(+/-)-tert-butyl ]-(3-(3-amino 6-bromopicolinamido)pyridin-4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-yl 20 carbamate, (20%). LCMS (m/z): 623.2 (MH*); LC R, = 4.12 min. -199- Synthesis of trans-tert-Butyl 1-(3-(3-amino-6-bromo-5-fluoropicolinamido)pyridin-4-yl) 4-(tert-butyldimethylsi lyloxy)piperidin-3-ylcarbamate OTBDMS , NHBoc Br N N F N N-

NH

2 [03441 Following Method 11 of Example 305, trans-(+/-)-tcrt-butyl ]-(3 5 aminopyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and 3-amino 6-bromo-5-fluoropicolinic acid was reacted yielding trans-(+/-)-tert-butyl 1-(3-(3-amino 6-bromo-5-fluoropicolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-yl carbamate. LCMS (n/z): 641.2 (MH*); LC Rt = 4.47 min. Synthesis of trans-(+/-)-tert-Butyl 1-(3-(3-amino-6-bromo-5-fluoropi colinamido)pvridin 10 4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate NHBoc -',OTBDMr N N F N N

NH

2 [03451 Following Method 11 of Example 305, trans-(+/-)-tert-butyl 1-(3 aminopyridin-4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-ylcarbamate and 3-amino 6-bromo-5-fluoropicolinic acid was reacted yielding trans-(+/-)-tert-butyl 1-(3-(3-amino 15 6-bromo-5-fluoropicolinamido)pyridin-4-yl)-3-(tert-butyldimethylsilyloxy)piperidin-4-yl carbamate. LCMS (nz/z): 641.2 (MH ); LC R, = 4.73 min. -200- METHOD 20 Synthesis of 5-amino-2-(2,6-difluorophenyl)pvyrimidine-4-carboxylic acid F F N N HO 8 NH 2 5 103461 A 2.68 M NaOEt in EtOH solution (3 eq) was added to an ice-bath cooled mixture of 2, 6-difluorobenzimidamide hydrochloride (2 eq) in EtOH (0.1 M). The resulting mixture was allowed to warm to rt and stirred under N 2 for 30 min. To the reaction mixture was added drop wise a solution of mucobromic acid (I eq) in EtOH and the reaction was heated in a 50 'C oil bath for 2.5 hr. After cooling to rt the reaction 10 mixture was concentrated in vacuo. H 2 0 and 1.0 N NaOH were added and the aqueous mixture was washed with EtOAc. The aqueous phase was acidified to pH = 4 with 1.0 N HCI then extracted with EtOAc. Combined organic extracts were washed once with brine, then dried over anhydrous Na 2

SO

4 , filtered, and concentrated in vacuo to give 5 bromo-2-(2, 6-difluorophenyl)pyrimidine-4-carboxylic acid. The crude product was used 15 for the next step without further purification. LC/MS (m/z): 316.9 (MH). LC: R': 2.426 min. [03471 CuSO 4 (0.1 eq) was added to a mixture of 5-bromo-2-(2,6 difluorophenyl)pyrimidine-4-carboxylic acid (1 eq) and 28% aqueous ammonium hydroxide solution in a microwave reaction vessel. The reaction mixture was heated in a 20 microwave reactor at 110 *C for 25 min. The reaction vessel was cooled in dry ice for 30 min then unsealed and concentrated in vacuo. To the resulting solids was added 1.0 N HCl and the mixture was extracted with EtOAc. Combined organic extracts were washed once with brine, then dried over anhydrous Na 2

SO

4 , filtered, and concentrated in vacuo to give 5-amino-2-(2,6-difluorophenyl)pyrimidine-4-carboxylic acid. The crude product 25 was used for the next step without further purification. LC/MS (m/z): 252.0 (MH*). LC: R,: 2.043 min. -201- Synthesis of 5-amino-2-(2-fluorophenyl)pyrimidine-4-carboxylic acid F N "N HO 8 NH 2 [0348] Following method 20, 5-amino-2-(2-fluorophenyl)pyrimidine 4-carboxylic acid was prepared starting from 2-fluorobenzimidamide hydrochloride. 5 LC/MS (m/z): 234.0 (MH"), RI: 0.70 min. Synthesis of 5-amino-2-phenvlpyrimidine-4-carboxylic acid N "N HO

NH

2 103491 Following method 20, 5-amino-2-phenylpyrimidine-4-carboxylic acid was prepared starting from benzimidamide hydrochloride. LC/MS (m1/z): 216.1 (MH5. 10 Synthesis of ethyl 5-amino-2-chloropyrimidine-4-carboxylate C N N 8 NH 2 [0350] 10 % Palladium on carbon (0.2 eq) was added to a N 2 -flushed mixture of ethyl 2,6-dichloro-5-nitropyrimidine-4-carboxylate (1 eq) and magnesium oxide (2 eq) in 1,4-dioxane (0.15 M). The reaction was purged with H 2 under atmospheric pressure at 15 rt. After 16 h additional portions of 10 % Pd/C (0.3 eq) and MgO (5 eq) were added and the reaction continued to purge with H 2 under atmospheric pressure for 6 h at rt. The crude solids were filtered through a pad of Celite on a paper lined Buchner funnel and washed with CH 2 Cl 2 . The filtrate was transferred to a separatory funnel, washed twice with H 2 0 and once with brine, then dried over anhydrous Na 2

SO

4 , filtered, and 20 concentrated in vacuo. The crude product was dissolved in CH 2 Cl 2 , loaded onto a SiO 2 -202column, and purified by flash chromatography (10-20-30 % EtOAc in hexanes) to give ethyl 5-amino-2-chloropyrimidine-4-carboxylate. LC/MS (n/z): 202.0 (MH*). Synthesis of 5-amino-2-chloropyrimidine-4-carboxylic acid CI N N HO 5 [03511 A 0.5 M aqueous solution of LiOH (1.5 eq) was added to a stirring mixture of ethyl 5-amino-2-chloropyrimidine-4-carboxylate (1 eq) in H 2 0 (0.1 M) and THF (0.1 M). The reaction was maintained for 2 h at rt. 1.0 N HCI was added and the crude mixture was concentrated in vacuo to remove residual THF. The resulting solids were collected on a paper lined Buchner funnel and dried for 16 h under vacuum to give 10 5-amino-2-chloropyrimidine-4-carboxylic acid. LC/MS (n/z): 174.0 (MH*). HPLC: R': 1.148 min. Synthesis of 3-nitro-5-phenylpicolinonitrile N NC'

NO

2 [0352] 5-bromo-3-nitropicolinonitrile (1 eq) and phenylboronic acid (1.5 eq) 15 was mixed with 15 mL of 1,4-dioxane and 5 mL of 2 M Na 2

CO

3 aqueous solution in a glass pressure tube. The reaction mixture was degassed by anhydrous N 2 stream for 5 min followed by the addition of Pd(dppf)C1 2 -DCM (0.1 eq). The reaction mixture was stirred at 100 0 C for 3 hours. Then the mixture was diluted with 100 mL of ethyl acetate and washed with water, brine, then dried over MgSO 4 , filtered, and evaporated under reduced 20 pressure to give crude product, which was triturated by DCM, ether, hexanes to give the pure titled compound. LC/MS (ni/z): 226.1 (MH~). -203- Synthesis of 3-amino-5-phenylpicolinic acid HO "

NH

2 [0353] To a solution of 3-nitro-5-phenylpicolinonitrile (1 eq) in 10 mL of DMF was added tin (11) chloride dehydrate (7.0 eq) at room temperature. The reaction 5 mixture was stirred at that temperature overnight. The mixture was diluted with 150 mLof ethyl acetate and 30 mL of triethyl amine. After filtration, the filtrate was concentrated under reduced pressure to give a solid, which was added 2 mL of concentrated HCL. The mixture was stirred in microwave at 90'C for 10 minutes. After standing over night, the solid was collected by filtration, which was dissolved in 10 mL of IN NaOH. The 10 resulting mixture was extracted with 50 mL of ethyl acetate. The aqueous layer was acidified by I N HCI to pH 7.0 to yield 3-amino-5-phenylpicolinic acid, which was collected by filtration. LC/MS (m/z): 215.1 (MH). Synthesis of 6-bromo-5-fluoropicolinic acid Br NF HO 15 [0354] To 2-bromo-3-fluoro-6-methylpyridine (2.0g, 10.58 mmoles) in H 2 0 (30 mL) was added potassium permanganate (1.67g, 10.58 mmoles). The solution was heated at 100 0 C for 5 hours at which time more potassium permanganate (1.67g, 10.58 mmolcs) was added. After heating for an additional 48 hours the material was filtered through celite (4cm x 2 inches) and rinsed with H 2 0 (150 mL). The combined aqueous 20 was acidified with IN HCI to pH4, extracted with ethyl acetate (200 mL), washed with NaCI(sat.), dried over MgSO 4 , filitered and concentrated to yield 6-bromo 5-fluoropicolinic acid (17%) as a white solid. LCMS (m/z): 221.9 (MH+); LC Rt = 2.05 min. -204- Synthesis of (S)-tert-butyl l-(3-(6-bromo-5-fluoropicolinamido)pyridin-4-yl)piperidin-3 ylcarbamate BocHN Br N N/ F H | N N 103551 Following Method 11 (Example 305), (S)-tert-butyl 1-(3 5 aminopyridin-4-yl)piperidin-3-ylcarbamate was coupled to 6-bromo-5-fluoropicolinic acid yielding crude (S)-tert-butyl 1-(3-(6-bromo-5-fluoropicolinamido)pyridin 4-yl)piperidin-3-ylcarbamate (92%) which was used as is. LCMS (m/z): 496.2 (MH+); LC Rt = 2.90 min. Synthesis of 6-bromo-3-fluoropicolinic acid Br HO -I 10 F [0356] To 6-bromo-3-fluoro-2-methylpyridine (2.0g, 10.58 mmoles) in H 2 0 (200 mL) was added potassium permanganate (1.67g, 10.58 mmoles). The solution was heated at 100'C for 16 hours at which time upon cooling the material was filtered through celite (4cm x 2 inches) and rinsed with H 2 0 (150 mL). The combined aqueous was 15 acidified with IN HCI to pH4, extracted with ethyl acetate (2x200 mL), washed with NaCl(sat.), dried over MgSO 4 , filtered and concentrated to yield 6-bromo 3-fluoropicolinic acid (18%) as a white solid. LCMS (m/z): 221.9 (MH+); LC Rt = 1.71 min. Synthesis of (S)-tert-butyl 1-(3-(6-bromo-3-fluoropicolinamido)pyridin-4-yl)piperidin 20 3-ylcarbamate BocHN Br N H N'" C N j F N -205- 10357] Following Method 11 (Example 305), (S)-tert-butyl 1-(3 aminopyridin-4-yl)piperidin-3-ylcarbamate was coupled to 6-bromo-3-fluoropicolinic acid yielding (S)-tert-butyl 1-(3-(6-bromo-3-fluoropicolinamido)pyridin-4-yl)piperidin 3-ylcarbamate which was used directly as is. LCMS (m/z): 496.2 (MH+); LC Rt = 2.71 5 min. Synthesis of (S)-tert-butyl l-(3-(6-bromopicolinamido)pyrdin-4-yl)piperidin-3 ylcarbamate BocHN Br H N N' N 103581 Following Method I1 (Example 305), (S)-tert-butyl 1-(3 10 aminopyridin-4-yl)piperidin-3-ylcarbamate was coupled to 6-bromopicolinic acid yielding, after column chromatography (EtOAc as eluant), (S)-tert-butyl 1-(3-(6 bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (82%). LCMS (m/z): 478.1 (MH+); LC Rt = 2.84 min. Synthesis of(S)-tert-butyl 1-(3-(5-amino-2-chloropvrimidine-4-carboxamido)pyridin-4 15 yl)piperidin-3-ylcarbamate BocHN N N N I N I

NH

2 [0359] Following Method 11 (Example 305), (S)-tert-butyl 1-(3 aminopyridin-4-yl)piperidin-3-ylcarbamate was coupled to 5-amino-2-chloropyrimidine 4-carboxylic acid yielding, after column chromatography (EtOAc as eluant), (S)-tert 20 butyl 1-(3-(5-amino-2-chloropyrimidine-4-carboxamido)pyridin-4-yl)piperidin-3-yl carbamate (10%). LCMS (m/z): 433.1 (MH+); LC Rt = 2.46 min. -206- METHOD 21 Synthesis of 2-chloro-6-isobutoxypyrazine C l , , N O ) ' N [0360] A flame-dried round bottom flask was charged with a suspension of 95 5 % NaH (1.1 eq) in anhydrous THF (0.3 M). The stirring mixture was cooled to 0 *C in an ice-water bath and 2-methyl-1-propanol (1 eq) was added drop wise via syringe. After 30 min 2, 6-dichloropyrazine (1 eq) was added, the reaction was warmed to rt and stirred for 3 h. The crude mixture was quenched with saturated aqueous NH 4 Cl and extracted with EtOAc. The combined organic phases were washed once each with H 2 0 and brine, then 10 dried over anhydrous Na 2

SO

4 , filtered, and concentrated in vacuo. The crude residue was dissolved in CH 2

CI

2 , loaded onto a SiO 2 column, and purified by flash chromatography (9:1 hexanes/EtOAc fluent) to give 2-chloro-6-isobutoxypyrazine. LC/MS (m/z): 187.1 (MH). Synthesis of 2-chloro-6-(cycloprop~ylmethoxy)pyrazine CI N O 15 N [0361] Following Method 21, 2-chloro-6-(cyclopropylmethoxy)pyrazine was prepared. LC/MS (m/z): 185.0 (MH*). Synthesis of 2-chloro-6-ethoxypyrazine Cl N O0 N 20 [0362] Following Method 21, 2-chloro-6-ethoxypyrazine was prepared. LC/MS (m/z): 159.0 (MH*). Synthesis of 2-chloro-6-isopropoxypyrazine CI ~N;O N -207- [03631 Following Method 21, 2-chloro-6-isopropoxypyrazine was prepared. LC/MS (n/z): 173.1 (MH*). Synthesis of 2-chloro-6-propoxypyrazine Cl , N O ,. N 5 [03641 Following Method 21, 2-chloro-6-propoxypyrazine was prepared. LC/MS (n/z): 173.1 (MH 4 ). Synthesis of 2-(benzyloxy)-6-chloropyrazine CI ~N O N / [03651 Following Method 21, 2-(benzyloxy)-6-chloropyrazine was prepared. 10 LC/MS (n/z): 221.0 (MH ). METHOD 22 Synthesis of 5-bromo-3-(2-methoxyethoxy)pyrazin-2-amine OIN Br

H

2 N N [0366] A flame-dried round bottom flask was charged with a suspension of 95 15 % NaH (1.3 eq) in anhydrous THF (0.2 M). The stirring mixture was cooled to 0 *C in an ice-water bath and 2-methoxyethanol (1.2 eq) was added drop wise via syringe. After 30 min 3,5-dibromopyrazin-2-amine (1 eq) was added, the reaction was warmed to rt and stirred for 3 h. The crude mixture was quenched with saturated aqueous NH 4 C and extracted with EtOAc. The combined organic phases were washed once each with H 2 0 20 and brine, then dried over anhydrous Na 2

SO

4 , filtered, and concentrated in vacuo to give 5-bromo-3-(2-methoxyethoxy)pyrazin-2-amine. LC/MS (n/z): 250.0 (MH). Synthesis of 5-bromo-3-(2,2,2-trifluoroethoxy)pyrazin-2-amine F3CyOX N Br

H

2 N N -208- [03671 Following Method 22, 5-bromo-3-(2,2,2-trifluoroethoxy)pyrazin-2 amine was prepared. LC/MS (m/z): 274.0 (MH*). METHOD 23 Synthesis of 3-(2-methoxyethoxy)-5-(4,4,5,5-tetramethyl 5 1,3,2-dioxaborolan-2-yl)pyrazin-2-amine -sp O-,: N B, H2N IN rsv 103681 To a solution of 5-bromo-3-(2-methoxyethoxy)pyrazin-2-amine (1 eq) in dioxane (0.25 M) in a microwave reaction vessel was added bispinacolatodiboron (2 eq), Pd(dba) 2 (0.05 eq), PCy 3 (0.075 eq) and KOAc (3 eq). The reaction mixture was 10 then heated twice in a microwave reactor at I 10*C for 600 sec. The crude product was used for the next step without workup or further purification. LC/MS (m/z): 214.1/296.1 (MH*). Synthesis of 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl) 3-(2,2,2-trifluoroethoxypyrazin-2-amine F3C"-O1 N 1YB, 15 H 2 N N [03691 Following Method 23, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 3-(2,2,2-trifluoroethoxy)pyrazin-2-amine was prepared from 5-bromo-3-(2,2,2 trifluoroethoxy)pyrazin-2-amine. LC/MS (m/z): 238.1 (MH*). METHOD 24 20 Synthesis of tert-butyl 6-chloro-2-methylpyrimidin-4-ylcarbamate H N

-

O CI -209- 10370] To a solution of 6-chloro-2-methylpyrimidin-4-amine (1.0 equiv.) in THF (0.17M) was added BOC 2 0 (1.1 equiv.) and DMAP (cat.). The reaction was allowed to stir overnight, then concentrated to a yellow crude, and filtered through a pad of SiO 2 eluting with EtOAc and hexanes (1:1) to afford an off-white solid (78%). LCMS 5 (n/z): 244.1 (MH); LC R, = 3.69 min. Synthesis of 4-chloro-N,N-di-BOC-6-methylpyrimidin-2-amine N NBOC 2 C1 [03711 Method 24 was followed using 4-chloro-6-methylpyrimidin-2-amine (1.0 equiv.), BOC 2 0 (2.0 equiv.), and DMAP (cat.) to afford 4-chloro-NN-di-BOC-6 10 methylpyrimidin-2-amine in 71%. LCMS (n/z): 344.2 (MH); LC Rt = 4.3 min. Synthesis of 4-chloro- N,N-di-BOC-6-methoxypyrmidin-2-amine 0t O N N 0 C1 10372] Method 24 was followed using 4-chloro-6-methoxypyrimidin-2-amine (1.0 equiv.), Boc 2 0 (2.0 equiv.), and DMAP (cat.) to afford 4-chloro- NN-di-BOC-6 15 methoxypyrimidin-2-amine in >95%. LCMS (m/z): 360.2 (MH); LC Rt = 5.70 min. Synthesis of 6-chloro- NN-di-BOC-2-(methylthio)tyrimidin-4-amine IIs N NBOC 2 C1 [0373] Method 24 was followed using 6-chloro-2-(methylthio)pyrimidin-4 amine (1.0 equiv.), BOC 2 0 (2.0 equiv.), and DMAP (cat.) to afford 6-chloro- NN-di 20 BOC-2-(methylthio)pyrimidin-4-amine in >95%. LCMS (m/z): 376.1 (MH); LC R = 4.9 min. -210- Synthesis of tert-butyl 6-chloro-2-(trifluoromethyl)pyrimidin-4-ylcarbamate H F3C NT N O C1 [0374] Method 24 was followed using 6-chloro-2-(trifluoromethyl)pyrimidin 4-amine (1.0 equiv.), BOC 2 0 (1.0 equiv.), and DMAP (cat.) to afford tert-butyl 6-chloro 5 2-(trifluoromethyl)pyrimidin-4-ylcarbamate in 64%. LCMS (n/z): 298.1 (MH*); LC R, = 4.73 min. Synthesis of benzyl 4-chloropyridin-3-ylcarbamate C1 H NO [03751 A solution of benzyl chloroformate (1.1 equiv.) in THF (1.85 M) was 10 slowly added to a solution of 3-amino-4-chloropyridine (1.0 equiv.) and pyridine (1.5 equiv.) in THF (1.0 M) and stirred at rt for 3.5 hours (formation of a precipitate over time). The reaction was quenched with H 2 0 (100 mL), extracted with EtOAc (200 mL), washed with NaCl(sat.) (75 mL), dried over MgSO 4 , filtered and the volatiles were removed in vacuo. The product precipitated from a mixture of hexane/EtOAc yielding 15 benzyl 4-chloropyridin-3-ylcarbamate (34%). LCMS (m/z): 263.1 (MH4); LC R = 2.33 min. Synthesis of benzyl 4-(4,4,5,5-tetramethyl- 1,3,2-dioxaboronlan.2-yl)pyridine-3 ylcarbamate H N 20 [0376] A solution of benzyl 4-chloropyridin-3-ylcarbamate (1.0 equiv.), bis(pinacolato)diboron (2.0 equiv.), Pd 2 (dba) 3 (0.05 equiv.), PCy 3 (0.075 equiv.), KOAc (2.0 equiv.) in dioxane (0.19 M) was degassed by bubbling nitrogen through for 10 min in -211a round-bottomed flask. The flask was heated to 90 C for 3 hours, cooled to room temperature, filtered through activated charcoal and Celite and washed with EtOAc. Upon concentration of the filtrate, a thick dark brown product was obtained. LCMS (m/z): 273 (MH* for the corresponding boronic acid); LC R, = 1.93 min. 5 METHOD 25 Synthesis of tert-butyl 6-(3-(benzylcarbamate-amino) pyridin-4-yl)-2-(trifluoromethyl)pyrimidin-4-ylcarbamate BOCHN N r CF 3 N NHCBZ N [03771 To the crude solution of benzyl 4-(4,4,5,5-tctramcthyl-1,3,2 10 dioxaboronlan.2-yl)pyridine-3-ylcarbamate (3.0 equiv.) was added Pd(dppf)C1 2 -DCM (0.10 equiv.), tert-butyl 6-chloro-2-(trifluoromethyl)pyrimidin-4-ylcarbamate (1.0 equiv.), and DME/2M Na 2

CO

3 (3:1, 0.08 M). The reaction was heated to 90 C for one hour, then cooled to room temperature, H 2 0 and EtOAc were added, the organic layer was extracted, washed with brine and dried with Na 2

SO

4 . Upon concentration, the crude 15 was passed through a pad of SiO 2 , washing with EtOAc. The reaction was concentrated to almost dryness, and hexane was added. The precipitate was filtered to give the product as a light yellow powder. The filtrate was concentrated to almost dryness, added more hexane and filtered the precipitate. Total yield = 50%. LCMS (z/z): 490.1 (MH*); LC R, = 4.11 min. 20 Synthesis of benzyl 4-(2-(di-BOC-amino)-6-methylpyrimidin-4-yl)pyridin-3-ylcarbamate (BOC) 2 N N N / NHCBZ N 103781 Method 25 was followed using 4-chloro-NN-di-BOC-6 methylpyrimidin-2-amine (1.0 equiv.), benzyl 4-(4,4,5,5-tetramethyl-1,3,2 dioxaboronlan.2-yl)pyridine-3-ylcarbamate (3 equiv.), Pd(dppf)C1 2 -DCM (0.] 0 equiv.) in -212- DME/2M Na 2

CO

3 (3:1, 0.07M) at 70 C for 30 min. Purification via SiO 2 column chromatography eluting with EtOAc and hexanes (2.5:1) afforded benzyl 4-(2-(di-BOC amino)-6-methylpyrimidin-4-yl)pyridin-3-ylcarbamate in 69% yield. LCMS (n/z): 536.2 (MH*); LC R, = 4.2 min. 5 METHOD 26 Synthesis of tert-butyl 6-(3-aminopyridin-4-yl)-2-(trifluromethyl)pyrimidin-4 ylcarbamate BOCHN N CF3 N

NH

2 N 103791 A solution of tcrt-butyl 6-(3-(benzylcarbamate-amino)pyridin-4-yl) 10 2-(trifluoromethyl)pyrimidin-4-ylcarbamate was stirred in EtOAc and EtOH (3:1, M) (heterogeneous solution). Pd/C (10% by weight) was added and the reaction was stirred under a hydrogen balloon for 2 days. Upon completion, the solution was filtered through Celite and washed with EtOAc. The filtrate was concentrated to give a brown solid (>95%). LCMS (m/z): 356.1 (MH 4 ); LC R, = 2.80 min. 15 Synthesis of 4-(3-aminopyridin-4-yl)-N,N-di-BOC-6-methylpvrimidin-2-amine

(BOC)

2 NY N N /

NH

2 N [0380] Method 26 was followed using benzyl 4-(2-(di-BOC-amino) 6-methylpyrimidin-4-yl)pyridin-3-ylcarbamate (1.0 equiv.), Pd/C (20% by weight) in EtOAc yielding 4-(3-aminopyridin-4-yl)-N,N-di-BOC-6-methylpyrimidin-2-amine in 20 90% yield. LCMS (n/z): 402.3 (MH*); LC Rt = 3.0 min. -213- Synthesis of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine B

NH

2 N 103811 A solution of benzyl 4-chloropyridin-3-ylcarbamate (1.0 equiv.), bis(pinacolato)diboron (2.0 equiv.), Pd 2 (dba) 3 (0.05 equiv.), PCy 3 (0.075 equiv.), KOAc 5 (2 equiv.) in dioxane (0.19 M) was degassed by bubbling nitrogen through for 10 min in a round-bottomed flask. The flask was heated to 90 C for 16 hours, cooled to room temperature, filtered through activated charcoal and Celite, washed with EtOAc and concentrated to give a thick dark brown product. LCMS (m/z): 139.0 (MH for the corresponding boronic acid). 10 Synthesis of 6-(3-aminop~yridin-4-yl)-NN-di-BOC-2-(methylthio)pyrimidin-4-amine

(BOC)

2 N N S N

NH

2 N [03821 Method 26 was followed using 6-chloro- N,N-di-BOC-2-(methyl thio)pyrimidin-4-amine (1.0 equiv.), 4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2 yl)pyridin-3-amine (3.0 equiv.), Pd(dppf)C12-DCM (0.10 equiv.) in DME/2M Na 2

CO

3 15 (0.07M) at 90 0 C for 30 min. Purification via SiO 2 column chromatography eluting with EtOAc and hexanes (1:1) afforded 6-(3-aminopyridin-4-yl)-N,N-di-BOC-2-(methyl thio)pyrimidin-4-amine in 32% yield. LCMS (m/z): 434.2 (MH+); LC R, = 3.56 min. Synthesis of tert-butyl 6-(3-aminopyridin-4-yl)-2-methylpyrimidin-4-ylcarbamate BOCHN N N

NH

2 N -214- [03831 Method 26 was followed using tert-butyl 6-chloro-2-methylpynmidin 4-ylcarbamate (1.0 equiv.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3 amine (3.0 equiv.), Pd(dppf)C1 2 -DCM (0.10 equiv.) in DME/2M Na 2

CO

3 (3:1, 0.07M) at 80 "C for 30 min. Purification via SiO 2 column chromatography eluting with EtOAc 5 afforded tert-butyl 6-(3-aminopyridin-4-yl)-2-methylpyrimidin-4-ylcarbamate in 26% yield. LCMS (m/z): 302.1 (MH); LC Rt= 2.23 min. Synthesis of 4-(3-aminopvridin-4-yl)-6-methoxy-NN-di-BOC-pyrimidin-2-amine

(BOC)

2 N N N/

NH

2 N [0384] Method 26 was followed using 4-chloro- NN-di-BOC-6 10 methoxypyrimidin-2-amine (1.0 equiv.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-3-amine (3.0 equiv.), Pd(dppf)C1 2 -DCM (0.10 equiv.) in DME/2M Na 2

CO

3 (0.07M) at 90 C for 30 min. Purification via SiO 2 column chromatography cluting with EtOAc and hexanes (1:1) afforded 4-(3-aminopyridin-4-yl)-6-methoxy-N,N-di-BOC pyrimidin-2-amine in 13% yield). LCMS (m/z): 418.1 (MH*). 15 Synthesis of N2-(3,4-dimethoxybenzyl)-6-(trifluoromethyl)4,4'-bipyridine-2,3'-diamine

F

3 C N N

NH

2 N [0385] Method 26 was followed using N-(3,4-dimethoxybenzyl)-4-iodo-6-(tri fluoromethyl)pyridin-2-amine (1.0 equiv.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan 2-yl)pyridin-3-amine (3 equiv.), Pd(dppf)C1 2 DCM (0.10 equiv.) in DME/2M Na 2

CO

3 20 (3:1, 0.07 M) at 50 *C for 45 min. Purification via reverse phase HPLC afforded N2-(3,4 dimethoxybenzyl)-6-(trifluoromethyl)-4,4'-bipyridine-2,3'-diamine in 38 % yield. LCMS (m/z): 402.1 (MH); LC Rt = 3.0 min. -215- METHOD 27 Synthesis of tert-butyl 6-(3-(3-amino-6-bromopicolinamido)pyridine-4-yl)-2 (trifluoromethyl)pyrimidin-4-ylcarbamate

F

3 C N NHBOCBr N / N H N| N N/ T NH2 5 [03861 A solution of tert-butyl 6-(3-aminopyridin-4-yl)-2-(trifluro methyl)pyrimidin-4-ylcarbamate (1.0 equiv.), 3-amino-6-bromopicolinic acid (1.0 equiv.), HOAt (1.0 equiv.), and EDC (1.0 equiv.) in DMF at a concentration of (0.2 M) was stirred for 3 hrs then heated to 50 *C overnight (homogeneous solution). Water was added to the reaction and the precipitate was filtered. The solid was further purified via 10 SiO 2 column chromatography eluting with DCM/MeOH (10%) to yield a brown solid as the desired product (81%). LCMS (m/z): 554.1/556.1 (MH*); LC R,= 3.77 min. Synthesis of 3-amino-6-bromo-N-(4-(6-(di-BOC-amino)-2-(methylthio)pyrimidin-4 vl)pVyridin-3-yl)picolinamide S N N(BOC)l~r H| N N H H 15 N I NH2 [0387] Method 27 was followed using 6-(3-aminopyridin-4-yl)-N,N-di-BOC 2-(methylthio)pyrimidin-4-amine (1.0 equiv.), 3-amino-6-bromopicolinic acid (1.0 equiv), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in DMF yielding 3-amino-6-bromo-N (4-(6-(di-BOC-amino)-2-(methylthio)pyrimidin-4-yl)pyridin-3-yl)picolinamide in 30 % 20 yield. LCMS (m/z): 632.1/634.0 (MH); LC R = 4.55 min. -216- Synthesis of tert-butyl 6-(3-(3-amino-6-bromopicolinamido)pyridine-4-yl)-2 methylpyrimidin-4-ylcarbamate N NHBOC Br N /N/ H N [03881 Method 27 was followed using tert-butyl 6-(3-aminopyridin-4-yl) 5 2-methylpyrimidin-4-ylcarbamate (1.0 equiv.), 3-amino-6-bromopicolinic acid (1.0 equiv), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in DMF yielding tert-butyl 6-(3-(3 amino-6-bromopicolinamido)pyridine-4-yl)-2-methylpyrimidin-4-ylcarbamate in 74 % yield. LCMS (m/z): 499.9/501.9 (MH*); LC Rt= 3.36 min. Synthesis of 3-amino-6-bromo-N-(4-(2-(di-BOC-amino)-6-methylpyrimidin-4-yl)pyridin 10 3-yl)picolinamide N

NBOC

2 Br H N N " N T NH 2 103891 Method 27 was followed using 4-(3-aminopyridin-4-yl)-N,N-di-BOC 6-methylpyrimidin-2-amine (1.0 equiv.), 3-amino-6-bromopicolinic acid (1.0 equiv), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in DMF yielding 3-amino-6-bromo-N-(4-(2-(di 15 BOC-amino)-6-mcthylpyrimidin-4-yl)pyridin-3-yl)picolinamidc in 12% yicld. LCMS (m/z): 602.2 (MH'); LC R,= 3.60 min. Synthesis of tert-butyl 6-(3-(3-amino-6-bromo-5-fluoropicolinamido)pyridin-4-yl)-2 methylpvrimidin-4-ylcarbamate NY, N NHBOCBr N /F H N -217- [03901 Method 27 was followed using tert-butyl 6-(3-aminopyridin-4-yl)-2 methylpyrimidin-4-ylcarbamate (1.0 equiv.), 3-amino-6-bromo-5-fluoropicolinic acid (1.0 equiv.), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in DMF yielding tert-butyl 6-(3-(3 amino-6-bromo-5-fluoropicolinamido)pyridin-4-yl)-2-methylpyrimidin-4-ylcarbamate in 5 15% yield. LCMS (m/z): 520.1 (MW); LC R,= 3.4 min. Synthesis of tert-butyl 4-(3-(3-amino-6-bromo-5-fluoropicolinamido)pyridin-4-yl)-6 methylpyrimidin-2-ylcarbamate N NHBOC Br N N F H | N N I NH 2 10 103911 Method 27 was followed using tert-butyl 4-(3-aminopyridin-4-yl) 2-methylpyrimidin-4-ylcarbamate (1.0 equiv.), 3-amino-6-bromo-5-fluoropicolinic acid (1.0 equiv.), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in DMF yielding tert-butyl 4-(3-(3 amino-6-bromo-5-fluoropicolinamido)pyridin-4-yl)-6-methylpyrimidin-2-ylcarbamate 20% yield. LCMS (m/z): 618.1 (MH); LC R,= 3.5 min. 15 Synthesis of tert-butyl 6-(3-(6-bromopicolinamido)pyridin-4-yl)-2 (trifluoromethyl)pyrimidin-4-ylcarbamate

F

3 C N NHBOCBr N / N H N N N N [03921 Method 27 was followed using tert-butyl 6-(3-aminopyridin-4-yl) 2-(trifluoromethyl)pyrimidin-4-ylcarbamate (1.0 equiv.), 6-bromopicolinic acid (1.0 20 equiv.), EDC (1.0 equiv.), and HOAt (1.0 equiv.) in NMP yielding tert-butyl 6-(3-(6 bromopicolinamido)pyridin-4-yi)-2-(trifluoromethyl)pyrimidin-4-ylcarbamate >95% yield. LCMS (m/z): 539/541 (MH); LC Rt= 3.97 min.. -218- Synthesis of 2-chloro-3-iodo-6-(trifl uoromethyl)pyridine CI N CF 3 10393] To a cooled solution (-78 *C) of n-BuLi (1.0 equiv.) in THF (0.8M) was added diisopropylamine (1.0 equiv.) dropwise, maintaining the internal temperature under 5 - 70 oC. The solution was stirred for 30 min, then 2-chloro-6-(trifluromethyl)pyridine (1.0 equiv.) in THF was added dropwise. The solution was stirred for another 30 min, then 12 was added as a solid. Stirred for 1 hr at - 78 0 C, then allowed the reaction to warm to room temperature overnight. The solution was quenched by addition of H 2 0, extracted with EtOAc, then washed with brine, and concentrated. The crude material was 10 purified via Si0 2 column chromatography eluting with EtOAc and hexanes (1:10) to yield 2-chloro-3-iodo-6-(trifluromethyl)pyridine in 35% yield. LCMS (m/z): 307.8 (MH *); LC Rt= 4.18 min. Synthesis of 2-chloro-4-iodo-6-(trifluoromcthyl)pyridine Cl N CF 3 15 103941 To a cooled (-75 *C) solution of THF was added n-BuLi (1.1 equiv.), followed by diisopropylamine (1.1 equiv.), dropwise. The reaction was stirred for 10 min, then 2-chloro-3-iodo-6-(trifluoromethyl)pyridine (1.0 equiv.) was added dropwise in THF. The solution was stirred at - 75 C for 1 hr, then quenched with the addition of IN HCI, extracted with EtOAc, washed with brine, dried with MgSO 4 , and concentrated to 20 give a tan solid in 85% yield. LCMS (m/z): 307.8 (MH*); LC R, = 4.28 min. Synthesis of N-(3,4-dimethoxybenzyl)-4-iodo-6-(trifluoromethyl)pyridin-2-amine - ~ H N NCF 3 [03951 A solution of 2-chloro-4-iodo-6-(trifluoromethyl)pyridine (1.0 equiv.), (3,4-dimethoxyphenyl)methanamide (5.0 equiv.), and Et 3 N (5.0 equiv.) in NMP (0.7M) -219was microwaved to 100 C for 10 min. The solution was directly purified via reverse phase HPLC, the pure fractions were neutralized with solid NaHCO 3 , extracted with EtOAc, dried with MgSO 4 , and concentrated to give N-(3,4-dimethoxybenzyl)-4-iodo-6 (trifluoromethyl)pyridin-2-amine in 36% yield. LCMS (m/z): 347.1 (MH*); LC R= 3.96 5 min. Synthesis of methyl 3-amino-6-(2.6-diflurophenylpicolinate F F N ,

NH

2 [0396] A solution of methyl 3-amino-6-bromopicolinate (1.0 equiv.), 2,6-difluorophenyl-boronic acid (3.0 equiv), and Pd(dppf)C1 2 -DCM (0.1 equiv.) in 3:1 10 DME/ 2M Na 2

CO

3 (0.5M) was subjected to microwave irradiation at 120'C for 15 min intervals. The reaction was filtered and washed with EtOAc. The organic was partitioned with H 2 0 (25mL), was further washed with NaCl(sa,.) (25mL), was dried over MgSO 4 , and the volatiles were removed in vacuo. The residue was diluted in EtOAc and passed through a silica gel plug and the volatiles were removed in vacuo yielding methyl 15 3-amino-6-(2,6-difluorophenyl)picolinate (47%). LCMS (m/z): 265.1 (MH*); LC R, = 2.70 min. Synthesis of 3-amino-6-(2,6-difluorophenvl)picolinic acid F F N. HO

NH

2 20 10397] To a solution of methyl 3-amino-6-(2,6-difluorophenyl)picolinate (1.0 equiv) in THF (0.5M), was added IM LiOH (4.0 equiv). After stirring for 4 hours at 60*C, 1 N HCI (4.0 equiv.) was added and the THF was removed in vacuo. The resulting -220solid was filtered and rinsed with cold H 2 0 (3 x 20mL) to yield 3-amino-6-(2,6 difluorophenyl)picolinic acid (90%). LCMS (m/z): 251.1 (MH); LC Rt = 2.1 min. Synthesis of methyl 3-amino-6-(thiazol-2-yl)picolinatc S N N

NH

2 5 103981 A solution of methyl 3-amino-6-bromopicolinate (1.0 equiv.), 2-thiazolylzinc bromide 0.5 M solution in THF (3.0 equiv.), and Pd(dppf)C1 2 -DCM (0.05 equiv.) was stirred at 80'C for 1.5 hours. The reaction was filtered and washed with EtOAc. The organic was washed with H 2 0 (100mL), and further washed with NaClsat.) (50nL), dried over MgSO 4 , and the volatiles were removed in vacuo. The product was 10 crystallized with hexane/EtOAc (1:1) to yield methyl 3-amino-6-(thiazol-2-yl)picolinate (5 1%). LCMS (in/z): 236.1 (MH5; LC R 1 = 2.3 min. Synthesis of 3-amino-6-(thiazol-2-yl)picolinic acid S N N HO

NH

2 [0399] To a solution of methyl 3-amino-6-(thiazol-2-yl)picolinate (1.0 equiv) 15 in THF (0.5M), was added IM LiOH (4.0 equiv). After stirring for 4 hours at 60 0 C, 1 N HCl (4.0 equiv.) was added and the THF was removed in vacuo. The resulting solid was filtered and rinsed with cold H20 (3 x 20mL) to yield 3-amino-6-(thiazol-2-yl)picolinic acid (61%). LCMS (m/z): 222.1 (MH+); LC Rt = 1.9 min. -221- Synthesis of methyl 3-amino-6-(2-fluoro-5-isopropylcabamoyl)phenyl)picolinate 0 N ' F H FN ,0

NH

2 10400] A solution of methyl 3-amino-6-bromopicolinate (1.0 equiv.), N-iso propyl 3-borono-4-fluorobenzamide (1 .1 equiv.), and Pd(dppf)C1 2 -DCM (0.15 equiv.) in 5 DME/2M Na 2

CO

3 (3:1), at a concentration of 0.5 M, was stirred at 120'C for 1.5 hours. The reaction was filtered and washed with EtOAc. The organic was partitioned with H20 (25mL), washed with NaC(sa.) (25mL), dried over MgSO 4 , and the volatiles were removed in vacuo. The residue was diluted in EtOAc and passed through a silica gel plug and the volatiles were removed in vacuo yielding methyl 3-amino-6-(2-fluoro-5-iso 10 propylcabamoyl)phenyl)picolinate (60%). LCMS (n/z): 332.2 (MH); LC R, = 2.9 min. Synthesis of 3-amino-6-(2-fluoro-5-isopropylcabamoyl)phenyl)picolinic acid 0 N F H F N HO

NH

2 10401] To a solution of methyl 3-amino-6-(2-fluoro-5 isopropylcabamoyl)phenyl)picolinate (1.0 equiv) in THF (0.5M), was added IM LiOH 15 (4.0 equiv). After stirring for 4 hours at 60'C, I N HCI (4.0 equiv.) was added and the THF was removed in vacuo. The resulting solid was filtered and rinsed with cold H 2 0 (3 x 20mL) to yield 3-amino-6-(2-fluoro-5-isopropylcabamoyl)phenyl)picolinic acid (98%). LCMS (m/z): 318.1 (MH*); LC R,= 2.4 min -222- Synthesis of 3-amino-N-(4-chloropyridin-3-yl)-6-(2,6-difluorophenyl)picolinamide C1 C F F H I H NH N N/ NH2 [0402] A solution of 3-amino-6-(2,6-difluorophenyl)picolinic acid (1.0 equiv.), 4-chloropyridin-3-amine (2.0 equiv.), HOAt (1.0 equiv.), and EDC (1.0 equiv.) in DCM 5 at a concentration of (0.2M) was stirred for 24 hr. Water was added to the reaction, followed by EtOAc. The organic layer was separated, dried with brine, MgSO 4 , and concentrated. The crude material was purified via SiO 2 column chromatography eluting with EtOAc and hexanes (1:1) to give the product as a light yellow solid (21% yield). LCMS (n/z): 36 1.1(MH*); LC Rt= 3.28 min. 10 METHOD 28 Synthesis of 3-amino-6-(2,6-diflurophenyl)-N-(3'-fluoro4,4'-bipyridin-3-yl)picolinamide N F F F N H N N

NH

2 [0403] A solution of 3-amino-N-(4-chloropyridin-3-yl)-6-(2,6-difluoro phenyl)picolinamide (1.0 equiv.), 3-fluoropyridin-4-yl boronic acid (3.0 equiv.), and 15 Pd(dppf)Cl 2 -DCM (0.10 equiv.) in DME/2M Na 2

CO

3 (3:1) was heated to 120 *C with microwave irradiation for 10 min. Upon cooling, the reaction was extracted with EtOAc, the organic layer was dried with Na 2

SO

4 and concentrated. The crude material was purified via reverse phase HPLC. The product fraction was lyophilized to give 3-amino 6-(2,6-diflurophenyl)-N-(3'-fluoro-4,4'-bipyridin-3-yl)picolinamide as the TFA salt in 20 12% yield. LCMS (m/z): 404.1 (MH); LC R 1 = 2.92 min. [04041 The following compounds were prepared using Method 28: -223- Example Structure Name MH+ LC F ..- F -amino-N-(5-fluoro 601I __ ,4'-bipyridin-3'-yl)-6-(2- 441 29 601H N-I fuorophenyl)pyridine-2- 441 29 N N N 2 N. N N F -amino-6-(2 602 N'fuorophenyl)-N-(4- 371 26 H yrimidin-5-ylpyridin-3- 371 26 Il)pyridine-2-carboxamide F F NH 2 3-amino-N-[6-amino-5-(tri F NF fuoromethyl)-3,4' 603 HN' ipyridin-3'-yi]-6-(2- 469.1 2.90 N N Nuorophenyl)pyridine-2 - 0 NH2 arboxamide N2 FH 3-amino-N-(6-amino-3 ,4 604 N- bipyridin-3'-yI)-6-(2-fluoro- 411 20 H I henyl)pyridine-2- 411 20 NN N N 0 NH2 arboxamide H 2 N N F 3-amino-N-(2'-amIno-4,4 t 605 HN bipyridin-3-yl)-6-(2- 401.1 2.13 N N fuorophenyl)pyridine-2 N N F -amino-N-4,4'-bipyridin 606 F 3-yl-6-(2-fluorophenyl)- 386.1 2.36 N pyridine-2-carboxamide N N 2 F N F ..- -amino-N-(2',6'-difluoro 607 ~ N4,4'-bipyridin-3-yl)-6-(2,6- 401 33 H difluorophenyl)pyridine-2 Nryl arboxamide N 0 NH2 NCH ,H3 NH N-Amino-6-(2,6-difluoro 0 1N~ NH F phcnyl)-pyridinc-2 H0 N- carboxylic acid (6'-amino- 449.1 2.44 N N N'-methoxy-[4,4']bi N 0 NH 2 yridinyl-3-yl)-amide -224- Example Structure Name MH+ LC C H, I 0 N F -amino-6-(2 609I N uorophcnyl)-N-(5- 462 26 609H N-I ethoxy-3,4'-bipyridin-3'- 462 26 N - y ylH )pyridinc-2-carboxamidc N 2 H N I -amino-6-(2 610 H 3 0.o I N" fuorophenyl)-N-(3'- 416.1 2.47 H y ethoxy-4,4'-bipyridin-3 NN N 0 NH2 1I)pyridine-2-carboxamide N I F 3-amino-6-(2 61 HC.

0 N- fuorophenyl)-N-(2- 416.1 3.07 61 30 H I ethoxy-3,4'-bipyridin-3' N ylN, )pyridine-2-carboxamide N O -amino-6-(2,6 SF difluorophenyt)-N-(2' 62N- 1 ydroxy-5'-methyl-4,4'- 434.0 2.22 62 H3C H ________ _ NH ipyridin-3-yl)pyridine-2 N 0N2 carboxamide N F -amino-6-(2 fuorophenyl)-N-(3' 613 HC N~ I ethyl-4,4'-bipyridin-3- 400.1 2.31 N HO N F 3-amino-6-(2 614~ flIuorophenyl)-N-(2'- 420 22 614 H N- I h~ydroxy-4,4'-bipyridin-3- 420 22 N N F 3-amino-N-(3'-chloro-4,4' 615 - Nipyridin-3-yl)-6-(2 61 l H Nfuorophenyl)pyridine-2- 420.1 3.02 NN Ny carboxamide N NH 2 N N F 3-amino-N-(3'-fluoro-4,4' 616 F ipyrdin-3-yi)-6-(2 H I fuorophenyl)pyridine-2- 441 29 A carboxamide N 0 NH, -225- Exam le Structure Name MH+ LC

H

2 N N FI F 3-amino-N-(2'-amino-4,4' *' F F 617 Nbipyridin-3-yI)-6-(2,6 617 N- 419.1 2.09 H difluorophenyl)pyridine-2 0 NH 2 carboxamide N 2 N N F F -amino-N-(2'-cyano-4,4' 618 N ipyridin-3-yl)-6-(2,6- 429.1 2.93 H I difluorophenyl)pyridine-2 N N o NH carboxamide N 2 METHOD 29 Synthesis of 3-amino-N-(4-(6-aminopyrazin-2-yl)pyridine-3-yl)-6-(2 fluorophenyl)picolinamide

H

2 N N F N / N;0 H N NH,, 5 N N2 [0405] A solution of 3-amino-N-(4-chloropyridin-3-yl)-6-(2,6-difluoro phenyl)picolinamide (1.0 equiv.), bis(pinacolato)diboron (2.0 equiv.), Pd(dppf)C1 2 -DCM (0.10 equiv.), KOAc (2.0 equiv.) in dioxane (0.19 M) was stirred in the microwave for 5 min at 120 'C then 10 min at 120 *C. The reaction was filtered and concentrated. To the 10 crude was added 6-chloropyrazin-2-amine (2.0 equiv.) and more Pd(dppf)C1 2 -DCM (0.10 equiv.) in DME/2M Na 2

CO

3 (3:1, 0.1M). The reaction was heated to 100 "C in the oil bath for 2 hrs. Cooled to room temperature, added H 2 0 and EtOAc, the organic layer was extracted, dried with brine and Na 2

SO

4 , and concentrated. The crude mixture was purified via reverse-phase HPLC and the pure fractions were lyophilized to give 3-amino 15 N-(4-(6-aminopyrazin-2-yl)pyridine-3-yl)-6-(2-fluorophenyl)picolinamide as the TFA salt in 19% yield. LCMS (m/z): 402.1 (MH*); LC Rt = 2.58 min. [0406] The following compounds were prepared using Method 29: -226- Example Structure Name MH+ LC 'NC NN -arnino-N-(2'-amino-6 t H~C N NH ethyl-4,4'-bipyridin-3-yI)-6 619 N~ , ,F 2,-difluorophenyl)-5- 412 22 Ny 'N uoropyridine-2 N 0 H2 carboxamide C3N NH -Amino-6-(2,6-difluoro N F F phenyl)-pyridine-2 620 H - Narboxylic acid (6'-amino-2'- 447.1 2.34 H e thyl -[4,4'] bipyridinyl-3 -yI) - NH 2 mide NT__NH_2 F F 'N-amino-N-[2'-chloro-6' F1N_ CI1 F: F (trifluoromcthyl)-4,4' IF 621 HN- ipyridin-3-yI]-6-(2,6- 506.1 3.75 N dNifluorophenyl)pyridine-2 NH 2 arboxamide NH 2 6H NH 2 I -Amino-6-(2,6-difluoro N F F henyl)-pyridine-2 622 H N carboxylic acid (6-amino-4- 449.1 2.46 H methoxy-[2,4']bipyridinyl-3' N NH, H___N_ N NH 1)-amide

H

2 N F -amino-N-(2 -amino-6' 623 m~ethyl-4,4'-bipyridin-3-yl)-6- 431 22 H ~~2,6-di fluorophenyl)pyri dine- 431 22 N 0 NH-carboxamide N N 2

H

2 N N CH3 ..- amino-N-(2'-amino-6' 624 methy1-4,4bipy 7 Ti-din3yI)-6 20 2 624 H (~2-fluorophenyl)pyridine-2- 2.0 22 Ny~y arboxamide N 2 H H 2 N N - F 3-amino-N-[4-(6-amino 625N pyrazin-2-yI)pyridin-3-yI]-6 65H NI 2-fluorophenyl)pyridinc-2- 402.1 2.58 -rPI arboxamide N' NH 2 ( ' -amino-N-[4-(2-amino-6 H, NrH ethylpyrimidin-4-yl) 626 N HN ~ yridin-3-yi]-6-(2-fluoro- 416.1 2.62 N 'Ny henyl)pyridin12 N 0 NH 2 arboxamidc -227- Example Structure Name MH+ LC H N'H 3-amino-N-[4-(2,6 H2N 2 F diaminopyrimidin-4 627 N N' yI)pyridin-3-yl]-6-(2- 417.0 2.13 H Y I N fluorophenyl)pyridine-2 N O NH2 Carboxamide 3-amino-N-[4-(2 HN N F F aminopyrimidin-4-yl)pyridin 628 N H N 3-yl]-6-(2,6- 420.1 2.51 N difluorophenyl)pyridine-2 N O NH2 Carboxamide H 3-amino-N-[4-(6

H

2 N N F F aminopyrimidin-4-yl)pyridin 629 N H N 3-yl]-6-(2,6-difluoro- 420.1 2.56 N phenyl)pyridine-2 N O NH2 carboxamide N F - F 3-amino-N-(2-amino-3,4' 630 HN H Nipyridin-3'-yl)-6-(2,6 630 H2N N 419.1 2.12 N difluorophenyl)pyridine-2 | Ocarboxamide N 2 METHOD 30 Synthesis of (s)-3-amino-N-(4-(3-aminopiperidin- I -yl)pyridine-3-yl) 6-cyclohexylpicolinamide

H

2 N N N H N/ 5 N NH 2 104071 A solution of (S)-tert-butyl 1-(3-(3-amino-6-bromo picolinamido)pyridin-4-yl)piperidin-3-ylcarbamatc (1.0 cquiv.), cyclohexylzinc bromide (0.5 M solution in THF, 3.0 equiv), Pd 2 (dba) 3 (0.1 equiv.), and P(2-furyl) 3 (0.2 equiv.) were heated to 65 C for 18 hrs. Two more equivalents of zinc bromide reagent were 10 added if the reaction was not complete after 18 hrs. The mixture was cooled to rt and concentrated to give the crude material. The crude mixture was then stirred in DCM/TFA -228- (25%) until completion. Concentrated the reaction to dryness and purified via reverse phase HPLC. The pure fractions were lyophilized to give the TFA salt product (40%). LCMS (m/z): 395.3 (MH*); LC R, = 2.34min. Synthesis of 3-amino-N-(4-(6-amino-2-(trifluoromethyl)pyimidin-4-yl)pyridin-3-Y)-6 5 (thiazol-2-yl)picolinamide

F

3 C N NH 2 No S N N H | N N

NH

2 [04081 Following method 30, a solution of tert-butyl 6-(3-(3-amino-6 bromopicolinamido)pyridine-4-yl)-2-(trifluromethyl)pyrimidin-4-ylcarbamate (1.0 equiv.), 2-thiazolyl-zincbromide (3.5 equiv.), and Pd(dppf)C 2 -DCM (0.10 equiv.) in THF 10 was microwaved at 100 C for 15 min. The reaction was concentrated to dryness under vacuo, then stirred in DCM/TFA (25%) for two hours. Upon concentration and purification via reverse phase HPLC, 3-amino-N-(4-(6-amino-2-(trifluoro methyl)pyrimidin-4-yl)pyridin-3-yl)-6-(thiazol-2-yl)picolinamide was obtained as the TFA salt in 48% yield. LCMS (nz/z): 459.1 (MH); LC R, = 2.46 min. 15 104091 The following compounds were also prepared using Method 30: Example Structure Name MH+ LC Chiral G"NH2 S N N- {4-[(3S)-3-amino 631 N Nipedin-I-yl]pyiidin-3-yl}- 381.1 1.54 H 6-(1,3-thiazol-2-yl)pyridine NO 2-carboxamide 0 ChIrsi

,%NH

2 S AN 3-amino-N- {4-[(3S)-3 632 N N ~ aminopiperidin- 1 -yl]pyridin- 396.1 1.56 3-yl}-6-(1,3-thiazol-2-yl) N ONH pyridine-2-carboxamide 2 -229- Example Structure Name MH+ LC F F N NH 2 3-Amino-6-cyclohexyl F N ' pyridine-2-carboxylic acid 633 N H N [4-(6-amino-2-trifluoro- 457.9 3.44 N methyl-pyrimidin-4-yl) | /

NH

2 pyridin-3-yl]-amide

CH

3

CH

3

H

2 N 3-Amino-6-(1 -ethyl-propyl) pyridine-2-carboxylic acid 634 N H N (3-amino-3,4,5,6-tetrahydro- 383.2 2.44 N 2H-[1,4']bipyridinyl-3'-yl) NH2 amide ______ NNH 2

H

2 N 6-Cyclohexyl-pyridine-2 carboxylic acid (3-amino 635 N H N - 3,4,5,6-tetrahydro-2H- 380.2 2.24 NN [1,4']bipyridinyl-3'-yl) (I -amide

H

2 N 3-Amino-6-cyclohexyl pyridine-2-carboxylic acid 636 N H N (3-amino-3,4,5,6-tetrahydro- 395.3 2.34 N 2H-[ 1,4']bipyridinyl-3'-yi) |

NH

2 amide H2N

H

3 3-amino-N- {4-[(3S)-3 637 N H N aminopiperidin-I-yl]pyridin- 327.1 1.38 N 3-yl}-6-methylpyridine-2 0 NH carboxamide HN2 3-amino-N-{4-[(3S)-3 638N N' aminopiperidin-1-yl]pyridin N 3-yi)-6-cyclopropyl H2 pyridine-2-carboxamide

H

2 N

CH

3 3-amino-N-{4-[(3S)-3 639 N H N aminopiperidin-l-yl]pyridin- 341.1 1.59 ).N 3-yl}-6-ethylpyridine-2 0 NH carboxamide N 2 FF F2 FF NN2 S, N 3-aminO-N-[2'-amino-6' Ftrifluoromethyl)-4,4' 640 H N bipyridin-3-yl]-6-(1,3- 458.1 2.59 N thiazol-2-yl)pyridine-2 N 0 NH 2 rarboxamide N1 -230- Example Structure Name MH+ LC

H

2 C N H 2 S .N -amino-N-(2'-amino-6' 641 -H N methyl-,-byrdn3y) 404.1 1.79 N 6 -(I,3-thiazol-2-yI)pyridine -0 NH -carboxamide NH2 F F- NNH 2 s -amino-N-{4-[6-amino-2 F NI ~ triflucromcthyl)pyrimidin 642 H N' -yI]pyridin-3-yl}-6-(1,3- 459.1 2.46 N t hiazol-2-yl)pyridine-2 N 0 H2 carboxamide H3C- NH2N S -amino-N-[4-(6-amino-2

H

3 Cy NH 2 N~ S ethylpyrimidin-4 643 H N1y)pyridin-3-yI]-6-(I,3- 405.0 1.74 N t hiazol-2-yl)pyridine-2 N 0N2 carboxamide

H

2 N -Amino-6-cyclopentyl pyridine-2-carboxylic acid 644 N N 3-amino-3,4,5,6-tetrahydro- 381.3 2.13 N 2H-[ I ,4']bipyridinyl-3'-yi) N NH 2 mide

H

2 N 6-Adamantan- I -yI-3-amino **,*-n yridine-2-carboxylic acid 645 KN N. 3-amino-3 ,4,5 ,6-tctrahydro- 447.2 2.70 N 2H-[ 1,4 t ]bipyridinyl-3'-yl) amide N

NH

2

H

2 N 3-Amino-6 bicyclo[2.2. I ]hept-2-yI 646 KN)N..~~. yridine-2-carboxylic acid 472 23 H ( 3-amino-3,4,5,6-tetrahydro N 2H-[ I ,4']bipyridinyl-3'-yI) _____N

NH

2 amide F-N~ NH 2 S AN N-{4-[6-amino-2-(trifluoro 647 FN I H N ~ ethyl)pyrimidin-4-yl]- 444.1 2.67 N pyii-'y 6(,3tizl ______ _ N~ ~-yI)pyridine-2-carboxarnide -231- Synthesis of 4-chloro-6-methylpyridin-2-amine

NH

2 C1 [04101 To a 10% aqueous solution of dioxane (0.1 M) was added 4,6 dichloropyridin-2-amine (1.0 equiv.), trimethylboroxine (1.5 equiv.), Pd(PPh 3

)

4 (0.10 5 equiv.) and K 2

CO

3 (3.0 equiv.). The solution was heated in an oil bath to 120 C for 18 hrs, cooled to room temperature (not all of starting material was consumed), extracted with EtOAc, dried with Na 2

SO

4 , and concentrated. The crude material was purified via SiO 2 column chromatography eluting with 5% McOH/DCM to yield an off-white solid in 23% yield. LCMS (n/z): 143 (MH*); LC R, = 1.11 min. 10 Synthesis of 6-methyl-3'-nitro-4,4'-bipyridin-2-amine N

NH

2

NO

2 N 104111 To a solution of 4-chloro-6-methylpyridin-2-amine (1.0 equiv.) in dioxane was added bis(pinacolato)diboron (2.0 equiv.), Pd 2 (dba) 3 (0.05 equiv.), PCy 3 (0.075 equiv.), and KOAc (3.0 equiv.). The reaction was heated for 3 hrs at 110 *C, then 15 filtered, and concentrated. The crude material was dried under vacuo, then dissolved in DME/2M Na 2

CO

3 (3:1), 4-chloro-3-nitropyridine (2.0 equiv.) was added, followed by Pd(dppf)C1 2 -DCM (0.1 equiv.). The mixture was heated to 120 "C for I hr, then EtOAc and H 2 0 were added, the organic phase was removed, dried with Na 2

SO

4 , and concentrated. Purification via SiO 2 column chromatography cluting with EtOAc yielded 20 6-methyl-3'-nitro-4,4'-bipyridin-2-amine in 35% yield. LCMS (mn/z): 231.1 (MH*) LC Rt = 1.47 min. -232- Synthesis of 6-ethyl-N,N-di-BOC-3'-nitro-4,4'-bipyridin-2-amine N NBOC 2

NO

2 N [04121 To a solution of 6-methyl-3'-nitro-4,4'-bipyridin-2-amine in THF (0.09M) was added BOC 2 0 (2.2 equiv.), Et 3 N (2.5 equiv.), and DMAP (cat.). After 5 5 hrs, the solution was concentrated and filtered through a plug of SiO 2 eluting with EtOAc to yield 6-ethyl-N,N-di-BOC-3'-nitro-4,4'-bipyridin-2-amine in >95% yield. LCMS (n/z): 431.1 (MH 4 ); LC R = 4.29 min. Synthesis of 6-ethyl-N2,N2-di-BOC-4,4'-bipyridine-2,3'-diamine N NBOC 2

NH

2 N 10 10413] To a solution of 6-methyl-N,N-di-BOC-3'-nitro-4,4'-bipyridin-2-amine in EtOH/EtOAc (1:1, 0.2M) was added Pd/C (10 % by weight) and the reaction was stirred under a H 2 balloon for 18 hrs. Filtered through Celite, washed with EtOAc and concentrated the filtrate to afford 6-ethyl-N 2

,N

2 -di-BOC-4,4'-bipyridine-2,3'-diamine in >95% yield. LCMS (m/z): 401.0 (MH*); LC Rt = 2.81 min. 15 Synthesis of 3-amino-6-bromo-N-(2'-(di-BOC-amino)-6'-methyl-4,4'-bipyridin-3 yllpicolinamide N

NBOC

2 Br N ' H N | NN N NH 2 [0414] Method 27 was followed using 6-methyl-N 2

,N

2 -di-BOC-4,4' bipyridine-2,3'-diamine (1.0 equiv.), 3-amino-6-bromopicolinic acid (1.0 equiv.), EDC 20 (1.0 equiv.), HOAt (1.0 equiv.) in NMP (0.48M) to yield 3-amino-6-bromo-N-(2'-(di -233- BOC-amino)-6'-methyl-4,4'-bipyridin-3-yl)picolinamide (35%). LCMS (m/z): 599.1/601.1 (MH*); LC R, = 3.69 min. Synthesis of 4-chloro-6-ethylpyridin-2-amine

H

2 N N CI 5 10415] To a solution of 4,6-dichloropyridin-2-amine (1.0 equiv.) in THF (0.1M) was added Pd(dppf)C1 2 -DCM (0.1M), K 2

CO

3 (3.0 equiv.), and Et 2 Zn (1.2 equiv.). The reaction was heated to 70 C for 18 hrs. Upon cooling to room temperature,

NH

4 Cl(sat.) was added, the mixture was extracted with EtOAc, dried with Na 2

SO

4 , and concentrated. The crude material was purified via SiO 2 column chromatography eluting 10 with DCM/MeOH (2%) to yield 4-chloro-6-cthylpyridin-2-amine in 33% yield. LCMS (n/z): 157.1 (MH 4 ). Synthesis of 4-chloro-6-ethyl-NN-di-BOC-pyridin-2-amine

NBOC

2 Cl 10416] Method 24 was followed using 4-chloro-6-ethylpyridin-2-amine (1.0 15 equiv.), BOC 2 0 (2.0 equiv.), and DMAP (cat.) in DCM to yield 4-chloro-6-ethyl-NN-di BOC-pyridin-2-amine (27% yield). LCMS (m/z): 357.1 (MH); LC R, = 4.11 min. Synthesis of 6-ethyl-NN-di-BOC-4 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine N NBOC 2 O B 20 All [04171 A solution of 4-chloro-6-ethyl-NN-di-BOC-pyridin-2-amine (1.0 equiv.), bis(pinacolato)diboron (2.0 equiv.), Pd 2 (dba) 3 (0.05 equiv.), PCy 3 (0.075 equiv.), -234- KOAc (2.0 equiv.) in dioxane (0.19 M) was degassed by bubbling nitrogen through for 10 min in a round-bottomed flask. The flask was heated to 90 *C for 3 hours, cooled to room temperature, filtered through activated charcoal and Celite and washed with EtOAc. Upon concentration of the filtrate, a thick dark brown crude 6-ethyl-NN-di-BOC 5 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine. LCMS (m/z): 367.1 (MH* for the corresponding boronic acid). Synthesis of 3-amino-N-(2'-amino-6'-fluoro-4,4'-bipyridin-3-yl)-6-(2,6 difluorophcnyl)picolinamidc

H

2 N N F F F N H N N NH 2 10 104181 A solution of 3-amino-N-(2',6'-difluoro-4,4'-bipyridin-3-yl)-6-(2,6 difluorophenyl)picolinamide (1.0 equiv.) in NMP and NH 4 0H (2:3, 0.05M) was heated in the microwave at 120 C for 8 min. The mixture was directly purified via reverse phase HPLC to afford 3-amino-N-(2'-amino-6'-fluoro-4,4'-bipyridin-3-yl)-6-(2,6 difluorophenyl)picolinamide as the TFA salt. LCMS (n/z): 437.1 (MH); LC Rt = 2.79 15 min. Synthesis of 5-amino-N-(2'-amino-6'-methyl 4,4'-bipyridin-3-yl)-3'-fluoro-2,2'-bipyridine-6-carboxamide

H

2 N N N- F N;0 H N N NH 2 104191 To a solution of degassed dioxane (0.03M) was added 3-amino 20 6-bromo-N-(2'-(di-BOC-amino)-6'-mcthyl-4,4'-bipyridin-3-yl)picolinamidc (1.0 equiv.), bis(pinacolato)diboron (2.0 equiv.), Pd 2 (dba) 3 (0.05 equiv.), PCy 3 (0.075 equiv.), and KOAc (3.0 equiv.). The solution was heated to 90 C for 16 hrs until all starting material -235was consumed. Filtered the reaction and concentrated the filtrate. The crude was dried under vacuo, then dissolved in DME/2M Na 2

CO

3 (3:1, 0.05M), followed by addition of 2-bromo-3-fluoropyridine (2.0 equiv.) and Pd(dppf)C1 2 -DCM (0.10 equiv.). The reaction was heated to 100 *C in an oil bath until consumption of the boronic ester. Cooled to 5 room temperature, added H 2 0 and EtOAc, the organic phase was washed with brine, then dried with Na 2

SO

4 , and concentrated. The crude material was purified via SiO 2 column chromatography eluting with EtOAc and hexanes (1:1) and the pure product was concentrated and stirred in DCM/TFA (25%) until completion of the deprotection. The reaction was concentrated to dryness and purified via reverse phase HPLC to afford 10 5-amino-N-(2'-amino-6'-methyl-4,4'-bipyridin-3-yl)-3'-fluoro-2,2'-bipyridine-6 carboxamide. LCMS (m/z): 416.2 (MH*); LC R 1 = 1.77 min. METHOD 31 Synthesis of 3-amino-N-(4-(6-amino-2-(trifluoromethyl) pyrimidin-4-yl)pyridin-3-yl)-6-(thiazol-4-yl)picolinamide .f-s

H

2 N N CF 3 N N N H | N N 15 N NH 2 [0420] A solution of tert-butyl 6-(3-(3-amino-6-bromopicolinamido)pyridine 4-yl)-2-(trifluromethyl)pyrimidin-4-ylcarbamate (1.0 equiv.), 4-(tributylstannyl)thiazole (3.0 equiv.), and Pd(PPh 3

)

4 (0.10 cquiv.) in dioxanc (0.1OM) was microwaved at a 120 'C for 10 min. The reaction was then purified directly via reverse phase HPLC and 20 lyophilized. The product was then stirred in DCM/TFA (25%) until completion of the deprotection, concentrated and purified via reverse phase HPLC and lyophilized to give 3-amino-N-(4-(6-amino-2-(trifluoromethyl)pyrimidin-4-yl)pyridin-3-yl)-6-(thiazol-4-yl) picolinamide in 14% yield as the TFA salt. LCMS (m/z): 459.1 (MH*); LC R, = 2.49 min. -236- Synthesis of (S)-3-amino-N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-6-(oxazol-2 yl)picolinamide H2N N N N H N N.. N NH 2 104211 Method 31 was followed using (S)-tert-butyl 1-(3-(3-amino 5 6-bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (1.0 equiv.), 2-(tributyl stannyl)oxazole (3.0 equiv.), and Pd(PPh3)4 (0.10 equiv.) in dioxane yielding (S)-3 amino-N -(4-(3 -aminopiperidin- 1-yl)pyridin-3 -yI)-6-(oxazol-2-yl)picolinamide in 55% yield as the TFA salt. LCMS (m/z): 380.1 (MH+i); LC Rt = 1.55 min. Synthesis of (S)-3-amino-N-(4-(3-aminopiperidin-1I-yl~pyridin-3-yl)-6 10 cyclopropylpicolinamide HN NIH N N N. N NH 2 [0422] Method 31 was followed using (S)-tert-butyl 1-(3-(3-amino 6-bromopicolinamido)pyridin-4-yl)piperidin-3-ylcarbarnate (1.0 equiv.), 2-cyclopropyl 4,4,5,5-tetramethyl-1,3,2-dioxaborolante (3.0 equiv.), and Pd(dppf)C1 2 -DCM (0.10 15 equiv.) at 140 *C for 10 mi yielding (S)-3-amino-N-(4-(3-arinopiperidin-1-yl)pyridin 3-yl)-6-cyclopropylpicolinamide in 8% yield. LCMS (m/z): 353.1 (MH*); LC R 1 = 1.59 min. -237- METHOD 32 Synthesis of 3-amino-N-(4-((3R,4R)-3-amino 4-hydroxypiperidin- 1 -yl)pyridin-3-yl)-6-(2,6-difluorophenyl)picolinamide OH H2N FI F F N N H N N N N NH 2 5 [0423] 3-amino-6-(2,6-difluorophenyl)picolinic acid and tert-butyl (3R,4R)-1 (3-aminopyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate were coupled following method 11 (example 249), to yield tert-butyl (3R,4R)-1-(3-(3-amino-6 (2,6-difluorophenyl)picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)pipendin 10 3-ylcarbamate after HPLC purification. Alternatively, tert-butyl (3R,4R)-l-(3-(3-amino 6-(2,6-difluorophenyl)picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy) piperidin-3-ylcarbamate could be obtained starting with tert-butyl (3R,4R)-1-(3-(3 amino-6-bromo-picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-yl carbamate and 2,6 difluorophenylboronic acid following the Suzuki procedure outlined in 15 method 14. The TBDMS deprotection of tert-butyl (3R,4R)-1-(3-(3-amino-6-(2,6 difluorophenyl)picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-yl carbamate was performed with 6N HCI, THF, methanol (1:2:1) at room temperature for 2 h. After volatile materials were removed, the crude material was stirred in 30% TFA in dichloromethane for 2 hours. After volatile materials were removed in vacuo, 20 purification and lyophilization yielded 3-amino-N-(4-((3R,4R)-3-amino-4-hydroxy piperidin- I -yl)pyridin-3-yl)-6-(2,6-difluorophcnyl)picolinamide. HPLC. LCMS (m/z): 441.2 (MH*); LC R, = 2.03 min. 104241 The following compounds were made using method 32: -238- Example Structure Name MH+ LC ,%OH Ciral -Amino-2-(2,6-difluoro F F phenyl)-pyrimidine-4 648 IHIN~ N carboxylic acid (3-hydroxy- 427.2 2.18 I1~ONH 3,,5,6tetrahydro-2H-[ 1,4']bi ,%OH -Amino-2-(2-fluoro-phenyl) F yrimidine-4-carboxylic acid LYYI H-[ 1 ,4']bipyridinyl-3'-yl) IN) 0 NH- 2 amide 4"Chiral 650 N .. NN -carboxylic acid (3-hydroxy- 312 23 650H I,4,5,6-tetrahydro-2H-[ I ,4']bi- 312 23 N YYI yridinyl-3'-yI)-amide IN 0 N2 0 CH 3 Cho 3-Amino-6-(2-fluoro-5 NIJIH, sopropylcarbamoyl-phenyl) 65] O F H nyrdine-2-carboxylic acid (3- 493.2 2.46 N HN 1 ydroxy-3 ,4,5 ,6-tetrahydro IAy11N 2H-[ 1 ,4']bipyridinyl-3'-yl) N'0 NH, amide 0,,OH~ 1 HC~a -Amino-6-(2,6-difluoro-3 JF F CH sopropoxy-phenyl)-pyridine 652 N N- 1 -carboxylic acid (3-hydroxy- 484.3 2.94 N 0 NH 2 pyridinyl-3'-yi)-amide Chiral 0 3-Amino-6-(2,6-difluoro F phenyl)-pyridine-2-carboxylic 653 H N; cid (3-hydroxy-3 ,4,5 ,6-tetra- 426.2 2.66 N N ydro-2H-[ 1,4']bipyridinyl-3' KN) 0 NH 2 1l)-amide ci CH 3-Amino-6-(5-chloro-2-fluoro 654 F -methyl-phenyl)-pyridine-2 64(N N carboxylic acid (3-hydroxy- 456.1 3.15 N . 3,4,5,6-tetrahydro-2H-[ 1,4']bi N H2 pyridinyl-3'-yI)-amide OH 3 -Amino-6-(3-chloro-2-fluoro TF phenyl)-pyridine-2-carboxylic 655 N HN;' cid (3-hydroxy-3,4,5,6-tetra- 442.1 2.96 yyydro-2H--[ I ,4']bipyridinyl-3' -239- Example Structure Name MH+ LC HN-O 3-Amino-6-(2-fluoro-5-phenyl 0 carbamoyl-phenyt)-pyridine-2 656 (,O F arboxylic acid (3-hydroxy- 527.2 2.88 3,4,5,6-tetrahydro-2H-[ 1,4']bi 0 NH, yridinyl-3'-yI)-amide HC. NCI 3-Amino-6-(5-dimethyl 657~ ~ F arbamoyl-2-fluoro-phenyl)- 492 22 657 CH F p~yridine-2-carboxylic acid (3- 492 22 (N HN' ydroxy-3 ,4,5 ,6-tetrahydro N~~ ~ 2H-[ I ,4']bipyridinyl-3'-yI) N amid IH 3-Amino-6-(2,6-difluoro F phenyl)-pyridine-2-carboxylic 658 N H:N- acid (3-hydroxy-3,4,5,6-tetra- 426.2 2.63 (JN hydro-2H-[ I ,4']bipyridinyl-3' N NH, 1)-amide Chiral OH -Amino-6-(2-fluoro-phenyl) ~ O 'F pyridine-2-carboxylic acid (3 659 CNH N- hydroxy-3,4,5,6-tetrahydro- 408.2 2.66 I~ Z H-[ 1 ,4']bipyridinyl-3'-yI) 1 )-0 NH 2 amide Chiral %OH 3-Amino-6-(2-fluoro-phenyl) O ~O -F pyridine-2-carboxylic acid (3 660 H N- hydroxy-3,4,5,6-tetrahydro- 408.2 2.65 rty-1 N 2~.H-[ I ,4']bipyridinyl-3'-yI) O N H 2 amie OH I -Amino-6-(2-fluoro-phenyl) A-I F pyridine-2-carboxylic acid (3 661 N~ N ydroxy-3,4,5,6-tetrahydro- 408.2 2.64 ~~2H-[ 1 ,4']bipyridinyl-3'-yI) N H2 amide OH 5-Amino-2-(2-fluoro-phenyl)

~

2 AF pyrim-idine-4-carboxylic acid 662 N 3-amino-4-hydroxy-3,4,5,6- 424.2 1.67 7 Ny.Z&)etrahydro-2H..[ I ,4']bi ______0 N 2 pyridinyl-3'-yl)-arnide OH -Amino-2-(2,6-difluoro !% NH~jIh.I F hnl-yiiie4 663 KN)N.~k. Ncarboxylic acid (3-amino-4- 422 15 663 N H N I N hydroxy-3,4,5,6-tetrahydro- 422 15 Y-YI H-[ 1 ,4']bipyridinyl-3'-yI) (N 2amide -240- Example Structure Name MH+ LC H3C *CH -Amino-6-(2,6-difluoro-3 OH 0.~H isopropoxy-phenyl)-5-fluoro (i.).sNF pyridine-2-carboxylic acid (3 664 mn-hyry-45 517.2 2.48 N I "I ydro-2H-[ I ,4']bipyridinyl-3' 0 NH, 1 )-amide HC _CH3 -Amino-6-(2,6-difluoro-3 OH ' 0 sopropoxy-phenyl)-pyridine 665 -31YN HI& F 2-carboxylic acid (3-amino-4- 492 23 N .~ ydroxy-3,4,5 ,6-tetrahydro- 492 23 N 2 H-[ 1,4']bipyridinyl-3'-yl) NO aHmide H3C ' CH3 -Amino-6-(2,6-difluoro-3 H, 0 i-H sopropoxy-phenyl)-5-fluoro 666 0o~ q1" F pyrdine-2-carboxylic acid (4- 572 24 66 HNyF amino-3-hydroxy-3,4,56-tetra- 572 24 N yy_ ydro-2H-[ 1 ,4']bipyridinyl-3' ________0 NH,____________ 1)- amid e H3C rCH3 -Amino-6-(2,6-difluoro-3 NH ; 0 sopropoxy-phenyl)-pyri dine 667 F'' 2-carboxylic acid (4-amino-3- 499.2 2.36 N N ydroxy-3 ,4,5 ,6-tetrahydro 2H-[ 1 ,4']bipyridinyl-3'-yI) N 0 NH, amide HC NH -Amino-6-(2-fluoro-5 hC NH sopropylcarbamoyl-phcnyl) 668 0 pyridine-2-carboxylic acid (4 668 N'%" mino-3-hydroxy-3 ,4,5 ,6-tetra- 508.3 1.96 NX hydro-2H-[ 1 ,4']bipyridinyl-3' ________0 ______________ yl)-amide OH2 S -Amino-6-thiazol-2-yl LI pyrdinc-2-carboxylic acid (3 669 N HN a~mino-4-hydroxy-3,4,5,6-tetra- 412.1 1.48 N ydro-2H-[ 1,4']bipyridinyl-3' 0 2H 1l)-arnide %H 2 -Amino-2-phenyl-pyrimidine 4-carboxylic acid (3-amino-A 670 N H N N ydroxy-3,4,5,6-tetrahydro- 406.2 1.72 (tr Y' H-[ 1 ,4']bipyridinyl-3'-yl) 'J . -Amino-6-(2-fluoro-5 Hi,C NH isopropylcarbamoyl-phenyl) 671 OH N 0 yridine-2-carboxylic acid (3- 583 20 N amino-4-hydroxy-3,4,5,6-tetra- 583 20 N ydro-2H-[ I ,4']bipyridinyi-3' N H )-md -241- Example Structure Name MH+ LC Chiral HOO,~ I-Amino-6-(2,6-difluoro -I?-H~ F phenyl)-pyridine-2-carboxylic 672 NH I acid (3-amino-5-hydroxy- 441.2 1.89 N yy ,4,5,6-tctrahydro-2H-[ 1 ,4']bi ____0_ NH yridinyl-3'-yI)-amide CH3 I-Amino-2-(2,6-difluoro (-NIFF - F phcnyl)-pyrimidinc-4 673 N HNv N carboxyl ic aci d (3-amino-3- 440.1 1.76 N methyl-3 ,4,5,6-tetrahydro-2H 0NH, [I,4']bipyridinyl-3'-yl)-amide CH I -Amino-6-(2-fluoro-phenyl) &yNH, F pyridine-2-carboxylic acid (3 64N N- 'mino-3-methyl-3,4,5,6-tetra- 421.2 2.13 N ydro-2H-[ I ,4']bipyridinyl-3 0oH y-amino6(2fuoo5 N N * sopropylcarbamoyl-phenyl) 675 OLN, HC' CH, pyri dine-2-carboxylic acid (3- 562 20 N N mino-3-methyl-3 ,4,5 ,6-tetra- 562 20 N 0 H2 ydro-2H-[ I ,4']bipyridinyl-3' N y)-amide ___ CH, 5~.-Amino-2-(2-fluoro-phcnyl) (yNk 2 NF pyrimidine-4-carboxylic acid 676 N HN N (3-amino- 3-methyl-3 ,4,5,6- 422.1 1.73 N tetrahydro-2H-[ 1 ,4']bi 0No H2 pyrdinyl-3'-yl)-amide o 3-Amino-6-(2-fluoro-5 I.N CH 3 isopropylcarbamoyl-phenyl) HO,~~~~~ "NH yiic2cabxcai 3 677 0 F508.1 1.89 N H N mino-5-hydroxy-3,4,5 ,6-tetra I ydro-2H-[ I ,4']bipyridinyl-3' KN 0 N 2 1l)-amide____ Chi "I 3-Amino-6-(2-fl uoro-phenyl) HO CSNH 2 F pyridine-2-carboxylic acid (5 678 N N' Hmino-3-hydroxy-3,4,5,6-tetra- 423.2 1.87 Ny hydro-2H-[ 1 ,4']bipyridinyl-3' 0 N2 1l)-amide OH 3-Amino-6-(2,6-difluoro H2 N4C F F phenyl)-pyridine-2-carboxylic 679 N HN acid (3-arnino-4-hydroxy- 441.2 2.04 N 3,4,5,6-tetrahydro-2H-[ I ,4']bi ________0 t.NONH, pyrdinyl-3'-yl)-amide -242- Example Structure Name MH+ LC OH -Amino-6-(2,6-difluoro FH2,( F phenyl)-pyridine-2-carboxylic 680 N H N acid (3-amino-4-hydroxy- 441.2 2.04 N y i- ,4,5,6-tetrahydro-2H-[ I ,4']bi N 0 H2 pyridinyl-3'-yl)-amide Chiral HO N -Fluoro-6-phenyl-pyridine-2 2 **, arboxylic acid (3-amino 681 NKN F hydroxy-3,4,5 ,6-tetrahydro- 408.1 1.99 H 2H-[ I ,4']bipyridinyl-3'-yl) N Chiral OH H2N -Fluoro-6-(2-fluoro-phenyl) F pyridine-2-carboxylic acid (3 682 NK) F amino-4-hydroxy-3,4,5 ,6-tetra- 426.1 2.01 N N o; y1)-amide Chiral HO N-(2,6-Difluoro-phenyl)-5 2T~~j F F uoro-pyridinc-2-carboxylic 683 N N F acid (3-arnino-4-hydroxy- 444.1 1.99 H 3,4,5,6-tetrahydro-2H-[1,4']bi pyrny-3'-yI)-amide Chiral NH 0/ -Fluoro-6-(2-fluoro-phcnyl) \N2 F pyridine-2-carboxylic acid (5 684 CK) , F amino-3-hydroxy-3,4,5,6-tctra- 426.1 1.89 N 1l)-amide Chiral Io/ H -Amino-6-(2-fluoro-5 10 AH F propoxy-phenyl)-pyridine-2 F arboxylic acid (5-amino-3 6:85481. 2.N 68 H N ydroxy-3,4,5,6-tetrahydro- 411 23 NN H-[ I ,4']bipyridinyl-3'-yI) _ _ _ _~~ NH 2 _ _ _ _ _ _ _ _ _ _ _ _ -243- METHOD 33 Synthesis of (S)-tert-butyl 1-(3-(3-amino-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 yl)picolinamido)pyridin-4-vl)piperidin-3-vlcarbamate BocHNsB N H N' N H| N N N NH 2 5 104251 A solution of (S)-tert-butyl 1-(3-(3-amino-6-bromo picolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (1.0 eq), bis(pinacolato)diboron (2.0 cquiv.), KOAc (3 equiv.), triscyclohcxylphosphinc (0.075 eq.) in dioxane (0.16 M) was degassed by bubbling argon through for 10 min at which time Pd 2 (dba) 3 (0.05eq.) was added. The glass vessel was sealed and heated at 90 C for 3 hours, cooled to room 10 temperature, filtered, washed with EtOAc and concentrated to give a thick dark brown crude product which was used as is. LCMS (m/z): 457.2 (MH* for the corresponding boronic acid). Synthesis of (S)-tert-butyl 1-(3-(3-amino-6-bromo-5-fluoropicolinamido)pyridin-4 yl)piperidin-3-ylcarbamate BocHN Br N N' F N H | 15 N NH 2 10426 Following Method 11 of Example 305, (+/-)-tert-butyl 1-(3 aminopyridin-4-yl)-4-fluoropiperidin-3-ylcarbamate and 3-amino-6-bromo-5-fluoro picolinic acid were reacted yielding (S)-tert-butyl 1-(3-(3-amino-6-bromo-5-fluoro picolinamido)pyridin-4-yl)piperidin-3-ycarbamate (40%). LCMS (m/z): 509.0 (MH*), 20 LC R, = 3.04 min. Synthesis of (S)-tert-butyl 1-(3-(3-amino-5-fluoro-6-(4,4,5,5-tetramethyl- 1,3,2 dioxaborolan-2-yl)picolinamido)pyridin-4-yl)piperidin-3-ylcarbamate -244- BocHN nB' N N' F H | N NH N

NH

2 104271 Starting with (S)-tert-butyl 1-(3-(3-amino-6-bromo-5-fluoro picolinamido)pyridin-4-yl)piperidin-3-ycarbamate, method 33 was followed yielding (S)-tert-butyl 1-(3-(3-amino-5-fluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) 5 picolinamido)pyridin-4-yl)piperidin-3-ylcarbamate. LCMS (m1/z): 475.2 (MH' for the corresponding boronic acid); LC R,= 2.16 min. Synthesis of tert-butyl (3R,4R)-1-(3-(3-amino-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan 2-yl)picolinamido)pyridin-4-yi)-4-(tert-butvldimethylsilyloxyTiperidin-3-vlcarbamate OTBDMS BocHN sB' N N/ N N N NH 2 10 104281 Starting with tert-butyl (3R,4R)-1-(3-(3-amino-6-bromo-picolinamido) pyridin-4-yl)-4-(tert-butyldimcthylsilyloxy)piperidin-3-ylcarbamate, method 33 was followed yielding tert-butyl (3R,4R)-1-(3-(3-amino-6-(4,4,5,5-tetramethyl-1,3,2 dioxaborolan-2-yl)picolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3 ylcarbamate. LCMS (m/z): 587.3 (MH* for the corresponding boronic acid). 15 METHOD 34 Synthesis of (S)-5-amino-N-(4-(3-aminopiperidin- I -vl) pyridin-3-vl)-2,2'-bipyridine-6-carboxamide H2N N N H N N N N N

NH

2 -245- [04291 A solution of (S)-tert-butyl 1-(3-(3-amino-6-(4,4,5,5-tetramethyl-1,3,2 dioxaborolan-2-yl)picolinamido)pyridin-4-yl)piperidin-3-ylcarbamate (1.Oeq), 2-bromo pyridine (1.0 eq) and Pd(dppf)C1 2 -DCM (0.10 equiv.) in 3:1 dimethoxyethane/2M Na 2

CO

3 was heated in the microwave at I I 0 C for 15 minutes. The organic layer was 5 separated, the volatiles were removed in vacuo and the crude material was purified by RP HPLC to yield the N-Boc product after lyophilization. The Boc group was removed by treating with 25% TFA/CH 2

CI

2 for 2 hours. After removal of volatiles in vacuo, purification by RP HPLC and lyophilization (S)-5-amino-N-(4-(3-aminopiperidin-1-yl) pyridin-3-yl)-2,2'-bipyridine-6-carboxamide was obtained (12%). The free base and 10 HCI salt can be obtained as described in Method 9 (Example 115). HPLC. LCMS (m/z): 390.2 (MH'); LC Rt = 1.11 min. HCI salt, 1 H NMR (DMSOd 6 ): 6 10.46(s, 1H), 9.15(s, IH), 8.61-8.65(m, IH), 8.44-8.47(m, IH), 8.34(d, J=9.0Hz, 2H), 7.90-8.05(m, 3H), 7.41(d, J=8.7Hz, 2H), 7.22-7.33(m, 3H), 2.75-3.60 (m, 5H), 1.20-1.95(m, 4H). [0430] For compounds prepared using method 34 that contained hydroxyl 15 functionalities, the silyl protecting groups were removed prior to Boc removal as described in Method 32. 104311 The following compounds were prepared using method 34: Example Structure Name MH+ LC 3-Amino-6-(4-cyano-2-fluoro FNH phenyl)-pyridine-2-carboxylic 686 acid (3-amino-3,4,5,6-tetra- 432.2 2.15 N N Iydro-2H-[1,4']bipyridinyl-3' O NH2 I)-amide CH3 ChrA HC 3-Amino-6-[2-fluoro-5-(3 methyl-but- 1 -enyl)-phenyl] 687 'fNH pyridine-2-carboxylic acid (3- 475.2 2.83 N N amino-3,4,5,6-tetrahydro-2H N NH, [1,4'bipyridinyl N Chiral 0,.%NH2 S / 3-Amino-6-thiazol-5-yl 688 N N pyridine-2-carboxylic acid (3- 396.1 1.52 ( H I amino-3,4,5,6-tetrahydro-2H N O NH2 [1 ,4']bipyTidinyl-3'-yl)-amide N 2 -246- Example Structure Name MH+ LC 0 CH 3~ 3-Amino-6-[2,6-difluoro-3 N :11 INCH3 (isopropyl-methyl-carbamoyl) 689 F CH henyl]-pyriidine-2carboxylic 54322 N N- Iacid (3-amino-3,4,5,6-tetra N hydro-2H-[1 ,4']bipyridinyl-3' N 0 NH, yl)-amide_______ OH 5NI-Amino- 3'-fluoro-[2,2 "bi K) yridinyl-6-carboxylic acid (3 690 N NH Iydroxy-3,4,5,6-tetrahydro-2H- 409.2 1.72 y N [1,4']bipyridinyI-3'-yl)-amide N 0 2N o NH.Chira I 5'-Amino-[2,2']bipyridinyl-5,6' 691 .NH 2 N dicarboxylic acid 5-amide 6'-[(3- 433.2 1.30 No N ~ amino-3,4,5 ,6-tetrahydro-2H NH2 Chrl3-Amino-6-isoquinolin-4-yI 692 N~~~ yridine-2-carboxylic acid (3- 40215 Nz-AN,, amino-3 ,4 ,5,6-tetrahydro-2H KNJ ~ H, [I,4']bipyridinyl-3'-yI)-arnide Chirral Cu%~NH 2 N: N5-Amino- I'-oxy-[2,2']bi 693 N N ~ ~ ~ lcroxlcai 3 406.2 1.37 H amno-,4,5 ,6-tetrahydro-2H ~ NH [I,4']bipyridinyl-3'-yI)-amide N 2, 0 H 1 1 l"N.sNH N CH,- Ch ira 3-Amino-6-(3-methoxy-pyrazin 694NH N -- 0-yl)-pyridine-2-carboxylic acid 41217 694 N H N- ~ (3-amIno-3,4,5,6-tetrahydro-2H- 41217 [1,4']bipyridinyl-3'-yI)-amidc: r 5 -Amino-6'-benzyloxy-[2,2']bi 695 N N yridinyl-6-carboxylic acid (3- 496.3 2.77 ( I [I ,4']bipyridinyl-3'-yI)-amIde ,CH.Ch~ra I 5-Amino-5'-methoxy-[2,2']bi 696 01yNH N pyrdinyI-6-carboxylic acid (3- 420.2 1.38 N H Namino-3,4,5 ,6-tctrahydro-2H N[1 ,4']bipyridinyl-3'-yl)-amide -247- Example Structure Name MH+ LC rl) Chiral NF1 2 N ' ~-CH 3 5-AmIno-3'-methoxy-[2,2']bi 697 NH Npyridinyl-6-carboxylic acid (3 NH amino-3,4,5,6-tetrahydro-2H- 40212 ~ NH 2 1,4']bipyridinyl-3'-yI)-amidc CH, C,,J Uz =o 5 -Amino- 5'-methanesulIfonyl NHN [2,2']bipyridinyl-6-carboxylic 698 (yN2acid (3-amino-3,4,5,6-tetra- 468.2 1.70 HN hydro-2H-[1 ,4']bipyridinyl-3' ___0_N112N 1)-amide HC~ C!.., 5-Amino-5'-methylsulfanyl NH [2,2']bipyridinyl-6-carboxylic 699 IN2I cid (3-amino-3,4,5,6-tetra- 436.2 1.54 N , I ydro-2H-[ I 4']bipyridinyl-3'. 0____ N 1)-amide I Chira II N 115-Amino-3',5'-dichloro-[2,2']bi 700 (U CI pidinyI6carboxylic acid (3- 458.1 2.17 N H N- amino-3 ,4,5 ,6-tetrahydro-2H ( N [1 ,4ijbipyridinyl-3'-yI)-amide N , 0 NHz CI Chiral 5 -Amino- 5'-chloro-3'-methyl NH N_ CH: [2,2'Jbipyridinyl-6-carboxylic 701 0N 1 acid (3-amino-3 ,4,5 ,6-tetra- 438.2 1.92 H ydIo-2H-[1,4']bipyridinyl-3' N)0 NH 2 yl)-amide IN

S~NH

2 N F 5-Amino-3'-fluoro-[2,2']bi 702 p~yridinyl-6-carboxylic acid (3- 48216 N H NIamino-3,4,5,6-tetrahydro-2H- 48216 0 NH, 1,4']bipyridinyl-3'-yl)-amide N \Chira I ND/ 5-Amino-6'-pyrazol- Il-yl <NH, N [2,2']bipyridinyl-6-carboxylic 703 C)H N- acid (3-amino-3,4,5,6-tetra- 456.2 2.21 I N N ydro-2H-[1 ,4']bipyridinyl-3' 0 H yl)-amide

NH

2 Ciral N 0 5'-Amino-[2,2']JbipyridinyIA,6' 704 CNH, N dicarboxylic acid 4-amide 6'-[(3- 433.2 1.28 NH N amino-3,4,5,6-tctrahydro-2H 0 [],4']bipyridinyL-3'-yI)-amide] -248- Example Structure Name MH+ LC

NHI

0 CH ,Cia 5,5'-D iam ino-6'-m ethoxy <NsNH2. N [2,2ljbipyridinyl-6-carboxylic 705 INH acid (3-amino-3,4,5 ,6-tetra- 435.2 1.70 N i.ydro-2H-[1,4']bipyridinyl-3' N NH 2 1)-amide H30 Chiral NH IN0 6'-AcetyI-5-amino-[2,2']bi 706 0",NH N. Nyridinyl-6-carboxylic acid (3- 432.2 2.06 IN H N mino-3,4,5,6-tetrahydro-2H 11I N 0N2 [I ,4']bipynidinyl-3'-yl)-amide NH N11 H3Chial 5-Amino-3'-fluoro-4'-methyl ~NjNHN~F [2,2']bipyridinyl-6-carboxylic 707 H N-acid (-amino-3,4,5,6-tetra- 422.2 1.48 Nk N hydro-2H-[1,4']bipyridinyl-3' K)0 NH 2 y)-amide F Chiral

ICH

3 5-Amino-5'-fluoro-6'-methyl ~NH2N N [2,2']bipyridinyl-6-carboxylic 708 KJ N- acid (3-amino-3,4,5,6-tetra- 422.2 1.75 6N hydro-2H-[1 ,4']bipyridinyl-3' N 0 NH 2 1l)-amide H30 11 Chiral 5 -Amino-3'-fluoro-6'-methyl O N2N F [2, 2']bipyrdinyl-6-carboxylic 709 NH Nacid (3-amino-3,4,5,6-tctra- 422.2 1.49 1 N hydro-2H-[1,4']bipyridinyl-3' KN)0 H 2 1)-amide -CChiraI

SNH

2 I N 5-Amino-6'-chloro-[2,2']bi 710 N N ~ yridinyl-6-carboxylic acid (3- 424.2 2.06 H amn-,4,5 ,6-tetrahydro-2H I-kN) NH [1 ,4']bipyridinyl-3'-yl)-amide . NH 2 Chral

,-"-%NH

2 I N 5,6'-Diamino-[2,2']bipyridinyl-6 711 N ~carboxylic acid (3-amino- 45212 711HN',4,5,6-tetrahydro-2H-[1,4']bi- 45212 0 NH2 pyridinyl-3'-yri)-amildc: FChiraI G ,%NH, N 5-Amino-6'-fluoro-[2,2']bi 712 I yridinyl-6-carboxylic acid (3- 48218 H _,Iamino-3,4,5,6-tetrahydro-2H N 0 NH [ ,4~ bipyridinyl-3-yl)-am idc -249- Example Structure Name MH+ LC I CNJMI 5-Amino-5'-chloro-[2,2']bi 71 NH 2 N pyridinyl-6-carboxylic acid (3- 424.2 1.85 N1 0 H N amino-3,4,5,6-tetrahydro-2H F Ch-l F 'F 5 -Amino-5'-trifluoromethyl NH, N 11[2,2']bipyridinyl-6-carboxylic 714 acid (3-amino-3 ,4,5,6-tetra- 458.2 2.15 NH Nydro-2H-[1,4']bipyridinyl-3' (.N H, I)-amide N ~h F F Chrl 5-Amino-4'-trifluoromethyl NN .- [2,2']bipyridinyl-6-carboxylic 715 I.N N acid (3-amino-3,4,5,6-tetra- 458.2 2.08 N hydro-2H-[1,4']bipyridinyl-3' Ni0 NH, 1)-amide Chiral ,NH 1 N 5 ,3'-Diamino-[2,2']bipyridinyl-6 716 N N 2 carboxylic acid (3-amino- 45210 N H N 3,4,5,6-tctrahydro-2H-[1,4']bi- 45210 0 NH2 pyridinyl-3'-yI)-amide Chiral NHNI CH 3 5-Amino-4'-ethyl-[2,2']bi pyridinyl-6-carboxylic acid (3- 48214 717 N mino-3,4,5,6-tetrahydro-2H- 48214 N 0N ~ H, [,4']bipyrIdinyl-3'-yl)-amide F F Chirali F 11 "'5-Amino-6'-trifluoromethyl NH [2,2]jbipyridinyl-6-carboxylic 718 N) acid (3-amino-3,4,5,6-tetra- 458.2 2.40 IAI e N ydro-2H-[1 ,4']bipyridinyl-3' N ' 0 N2 1l)-am ide G1 NH N 11 clCia -Amino-3'-chloro-[2,2'bi 71p~yridinyl-6-carboxyli c acid (3- 424.1 1.81 719 NH N mino-3 ,4,5 ,6-tetrahydro-2H NH, [1 ,4']bipyridinyl-3'-yl)-amidc F C1,11. F _F -Amino-3 '-chloro-5 '-trifluoro NH 2N 11Cl ethyl-[2,2']bipyridinyl-6 720 carboxylicylc acid (3-amino- 492.2 2.29 H<, N1,4,5 ,6-tetrahydro-2H-[ I ,4']bi _______~~ NH,________ _ pyridinyl-3'-yl)-amide -250- Example Structure Name MH+ LC Chiral NH 'F 5:-Amino-3'-trifl uorom ethyl N2 -I F [2,2']bipyridinyl-6-carboxylic 71 'N~ H N I acid (3-amino-3,4,5,6-tetra- 458.2 1.94 N hydro-2H-[ 1,4']bipyridinyl-3' N)0 NH2 y)-amide IH3 CJ~ra IN 0 3-Amino-6-(6-methoxy-pyrazin 722 0,NH I-N 2-yI)-pyridine-2-carboxylic acid 41219 N IN' (3-amino-3,4,5,6-tetrahydro-2H- 41219 (1 NH, [ 1,4']bipyridinyl-3'-yI)-amide HC Viral NH N -Amino-6'-ethoxy-[2,2']bi 723 p~yridinyl-6-carboxylic acid (3- 44220 723 H mino3,4,56-tetrahydro-2H-. 44220 N H H C Chiral NH 2n1N -Amino-4'-methyl-[2,2']bi 724 N Npyridinyl-6-carboxylic acid (3 72 N a o3,45,6-ttrhdr2- 404.2 1.26 H, C*-m 5-Amino-5'-methyl-[2,2']bi 725 ,iyNH2 N pyrdinyl-6-carboxylic acid (3- 404.2 1.25 IN N amino-3,4,5,6-tetrahydro-2H 726 N~~~ yridinyl-6-carboxylic acid (3- 44211 72 ,4 amino-3,4,5,6-tetrahydro-2H- 44211 IN . 0 NH 2 [1,4']bipyridinyl-3'-yI)-amide NH - IN5-Amino-5'-fluoro-[2,2']bi 727 (-pH2.Nyridinyl-6-carboxylic acid (3- 408.2 1.64 IN HN- amino-3,4,5,6-tetrahydro-2H N 0H, [1,4']bipyridinyl-3'-yl)-amide N l NH 2 Chia NH2 3-Amino-6-(2-amino-pyrimidin 728 -yI)-pyridine-2-carboxylic acid 11 728 N H N (3-amino-3,4,5,6-tetrahydro-2H- 406.1 11 ______ K) 0 H, 1,4']bipyridinyl-3'-yl)-amide -251- Example Structure Name MH+ LC NH, CJ~a N 3-Amino-6-(5-amino-pyrazin-2 72 C~~H, N 1)-pyidin-2-carboxylic acid 406.1 1.37 N2 N (3-amino-3,4,5,6-tetrahydro-2H Chra NH2 I5-Amino- [2,2']bpyrid inyl-6 K) carboxylic acid (3-amino 730 N H~ I 3,,6-tetrahydro-2H-[]I,4']bi- 390.2 1.11

NH

2 yidinyl-3'-yl)-armide NH CH Ch,.j N 6' -Amino-6-(5-amino-6 NH2N N methoxy-pyrazin-2-yI)-pyridine 731 N.2,-carboxylic acid (3-amino- 436.2 1.50 3,,,-tetrahydro-2H-[I ,4']bi 0 N, yridinyl-3 -yl)-amide H)C , NH 3-Amino-6-(2,6-difluoro-3 HC NHsopropylcarbamoyl-phenyl) 732 OH NH F 0F yridine-2-carboxylic acid (3- 56319 N NN amino-4-hydroxy-3 ,4,5 ,6-tetra- 56319 - hydro-2H-[ 1,4']bipyridinyl-3' 0 N21 yl-dmlde HICIZ". -Amino-6-(2,6-difluoro-3 HC NH sopropylcarbamoyl-pheny 1) 733 %.NH F p 0yridine-2-carboxylic acid (3- 528.3 2.02 K) amino-4-fluoro-3 ,4,5 ,6-tetra N 2 5-Amino-3'-fluoro-[2,2']bi F pyridinyl-6-carboxylic acid (4 734 NHNN amino-3 -hydroxy-3 ,4,5 ,6-tetra- 424.2 1.25 0 H, 1)-amide OH l' 5-Amino-3'-fluoro-[2,2'lbi pyridinyl-6-carboxylic acid (3 735 N HN amino-4-hydroxy-3 ,4,5 ,6-tetra- 424.2 1.37 N yj ydro-2H-[1 ,4']bipyridinyl-3' N H 2 1)-amide CH - 3-Amino-6-(2,6-difluoro-3 HC NH sopropylcarbamoyl-phenyl)-5 736 ()N IF fuoro-pyiine-2-aroxyic 528.2 2.13 F acid (3-amino-3,4,5,6-tetra hydro-2H-[1 ,4']bipyridinyl-3' ________N [yN, I-amide -252- Example Structure Name MH+ LC H C Chiral IIN~rI 'N5-Amino-3,3'-difluoro-4' N' methyl-[2,2'Ejbipyridinyl-6 737 N N arboxylic acid (3-amino- 440.2 1.88 SH N 3,4,5,6-tetrahydro-2H-[ 1,4']bi 0, H 2 pyndinyl-3'-yl)-amide J'shy- 3-Amino-5-fluoro-6-(6-propoxy 738 N ,N F carboxylic acid (3-amino- 467.2 2.34 N. 3,4,5,6-tetrahydro-2H-[I ,4']bi 0 NH, pyridinyl-3'-yl)-amide r~0 CH3Cra 3-Arino-5-fluoro-6-(6 739 NH 2 .- N FCH 3 isopropoxy-pyrazin-2-yI) 39 N HN' F yrdine-2-carboxylic acid (3- 467.2 2.31 N amino-3,4,5,6-tetrahydro-2H lN 0NH2 [1,4']bipyridInyl-3'-yl)-amide, 11"y0-IHCia 3 -Amino-6-(6-ethoxy-pyrazin-2 Io"'-"H2 N I)-5-fluoro-pyridine-2 70 N.HN F carbxy'c acid (-mn 453.2 2.11 (yN N.3,4,5,6-tctrahydro-2H-rl ,4']bi N 0 NH 2 pyridinyl-3'-yI)-amide 9H 3 Chrwi .. N.0-H3 3 -Amino- 5-fl uoro-6-(6 (-.N.N isobutoxy-pyrazin-2-yl) 741 N N'N F pyridine-2-carboxylic acid (3- 481.2 2.53 NHH NH, 0 CA a 5,5'-D iam ino-6'-(3 -amino INH N CH, 3,4,5,6-tetrahydro-2H-[ 1,4']bi 742 _ I F pyridinyl-3'-ylcarbamnoyl)-3,3'- 499.2 1.86 N H:N , IAI , Ndifluoro-[2,2'Ijbipyridinyl-6 0 NH 2 carboxylic acid methyl ester Chiral N. 5-Amino-3'-chloro-3-fluoro o INH 2 N CI [2,2']bipyridinyl-6-carboxylic 73NH N- acid (3-amino-3,4,5,6-tetra- 442.2 1.96 Ai"N N.ydro-2H-[1,4']bipyridinyl-3' O N H 2 1l)-amide ChimlI ~NH . N 5-Amino-3,3'-dIfluoro-[2,2']bI 744 Q F pyridinyl-6-carboxylic acid (3- 46217 74LNH N I amino-3,4,5,6-tetrahydro-2H- 46217 -253- Example Structure Name MH+ LC NN CH 3 Chiral 5 -Amino-3 ,3'-difluoro-6' (U~N~i~ -Nethyl-[2,2'Ejbipyridinyl-6 '75N N- carboxylic acd(3-amino- 440.2 1.82 FHci N ~'3,4,5,6-tetrahydro-2H-[1I,4']bi 0 NH 2 pyrid'nyl-3'-yl)-amide H 2 N N H3N1 -Amino-3'-fluoro-[2,2']bi 746 ~ N 3 N- pyridinyl-6-carboxylic acid (2'- 416.2 1.77 F amino-6'-methyl-[4,4']bi N 1 %%NH -N 3-Amino-6-(6-propoxy-pyrazin 2 CH, -yi)-pyridinc-2-carboxylic acid 74 H N (3-amino-3,4,5,6-tetrahydro-2H- 449.2 2.34 N N 0 NH, [,4']bipyridinyl-3'-yI)-amide N 'r0-rCH 3Chiral 3-Amino-6-(6-isopropoxy %%jfNH 2 -N CH 2 3yrazin-2-yI)-pyridine-2 748 N H N- carboxylic acid (3-amino- 449.2 2.29 N 1 N. 3,4,5,6-tetrahydro-2H-[I ,4']bi 0 H 2 yridinyl-3'-yl)-amide 0) Chira ,N2 CH, 3-Amino-6-(6-ethoxy-pyrazin-2 749 N) N- yl)-pyridine-2-carboxylic acid 45221 H (3-amino-3,4,5,6-tetrahydro-2H- 45221 0 NH2 [1 ,4']bipyridinyl-3'-yI)-amide hr 3-Amino-6-(6-benzyloxy KYNH 2 N pyrazin-2-yi)-pyridine-2 750 H N ~ carboxylic acid (3-amino- 497.1 2.62 Ikkt 3,4,56-tftahydro-2H-[I ,4']bi ______ N)0 NH2 yridinyl-3 -yl)-amide -254- Example 751 3-Amino-N-(4-((S)-3-aminopiperidin- I -yl)pyridin-3-yl)-6-(2,6-difluoro-3 hydroxyphenyl)-5-fluoropicolinamide OH NH F F N N F N N/ NH2

NH

2 5 [04321 Method 2 of Example 49 was followed using 3-amino-N-(4-((S)-3 aminopiperidin- 1 -yl)pyridin-3-yl)-6-(3-(benzyloxy)-2,6-difluorophenyl)-5 fluoropicolinamide with 20 wt% Pd/C in methanol (0.1 M solution). The Boc protected product was purified by preparative HPLC. After volatile materials were removed, the crude material was stirred in 30% TFA in dichloromethane. After volatile materials were 10 removed in vacuo, 3-amino-N-(4-((S)-3-aminopiperidin-1-yl)pyridin-3-yl)-6-(2,6 difluoro-3-hydroxyphenyl)-5-fluoropicolinamide was obtained by preparative HPLC. LCMS (m/z): 459.2 (MH); LC R 1 = 2.10 min. Synthesis of methyl 3-amino-6-cyclohexylpicolinate N

NH

2 15 [04331 A solution of methyl 3-amino-6-bromopicolinate (1.0 equiv.), cyclohexyl zincbromide 0.5 M solution in THF (1.5 equiv.), and tetrakis(triphenylphosphine)-palladium(0 ) (0.05 equiv.) was stirred at 50'C for 15 minutes. The reaction was filtered and washed with EtOAc. The organic was washed with H 2 0 (IOOmL), NaCl(at.) (50mL), dried over MgSO 4 , and the volatiles were removed 20 in vacuo. The product was purified on silica utilizing the Isco 0-65% gradient of hexane/EtOAc to yield methyl 3-amino-6-cyclohexylpicolinate (98%). LCMS (n/z): 235.2 (MH*); LC Rt = 1.89 min. -255- Synthesis of 3-amino-6-cyclohexylpicolinic acid N HO

NH

2 [0434] To a solution of methyl 3-amino-6-cyclohexylpicolinate (1.0 equiv) in THF, at a concentration of 0.5 M, was added IM LiOH (4.0 equiv). After stirring for 4 5 hours at room temperature, 1 N HCI (4.0 equiv.) was added and the THF was removed in vacuo. The resulting solid was filtered, rinsed with cold H 2 0 (3 x 20mL) yielding 3 amino-6-cyclohexylpicolinic acid (18%). LCMS (m/z): 221.0 (MH); LC Rt = 4.1 min [0435] To a solution of (3R,5R)-3-(tert-butyldimethylsilyloxy)-5 fluoropiperidine ( 1 eq) in 30 mL of methanol was added 3.8M HCl in isopropanol (4 eq). 10 The reaction mixture was allowed to stand at room temperature for 3 hours at which point it was concentrated under reduced pressure. The resulting residue was diluted with 120 mL of EtOAc, washed with sat. aq. sodium bicarbonate, brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (EtOAc : hexanes= 2 : 1) to give (3R,5R)-benzyl 3-fluoro-5 15 hydroxypiperidine-1-carboxylate, (94%). LC/MS (n/z): 254.2 (MH'). Synthesis of (3S,5R)-bcnzyl 3-azido-5-fluoropipcridine-1-carboxylate N Cbz [0436] To a solution of (3R,5R)-benzyl 3-fluoro-5-hydroxypiperidine-1 carboxylate ( 1 eq) in 14 mL of dichloromethane was added triethyl amine ( 3 eq) and 20 methanesulfonyl chloride ( 1.5 eq) at 0 0 C. The reaction mixture was allowed to stir at room temperature for 1.5 hours. The crude mixture was diluted with 120 mL of diethyl ether, washed with sat. aq. sodium bicarbonate, brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was dissolved in 16 mL of NMP. Sodium azide (3.0 eq) was added and the resulting suspension was stirred at 80"C 25 overnight. The reaction mixture was diluted with 200 mL of EtOAc and 100 mL of -256hexanes, washed with water, brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (EtOAc hexanes= 1 : 3) to give the titled compound (90%). LC/MS (m/z): 251.1 (MH 4 -28). Synthesis of(3S,5R)-benzyl 3-(tert-butoxycarbonylamino)-5-fluoropiperidine- 1 5 carboxylate F,,,.n.,NHBoc N Cbz [04371 To a solution of (3S,5R)-benzyl 3-azido-5-fluoropiperidine-1 carboxylate (1 eq) in a mixture of 11 mL of pyridine and 1.5 mL of ammonium hydroxide was added I M trimethylphosphine ( 3 eq) at room temperature. The reaction mixture was 10 stirred at room temperature for 3 hours at which point the solvents were removed under reduced pressure to give a yellow oil. The oil was again dissolved in 100 mL of ethanol and concentrated to remove ammonium hydroxide completely. The residue was dissolved in 12 ml of 1,4-dioxane and 12 mL of sat. aq. NaHCO 3 was added. Di-tert-butyl dicarbonate (4 eq) in 6 mL of THF was added dropwise at 0 0 C. The mixture was allowed 15 to stir at room temperature for I hour. The crude mixture was diluted with 150 mL of EtOAc, washed with brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (EtOAc : hexanes= I 1) to give the titled compound (95%). LC/MS (m/z): 253.1 (MW-1 00). Synthesis of tert-butyl (3S,5R)-5-fluoro- I -(3-nitropyridin-4-yl)piperidin-3-ylcarbamate 20 F,.. .,NHBoc N

~.NO

2 N . 104381 To a solution of (3S,5R)-benzyl 3-(tert-butoxycarbonylamino)-5 fluoropiperidine-1-carboxylate (1 eq) in 28 methanol was added 10% Pd/C ( 0.1 eq). The resulting suspension was stirred at H 2 atmosphere for I hours. The crude solids were 25 filtered through a pad of Celite on a paper lined Buchner funnel, washed with MeOH, -257then concentrated in vacuo. The residue was dissolved in 33 mL of isopropanol and DIPEA (2.5 eq) and 4-chloro-3-nitropyridine (1.5 eq) were added. The reaction mixture was stirred at 80'C for 2 hours, at which point the reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. The residue was diluted with 5 150 mL of EtOAc, washed with brine, then dried over anhydrous MgSO 4 , filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (5% methanol in EtOAc : hexanes= 1 : 1) to give the titled compound (90%). LC/MS (n/z): 341.1 (MH*). HPLC: Rt: 2.115 min. Synthesis of tert-Butyl (3 S,5R)- I -(3-aminopyridin-4-yl)-5-fluororpiperidin-3-ylcarbamate 10 F,,,. n ,NHBoc N N INH 2 N [0439] Following Method 2 of Example 49, tert-butyl (3S,5R)-5-fluoro-1-(3 nitropyridin-4-yl)piperidin-3-ylcarbamate was reduced yielding tert-Butyl (3S,5R)-1-(3 aminopyridin-4-yl)-5-fluoropiperidin-3-ylcarbamate. LC/MS (m/z): 311.1 (MH*). 15 Synthesis of tert-butyl (3S,5R)-I-(3-(3-amino-6-bromopicolinamido)pyridin-4-yl)-5 fluoropiperidin-3-ylcarbamate F,,..n,,NHBoc Br NN' H| N N N NH 2 [0440] Following Method 11 of Example 305, tert-Butyl (3S,5R)-1-(3 20 aminopyridin-4-yl)-5-fluoropiperidin-3-ylcarbamate and 3-amino-6-bromopicolinic acid were coupled yielding after column chromatography tert-butyl (3S,5R)-1-(3-(3-amino-6 bromopicolinamido)pyridin-4-yl)-5-fluoropiperidin-3-ylcarbamate. LC/MS (m/z): 509.1/511.1 (MH). -258- Synthesis of cis (+/-)-I -benzyl 3-methyl 5-(tert-butoxycarbonylamino)piperidine- 13 dicarboxylate 0 NHBoc N Cbz 10441] To a solution of cis (+I-)-1-(benzyloxycarbonyl)-5-(tert 5 butoxycarbonylamino)piperidine-3-carboxylic acid (1.Oeq), methanol (20 eq.) and EDC (1.3 eq) in dichloromethane at a concentration of 0.25 M at O*C was added dimethylaminopyridine (0.1 eq). After stirring for 48 hours as the reaction was allowed to warm to rt the volatiles were removed in vacuo. Upon addition of ethyl actetate and washing with H 2 0 (3x), IN HCI, NaHCO 3 (sat.) and brine, the solution was dried over 10 MgSO 4 , filtered, concentrated and purified by column chromatography (25% ethyl acetate/hexancs) to yield cis (+/-)- I -benzyl 3-methyl 5-(tert butoxycarbonylamino)piperidine-1,3-dicarboxylate. LCMS (m/z): 293.1 (MH-Boc*); LC R, = 4.09 min Synthesis of cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5-(hydroxymethyl)piperidine 15 1 -carboxylate HO NHBoc N Cbz 104421 A solution of cis (+/-)-l-benzyl 3-methyl 5-(tert butoxycarbonylamino)piperidine-1,3-dicarboxylate (1.Oeq.) in THF at a concentration of 0.08 M was cooled at 0*C and then LiCI (2.3 eq.) and sodium borohydride (2.3 eq.) were 20 added. After stirring for 20 hours as the reaction warmed to rt, the pH was adjusted with IM citric acid to pH 4-5. After removal of the volatiles in vacuo, the product was extracted in dichloromethane, washed with H 2 0 and brine, dried over MgSO 4 . Upon filtering and removal of the volatiles in vacuo, cis (+/-)-benzyl 3-(tert butoxycarbonylamino)-5-(hydroxymethyl)piperidine-l-carboxylate was obtained as a 25 white foamy solid. LCMS (m/z): 265.0 (MH-Boc*); LC Rt = 3.37 min. -259- Synthesis of cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5-((tert butyldimethylsilyloxy)methyl)piperidine- 1 -carboxylate TBDMSO NHBoc N Cbz [0443] A solution of cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5 5 (hydroxymethyl)piperidine-1-carboxylate (1.0 eq.), imidazole (1.1 eq.), tert-butyl dimethylsilylchloride (1.1 eq.) and dimethylaminopyridine (0.1 eq.) in dichloromethane at a concentration of 0.1 M was sirred for 18 hours at which time the volatiles were removed in vacuo. Direct purification of the crude material by column chromatography (20% ethyl acetate/hexanes) yielded cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5 10 ((tert-butyldimethylsilyloxy)methyl)piperidine- 1 -carboxylate. LCMS (m/z): 379.0 (MH Bock); LC R, = 5.95 min. Synthesis of cis (+/-)-tcrt-butyl 5-((tert-butyldimcthylsilyloxy) methyl)piperidin-3-ylcarbamate TBDMSO NHBoc N H 15 104441 Method 17 was followed to deprotect cis (+/-)-benzyl 3-(tert butoxycarbonylamino)-5-((tcrt-butyldimcthylsilyloxy)methyl)piperidine- 1 -carboxylate yielding cis (+/-)-tert-butyl 5-((tert-butyldimethylsilyloxy)methyl)piperidin-3 ylcarbamate. LCMS (m/z): 344.1 (MH*). Synthesis of cis (+/-)-tert-butyl 5-((tert-butyldimethylsilyloxy)methyl)-l -(3-nitropyridin 20 4-yl)piperidin-3-ylcarbamate TBDMSO NHBoc N

NO

2 - N -260- 104451 Method I of Example I was followed using cis (+/-)-tert-butyl 5-((tert butyldimethylsilyloxy)methyl)piperidin-3-ylcarbamate and 4-chloro-3-nitropydidine yielding cis (+/-)-tert-butyl 5-((tert-butyldimethylsilyloxy)methyl)-1-(3-nitropyridin-4 yl)piperidin-3-ylcarbamate. LCMS (n/z): 467.0 (MH*); LC Rt = 4.02 min. 5 Synthesis of cis (+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-5-((tert butyldimethylsilyloxy)methyl)piperidin-3-ylcarbamate TBDMSO NHBoc N CN INH 2 [04461 Following Method 2 of Example 49, cis (+/-)-tert-butyl 5-((tert butyldimcthylsilyloxy)mcthyl)-1-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate was 10 reduced yielding cis (+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-5-((tert butyldimethylsilyloxy)methyl)piperidin-3-ylcarbamate. LCMS (m/z): 437.2 (MH*); LC Rt = 3.86 min. Synthesis of cis (+/-)-tert-butyl 1-(3-(3-amino-6-bromopicolinamido)pyridin-4-yl)-5 (hydroxymethyl)piperidin-3-ylcarbamate HO " NHBoc Br N N' H N 15 N NH 2 104471 Following Method 11 of Example 305, cis (+/-)-tert-butyl 1-(3 aminopyridin-4-yl)-5-((tert-butyldimethylsilyloxy)methyl)piperidin-3-ylcarbamate and 6 bromo-3-aminopicolinic acid were coupled. Following purification by RP HPLC the product fractions were allowed to stand at rt overnight in the 0.1 % TFA 20 acetonitrile/water solution which removed the silyl group. Upon subsequent lyophilization, cis (+/-)-tert-butyl 1-(3-(3-amino-6-bromopicolinamido)pyridin-4-yl)-5 (hydroxymethyl)piperidin-3-ylcarbamate was obtained and used in Suzuki reactions directly. LCMS (m/z): 521.0/523.1 (MH-); LC R, = 2.58 min. -261- Synthesis of cis (+/-)-tert-butyl 1-(3-(6-bromo-3-fluoropicolinamido)pyridin-4-vl)-5 (hydroxymethyllpiperidin-3-ylcarbamate HO NHBoc Br N H N F N [04481 Following Method 11 of Example 305, cis (+/-)-tert-butyl 1-(3 5 aminopyridin-4-yl)-5-((tert-butyldimethylsilyloxy)methyl)piperidin-3-ylcarbamate and 6 bromo-3-fluoropicolinic acid were coupled. Following purification by RP HPLC the product fractions were allowed to stand at rt overnight in the 0.1 % TFA acetonitile/water solution which removed the silyl group. Upon subsequent lyophilization, cis (+/-)-tert-butyl 1-(3-(6-bromo-3-fluoropicolinamido)pyridin-4-yl)-5 10 (hydroxymethyl)piperidin-3-ylcarbamate was obtained and used in Suzuki reactionds directly. LCMS (m/z): 524.0/526.0 (MH-); LC R, = 2.90 min. Synthesis of cis (+/-)-benzl 3-(tert-butoxycarbonylamino)-5-(fluoromethyl)piperidine- 1 carboxylate F NHBoc N Cbz 15 104491 A solution of cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5 (hydroxymethyl)piperidinc- 1 -carboxylate ( 1 eq.), perfluorobutanesulfonylfluoride (2 eq.), triethylamine-HF (4 eq.) and triethylamine (6 eq.) in tetrahydrofuran at a concentration of 0.16 M was stirred for 36 hours. Upon dilution with ethyl acetate (50x) the solution was washed with IN HCI, NaHCO 3 (sat) and brine, was dried over MgSO 4 , 20 filtered, concentrated and purified by column chromatography (25-40% ethyl acetate/hexanes) to yield cis (+/-)-benzyl 3-(tert-butoxycarbonylamino)-5 (fluoromethyl)piperidine-I-carboxylate (45% yield). LCMS (n/z): 267.1 (MH 4 *); LC Rt = 4.23 min. -262- Synthesis of cis (+/-)-tert-butyl 5-(fluoromethyl)piperidin-3-ylcarbamate NHBoc N H 10450] Method 17 was followed to deprotect cis (+/-)-benzyl 3-(tert butoxycarbonylamino)-5-(fluoromethyl)piperidine-1-carboxylate yielding cis (+/-)-tert 5 butyl 5-(fluoromethyl)piperidin-3-ylcarbamate. LCMS (m/z): 233.1 (MH*). Synthesis of cis (+/-)-tert-butyl 5-(fluoromethyl)- I -(3-nitropyridin-4-yl)piperidin-3 ylcarbamate F NHBoc N

.NO

2 N 10 [04511 Method I of Example I was followed using cis (+/-)-tert-butyl 5-(fluoromethyl)piperidin-3-ylcarbamate and 4-chloro-3-nitropyridine yielding cis (+/-)-tert-butyl 5-(fluoromethyl)-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate . LCMS (n/z): 355.1 (MH); LC Rt = 2.41 min. Synthesis of cis (+/-)-tert-butyl 1-(3-aminopvridin-4-yl)-5-(fluoromethyl)piperidin-3 15 ylcarbamate NHBoc N N INH 2 N [0452] Following Method 2 of Example 49, cis (+/-)-tert-butyl 5 (fluoromethyl)-I-(3-nitropyridin-4-yl)piperidin-3-ylcarbamate was reduced yielding cis (+/-)-tert-butyl 1-(3-aminopyridin-4-yl)-5-(fluoromethyl)piperidin-3-ylcarbamate. LCMS 20 (n/z): 325.1 (MH); LC Rt = 2.27 min. -263- Synthesis of tert-butyl (3R,4R)-1-(3-(6-bromo-5-fluoropicolinamido)pyridin-4-vl)-4-(tert butyldimethylsilyloxy)piperidin-3 -ylcarbamate OTBDMS BocHN Br N N F H| N N 104531 Following Method 11 of Example 305, tert-butyl (3R,4R)-1-(3 5 aminopyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and 6-bromo 5-fluoropicolinic acid were coupled to yield tert-butyl (3R,4R)-]-(3-(6-bromo-5 fluoropicolinamido)pyridin-4-yl)-4-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate LCMS (n/z): 510.0/512.0 (MH*); LC R, = 4.51 min. Synthesis of tert-butyl (3S ,5 R)- 1 -(3 -(6-bromo-5-fluoropicolinamido)pyridin-4-yl)-5-(tert 10 butyldimethylsilyloxy)piperidin-3-ylcarbamate TBDMSO,,, ,NHBoc Br N N F N 104541 Following Method 11 of Example 305, tert-butyl (3S,5R)-1-(3 aminopyridin-4-yl)-5-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and 6-bromo 5-fluoropicolinic acid were coupled to yield tert-butyl (3S,5R)-1-(3-(6-bromo-5 15 fluoropicolinamido)pyridin-4-yl)-5-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate. LCMS (n/z): 624.1/626.1 (MH 4 ). Synthesis of tert-butyl (3S,5R)- 1-(3-(3-amino-6-bromopicolinamidolpyridin-4-vl)-5-(tert butyldimethylsilyloxy)piperidin-3-ylcarbamate TBDMSO,,, 0 ,NHBoc Br N H N' N N'H2

NH

2 -264- [04551 Following Method 11 of Example 305, tert-butyl (3S,5R)-]-(3 aminopyridin-4-yl)-5-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate and 6-bromo 3-aminopicolinic acid were coupled to yield tert-butyl (3S,5R)-1-(3-(3-amino-6 bromopicolinamido)pyridin-4-yl)-5-(tert-butyldimethylsilyloxy)piperidin-3-ylcarbamate. 5 LCMS (n/z): 621.1/623.2 (MH*). Synthesis of (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4 (methylsulfonyloxy)piperidine- 1 -carboxylate OMs (N.',\NHBoc Cbz [04561 To a solution of (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4 10 hydroxypiperidine-1-carboxylate in dichloromethane (0.13 M) was added triethylamine (1.5 equiv.) followed by methanesulfonyl chloride (1.3 equiv.). The reaction was allowed to stir at room temperature for 15 h. The solution was then quenched with saturated NaHCO 3 , extracted with dichloromethane, dried with sodium sulfate, and concentrated to give the crude product in >95% yield. LCMS (m/z): 428.9/328.9 (MH 4 ), LC Rt = 3.81 15 min. Synthesis of (3aR.7aS)-benzyl 2-oxohexahvdrooxazolof4,5 -c lpvri dine-5 (6H)-carboxylate 0 \NH N Cbz 104571 A solution of (3R,4R)-benzyl 3-(tert-butoxycarbonylamino)-4 (methylsulfonyloxy)piperidine-1-carboxylate in pyridine (0.16 M) was heated to 120 C 20 in the microwave for 10 minutes. The solution was then concentrated to almost dryness and the forming solid was filtered to give the desired product. The filtrate was further purified via silica gel column chromatography eluting with ethyl acetate (100%) to give the product in 75% combined yield. LCMS (m/z): 277.1 (MH*), LC Rt = 2.33 min. -265- Synthesis of (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4 (methylsulfonyloxy)piperidine-1-carboxylate OMs NHBoc N Cbz [04581 To a solution of (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4 5 hydroxypiperidine-1-carboxylate in dichloromethane (0.13 M) was added triethylamine (1.5 equiv.) followed by methanesulfonyl chloride (1.3 equiv.). The reaction was allowed to stir at room temperature for 15 h. The solution was then quenched with saturated NaHCO 3 , extracted with dichloromethane, dried with sodium sulfate, and concentrated to give the crude product in >95% yield. LCMS (n/z): 428.9/328.9 (MH*), LC Rt = 3.81 10 min. Synthesis of (3aS,7aR)-benzyl 2-oxohexahydrooxazolo[4,5-clpyridine-5(6H)-carboxylate NH N Cbz [0459] The previously described method for the enantiomeric compound was followed using (3S,4S)-benzyl 3-(tert-butoxycarbonylamino)-4-(methylsulfonyloxy) 15 piperidine-1-carboxylate (1.0 equiv.) to yield (3aS,7aR)-benzyl 2-oxohexahydro oxazolo[4,5-c]pyridine-5(6H)-carboxylate in 62% yield. LCMS (n/z): 277.1 (MH*), LC R, = 2.33 min. Synthesis of (3aR,7aS)-5-benzyl 3-tert-butyl 2-oxotetrahydrooxazolo[4,5 -c]pyridine 3,5(2H,6H)-dicarboxylate 0 NBoc 01% N 20 Cbz [04601 To a solution of (3aR,7aS)-benzyl 2-oxohexahydrooxazolo[4,5 c]pyridinc-5(6H)-carboxylate (1.0 equiv.) in dichloromethane (0.09 M) was added -266-

BOC

2 0 (1.1 equiv.), triethylamine (1.1 equiv.), and a catalytic amount of DMAP. The reaction was stirred at room temperature for one hour at which point it was concentrated under vacuo and filtered through a plug of silica gel eluting with ethylacetate. The product was dried under vacuo to give a white solid in 75% yield. LCMS (m/z): 277.2 5 (MH*), LC R, = 3.43 min. Synthesis of (3aS,7aR)-5-benzyl 3-tert-butyl 2-oxotetrahydrooxazolo[4,5 -clpyridine 3,5(2H,6H)-dicarboxylate NBoc N Cbz [04611 The previously described method for the enantiomeric compound was 10 followed using (3aS,7aR)-benzyl 2-oxohexahydrooxazolo[4,5-c]pyridine-5(6H) carboxylate (1.0 equiv.) to yield (3aS,7aR)-5-benzyl 3-tert-butyl 2-oxotetra hydrooxazolo[4,5-c]pyridine-3,5(2H,6H)-dicarboxylate in 90% yield. LCMS (mI/z): 277.2 (MH 4 ), LC R, = 3.43 min. Synthesis of (3aR,7aS)-tert-butyl 5-(3-nitropyridin-4-vl)-2-oxohexahydrooxazolo[4,5 15 clpyridine-3(2H)-carboxylate 0 \NBoc N

NO

2 CN [04621 Following Method 17, the Cbz group of of (3aR,7aS)-5-benzyl 3-tert butyl 2-oxotetrahydrooxazolo[4,5-c]pyridine-3,5(2H,6H)-dicarboxylate was removed and the resulting amine was reacted with 4-chloro-3-nitropyridine following Method 1 to 20 yield (3aR,7aS)-tert-butyl 5-(3-nitropyridin-4-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine 3(2H)-carboxylate as a yellow foam in 89 % yield. LCMS (n/z): 365.1 (MH 4 ), LC Rt = 1.79 min. -267- Synthesis of (3aSaR)-tert-butyl 5-(3-nitropyridin-4-yI) 2-oxohexahydrooxazolo[4,5-clpyridine-3(2H)-carboxylate NBoc N

NO

2 CN [0463] The previously described method for the enantiomeric compound was 5 followed using (3aS,7aR)-5-benzyl 3-tert-butyl 2-oxotetrahydrooxazolo[4,5-c]pyridine 3,5(2H,6H)-dicarboxylate (1.0 equiv.) to yield (3aS,7aR)-tert-butyl 5-(3-nitropyridin-4 yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-3(2H)-carboxylate in 88% yield. LCMS (m/z): 365.1 (MH), LC R, = 1.79 min. Synthesis of (3aR,7aS)-tert-butyl 5-(3-aminopyridin-4-yl)-2-oxohexahydro 10 oxazolo[4,5-clpyridine-3(2H)-carboxylate 0 ,NNBoc N CN NH 2 104641 Following Method 2 of Example 49, (3aR,7aS)-tert-butyl 5-(3 nitropyridin-4-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-3(2H)-carboxylate in EtOH and EtOAc (1:1, 0.15 M) was reduced yielding (3aR,7aS)-tert-butyl 5-(3-aminopyridin-4 15 yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-3(2H)-carboxylate in >95% yield. LCMS (m/z): 335.0 (MH*), LC Rt = 1.68 min. -268- Synthesis of (3aS,7aR)-tert-butyl 5-(3-aminopyridin-4-yl)-2-oxohexahydrooxazolo[4,5 clpyridine-3(2H)-carboxylate NBoc N

NH

2 N [0465] The previously described method for the enantiomeric compound was 5 followed yielding (3aS,7aR)-tert-butyl 5-(3-aminopyridin-4-yl)-2-oxohexahydro oxazolo[4,5-c]pyridine-3(2H)-carboxylate in 97% yield. LCMS (m/z): 335.0 (MH+), LC Rt = 1.68 min. Synthesis of (3aR,7aS)-tert-butyl 5-(3-(3-amino-6-(2,6-difluorophenyl)picolinamido) pyridin-4-yl)-2-oxohexahydrooxazolo[4,5-clpyridine-3(2H)-carboxylate 0 .NBoc F F NN H N N 10 N NH2 10466] To a solution of (3aR,7aS)-tert-butyl 5-(3-aminopyridin-4-yl)-2 oxohexahydrooxazolo[4,5-c]pyridine-3(2H)-carboxylatc (1.0 equiv.) in DMF (0.3 M) was added 3-amino-6-(2,6-difluorophenyl)picolinic acid (1.2 equiv.), EDC (1.2 equiv.) and HOAt (1.2 equiv.). The solution was stirred for 15 h. To the mixture was added 15 water and the precipitate was filtered. To the filtrate was added EtOAc, and the organic solution was extracted (3 times), dried with Na 2

SO

4 , and concentrated to give an orange syrup. The crude was triturated with EtOAc and hexanes mixture and the precipitate was filtered off to give pure product in 46% yield. LCMS (tn/z): 567.0 (MH), LC R, = 3.03 min. -269- Synthesis of (3aS,7aR)-tert-butyl 5-(3-(3-amino-6-(2,6 difluorophenyl)picolinamido)pyridin-4-yl)-2-oxohexahydrooxazolo[4,5-clpyridine 3(2H)-carboxylate 0 NBoc F N H N N N H.NH N CN INH2 5 [0467] The previously described method for the enantiomeric compound was followed using (3aS,7aR)-tert-butyl 5-(3-aminopyridin-4-yl)-2-oxohexahydro oxazolo[4,5-c]pyridine-3(2H)-carboxylate to give (3aS,7aR)-tert-butyl 5-(3-(3-amino-6 (2,6-difluorophenyl)picolinamido)pyridin-4-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine 3(2H)-carboxylate. LCMS (mz/z): 567.0 (MH), R= 2.86 min. 10 Synthesis of (3aR,7aS)-tert-butyl 5-(3-(3-amino-6-(2-fluoro-5 (isopropylcarbamoyl)phenyl)picolinamido)pyridin-4-yl)-2-oxohexahydrooxazolo[4,5 c]vyridine-3(2H)-carboxylate HN NBoc F N H N N HH N

NH

2 [0468] To a solution of (3aR,7aS)-tert-butyl 5-(3-aminopyridin-4-yl) 15 2-oxohexahydrooxazolo[4,5-c]pyridine-3(2H)-carboxylate (1.0 equiv.) in DMF (0.3 M) was added 3-amino-6-(2-fluoro-5-(isopropylcarbamoyl)phenyl)picolinic acid (1.2 equiv.), EDC (1.2 equiv.) and HOAt (1.2 equiv.). The solution was stirred for 15 h. To the mixture was added water and the precipitate was filtered. To the filtrate was added EtOAc, and the organic solution was extracted (3 times), dried with Na 2

SO

4 , and 20 concentrated to give an orange syrup. The crude was triturated with EtOAc and hexanes -270mixture and the precipitate was filtered off to give (3aR,7aS)-tert-butyl 5-(3-(3-amino-6 (2-fluoro-5-(isopropylcarbamoyl)phenyl)picolinamido)pyridin-4-yl)-2-oxohexahydro oxazolo[4,5-c]pyridine-3(2H)-carboxylate. LCMS (m/z): 634.3. METHOD 35 5 Synthesis of 3-amino-N-(4-((3R,4S)-3-amino-4-hydroxypiperidin-1-yl) pyridin-3-yl)-6-(2,6-difluorophenyl)picolinamide OH ,,NH2I F F N H N NH, N NH2 [0469] To a solution of (3aR,7aS)-tert-butyl 5-(3-(3-amino-6-(2,6-difluoro phenyl)picolinamido)pyridin-4-yl)-2-oxohexahydrooxazolo[4,5-c]pyridine-3(2H) 10 carboxylate in MeOH (0.06M) was added Cs 2

CO

3 (0.5 equiv.) and the reaction was stirred for 3 h. The mixture was then concentrated to dryness under vacuo and the crude was stirred in TFA and DCM (25% TFA) until completion. The reaction was concentrated and purified via reverse phase HPLC. Upon lyophilization, a white powder was obtained as the TFA salt. LCMS (m/z): 441.1 (MH'), LC R = 1.95 min. 15 The following compounds were prepared using Method 35: Example Structure Name MH+ LC OH Chiral NH2 3-Amino-6-(2,6-difluoro-phenyl) (I*F F pyridine-2-carboxylic acid (3 752 N N mino-4-hydroxy-3,4,5,6-tetra- 441.0 1.98 H hydro-2H-[ 1,4']bipyridinyl-3'-yl) N amidee I - NH 2 CN 0 Chiral OH H NH 3-Amino-6-(2-fluoro-5-isopropyl N2 C C carbamoyl-phenyl)-pyridine-2 753 CH 3 carboxylic acid (3-amino-4- 508.0 1.98 H Nydroxy-3,4,5,6-tetrahydro-2H SN 1,4']bipyridinyl-3'-yl)-amide -N

NH

2 -271- Example Structure Name MH+ LC Ch iral OH

,NH

2 3-Amino-6-(2,6-difluoro-phenyl) F F pyridine-2-carboxylic acid (3 754 N N amino-4-hydroxy-3,4,5,6-tetra- 441.1 1.95 H hydro-2H-[1,4']bipyridinyl-3'-yl) amide _ _ N

NH

2 Example 755 Synthesis of (S)-3-amino-N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-6-(2-fluoro-5 isopentylphenyl~picolinamide H2N F N H N' N H 5 NN 5N~ N H 2 [04701 Method 2 of Example 49 was followed using (S,Z)-tert-butyl 1-(3-(3 amino-6-(2-fluoro-5-(3-methylbut-I -enyl)phenyl)picolinamido)pyridin-4-yl)piperidin 3-ylcarbamate which after Boc deprotection with 25% TFA/CH 2

CI

2 yielded (S)-3-amino 10 N-(4-(3-aminopiperidin-1-yl)pyridin-3-yl)-6-(2-fluoro-5-isopentylphenyl)picolinamide (35%). LCMS (m/z): 477.3 (MH*); LC R, = 2.91 min. Example 756 Pim I ATP depletion assay [04711 The activity of PIM1 is measured using a luciferase-luciferin based 15 ATP detection reagent to quantify ATP depletion resulting from kinase-catalyzed phosphoryl transfer to a peptide substrate. Compounds to be tested are dissolved in 100% DMSO and directly distributed into white 384-well plates at 0.5 i1 per well. To start the reaction, 10 Il of 5 nM Piml kinase and 80 pM BAD peptide (RSRHSSYPAGT-OH) in assay buffer (50 mM HEPES pH 7.5, 5 mM MgCl 2 , 1 mM 20 DTT, 0.05% BSA) is added into each well. After 15 minutes, 10 pl of 40 pM ATP in -272assay buffer is added. Final assay concentrations are 2.5 nM PIM1, 20 pM ATP, 40 pM BAD peptide and 2.5% DMSO. The reaction is performed until approximately 50% of the ATP is depleted, then stopped with the addition of 20 pl. KinaseGlo Plus (Promega Corporation) solution. The stopped reaction is incubated for 10 minutes and the 5 remaining ATP detected via luminescence on the Victor2 (Perkin Elmer). Compounds of the foregoing examples were tested by the Piml ATP depletion assay and found to exhibit an IC 50 values as shown in Example 763, below. IC 50 , the half maximal inhibitory concentration, represents the concentration of a test compound that is required for 50% inhibition of its target in vitro. 10 Example 757 Pim2 ATP depletion assay [04721 The activity of PIM2 is measured using a luciferase-luciferin based ATP detection reagent to quantify ATP depletion resulting from kinase-catalyzed phosphoryl transfer to a peptide substrate. Compounds to be tested are dissolved in 15 100% DMSO and directly distributed into white 384-well plates at 0.5 pl per well. To start the reaction, 10 Al of 10 nM Pim2 kinase and 20 pM BAD peptide (RSRHSSYPAGT-OH) in assay buffer (50 mM HEPES pH 7.5, 5 mM MgCl 2 , 1 mM DTT, 0.05% BSA) is added into each well. After 15 minutes, 10 pl. of 8 AM ATP in assay buffer is added. Final assay concentrations are 5 nM PIM2, 4 AM ATP, 10 pM 20 BAD peptide and 2.5% DMSO. The reaction is performed until approximately 50% of the ATP is depleted, then stopped with the addition of 20 pl KinaseGlo Plus (Promega Corporation) solution. The stopped reaction is incubated for 10 minutes and the remaining ATP detected via luminescence on the Victor2 (Perkin Elmer). Compounds of the foregoing examples were tested by the Pim2 ATP depletion assay and found to 25 exhibit an IC 50 values as shown in Example 763, below. Example 758 Pim3 ATP depletion assay [04731 The activity of PIM3 is measured using a luciferase-luciferin based ATP detection reagent to quantify ATP depletion resulting from kinase-catalyzed 30 phosphoryl transfer to a peptide substrate. Compounds to be tested are dissolved in 100% DMSO and directly distributed into white 384-well plates at 0.5 Al per well. To -273start the reaction, 10 sl of 10 nM Pim3 kinase and 200 pM BAD peptide (RSRHSSYPAGT-OH) in assay buffer (50 mM HEPES pH 7.5, 5 mM MgCl 2 , 1 mM DTT, 0.05% BSA) is added into each well. After 15 minutes, 10 pl of 80 iM ATP in assay buffer is added. Final assay concentrations are 5 nM PIMI, 40 gM ATP, 100 IM 5 BAD peptide and 2.5% DMSO. The reaction is performed until approximately 50% of the ATP is depleted, then stopped by the addition of 20 gl KinaseGlo Plus (Promega Corporation) solution. The stopped reaction is incubated for 10 minutes and the remaining ATP detected via luminescence on the Victor2 (Perkin Elmer). Compounds of the foregoing examples were tested by the Pim3 ATP depletion assay and found to 10 exhibit an IC 50 values as shown in Example 763, below. Example 759 Flt3 AlphaScreen Assay 10474] The activity of Flt3 is measured using a homogeneous bead based system quantifying the amount of phosphorylated peptide substrate resulting from 15 kinase-catalyzed phosphoryl transfer to a peptide substrate. Compounds to be tested are dissolved in 100% DMSO and directly distributed into white 384-well plates at 0.5 pl per well. To start the reaction, 10 gl of 300 pM Flt3 kinase and 700 pM ATP in assay buffer (50mM Hepes, pH=7.5, 5mM MgCl2, 0.05% BSA, ImM DTT) is added into each well followed by 10 pl of 500 nM SHC peptide (Biotin-GGLFDDPSYVNVQNL-NH2) in 20 assay buffer. Final assay concentrations are 150 pM Flt3, 350 pM ATP, 250 nM SHC peptide and 2.5% DMSO. The reaction is performed for 2.5 hours, then stopped by the addition of 10 g1 60 mM EDTA. 25 pl of 1.2 jig/ml PY20 antibody, 48.4 pg/ml Protein A Alpha Screen beads, and 48.4 pg/ml streptavidin coated Alpha Screen beads in detection buffer (50 mM Tris pH 7.5, 0.01% Tween-20) is added to the stopped reactions. 25 The stopped reactions are incubated overnight in the dark. The phosphorylated peptide is detected via an oxygen anion initiated chemiluminescence/fluorescence cascade using the Envision plate reader (Perkin Elmer). Compounds of the foregoing examples were tested by the Flt3 Alpha assay and found to exhibit an IC 50 values as shown in Example 762, below. -274- Example 760 KDR AlphaScreen Assay [0475] The activity of KDR is measured using a homogeneous bead based system quantifying the amount of phosphorylated peptide substrate resulting from 5 kinase-catalyzed phosphoryl transfer to a peptide substrate. Compounds to be tested are dissolved in 100% DMSO and directly distributed to a white 384-well plate at 0.5 4l per well. To start the reaction, 10 gl of 2 gM VEGF5 peptide (Biotin GGGGQDGKDYIVLPI-NH2) in assay buffer (50mM Hepes, pH=7.5, 5mM MnCl2, 0.1% BSA, 0.01% Tween-20, ImM DTT) is added to each well followed by the addition 10 of 10 l of 250 pM KDR kinase and 2 juM ATP in assay buffer. Final assay concentrations are 125 pM KDR, I iM ATP, I 1 iM VEGF5 peptide and 2.5% DMSO. The reaction is performed for 2 hours, then stopped by the addition of 25 Al of 0.24 pg/ml PY20 antibody, 96.8 pg/ml Protein A Alpha Screen beads, and 96.8 pg/ml streptavidin coated Alpha Screen beads in stop/detection buffer (50mM Hepes, pH=7.5, 10mM 15 EDTA, 0.1% BSA, 0.01% Tween-20). The stopped reactions are incubated overnight in the dark. The phosphorylated peptide is detected via an oxygen anion initiated chemiluminescence/fluorescence cascade using the Envision plate reader (Perkin Elmer). Compounds of the foregoing examples were tested by the KDR Alpha Screen assay and found to exhibit an IC 50 values as shown in Example 762, below. 20 Example 761 Cell Proliferation Assay [0476] HEL 92.1.7 cells (ATTC No. TIB-180, an erythroleukemia line derived from malignant peripheral blood), MV4-11 cells (ATCC No. CRL-9591, a human acute monocytic leukemia line) and PC3 cells (ATCC No. CRL-1435, a human prostatic 25 adenocarcinoma line) were cultured in RPM11640 supplemented with 10% FBS, sodium pyruvate and antibiotics. Cells were plated in the same medium at a density of 1000 cells per well into 96 well tissue culture plates, with outside wells vacant, on the day of assay. [04771 KMSI1 (human myeloma cell line), were cultured in IMDM supplemented with 10% FBS, sodium pyruvate and antibiotics. Cells were plated in the 30 same medium at a density of 2000 cells per well into 96 well tissue culture plates, with outside wells vacant, on the day of assay. MM1.s (human myeloma cell line), were cultured in RPMI1640 supplemented with 10% FBS, sodium pyruvate and antibiotics. -275- Cells were plated in the same medium at a density of 5000 cells per well into 96 well tissue culture plates, with outside wells vacant, on the day of assay. 104781 Test compounds supplied in DMSO were diluted into DMSO at 500 times the desired final concentrations before dilution into culture media to 2 times 5 final concentrations. Equal volumes of 2x compounds were added to the cells in 96 well plates and incubated at 37 "C for 3 days. 104791 After 3 days plates were equilibrated to room temperature and equal volume of CellTiter-Glow Reagent (Promega) was added to the culture wells. The plates were agitated briefly and luminescent signal was measured with luminometer. The 10 percent inhibition of the signal seen in cells treated with DMSO alone vs. cells treated with control compound was calculated and used to determine EC 5 o values (i.e., the concentration of a test compound that is required to obtain 50% of the maximum effect in the cells) for tested compounds, as shown in Example 763. Example 762 15 In vitro PKCe Assay [04801 An in vitro PKCc assay was run using I OnM final concentration of human full length PKCe enzyme purchased from InVitrogen. Peptide substrate with the sequence ERMRPRKRQGSVRRRV-OH was used at final concentration of 40uM, and ATP at 20uM. Lipid activator, 0.05mg/ml of phosphatidylserine and 0.005mg/ml 20 diacylglycerol, was purchased from Millipore. Reaction buffer was consisted of 20mM Hepes pH7.4, 5mM MgCl 2 , and 0.03% Triton X-100. After 2-3 hours reaction time, the assay readout was developed with KinaseGlo Plus reagent from Promega. Representative compounds of the foregoing examples were tested by the PKCE assay and found to exhibit an IC 50 as shown below, where (+) represents an IC 50 greater than or equal to 25 25 rM, (++) represents an IC 50 greater than or equal to 10 ItM but less than 25 tM, (+++) represents an IC 50 greater than or equal to I paM but less than 10 gM, and (++++) represents an IC 50 less than I 4M. Example PKCE IC50 (pM) Flt3 1C50 (pM) KDR IC50 (pM) 118 ++++ ++++ 119 ++++ +++ 120 +++ 121 + ++++ 122 ++++ 123 +++ +++ -276- Example PKCE IC50 (pM) Flt3 IC50 (pM) KDR IC50 (pM) 124 ++ ++ 125 ++ ++ 126 +.+ +++ 127 ++++ 128 + 129 +++ 130 ++++ +++ 131 + ++ 132 .++ ++ 133 + 134 +++ +++ 135 ++++ +++ 136 +++ 137 ++++ 138 + 139 ++ 140 ++ 141 +++ 142 +++ 143 + 144 +++ 145 + 146 ++ 147 +++ 148 ++ 149 + 150 ++ 151 + 152 +.+ 153 + 154 ++ 155 +++ 156 +++ 157 + 158 + 159 + ++++ 160 + 161 + ++ 163 ++ 164 ++ 165 ++ 166 ++ 171 ++ -277- Example PKCE IC50 (pM) FIt3 IC50 (pM) KDR IC50 (pM) 173 ++++ ++ 174 +++ + 175 +++ + 175 +++ + 176 ++++ ++ 177 +.+ 178 ++++ 179 +++ 180 +++ 182 +++ ++ 183 ++ + 184 +++ ++ 185 +++ +++ 186 +++ +++ 187 .+ + 188 +.++ +++ 189 +++ 190 + 191 +.+ 192 + 193 +++ 194 + 195 ++++ + 196 +++ + 199 +++ +++ 201 ++++ ++ 202 +++ + 203 +++ + 204 ++++ 204 ++++ ++ 205 ++++ +++ 206 ++++ ++ 211 ++++ +++ 212 +++ ++ 213 ++ + 214 ++++ ++ 215 +++ + 216 ++ + 217 ++ + 217 +++ ++ 218 +++ + 219 + + 222 ++++ -278- Example PKCE IC50 (pM) FIt3 IC50 (pM) KDR IC50 (pM) 223 ++++ + 223 ++++ + 224 +++ + 225 +++ + 226 +++ + 227 +++ + 228 +++ ++ 229 + + 230 ++++ + 231 ++ ++ 232 ++ ++ 233 ++.+ 235 ++++ ++ 236 + ++ 237 +++ 238 + 239 .++ 240 ++++ 241 +++ 242 + 243 ++ + 244 +++ ++ 249 ++ 261 ++ 264 ++++ 265 ++ 268 ++ 275 ++ 304 +++ +++ 312 ++ 320 ++ + 322 ++ + 332 +++ + 333 ++ + 336 ++ + 340 ++ ++ 341 +++ ++ 342 +++ ++ 343 +++ ++ 344 ++ + 345 ++++ +++ 346 ++++ 347 +.+ -279- Example PKCE IC50 (pM) FIt3 IC50 (pM) KDR IC50 (pM) 348 ++++ 349 +++ 350 ++++ 351 ++++ 352 ++++ 353 +++ 354 ++ 355 +++ 356 ++ 357 +++ 359 ++++ ++ 360 +++ ++++ 361 ++++ ++++ 362 ++++ ++++ 363 ++++ ++++ 364 ++++ ++++ 364 ++++ +++ 365 +.++ ++ 366 .+++ ++ 367 ++++ +++ 368 +++ ++++ 369 +++ +.+ 370 ++++ +++ 371 +++ 372 ++++ ++ 373 ++++ ++++ 374 ++ +++ 375 ++ +++ 376 .+++ + 377 ++++ +++ 378 +.+ + 379 ++++ +++ 380 ++++ ++++ 381 .++ +++ 382 +.+ +++ 383 +++ +++ 384 +.+ +++ 385 +++ +++ 386 ++++ +++ 387 ++ ++ 388 ++++ +++ 389 +++++ 390 ++++ +++ -280- Example PKCE IC50 (pM) FIt3 IC50 (pM) KDR IC50 (pM) 391 +++ 400 ++ +++ 400 +++ 401 ++++ 402 +++ 403 ++++ 404 ++ 405 ++ 406 +++ 410 +++ 411 ++ + 418 ++ + 422 ++ + 424 +++ + 425 +++ ++ 427 ++ 431 +++ + 433 +++ ++ 434 ++ + 435 ++ 436 +++ +++ 437 +++ +++ 438 + 439 +++ +++ 440 + 441 ++ 447 ++ 454 ++ 455 ++ 482 + ++ 483 ++ + 484 ++ + 485 + ++ 487 ++ 505 ++ 519 ++ 520 +++ 521 +++ 522 +++ 523 ++ 524 +++ 534 ++ 535 ++ -281- Example PKCE IC50 (pM) FIt3 IC50 (pM) KDR IC50 (pM) 538 ++ 542 ++ 543 ++ 544 ++ 545 ++ 547 ++ 549 ++ 550 ++ 552 +++ +++ 590 +++ ++++ 592 +++ 593 + 594 + 595 + 596 + 597 +++ + 598 +++ +++ 612 +++ 614 +++ 629 ++ 644 ++ 648 ++ 649 ++ 650 ++ Example 763

IC

50 and EC 50 Activity of Compounds of the Invention 10481] Using the procedures of Examples 756 (Piml ATP depletion assay), 5 757 (Pim2 ATP depletion assay), and 758 (Pim3 ATP depletion assay), the IC 50 concentration of compounds of the previous examples were determined as shown in the following table, where (+) represents an IC 5 0 greater than or equal to 25 gM, (++) represents an IC 50 greater than or equal to 10 gM but less than 25 tM, (+++.) represents an IC 50 greater than or equal to I sM but less than 10 gM, and (++++) represents an IC 50 10 less than I gM. [0482] Using the procedures of Example 761 (cell proliferation assay), the

EC

50 concentration of compounds of the previous examples in were determined in HEL 92.1.7, MV4-11 cells and PC3 cells as shown in the following table, where (+) represents an EC 5 0 greater than 10 pM, (++) represents an EC 5 0 greater than 5 uM but less than or -282equal to 10 gM, (+) represents an EC5 0 greater than I gM but less than or equal to 5 iM, and (++++) represents an EC 50 less than or equal to 1 M. IC50 (pM) E 50 (pM) Ex.No PIMI PIM2 PIM3 L MV-4-11 PC3 KMSII MMI.s S92.1.7 118 ++++ +++ ++++ 119 +.+ ++++ ++++ 120 ++++ ++ ++++ 121 ++++ .++ ++++ 122 ++++ +++ ++ ++++ 123 ++++ +++ ++ ++++ 124 ++ + +++ 125 +++ + ++ 126 .+ + ++++ ++ 127 +++ + + 128 +++ + ++ 130 ++ ++ ++ + 131 ++++ ++++ ++++ ++++ 132 ++++ ++++ ++++ 133 ++++ ++++ ++ 134 ++ ++ ++ 135 ++++ ++++.± ++++ 136 ++ ++++ ++++ 137 ++++ ++ ++ 138 ++++ ++ ++ 139 ++++ ++++ ++++ 140 ++++ ++ ++++ 141 ++ ++ ++ 142 ++++ ++ ++++ +++ 143 ++++ ++++ ++++ +++ 145 ++++ ++++ ++++ +++ 146 ++++ ++ ++++ + 147 ++ ++ .+ ++ 148 ++ .+ ++++ + 150 ++++ ++++ ++++ +++ 151 ++++ ++++ ++++ + 152 ++++ ++++ ++++ 153 ++ ++ ++++ 154 ++ ++ ++ 155 ++ ++ ++ ++ 156 ++++ ++++ ++++ 157 ++ ++ ++++ + 158 ++++ ++++ ++++ 159 ++++ ++ ++++ ++ 160 ++ ++ ++++ + 161 ++++ ++++ ++++ + -283- IC50 (jiM) E 50 (pM Ex. No PIMI PIM2 PIM3 HIL MV-4-11 PC3 KMSII MM1.s 92.1.7 ____ 162 ++++ ++++ ++++ 163 ++++ ++++ ++++ 164 ++++ ++++ ++++ 165 ++++ ++++ ++++ 166 ++++ ++++ ++++ 167 ++++ +++ +++ 168 +++ ++++ ++++ 169 ++++ ++++ t+++ 170 +++ +++ ++++ 171 ++++ +++ ++++ 173 ++.. +tt.. +.... ++ ++ 174 ++++ ++++ ++++ + 177 ++++ ++++ .+++ + 175 ++++ ++++ ++++ + 176 ++++ ++++ + +++ +++ 177 ++++ ++.+ ++++ 178 ++++ ++++ ++++ 179 ++++ ++++ ++++ +++ 180 ++++ ++++ ++++ ++++ 181 ++++ ++++ ++++ +++ 182 ++++ +++ ++++ ++++ 183 ++++ ++++ ++++ ++++ 184 ++++ +++ ++++ ++++ 185 ++++ ++++ ++++ ++++ 186 ++++ ++++ ++++ 187 ++++ ++++. ++++ +++ ++++ +++ 188 ++++ +++ +++ 189 ++++ +++ ++++ 191 ++++ + +++ 192 + + + 193 ±+++ -+ +++ ++++ 194 + + + 195 ++++ ++++ ++++ + 196 +++ ++ +++ 197 + + + 198 + + + 199 +++ + + 199 +++ + ++ 199 +++ + ++ 200 ++ + + 201 +++. +++ ++++ ++ 202 +++ + +++ +++ 203 ++++ +++ ++++ ++++ 204 ++++ ++++ ++++ 205 ++++ ++++ ++++ +++ -284- IC50 (AM) E 50 (pM) Ex.No PIMI PIM2 PIM3 EL MV-4-11 PC3 KMSII MM1.s _______92.1.7 206 ++++ ++ ++++ 207 ++++ ++ ++++ ++ 208 +++ +++ ++++ ++++ 209 ++ + + 210 ++++ +++ ++++ ++++ 211 ++++ . ++++ ++++ 212 ++++ ++++ ++++ 213 +++ + +++ 214 ++++ +++ ++++ 215 ++++ +++ ++++ 216 +++ + 217 ++++ + +++ ++ 218 ++++ ++ ++++ 219 ++++ ++ ++++ 220 ++++ ++ ++++ 221 ++++ +++ ++++ 222 ++ ++ ++++ + 223 ++++ +++ ++++ 224 ++++ + 225 ++++ ++ ++++ 226 ++++ +++ ++++ 227 +++ + 228 ++++ -s ++++ ++ 229 ++++ +++ ++++ 230 ++++ ++++ ++++ 231 + .+ 232 ++ + ++ 233 +±+ + 234 +t+ + ++ 235 ++++ +++- ++++ + 236 +-++ ++- ++++ 237 ++-++ ++ ++++ 238 ++++ ++++ ++++ 239 ++++ ++++ ++++ + 240 ++++ ++++ ++++ 241 ++++ ++++ +.+ 242 ++++ ++++ ++++ 243 +++ ++ +++ 244 +++ ++ 245 + + ++ 246 ++++ ++++ ++++ 247 ++++ ++++ ++++ 248 ++++ .++ ++++ 249 ++++ +++ +++ 250 ++++ ++++ ++++ -285- IC50 (gM) E'50 (pM) Ex. No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMSI1 MMI.s _______92.1.7 251 ++++ ++++ ++++ 252 ++++ ++++ ++++ 253 ++++ ++++ ++++ 254 ++++ ++++ ++++ 255 ++++ ++++ ++++ 256 ++++ ++++ ++++ 257 ++++ ++++ ++++ 258 ++±+ ++++ ++++ 259 ++++ ++++ ++++ 260 ++++ ++++ +++ 261 ++++ ++++ ++++ 262 ++. ++ ++++ 263 ++++ ++++ ++++ 264 ++++ ++++ +++ 265 ++++ ++++ ++++ 266 ++++ ++++ +++ 267 +++ ++++ ++++ 268 ++++ ++++ I++++ 269 ++++ ++++ ++++ 270 ++++ ++++ ++++ 271 ++++ ++++ +++ 272 ++++ + .+++ 273 ++++- ++++ ++++ 274 ++++ ++++ +++ 275 ++++ ++++ ++++ 276 ++++ ++++ ++++ +++ ++ 277 ++++ ++++ ++++ 278 ++++ ++++ ++++ 279 ++++ ++++ ++++ 280 ++++ ++++ ++++ 281 ++++ ++++ +±++ 282 ++++ ++++ ++++ 283 +++ ++++ ++++ 284 ++++ ++++ ++++ 285 ++++ ++++ +++ 286 ++++ ++++ ++++ 287 ++++ ++++ ++++ 288 ++++ ++++. ++++. 289 ++++ ++++ ++++ 290 ++++ ++++ ++++ +++ +++ 291 ++++ ++++ ++++ 292 ++ ++++ ++++ ++++ ++++ 293 ++++ ++++ ++++ 294 ++++ +++. ++++ 295 +±++ +++ ++++ -286- IC50 (gM) EC50 ( M Ex.No PIMI PIM2 PIM3 HEL MVA-Il PC3 KMS11 MM1.s 92.1.7 296 ++++ ++++ ++++ 297 ++++ ++++ ++++ 298 +++ ++++ ++++ ++++ ++++ 299 ++++ +++ ++++ 300 ++++ +++. +++ ++++ ++++ 301 ++++ ++++ ++ 302 ++++ +++ ++++ 303 +++ ++++ +++ 304 ++++ + 312 ++++ +++ ++++ 317 ++++ ++++ ++++ +++ + +++ ++++ 318 ++++ +++ ±++ 319 ++++ +++ ++++ +++ 320 ++++ ++++ ++++ + 321 ++++ .+++ ++++ +++ 322 +++ ++++ ++++ ++++ ++ 323 ++++ ++++ ++++ ++++ +++ 324 ++++ ++++ ++++ t-$-t ++++ 325 ++++ +++.+ ++++ +++ 326 ++++ ++++ ++++ +++ 327 ++ ++++ ++++ +++ 328 ++++ ++++ ++++ +++ ++++ ++++ 329 ++++ ++++ ++++ ++ 330 ++++ +++ ++++ + 331 ++++ +++ +++ +++ 332 ++++ ++++ ++++ +++ 333 ±±++ +++± ++++ + 334 +++ ++ ++++ ++ 335 +++ +++± ++ ++ 336 ++++ ++++ ++ 337 ±±++ ++++ ++±± ++ 338 .+++ +++ ++++ 339 ++++ ++++ ++++ +++ 340 ++++ ++++ ++++ ++ 341 ++++ ++++ ++++ +++ 342 ++++ ++++ ++++ +++ 343 +++ ++++ ++++ +++ 344 .+++ ++++ ++++ + 345 ++++ ++++ ± +++ + ++. ++++ 346 ++++ ++++ ++++ ++++ 347 +++ ++++ ++++ ++++ 348 ±±±± ++++ ±++++ .. ± +++± 349 +±++ ++++ +++ +++ 350 ++++ ++++ ++++ ++++ 351 ++++ ++++ ++++ -287- IC50 (gM) E50 (gpM) Ex.No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMSII MM1.s _______ ________92.1.7 _ _ _ _ 352 ++++ ++++ ++++ ++++ 353 ++++ ++++ ++.+ ++++ 355 ++++ ++++ .+ + 356 ++++ ++++ ++++ + 357 ++++ ++++ ++++ +++ 358 ++++ ++++ ++++ ++++ 359 ++++ ++++ + +++ ++++ 360 +++ + +++ 361 ++++ ++++ ++++ 362 ++ .. ++ ++++ ++++ 363 ++++ ++++ ++++ ++++ 364 ++++ ++++ .. +++.+ 365 ++++ +++ ++++ + 366 ++++ +++ ++++ 367 ++++ ++++ ++++ ++++ 368 ++++ ++++ ++++++++ 369 ++++ ++++ ++++ 370 ++++ ++++ ++++ ++ 371 ++++ ++++ ++++ 372 ++++ ++++ ++++ +++ 376 ++++ ++++ ++++ + 377 ++ +++ ++++ 378 ++++ ++ +++ +++ 379 ++++. ++ ++++ 380 +++ +++ ++++ 381 ++++ ++++.. +++ 382 ++++ +++ +...++ 383 ++++ +++ ++++ 384 ++++ +++ +++ 385 ++++ +++ ++++ 386 ++++ +++ ++++ 387 +++ + +++ 388 ++++ ++ ++++ 389 ++++ +++ ++ ++ 390 ++++ + 391 +++ + +++ 393 ++++ ++++ ++++ +++ 395 +++ + ++ +++ 396 ++++ +++ ++++ 397 ++++ ++++ ++++ ++++ 398 +++ ++ +++ 399 ++++ ++++ ++++ ++++ 401 ++++ ++++ ++++ ++ 402 ++++ ++++ ++++ ++ 403 ++++ ++++ ++++ -288- IC50 (gM) E 50 (gM) Ex.No PIMI PIM2 PIM3 9HEL7 MV-4-11 PC3 KMSI MMI.s 404 ++++ ++++ ++++ 405 ++++ ++++ ++++ 406 ++++ ++++ ++++ 407 ++++ ++++ +++ 408 ++++ ++++. ++ 409 ++++ ++++ ++++ 410 ++++ ++++ ++++ +++ 411 ++++ ++++. +H+ 412 ++++ +++ ++++ ++ 413 ++++ ++++ ++++ ++++ 414 ++++ ++++ ++++ +++ 415 ++++ ++++ ++++ ++++ 416 ++++ ++++ ++++ 417 ++++ ++.+ .+++ 418 ++++ ++++ ++++ +++ 419 ++++ ++++ ++++ +++ 420 ++++ ++++ ++++ 421 ++++ ++++ ++++ +++ + 422 ++++ ++++ ++++ +++ + 423 ++++ ++++ ++++ +++ 424 ++++ ++++ ++++ +++ ++ 425 ++++ ++++ ++++ ++++ ++ ++++ ++++ 426 ++++ ++++ ++++ ++ 427 ++++ ++++ +++ +++ 428 ++++ ++++ ++++ ++ 429 +.++ +++. ++++ ++ 430 +.++ ++++ ++++ +++ 431 ++++ ++++ ++++ + 432 ++.++ ++++ ++ +++ 433 +++ ++++ ++++ +++ ++++ 434 ++++ ++++ ++++ ++ ++++ 435 +i +++ +++ 436 ++ + +++ 437 ++++ ++++ ++++ 438 +++ + +++ 439 +++ + + 440 + + ++ 441 +++ + +++ 442 ++++ ++++ +++++++ ++ 443 ++++ ++++ +++ ++ 444 ++++ +++ ++++ 445 ++++ ++++ ++++ ++ ++ 446 ++++ ++++ ++++ 447 ++++ +++ ++++ 448 ++++ i-i i++++ -289- IC50 (gM) E50 (pM) Ex. No PIMI P1M2 PIM3 9EL MV-4-11 PC3 KMSI MM1.s _______ _______ 92.1.7 _ __ ____ 449 ++++ ++++ ++++ 450 ++++ ++++ +++ 451 ++++ +++..+ ++++ 452 +.+++ ++++ +++ 453 ++++ ++++ ++++ 454 ++++ ++++ ++++ +++ ++ 455 ++++ ++++ ++++ 456 ++++ ++++ ++++ 457 +++± ++++ ++++ 458 ++++ ++++ ++++ 459 ++++ ++++ +++ 460 ++++ ++++ ++++ 461 ++++ ++++ +++ 462 ++++ ++++ ++++ +++ +++ 463 ++++ ++-+ ++++ 464 +++ +++ ++++ 465 ++++ ++++ ++++ 466 ++++ +++ ++++ 467 ++++ +++ ++++ 468 ++++ ++++ ++++ 469 ++++ ++++ ++++ 470 ++++ ++++ ++++ 471 +±++ ++++ +--++ 472 ++++ ++++ ++++ 473 ++++ ++++ ++++ 474 ++++ ++++ ++++ 475 ++.++ ++++± + 476 +++ ++++ +++ 477 +±++ ++++ ++++ 478 +++ +++ ++++ 479 ++++ ++++ ++++ 480 ++++ ++++ ++++ 481 ++++ ++++ ++++ 482 +++ +++. ++++ 483 ++++ ++++ ++++ 484 ++++ ++++ +++ 485 ++++ ++++ ++ 486 ++.++ ++++ ++ 487 ++++ ++++ ++++ 488 ++.++ ++ ++++ 489 +++ ++++ ++++ 490 +.++ +++ ++++ 491 +..-+ +++ ++++ ++ ++ + 492 +.+ ++++ ++++ 493 +±++ ++++ ++++ -290- 1C50 (gM) E''50 (M) Ex.No PIMI PIM2 PIM3 HE MV-4-11 PC3 KMSII MMI.s _______ ________ 92.1.7 ________ 494 ++++ ++++ ++.+ ++++ ++ 495 ++++ ++++ ++++ 496 ++++ ++ ++++ +++ ++++ 497 ++++ ++++ ++++ 498 ++++ ++++ ++++ 499 ++++ +++. ++++ 500 ++++ ++++ ++++ 501 ++++ ++++ ++++ 502 ++++ ++++ ++++ 503 ++++ ++++ ++++ 504 ++++ ++++ ++++ 505 ++++ ++++ ++++ 506 ++++ ++++ ++++ 507 ++++ +++. ++++ 508 ++++ +++ ++++ 509 +++ +++ ++++ 510 ++++ ++++ ++++ 511 ++++ .. ++ ++++ 512 ++++ ++++ ++++ 513 ++++ ++++ ++++ 514 ++++ ++++ ++++ 515 ++++ +++ ++++ 516 ++++ ++++ ++++ ++++ ++++ 517 +++ +++.+ +++++++ + 519 +++ +++ ++++ 520 ++++ ++++ ++++ ++ ++ 521 ++++ ++++ ++++ 522 ++++ ++++ +++ 523 ++++ .++ +++ 524 ++++ ++++ ++++ 525 ++++ ++++ ++++ 526 ++++ ++++ ++++ 527 ++++ ++++ ++++ 528 ++.++ ++++ ++ 529 ++++ +++.+ ++ 530 ++++ ++++ +++ 531 ++++ ++++ ++++ 532 +++ ++++ +++ 533 ++++ .. ++ ++++ 534 ++++ ++++ ++++ 535 ++++ ++++ ++++ 536 ++++ ..+++ ++++ 537 ++.+ ++++ ++++ 538 ++++ ++++ ++++ 539 ++++ ++++ ++++ -291- IC50 (gM) E 50 ( M) Ex.No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMSII MMI.s _____ _ ______92.1.7 540 ++++ ++++ ++++ 541 ++++ .+++ ++++ 542 ++++ ++++ ++++ 543 ++++ ++ ++++ 544 ++++ ++++ ++++ 545 ++ ++++ +++ 546 ++++ ++++ ++++ 547 ++++ ++++ ++++ 548 ++++ ++++ ++++ 549 ++++ ++++ ++++ 550 ++++- ++++ ++++ 551 ++++ ++++ ++++ 552 ++++ ++++ ++++ 553 ++++ ++++ ++++ 554 ++++ ++++ ++++ 555 ++++ ++++ ++++ 556 ++++ .. ++ ++++ 557 ++++ ++++ ++++ 558 ++++ ++++ ++++ 559 ++++ ++++ ++++ 560 ++++ +++-- ++++ 561 ++++ ++±+ ++++ 562 ++++ ++++ ++++ 563 ++++ ++ ++++ 564 ++++ +-I-++ ++++ 565 ++++ ++++ t+++ 566 ++++ ++++ -++++ 567 ++++ ++++ ++++ 568 ++++ ++++ ++++ 569 ++++ +++ ++++ 570 ++±± +++I ++++ +++ +++ 571 ++++ ++++ ++++ 572 ++++ ++++ ++++ 573 ++++ ++++ ++++ 574 ++++ +++. ++++ 575 ++++ ++++ +++ 576 ++++ ++++ ++++ 577 ++++ ++++ ++++ +++ +++ 578 ++++ ++++ ++++ 579 ++++ ++++ ++++v++++ ++ 580 ++++ +m-+ ++++ +++ +++ 581 ++++ ++++ ++++ 582 +.+ +++ ++++ 584 .++ +++ ++++ 585 ++++ ++++ ++++ -292- IC50 (gM) E 50 (pM) Ex. No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMS1I MM1.s 92.1.7 586 ++++ +++ ++++ 587 ++++ ++++ ++++ ++++ 588 ++++ ++++ +++ 589 ++++ ++++ ++++ 590 ++++ +++. ++++ +++ 591 ++++ ++++ ++++ ++ 592 ++++ ++++ ++++ +.++ 593 ++++ ++++ ++++ 594 ++++ ++++ ++++ 595 ++++ ++++ ++++ 596 ++++ ++++ ++++ 597 ++++ +++ ++++ 598 ++++ +++ ++++ 599 ++++ +++ +++ 600 ++++ +++ ++++ 601 ±±±± ++++ ++++ 602 ++++ +++ ++++ 603 ++++ ++++ ++++ 604 ++++ ++++ ++++ 605 ++++ +++ ++++ 606 ++++ ++++ ++++ 607 ±±±± ++±. ++++ 608 ++++ ++++ ++++ 609 ++++ ++++ ++++ 610 ++++ ++++ ++++ 611 ++++ ++++ ++++ 612 ++++ +++ ++++ 613 ++++ ++++ ++++ 614 ++++ ++ ++++ 615 ++++ ++++ ++++ 616 ++++ ++++ ++++ 617 ++++ ++++ ++++ 618 ++++ ++++ ++++ 619 ++++ ++++ ++++ 620 ++++ ++++ ++++ 621 +±+- ++++ ++ 622 ++++ ++++ ++++ 623 ++++ ++++ ++++..

624 ++++ ++++ ++++ 625 ++++ ++. H+++ 626 ++++ ++++. +++ 627 ++++ ++++ +++ 628 ++ ++++ .++ 629 ++++ ++ + H+ 630 ++++ ++++ ++++ -293- IC50 (pM) E'50 (gM) Ex. No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMS]1 MM1.s _______ _______92.1.7 _ _ _ _ 631 ++++ ++++ ++++ 632 ++++ ++++ ++++ 633 +++ .+++ ++++ 634 ++++ ++++ ++++ 635 +++ ++++ ++++ 636 ++++ ++++ ++++ 637 +++ ++++ ++++ 638 ++++ ++++ ++++ 639 ++++ ++++ ++++ 640 ++++ ++++ ++++ 641 ++++ ++++ ++++ 642 ++++ +++ ++++ 643 ++++ ++++ ++++ 644 ++++ ++++ ++++ 645 ++++ ++++ ++++ 646 ++++ ++++ ++++ 647 ++.+ +++.+ ++± 648 ++++ ++++ ++++ 649 ++++ .++ ++++ 650 ++++ ++++ ++++ 651 ++++ +++. ++++ 652 ++++ ++++ ++++ 653 ++++ ++++ ++++ 654 ++++ ++++ 655 ++++ ++++. ++++ 656 ++++ ++++ ++++ 657 ++++ ++++ ++++ 658 ++++ +++. ++++ 659 ++++ +++. ++++ 660 ++++ +++- ++++ 661 +.+ ++++. +++ 662 ++++ ++++.. +++ 663 ++++ ++++ +++ 664 +++.+++ ++. - ++ 665 ++++ ±+++ +++± 666 ++++ +++. ++++ 667 ++++ +++- ++++ 668 ++++ ++++ ++++ 669 .+++ +++ ++++ 670 ++++ ++++ ++++ 671 ++++ ++++ ++++ 672 ++++ ++++ ++++ 673 ++++ ++++ ++++ 674 t+++ ++++ ++++ 675 ++++ ++++ ++++ -294- IC50 (M) E 50 (pM) Ex. No PIMI PIM2 PIM3 HEL MV-4-11 PC3 KMSI1 MMI.s ______________ _______ 92.1.7 _ _ _ 676 ++++ ++++ ++++ 677 ++++ ++++ ++++ 678 ++++ +++ ++++ 679 ++ ++++ ++++ +t+ ++++ 680 ++++ ++++ ++ 681 ++++ ++++ ++++ 682 ++++ ++++ +++ 683 ++++ ++++ ++++ ++++ +++ 684 ++++ ++++ ++++ 685 ++++ ++++ ++++ 686 ++++- ++++ ++++ 687 ++++ ++++ ++++ 688 ++++ ++++ ++++ 689 ++++ ++++ ++++ 690 ++++ ++++ ++++ 691 ++++ ++++ ++++ 692 ++++ ++++ ++++ 693 ++++ ++++ ++++ 694 ++++ ++++ ++++ 695 ++++ ++++ ++++ 696 ++++ ++++ ++++ 697 ±++-++ +++ +++ 698 ++++ ++++ ++++ 699 +++ ++++ ++++ 700 ++++ ++++ ++ 701 ++++ ++++ ++++ 702 ++++ ++++ +..+++ ++ 703 ++++ ++++ +++ 704 ++++ +++ +++ 705 ++++ ++++ ++++ 706 ++++ ++++ ++++ 707 ++++ +++ +++ 708 +++ +++± +++ 709 ++++ +++. ++++ 710 ++++ ++++ +++ 711 ++++ ++++ ++++ 712 ++++ .+± ++ 713 ++++ ++++ ++++ 714 ++.++ ++++ ++ 715 ++++ +++ ++++ 716 ++++ ++++ ++++ 717 ++++ ++++ ++++ 718 ++++ ++++ ++++ 719 ++++ ++++ +++ 720 ++t+ ++++ ++++ -295- IC50 (gM) E50 (AM) Ex.No PIMI PIM2 PIM3 lEL MV-4-11 PC3 KMSII MMI.s 92.1.7 721 ++++ +++ ++++ 722 ++++ ++++ ++++ 723 ++++ ++++ ++++ 724 ++++ ++++ +++ 725 ++++ ++++ +++ 726 ++++ ++++ ++++ 727 +.++ +++. ++++ 728 ++++ ++++ +++ 729 +++ ++++ ++++ 730 ++++ ++++ ++++ 731 ++++ ++++ ++++ 732 ++++ ++++ ++++ 733 ++++ ++++ ++++ 734 ++++ ++++ +++ 735 ++++ ++++ ++++ 736 ++++ ++++ ++++ ++++ +++ 737 ++++ +++ ++++ 738 ++++ ++++ +++ 739 +++tt +++ ++++ 740 ++++ ++++ +++ 741 ++++ +++ ++++ 742 ++++ ++++ ++++ 743 ++++ ++++ +++ 744 . .++++ ++++ ++++ ++ + 745 ++++. ++++ ++++ 746 ++++ ++++ ++++ 747 ++ ++++ ++++ 748 ++++ ++++ ++++ 749 ++++ ++++ ++++ 750 ++++ ++++ +++ 751 ++++ ++++ ++++ 752 ++++ ++++ ++++ 753 ++++ ++++ ++++ +++ ++++ 754 ++++ ++++ ++++ ++++ +++ 755 ++++ ++++ ++++ [0483] While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. -296- C-\NRPonblDCCK.NG\5'-6 _I DOC-2IWS/2012 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising". will be understood to imply the inclusion of a stated integer or step or group of integers or steps 5 but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of' suggestion that that prior publication (or information derived 10 from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. - 296a -

Claims (15)

1. A compound of Formula I, or a stercoisomer, tautomer, or pharmaceutically acceptable salt thereof, Y H N Z1'Z2 X4) ' Z II I X 3 , X1 R1 X 2 (I) 5 wherein, X 2 is N and X 1 , X 3 and X 4 are CR 2 ; Y is substituted or unsubstituted heterocycloalkyl; Z 1 and Z 2 are CR 2 and Z 3 is N; R, is selected from the group consisting of hydrogen, halo, alkyl, amino and 10 -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen,'halo, hydroxyl, and substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, amino, aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminocarbonyloxy, aminosulfonyl, aminosulfonyloxy, aminosulfonylamino, amidino, 15 carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, sulfonyl, sulfonyloxy, thioacyl, thiol, alkylthio, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl, partially saturated cycloalkyl, aryloxy, heteroaryloxy, heterocyclyloxy, cycloalkyloxy, acyl, acylamino and acyloxy; R 3 is selected from the group consisting of hydrogen, -CO-R 4 and substituted or 20 unsubstituted alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; and R 4 is selected from the group consisting of alkyl, substituted alkyl, alkoxy, substituted alkoxy, amino, substituted amino, and alkylamino.

2. A compound of claim 1 wherein Y is substituted or unsubstituted piperidinyl or piperazinyl. 25

3. A compound of claim 1 or 2 wherein R, is hydrogen. - 297 - Harochnm oven\ jonbIIUC\RLE 733762 _.doc.-6101/2015

4. A compound of any one of claims 1 to 3 wherein each R2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, amino, and substituted or unsubstituted alkyl, aminoalkyl and phenyl.

5. A compound of claim 1 having the following Formula II, or a 5 stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, R2 Y H NR2 N Z3 R NR 2 wherein, Y is substituted or unsubstituted heterocycloalkyl; Z 3 is N; 10 R 1 is selected from the group consisting of hydrogen, halo, amino and -NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, and substituted or unsubstituted alkyl, alkoxy, amino, aryl, heteroaryl, cycloalkyl, hetero cycloalkyl; and R 3 is hydrogen. 15

6. A compound of claim 5 having the following Formula III, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, R2 R2 R2 N H NR NZ3 YR1 R2 N (III) wherein, -298- Z3 is N; R, is selected from the group consisting of hydrogen, halo, alkyl, amino and NHR 3 ; each R 2 is independently selected from the group consisting of hydrogen, halo, hydroxyl, and substituted or unsubstituted alkyl, alkoxy, amino, aryl, heteroaryl, 5 cycloalkyl, hetero cycloalkyl; and R 3 is hydrogen.

7. The compound of claim 1, selected from the group consisting of: QNY 119 H -1 N N NN N O 1 NH 2 121 N H N) NH 2 N N N 0 NH 2 123 H I N N N- 0 NH2 HC'N 2CH, 126 N HN 6 N N 0 O NH2 N2 o o 127 N HN N N N 0 NH, -299- H :rec\merwo en R}onbl\DCURE(7337628_ I.doc%.60 1/2015 128 N H N NN N N N 0 NH 2 NH Chiral 176 N H N t N N - 0 NH N 2 NH 2 Chiral 177 N H N N N - 0 NH N 2 o NH 2 NBr 178 N N N N - 0 NH 2 (N NH, N B 179 N N N N 0 NH, NH N H 2 B r 180 N H N N O N 0 N H N 2 NH 2 Br N N N N 0 NH2 - 300 - NH 2 CI 182 N H N NH 2 N N N N o NH 2 NH 2 c NH 183 H N SN N-N N O NH S NH2 184 N N ~ ONH 2 N 184 H NH2 N 0 NH N N 0 NH 2 N 185 N N NH 2 N N 0 NH2 N NH2 NH 186 N N N N N 0 NH2 ONH 2 N 188N H N 18N N NN ',N N 0 NH2 O NH 2 N N 189 N H N; N N N 0 NH 2 -301 - H:rec\lnIenvcveiNRPortb2DCC\REC0337628_ I dox-601/2015 dNH2 190 N H N N N N- 0 NH2 H N 191 N H N N r N N 0 NH2 NHChiral N N 192 N N N- 0 NH2 NH 2 193 N H N N N N 0 NH2 NH 2 195 H N N N 0 NH 2 NH 2 N N N N N,,zNN N 0 NH 2 NH 2 197 N N 0 NH 2 N H N C H s 3 198 H N A 0 N - 302 - H:\rec\!icrwor ci\NRPob\DCC\hREC07337628 L.dOce64liI/2{,I5 H N 199 N H N> N N - 0 NH2 NH 2 1 CH, 340 N N NH2 N N A 0 NH 2 NH / N N I FH 341 N N 2 N N NN NH CH 344 NH2 NH N 345 (NT N t N 2NH NH2 NH2 N AQ NH, 346 N N' N N N O NH 2 - , 30H 344 N HNA NH 2 -0 NH, NH 345 (Nf N H , 0N NN2 NH 346 N H NA - 303 - H:ec\AiICnvoci\NRPorbbDC0RE07337628 1 doc--6A; l/21S NHF 2 0 F 347 N N H N N N A 0 NH2 NH 2 F F 348 N N F N N 0 NH, 30N 2 N NH2 A' CH, 349 N NA N N (Nl O NH2 q J NH 2 F 350 N N NA O NH2 NH KN 1 2 C CH 3 351 N N N N A O NH2 N NH2 352 N N N N N NH 2 -0 353C NH, N N -'0 NH, N C>NHP 354 N NA AH N N 2 ' -304- HlrccIlerwyetN OlKPo I\UUL\tLY/f3l6 _ I doc /Ul20i1 H N-N N 0 NH 2 N NH 356 N N N N N O NH2 NH 2 357 N N' N N A O NH2 OH NH N 358 (N N' N H N N N A60 NH 2 N N HNH N 369 N N H N N A 0 NH N 2 362 N HH N N A 0 NH2 (N 2 0 N NH, 361 30 ( NI N' H I ' 0 NH2 (N2 CH N N H rI1 N NI-J 1 N 0A N H , - 305 - H :\re Inerwoven\NRPortbl\DCC\RE07337628_I docx-6A2I/2I1S H N)F A~F 363 N N H 4N N A 0 NH 2 NH 364 N N A O NH 2 N 366 KN)N N N A 0 NH 2 NH NH N N N H NH2 A 0 NH 2 NH 367 N N H IX N O N - 0 NH 2 NH 2 368 N N O NH 2 NH , 369 N N HI N N - 0 NH2 -36 NH2 370N N -0 NH 2 N -' 306, H:VWctiiawoven\NRPonbl\DCC\REC\733762-_Ldocx-610l/2(01 NH 2 CH 3 371 H N O- N - 0 NH2

8. A composition comprising a therapeutically effective amount of compound of any one of claims 1 to 7, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

9. The composition of claim 8 which further comprises at least one 5 additional agent for the treatment of cancer.

10. A method for inhibiting PIM kinase activity in a cell, comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 7.

11. A method for treating a condition by modulation of Provirus Integration of Maloney Kinase (PIM kinase) activity comprising administering to a patient in need of 10 such treatment an effective amount of a compound of any one of claims 1 to 7.

12. A method for inhibiting PIM kinase activity in a patient, comprising administering to the patient a composition comprising a pharmacologically effective amount of a compound of any one of claims I to 7.

13. A method for treating a cancer disorder in a patient, comprising 15 administering to the patient a composition comprising an amount of a compound of any one of claims I to 7 effective to inhibit PIM kinase activity in the patient.

14. Use of a compound of any one of claims 1 to 7 in the manufacture of a medicament for the treating a cancer disorder in a patient.

15. A compound of claim 1 substantially as hereinbefore described with 20 reference to any one of the Examples. - 307 -